Sentence,class,file
Mol Genet Metab 2009; 98:393-9; PMID: 19656701; http://dx.doi.org/10.1016/j.ymgme.2009.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Mol Genet Metab 2011; 102:170-5; PMID:21051253; http://dx.doi.org/10.1016/j.ymgme.2010.09.014 24.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Hum Mol Genet 2008; 17:2723-37; PMID:18550655; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Cell Physiol 2009; 219:344-53; PMID: 19117012; http://dx.doi.org/10.1002/jcp.21676 26.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Neurobiol Dis 2010; 40:370-7; PMID:20600908; http://dx.doi.org/10.1016/j.nbd.2010.06.010 27.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Am J Pathol 2005; 167:1713-28; PMID:16314482; http://dx.doi.org/10.1016/S0002-9440(10)61253-9 www.landesbioscience.com Autophagy 727,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Biol Chem 2006; 281:20483- 93; PMID:16714284; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Lancet 2008; 372:1342-53; PMID:18929906; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Virchows ArchB Cell Pathol Incl Mol Pathol 1984; 45:23-36; PMID:6199885; http://dx.doi.org/10.1007/BF02889849 33.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Lab Invest 2006; 86:1208-20; PMID:17075580; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Mol Ther 2005; 11:48-56; PMID:15585405; http://dx.doi.org/10.1016/j.ymthe.2004.09.017 35.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Appl Physiol 2010; 108:1383-8; PMID:20223998; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Cell 2010; 140:313-26; PMID:20144757; http://dx.doi.org/10.1016/j.cell.2010.01.028 37.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Cell Biol 2005; 171:603-14; PMID:16286508; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Biol Chem 2007; 282:24131-45; PMID:17580304; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Biol Chem 2008; 283:22847-57; PMID:18524774; http://dx.doi.org/10.1074/jbc.M802182200 40.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Biol Chem 1998; 273:21883-92; PMID:9705327; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Mol Ther 2006; 14:831-9; PMID:17008131; http://dx.doi.org/10.1016/j.ymthe.2006.08.00943.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Am J Med Genet C Semin Med Genet 2012; 160:13-21; PMID: 22253254; http://dx.doi.org/10.1002/ajmg.c.31317 44.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Mol Genet Metab 2010; 101:324-31; PMID:20801068; http://dx.doi.org/10.1016/j.ymgme.2010.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Nature 2004; 432:1032-6; PMID:15525940; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Biol Chem 2010; 285:34960-71; PMID:20810658; http://dx.doi.org/10.1074/jbc.M110.150839 52.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Nature 2000; 406:906-10; PMID:10972294; http://dx.doi.org/10.1038/35022604 53.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Cell 2003; 113:445-56; PMID:12757706; http://dx.doi.org/10.1016/S0092- 8674(03)00348-9 55.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Cell 2003;113:435-44; PMID:12757705; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Proc Natl Acad Sci U S A 2007; 104:4506-11; PMID:17360554; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Genes Dev 2008; 22:2645- 50; PMID:18832069; http://dx.doi.org/10.1101/gad.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Neuropathol Appl Neurobiol 2005; 31:536-44; PMID:16150124; http://dx.doi.org/10.1111/j.1365-2990.2005.00675.x 61.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Biol Chem 2004; 279:5470-9; PMID:14645229; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Neurosci 2008; 28:6926-37; PMID:18596167; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Pediatrics 2009; 123:1191- 207; PMID:19336380; http://dx.doi.org/10.1542/peds.2008-0635 65.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Neurosci 2011; 31:1837-49; PMID:21289194; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Science 1997; 277:228-31; PMID: 9211849; http://dx.doi.org/10.1126/science.277.5323.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Science 2000; 290:2298-301; PMID:11125141; http://dx.doi.org/10.1126/science.290.5500.2298 68.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Cell 2009; 137:1213-24; PMID:19563754; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Nat Rev Mol Cell Biol 2001; 2:657-68; PMID:11533723; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Biochemistry 2008; 47:11134-43; PMID:18823126; http://dx.doi.org/10.1021/bi801328u 73.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Hum Mol Genet 2007; 16:1495-503; PMID:17468177; http://dx.doi.org/10.1093/hmg/ddm100 76.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Am J Pathol 2007; 171:962-75; PMID: 17631520; http://dx.doi.org/10.2353/ajpath.2007.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Acta Neuropathol 1993; 85:175-84; PMID: 8382896; http://dx.doi.org/10.1007/BF00227765 79.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Hum Mol Genet 2010; 19:2987-97; PMID:20484222; http://dx.doi.org/10.1093/hmg/ ddq204 80.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Cell 2011; 146:37-52; PMID:21700325; http://dx.doi.org/10.1016/j.cell.2011.06.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Child Neurol2003; 18:443-9; PMID:12940649; http://dx.doi.org/ 10.1177/08830738030180070701 83.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Pediatr 1974; 84:519-26; PMID:4365943; http://dx.doi.org/10.1016/S0022-3476(74)80671-285.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Proc Natl Acad Sci U S A1999; 96:8562-6; PMID:10411915; http://dx.doi.org/ 10.1073/pnas.96.15.8562 87.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Am J Hum Genet 1999; 65:773-8; PMID:10441585; http://dx.doi.org/10.1086/302549 88.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Nat Genet 2000; 26:118-23;PMID:10973263; http://dx.doi.org/10.1038/79095 89.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Hum Mol Genet 2000; 9:2471-8; PMID:11030752; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Nature 2008; 455:992-6; PMID:18794901; http://dx.doi.org/10.1038/nature07311 92.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Am J Physiol Renal Physiol 2009; 296: F1245-54; PMID:19158345; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Nat Commun 2010; 1:38; PMID:20802798; http://dx.doi.org/10.1038/ncomms1037 94.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
FEBS Lett 2010;584:2013-21; PMID:20074572; http://dx.doi.org/10.1016/j.febslet.2009.12.056 95.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Physiology(Bethesda) 2011; 26:14-22; PMID:21357899; http://dx.doi.org/10.1152/physiol.00048.2010 96.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Nat Genet 2001; 28:64-8; PMID: 11326278; http://dx.doi.org/10.1038/ng0501-64 97.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Mol Genet Metab 2006; 89:339-48; PMID:16914343; http://dx.doi.org/ 10.1016/j.ymgme.2006.05.016 98.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
BMC Cell Biol 2007; 8:54; PMID:18154673; http://dx.doi.org/10.1186/1471-2121-8-54 99.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Dev Cell 2011; 21:421-30; PMID: 21889421; http://dx.doi.org/10.1016/j.devcel.2011.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Biol Chem 2006; 281:39041-50; PMID: 17056595; http://dx.doi.org/10.1074/jbc.M607982200 101.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Cell Sci 2010; 123:3112-24; PMID:20736310; http://dx.doi.org/10.1242/jcs.067330 103.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Traffic 2009;10:1157-67; PMID:19522758; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Am J Hum Genet2007; 81:1070-83; PMID:17924347; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Neuropathol Exp Neurol 2009; 68:125-35; PMID:19151629; http://dx.doi.org/10.1097/NEN.0b013e3181942cf0 106.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Nat Med 2005; 11: 1109-12; PMID:16200072; http://dx.doi.org/10.1038/nm1305 107.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Am J Hum Genet 2006;78:451-63; PMID:16465621; http://dx.doi.org/10.1086/500849 108.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Biochem Biophys Res Commun 1972;49:992-9; PMID:4345092; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Biochem Biophys Res Commun 1975; 67:956-64; PMID:1201084; http://dx.doi.org/10.1016/0006-291X(75)90768-8 110.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Hum Mutat 2005; 26:308-14; PMID:16116615; http://dx.doi.org/10.1002/humu.20205 112.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Cell 1995; 82:949-57; PMID:7553855; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Brain 2006; 129:1438-45; PMID: 16670177; http://dx.doi.org/10.1093/brain/awl107 115.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Trends Neurosci 2011; 34:401-10; PMID:21723623; http://dx.doi.org/ 10.1016/j.tins.2011.05.006 116.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Nature 2006; 441:885-9; PMID: 16625204; http://dx.doi.org/10.1038/nature04724 117.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Cell 2007; 131:1149-63; PMID: 18083104; http://dx.doi.org/10.1016/j.cell.2007.10.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Acta Neuropathol 1995; 90:547-51; PMID:8615074; http://dx.doi.org/10.1007/BF00318566 122.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Acta Neuropathol 1999; 97:585-94; PMID:10378377; http://dx.doi.org/10.1007/ s004010051034 124.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Ann Neurol 2002; 52:351-5; PMID: 12205649; http://dx.doi.org/10.1002/ana.10266 126.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Cell 2010; 141: 1146-58; PMID:20541250; http://dx.doi.org/10.1016/j.cell.2010.05.008 127.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
J Neurosci 2010; 30:12535-44; PMID:20844148; http://dx.doi.org/10.1523/JNEUROSCI.1920-10.2010128.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Nature 2006; 443:780-6; PMID:17051204; http://dx.doi.org/ 10.1038/nature05291 129.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Nat Genet 2004; 36:585-95; PMID: 15146184; http://dx.doi.org/10.1038/ng1362 130.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Hum Mol Genet 2002; 11:1107-17; PMID:11978769; http://dx.doi.org/10.1093/hmg/11.9.1107 131.,OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
Cell Death Differ 2009; 16:46-56; PMID:18636076; http://dx.doi.org/10.1038/cdd.2008.110 132.,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
PLoS One 2009; 4:e6951; PMID:19750228; http://dx.doi.org/10.1371/journal.pone.0006951 730 Autophagy Volume 8 Issue 5,Non-OADS,/arxiv_data1/oa_pdf/29/9c/auto-8-719.PMC3378416.pdf
"Recruitment of additional GJ channels along the outer *Correspondence to: Matthias M. Falk; Email: MFalk@lehigh.edu Submitted: 01/25/11; Revised: 01/16/12; Accepted: 01/17/12 http://dx.doi.org/10.4161/auto.19390Autophagy 8:5, 794 –811; May 2012; G2012 Landes Bioscience 794 Autophagy Volume 8 Issue 5",Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Mol Biol Cell 2009; 20:3342-52; PMID: 19458184; http://dx.doi.org/10.1091/mbc.E09-04-0288 3.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Science 2002; 296: 503-7; PMID:11964472; http://dx.doi.org/10.1126/science.1068793 4.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J MembrBiol 1995; 146:15-28; PMID:7563034; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
FEBS Lett 2008; 582:4039-46; PMID:18992245; http://dx.doi.org/10.1016/j.febslet.2008.10.043 6.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Cell Sci 2008; 121:4069-78; PMID:19033388; http://dx.doi.org/10.1242/jcs.033373 7.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Double-membrane gap junction internalizationrequires the clathrin-mediated endocytic machinery.FEBS Lett 2008; 582:2887-92; PMID:18656476; http://dx.doi.org/10.1016/j.febslet.2008.07.024 8.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Mol Biol Cell 2007; 18:337-47; PMID:17108328; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Eur J Neurosci 2004; 19:1005-15; PMID:15009148; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Cell Biol 1998; 140:1199-209;PMID:9490732; http://dx.doi.org/10.1083/jcb.140.5.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
"J Biol Chem 2003; 278:41294-301; PMID:12907686; http://dx.doi.org/10.1074/jbc.M304785200 12. van Zeijl L, Ponsioen B, Giepmans BN, Ariaens A, Postma FR, Várnai P, et al.",OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Cell Biol 2007; 177:881-91; PMID: 17535964; http://dx.doi.org/10.1083/jcb.200610144 13.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Circ Res 2010; 106:1153-63; PMID:20167932; http://dx.doi.org/10.1161/CIRCRESAHA.108.182147 14.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Cardiovasc Res 2004; 62:256-67; PMID: 15094346; http://dx.doi.org/10.1016/j.cardiores.2003.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Cell Biol 1981; 90:521-6; PMID:7287816; http://dx.doi.org/10.1083/ jcb.90.2.521 17.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Dev Biol 1979; 68:110-29; PMID:437313; http://dx.doi.org/10.1016/0012-1606(79)90247-1 18.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Cell Biol 1979; 83:576-87; PMID: 574870; http://dx.doi.org/10.1083/jcb.83.3.576 20.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Acta Anat (Basel) 1984; 120:214-9; PMID:6516782; http://dx.doi.org/ 10.1159/000145923 21.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Exp Cell Res 1997; 236:482-92; PMID:9367633; http://dx.doi.org/10.1006/excr.1997.3747 24.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Cell Sci 2004; 117:1211-20;PMID:14970263; http://dx.doi.org/10.1242/jcs.00951 25.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Biol Chem 2003; 278:30005-14; PMID:12767974; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Curr Biol 1998; 8:931-4; PMID:9707407; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Cell Biol 2008; 183:499-511; PMID: 18981233; http://dx.doi.org/10.1083/jcb.200806016 33.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Cell Sci 2008; 121:1649-60; PMID:18430781; http://dx.doi.org/10.1242/jcs.025726 34.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
EMBO J 2000; 19: 5720-8; PMID:11060023; http://dx.doi.org/10.1093/ emboj/19.21.5720 35.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Int J Biochem Cell Biol 2004; 36:2491-502; PMID:15325587; http://dx.doi.org/10.1016/j.biocel.2004.02.005 36.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Cell Biol 2005; 171:603-14; PMID:16286508; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Dev Cell 2004; 6:463-77; PMID:15068787; http://dx.doi.org/10.1016/S1534-5807(04)00099-1 38.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Eur J Biochem1997; 243:240-6; PMID:9030745; http://dx.doi.org/ 10.1111/j.1432-1033.1997.0240a.x 40.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Proc Natl Acad Sci U S A 1982; 79:1889-92; PMID:6952238; http://dx.doi.org/ 10.1073/pnas.79.6.1889 41.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Cell Struct Funct 1998; 23:33-42; PMID:9639028; http://dx.doi.org/10.1247/ csf.23.33 42.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
EMBO Rep 2001; 2:330-5;PMID:11306555; http://dx.doi.org/10.1093/embo- reports/kve061 43.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
EMBO J 2007; 26:313-24; PMID:17245426; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Nat Cell Biol 2009; 11:65-70; PMID:19079246; http://dx.doi.org/ 10.1038/ncb1813 46.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Biol Chem 2007; 282:24131- 45; PMID:17580304; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Exp Cell Res 2009; 315:3587-97; PMID:19835873; http://dx.doi.org/10.1016/j.yexcr.2009.10.003 48.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Cell Signal 2010; 22:1267-73; PMID: 20206687; http://dx.doi.org/10.1016/j.cellsig.2010.03.005 49.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Cell Sci 2009; 122:3883-93; PMID:19808888; http://dx.doi.org/10.1242/jcs.053801 50.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Cell 2004; 119:753-66; PMID:15607973; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Science 2004; 306:1037-40; PMID:15528445; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Science 2005; 307:727-31; PMID:15576571; http://dx.doi.org/10.1126/science.1106036 53.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Nat Rev Mol Cell Biol 2001; 2:195-201; PMID:11265249; http://dx.doi.org/10.1038/35056583 55.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
"Hicke L, Dunn R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins.Annu Rev Cell Dev Biol 2003; 19:141-72; PMID:14570567; http://dx.doi.org/10.1146/annurev.cellbio.",OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Cell 2003; 112:491-505; PMID: 12600313; http://dx.doi.org/10.1016/S0092-8674(03) 00110-7 57.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Nat Cell Biol 2002; 4:389-93; PMID: 11988742; http://dx.doi.org/10.1038/ncb790 58.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Sci STKE 2002; 2002:pe32; PMID:12122203; http://dx.doi.org/10.1126/stke.2002.141.pe32 59.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
EMBO J 2006; 25:932-42; PMID:16482222;http://dx.doi.org/10.1038/sj.emboj.7600989 60.,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Mol Cell 2005; 20:301-12; PMID:16246731; http://dx.doi.org/ 10.1016/j.molcel.2005.09.014 61.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Traffic 2006; 7:282-97; PMID:16497223; http://dx.doi.org/10.1111/ j.1600-0854.2006.00384.x 62.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Traffic 2006; 7:262-81; PMID:16497222; http://dx.doi.org/ 10.1111/j.1600-0854.2006.00383.x 63.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Traffic 2006; 7:258-61; PMID:16497221; http://dx.doi.org/ 10.1111/j.1600-0854.2006.00393.x 64.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Biol Chem 2003; 278:37409-12; PMID:12857745; http://dx.doi.org/10.1074/jbc.M30741620065.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Mol Cell Biol 2004; 24:8055-68; PMID:15340068; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Nat Cell Biol 2001; 3:939-43; PMID:11584278; http://dx.doi.org/10.1038/ncb1001-939 67.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
JBiol Chem 2004; 279:50089-96; PMID:15371442; http://dx.doi.org/10.1074/jbc.M402006200 68.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
J Cell Sci 2011; 124:910-20; PMID: 21378309; http://dx.doi.org/10.1242/jcs.073072 71.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Nat Methods 2008; 5:545-51; PMID:18454154; http://dx.doi.org/10.1038/nmeth.1209 73.,OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
Nat Biotechnol 2004; 22:445-9; PMID: 14990965; http://dx.doi.org/10.1038/nbt945 www.landesbioscience.com Autophagy 811,Non-OADS,/arxiv_data1/oa_pdf/52/77/auto-8-794.PMC3378421.pdf
"Do not distribute.microRNA 30A promotes autophagy in response to cancer therapy Yan Yu,1,* Lizhi Cao,1,* Liangchun Yang,1Rui Kang,2Michael Lotze2,3and Daolin Tang2,* 1Department of Pediatrics; Xiangya Hospital; Central South University; Changsha, Hunan China;2Department of Surgery; Hillman Cancer Center; University of Pittsburgh; Pittsburgh, PA USA;3Department of Immunology; Hillman Cancer Center; University of Pittsburgh; Pittsburgh, PA USA Keywords: microRNA, BCR-ABL tyrosine kinase, autophagy, chronic myelogenous leukemia, Beclin 1, Atg5 Submitted: 03/05/12 Revised: 03/09/12Accepted: 03/16/12http://dx.doi.org/10.4161/auto.20053 *Correspondence to: Yan Yu, Lizhi Cao and Daolin Tang;Email: yyaner8645@sina.com, lizhicao@gmail.com and tangd2@upmc.edu Punctum to: Yu Y, Yang L, Zhao M, Zhu S, Kang R, Vernon P, et al.",Non-OADS,/arxiv_data1/oa_pdf/54/4d/auto-8-853.PMC3378424.pdf
Targeting microRNA-30a- mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.Leukemia 2012; In press; PMID:22395361; http://dx.doi.org/10.1038/leu.2012.65microRNAs (miRNAs) are a class of small regulatory RNAs that regu- late gene expression at the post-transcrip- tional level.,Non-OADS,/arxiv_data1/oa_pdf/54/4d/auto-8-853.PMC3378424.pdf
"The overall objectives of the consortium include: (i) tostrengthen the collaboration among five of the largestand longest running birth cohort studies in low- andmiddle-income countries, including capacity buildingamong young scientists, epidemiologists and statisti-cians in the cohort teams; (ii) to jointly produce high-quality scientific evidence on the early origins of chronic diseases and human capital by analysingThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/54/f5/dyq251.PMC3378468.pdf
pre-hypertension for adolescents and hyper-tension for adults) 7because of the different ages of the individuals across cohorts.Table 3 Contact information for each study in the COHORTS collaboration SitePrincipal investigator for the COHORTS collaboration Email Website Pelotas (Brazil) Cesar G Victora cvictora@gmail.com http://www.epidemio-ufpel.org.br/_projetos_de_pesquisas/coorte1982/ NTCS (Guatemala) Reynaldo Martorell rmart77@sph.emory.edu http://www.sph.emory.edu/humancapital/index.php New Delhi (India) Santosh Bhargava dskbhargava@yahoo.com No websiteCebu (The Philippines) Linda Adair linda_adair@unc.edu http://www.icpsr.umich.edu/cocoon/DSDR/STUDY/00178.xml Bt20 (South Africa) Linda Richter LRichter@hsrc.ac.za http://web.wits.ac.za/Academic/Health/Research/BirthTo20/COHORTS 625,Non-OADS,/arxiv_data1/oa_pdf/54/f5/dyq251.PMC3378468.pdf
The trade of sheep in Norway is regulated by The Norwegian Food Safety Authority ( http://mattilsynet.no ).,Non-OADS,/arxiv_data1/oa_pdf/bd/37/436_2012_Article_2817.PMC3378835.pdf
"http://www.regjeringen.no/upload/ LMD/Fylkesnytt/vedlegg/Beiteheftet.pdf Sangster NC, Steel JW, Collins GH, Hennessy DR (1993) Com- parative kinetic disposition of oxfendazole in sheep and goatsbefore and during infection with Haemonchus contortus and Trichostrongylus colubriformis .JV e tP h a r m a c o lT h e r a p 16:245– 253 Sargison N, Scott P, Jackson F (2001) Multiple anthelmintic resistance in sheep.",Non-OADS,/arxiv_data1/oa_pdf/bd/37/436_2012_Article_2817.PMC3378835.pdf
http://www.ssb.no/ jordbruk_en/.,Non-OADS,/arxiv_data1/oa_pdf/bd/37/436_2012_Article_2817.PMC3378835.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/f3/89/gkr1278.PMC3378857.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/a7/57/gks001.PMC3378858.pdf
"Software and data availability GCcorrect is an R package implementing exploratory analysis, estimation and correction methods for GCcontent effects, and is available for download fromhttp://www.stat.berkeley.edu/ /C24yuvalb.",OADS,/arxiv_data1/oa_pdf/a7/57/gks001.PMC3378858.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/aa/70/gks006.PMC3378859.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/d3/93/gks007.PMC3378860.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/a9/15/gks009.PMC3378861.pdf
"The results for hard constraints were calculatedwithRNAfold and the option -C. Availability All source code accompanying this article can be down- loaded here: https://github.com/wash/probing.Nucleic Acids Research, 2012, Vol.",OADS,/arxiv_data1/oa_pdf/a9/15/gks009.PMC3378861.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/73/a0/gks011.PMC3378862.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/f3/fb/gks013.PMC3378863.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/1c/7c/gks014.PMC3378864.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/2e/96/gks017.PMC3378865.pdf
The ampliﬁcation was based on previously described Affymetrix protocols(http://www.biotechniques.com/article.asp?id=112343).,Non-OADS,/arxiv_data1/oa_pdf/2e/96/gks017.PMC3378865.pdf
Identiﬁcation of consensus sequence for OxyR binding Promoter regions were scanned with the web-based programs CONSENSUS and PATSER available athttp://rsat.ulb.ac.be/rsat/ to detect DBP consensus sequences.,OADS,/arxiv_data1/oa_pdf/2e/96/gks017.PMC3378865.pdf
Sequence logos were created with WebLogo (http://weblogo.berkeley.edu/).,OADS,/arxiv_data1/oa_pdf/2e/96/gks017.PMC3378865.pdf
The global representations of the deﬁned consensussequence were identiﬁed by Virtual Footprint (http://www.prodoric.de/vfp/vfp_regulon.php) for the entiregenome of P. aeruginosa PAO1.,OADS,/arxiv_data1/oa_pdf/2e/96/gks017.PMC3378865.pdf
"subunit alpha part 1 PA0903 alaS 1.42 106 1 ATAGTTATTGCCTAT 92 7.77 Alanyl-tRNA synthetase PA0963 aspS 1.02 304 2 ATAGGGAGAATCTAT 319 7.66 Aspartyl-tRNA synthetase PA1054 1.48 271 6 ATAGATTGCGATAAT 138 7.45 Probable NADH dehydrogenasePA1541 1.20 308 2 ATCGATTGGCTTTTT 237 6.36 Probable drug efﬂux transporterPA2053 cynT 1.07 102 2 ATTGGTCTGGTCTAT 86 7.36 Carbonate dehydratase PA3032 snr1 1.34 282 2 ATAGACTCAGGCTAT 201 7.53 Cytochrome cSnr1 PA3136 1.22 71 2 AAGTGTAGCGCCTAT 25 6.09 Probable secretion protein PA4268 rpsL 1.23 76 1 ATAGCTCCACTGATT 3 6.17 30S ribosomal protein S12 PA4406 lpxC 1.27 123 1 ACTGTTTTCAACAAT 30 6.50 UDP-3-O-acyl- N-acetylglucosamine deacetylase PA5291 1.36 103 1 ATCGTGATAGCTAAT 64 7.12 Probable choline transporterPA0938 1.27 16 1 ATCATCGGTAGTTAT 96 6.67 Hypothetical protein PA2044 1.25 101 1 ATTGATAAAACCTAT 95 7.84 Hypothetical protein PA2145 1.04 8 1 ATAGACCCATTCAAT 38 7.23 Hypothetical proteinPA2595 1.13 8 1 Conserved hypothetical protein aChIP-enriched OxyR-binding regions are shown by the PA number of the associated genes; the respective gene names, operon compositions (indicated by the number of affected genes) and gene annotations are extracted from http://www.pseudomonas.com.",Non-OADS,/arxiv_data1/oa_pdf/2e/96/gks017.PMC3378865.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/de/35/gks019.PMC3378866.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/b6/6e/gks023.PMC3378867.pdf
A movie showing the details of the crystal structure can be downloaded from http://www.bmsg.ulsop.ac.uk/ people/DengguoWei.html.,OADS,/arxiv_data1/oa_pdf/b6/6e/gks023.PMC3378867.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/6d/3a/gks025.PMC3378868.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/08/2c/gks026.PMC3378869.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/da/a1/gks029.PMC3378870.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/d6/af/gks030.PMC3378871.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/23/36/gks031.PMC3378872.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/30/63/gks032.PMC3378873.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/12/07/gks033.PMC3378874.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/8f/4e/gks034.PMC3378875.pdf
Phylogenetic analyses Protein sequences for 14 Arabidopsis SGS3-like proteins were obtained from the Arabidopsis website (http://www.arabidopsis.org).,OADS,/arxiv_data1/oa_pdf/8f/4e/gks034.PMC3378875.pdf
Full-length protein sequences of 14 SGS3-like proteins were aligned using CLUSTALW at The Biology Work Bench (http://workbench.sdsc.edu/).,OADS,/arxiv_data1/oa_pdf/8f/4e/gks034.PMC3378875.pdf
"To assess the degree of reliabil- ity for each branch on the tree, bootstrap conﬁdence values of each node were calculated with 1000 replicatesusing PAUP 4.0 (http://paup.csit.fsu.edu/).",OADS,/arxiv_data1/oa_pdf/8f/4e/gks034.PMC3378875.pdf
"FDM1 and FDM2 have redundant and essential roles in RdDM To examine the function of FDM1 and FDM2 , two T-DNA insertion lines, SALK_075378 for FDM1 (39) and SAIL_291_F01 for FDM2 (40) were obtained from theArabidopsis stock center (http://www.arabidopsis.org) and further characterized.",OADS,/arxiv_data1/oa_pdf/8f/4e/gks034.PMC3378875.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/98/b5/gks036.PMC3378876.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/43/25/gks037.PMC3378877.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/85/02/gks038.PMC3378878.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/3a/5f/gks039.PMC3378879.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/95/4e/gks040.PMC3378880.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/23/70/gks041.PMC3378881.pdf
"Cytogenetic analyses Karyotyping, metaphase chromosome counts and breakage studies were carried out at the Quebec Leukemia Cell Bank (http://www.bclq.org/en/index.html).Nucleic Acids Research, 2012, Vol.",OADS,/arxiv_data1/oa_pdf/23/70/gks041.PMC3378881.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/23/f8/gks042.PMC3378882.pdf
http://www.genome.gov/sequencingcosts/.,OADS,/arxiv_data1/oa_pdf/23/f8/gks042.PMC3378882.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/eb/ff/gks043.PMC3378883.pdf
Known miRNA se- quences and their genome locations were downloaded from miRBase version 16 (http://www.mirbase.org/).,OADS,/arxiv_data1/oa_pdf/eb/ff/gks043.PMC3378883.pdf
sapiens sequences and their gene annotations were retrieved from UCSC(http://hgdownload.cse.ucsc.edu/downloads.html).,OADS,/arxiv_data1/oa_pdf/eb/ff/gks043.PMC3378883.pdf
Secondary structure prediction mfold was used for secondary structure prediction (http://mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form).,OADS,/arxiv_data1/oa_pdf/eb/ff/gks043.PMC3378883.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/59/7a/gks044.PMC3378884.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/b3/50/gks045.PMC3378885.pdf
MATERIALS AND METHODS Sequence data The known boundary sequences were retrieved from National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/) by following the informa- tion provided in published literatures (SupplementaryTable S1).,OADS,/arxiv_data1/oa_pdf/b3/50/gks045.PMC3378885.pdf
The entire predic- tion data can be downloaded from our website (http://www.ccmb.res.in/rakeshmishra/cdBEST.html).,OADS,/arxiv_data1/oa_pdf/b3/50/gks045.PMC3378885.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/5a/39/gks046.PMC3378886.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/62/f0/gks049.PMC3378887.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/7c/1a/gks050.PMC3378888.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/08/c7/gks051.PMC3378889.pdf
"Since thediscovery of the ﬁrst miRNA ( lin-4)i n Caenorhabditis elegans (4), to date, over 16 000 miRNAs (including over 1400 in humans) have been identiﬁed (http://www.mirbase.org/) (5,6).",OADS,/arxiv_data1/oa_pdf/20/be/gks052.PMC3378890.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/20/be/gks052.PMC3378890.pdf
Figure 4 shows the predicted binding afﬁnitybetween gene rpr and the available 163 miRNAs from ‘http://www.microrna.org/microrna/home.do’.,OADS,/arxiv_data1/oa_pdf/20/be/gks052.PMC3378890.pdf
melanogaster (http://www.mirbase.org/).,OADS,/arxiv_data1/oa_pdf/20/be/gks052.PMC3378890.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/d1/a8/gks053.PMC3378891.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/68/76/gks054.PMC3378892.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/9c/19/gks056.PMC3378893.pdf
ACCESSION NUMBERS Raw microarray data can be accessed by GSE33688 and ChIP-seq data by GSE34896 from the NCBI Gene Expression Omnibus at http://www.ncbi.nlm.nih.gov/geo.,OADS,/arxiv_data1/oa_pdf/9c/19/gks056.PMC3378893.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/b3/64/gks057.PMC3378894.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/ae/36/gks059.PMC3378895.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/5b/8c/gks061.PMC3378896.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/ab/00/gks062.PMC3378897.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/51/73/gks063.PMC3378898.pdf
"Sequences were barcode sorted andquality trimmed (minimum Phred quality 20, minimumlength 25 bp) using the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) (Gordon,A and Hannon,G.J., unpublished results).",OADS,/arxiv_data1/oa_pdf/51/73/gks063.PMC3378898.pdf
"Putative protein–DNA binding events were detected using Pique, a novel microbially focused and freelyavailable peak calling application (available at https://github.com/ryneches/pique, version tag: halo_egw)(Neches,R.Y., Wilbanks,E.G.",OADS,/arxiv_data1/oa_pdf/51/73/gks063.PMC3378898.pdf
ACCESSION NUMBERS All high-throughput sequencing data generated in this work are available via BioTorrents (http://www.biotorrents.net/details.php?id=259) or from our labwebsite (www.bme.ucdavis.edu/facciotti/resources_data/data/).,OADS,/arxiv_data1/oa_pdf/51/73/gks063.PMC3378898.pdf
The open access Pique package and source codecan be obtained via github at https://github.com/ryneches/pique.,OADS,/arxiv_data1/oa_pdf/51/73/gks063.PMC3378898.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/2d/37/gks065.PMC3378899.pdf
"and Mevik,B.-H. (2007) pls: partial least squares regression (PLSR) and principal component regression (PCR).R package version 2.1-0, http://mevik.net/work/software/pls.html(17 March 2010, date last accessed).4722 Nucleic Acids Research, 2012, Vol.",OADS,/arxiv_data1/oa_pdf/2d/37/gks065.PMC3378899.pdf
"The lack of sensitivity and speciﬁcity of the developed computational algorithms is clearly shown by the fact that for the 1048 human miRNAs identiﬁed (miRBase release16 September 2010), experimentally validated targets have only been reported for 206 miRNAs (miRecords at http://mirecords.umn.edu/miRecords/).",Non-OADS,/arxiv_data1/oa_pdf/d8/5d/gks145.PMC3378903.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/d8/5d/gks145.PMC3378903.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/58/d5/gks147.PMC3378904.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/16/3a/gks149.PMC3378905.pdf
Genome regions with TFBS clusters were down-loaded from the PReMod database (45) available athttp://genomequebec.mcgill.ca/PReMod/.,OADS,/arxiv_data1/oa_pdf/16/3a/gks149.PMC3378905.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/42/46/gks150.PMC3378906.pdf
Dynamic trimming We used the program fastq_quality_trimmer (v 0.0.13 http://hannonlab.cshl.edu/fastx_toolkit/) to perform dynamic trimming of the original 100 bp and the 75 bp data sets to a Phred quality level of 30 (=0.001 probabil-ity of a base-call error as assessed by the Illumina base calling pipeline).,OADS,/arxiv_data1/oa_pdf/42/46/gks150.PMC3378906.pdf
"Data visualization SeqMonk (http://www.bio informatics.bbsrc.ac.uk/ projects/seqmonk) was used to view methylation data.It is a graphical Java application, which is distributedfor a wide range of computer platforms (Windows,Linux, MacOS X and as Java source code).",OADS,/arxiv_data1/oa_pdf/42/46/gks150.PMC3378906.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/8b/87/gks415.PMC3378907.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/09/6c/gks431.PMC3378908.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/c4/b1/gks456.PMC3378909.pdf
"169 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org Achieving asthma control is central to optimizing patient qual - ity of life and clinical outcomes.",Non-OADS,/arxiv_data1/oa_pdf/e0/9c/aair-4-169.PMC3378921.pdf
"2012 July;4(4):169-170. http://dx.doi.org/10.4168/aair.2012.4.4.169 pISSN 2092-7355 • eISSN 2092-7363 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e0/9c/aair-4-169.PMC3378921.pdf
"2012 July;4(4):169-170.  http://dx.doi.org/10.4168/aair.2012.4.4.169Volume 4, Number 4, July 2012 170 http://e-aair.orgpatient and health care professional.14 One limitation of this study is that it includes the potential for  unrecognized confounding factors, including selection bias, as  it was a retrospective study.11 This study examined a database of  primary physicians in the U.K. As such, there were missing data  for some patients, including smoking history, which could in - fluence outcomes.",Non-OADS,/arxiv_data1/oa_pdf/e0/9c/aair-4-169.PMC3378921.pdf
"171 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org INTRODUCTION The link existing between the upper and lower airways has  been observed repeatedly in the past, but the concept of united  airways disease (UAD) is a matter of recent years,1 thanks to the  increasingly detailed pathogenic knowledge acquired over the  last 15 years.",Non-OADS,/arxiv_data1/oa_pdf/b8/5f/aair-4-171.PMC3378922.pdf
2012 July;4(4):171-177. http://dx.doi.org/10.4168/aair.2012.4.4.171 pISSN 2092-7355 • eISSN 2092-7363 The nose and lung are both part of the respiratory tract.,Non-OADS,/arxiv_data1/oa_pdf/b8/5f/aair-4-171.PMC3378922.pdf
"Key Words:  Airways; allergic rhinitis; ARIA; asthma; rhinosinusitis; united airwaysThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b8/5f/aair-4-171.PMC3378922.pdf
"2012 July;4(4):171-177.  http://dx.doi.org/10.4168/aair.2012.4.4.171Volume 4, Number 4, July 2012 172 http://e-aair.orgactually play a systemic role via soluble mediators that involve  the bone marrow,9 which responds in a rapid and specific way  to nasal challenge, with an increased production of precursors  and mature eosinophils.10,11 Moreover, nasal allergen exposure  in patients suffering from AR may rapidly lead to a significant  pulmonary allergic inflammation, even subjects who don’t have  a history of asthma nor BHR.12 It has been demonstrated that a  segmental bronchial challenge may induce nasal symptoms  and inflammation in patients suffering from AR, 24 hours after  the test; on the other hand, even after a nasal challenge, a de - cline in respiratory function may be detected, 4-6 hours after  the test.13,14 All these observations have therefore contributed to the gene - sis of the term UAD, and the respiratory tract is now considered  as a single entity both morphologically and functionally.15 Anatomy of the respiratory tract The respiratory tree is functionally divided between the con - ductive paths and the portion deputed for gas exchange.",Non-OADS,/arxiv_data1/oa_pdf/b8/5f/aair-4-171.PMC3378922.pdf
"2012 July;4(4):171-177.  http://dx.doi.org/10.4168/aair.2012.4.4.171AAIR  173 http://e-aair.orgAllergic rhinitis and asthma Allergic rhinitis is considered a risk factor for developing asth - ma, but it is possible that this term is not totally correct in the  sense that this condition may represent an early stage of UAD  that can progress to full-blown asthma.4 Allergic rhinitis (AR) is the most common of all atopic diseas - es and it can develop at any age; nevertheless, most patients re - port the onset of symptoms before 30 years of age, during some  of the most productive years of life.29 AR was initially subdivided on the basis of the time of expo - sure, into seasonal, perennial and occupational diseases.",Non-OADS,/arxiv_data1/oa_pdf/b8/5f/aair-4-171.PMC3378922.pdf
"2012 July;4(4):171-177.  http://dx.doi.org/10.4168/aair.2012.4.4.171Volume 4, Number 4, July 2012 174 http://e-aair.orgper and lower airways.45 Sinonasal disease in asthmatics ap - pears to differ somewhat from that of the general population  and the temporal sequence of disease and parallel inflammato - ry pathways involved suggest that they may be progressive man - ifestations of a common disease process.46 Precipitants of asth - ma are generally also precipitants of sinusitis, and, therefore,  the association of sinusitis with asthma exacerbations may be  an epiphenomenon.47 It is not clear whether rhinosinusitis is a direct trigger for asth - ma or if the two conditions are just manifestations of a common  underlying process.",Non-OADS,/arxiv_data1/oa_pdf/b8/5f/aair-4-171.PMC3378922.pdf
"2012 July;4(4):171-177.  http://dx.doi.org/10.4168/aair.2012.4.4.171AAIR  175 http://e-aair.orgrhinitis, an increase in bronchial hyper-reactivity may be out - lined.",Non-OADS,/arxiv_data1/oa_pdf/b8/5f/aair-4-171.PMC3378922.pdf
"2012 July;4(4):171-177.  http://dx.doi.org/10.4168/aair.2012.4.4.171Volume 4, Number 4, July 2012 176 http://e-aair.orgphysema.",OADS,/arxiv_data1/oa_pdf/b8/5f/aair-4-171.PMC3378922.pdf
2012 July;4(4):171-177.  http://dx.doi.org/10.4168/aair.2012.4.4.171AAIR  177 http://e-aair.org60.,Non-OADS,/arxiv_data1/oa_pdf/b8/5f/aair-4-171.PMC3378922.pdf
"178 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org INTRODUCTION In the past 30 years, the prevalence of atopic sensitization, al - lergic rhinitis and asthma has increased dramatically particu - larly in younger populations.",Non-OADS,/arxiv_data1/oa_pdf/b0/4c/aair-4-178.PMC3378923.pdf
2012 July;4(4):178-183. http://dx.doi.org/10.4168/aair.2012.4.4.178 pISSN 2092-7355 • eISSN 2092-7363 The rising incidence of allergic disorders in developed countries is unexplained.,Non-OADS,/arxiv_data1/oa_pdf/b0/4c/aair-4-178.PMC3378923.pdf
"Key Words:  Air pollution; childhood; asthma; allergy; dieselThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b0/4c/aair-4-178.PMC3378923.pdf
"2012 July;4(4):178-183.  http://dx.doi.org/10.4168/aair.2012.4.4.178AAIR  179 http://e-aair.orgOther evidence supports a heretofore unproven hypothesis  that environmental exposure to traffic pollutants early in life,  and particularly diesel exhaust particles (DEPs), may have adju - vant immune effects by enhancing risk of sensitization to com - mon aeroallergens and increase likelihood of development of  allergic disorders.",Non-OADS,/arxiv_data1/oa_pdf/b0/4c/aair-4-178.PMC3378923.pdf
"2012 July;4(4):178-183.  http://dx.doi.org/10.4168/aair.2012.4.4.178Volume 4, Number 4, July 2012 180 http://e-aair.orgThe second model used in the studies employed land use re - gression (LUR) models for estimating personal exposure to traf - fic pollutants in primary residences and schools of the chil - dren.18 In the CCAAPS Study, this was achieved by measuring  elemental carbon in PM 2.5 air samples collected in 27 sampling  sites in the Greater Cincinnati area during the first year of the  study.",OADS,/arxiv_data1/oa_pdf/b0/4c/aair-4-178.PMC3378923.pdf
2012 July;4(4):178-183.  http://dx.doi.org/10.4168/aair.2012.4.4.178AAIR  181 http://e-aair.orgacting with the CT/TT IL-4C-589T SNP showed a significant  tenfold increased risk of wheezing in African American but not  Caucasian infants.,Non-OADS,/arxiv_data1/oa_pdf/b0/4c/aair-4-178.PMC3378923.pdf
"2012 July;4(4):178-183.  http://dx.doi.org/10.4168/aair.2012.4.4.178Volume 4, Number 4, July 2012 182 http://e-aair.orgsubset of 176 children from the CCAAPS cohort were studied at  age 1 and 7 for indoor exposure to 36 mold spore species using  PCR based analysis and expressed as the Environmental Rela - tive Moldiness Index (ERMI).",Non-OADS,/arxiv_data1/oa_pdf/b0/4c/aair-4-178.PMC3378923.pdf
2012 July;4(4):178-183.  http://dx.doi.org/10.4168/aair.2012.4.4.178AAIR  183 http://e-aair.orgwheezing at age 3 years.,Non-OADS,/arxiv_data1/oa_pdf/b0/4c/aair-4-178.PMC3378923.pdf
"184 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org INTRODUCTION Correct use of inhaler devices is fundamental to effective asth - ma management but represents an important challenge for pa - tients.",Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
2012 July;4(4):184-191. http://dx.doi.org/10.4168/aair.2012.4.4.184 pISSN 2092-7355 • eISSN 2092-7363 Purpose:   Correct  use of inhaler  devices  is fundamental  to effective  asthma  management  but represents  an important  challenge  for patients.,Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
"Key Words:   Asthma;  breath-actuated  inhaler;  inhaled  corticosteroids;  inhaler  device;  pressurised  metered-dose  inhaler;  short-acting  β2-agonistThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
"2012 July;4(4):184-191.  http://dx.doi.org/10.4168/aair.2012.4.4.184AAIR  185 http://e-aair.orgtype for each asthma medication.7-11 It would seem logical that  confusion could result from using different inhaler device types  for asthma controller and reliever therapy, especially for patients  just beginning inhaler therapy who lack long-term training and  practice with different devices.",Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
"2012 July;4(4):184-191.  http://dx.doi.org/10.4168/aair.2012.4.4.184Volume 4, Number 4, July 2012 186 http://e-aair.orgbinary outcomes.",Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
2012 July;4(4):184-191.  http://dx.doi.org/10.4168/aair.2012.4.4.184AAIR  187 http://e-aair.orgTable 2.,Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
"2012 July;4(4):184-191.  http://dx.doi.org/10.4168/aair.2012.4.4.184Volume 4, Number 4, July 2012 188 http://e-aair.orgcurrent smokers in the same device cohort.",Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
2012 July;4(4):184-191.  http://dx.doi.org/10.4168/aair.2012.4.4.184AAIR  189 http://e-aair.orghort (Table 4).,Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
"2012 July;4(4):184-191.  http://dx.doi.org/10.4168/aair.2012.4.4.184Volume 4, Number 4, July 2012 190 http://e-aair.orglower ICS doses (similar proportions of patients achieved asth - ma control in the higher ICS dose categories).",Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
"2012 July;4(4):184-191.  http://dx.doi.org/10.4168/aair.2012.4.4.184AAIR  191 http://e-aair.orgstudy design; the collection, analysis, and interpretation of data;  the writing of the manuscript; or the decision to submit the  manuscript for publication.",Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
Available from: http://www.gprd.com/.,Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
Available from: http://www.optimumpatientcare.,Non-OADS,/arxiv_data1/oa_pdf/19/b9/aair-4-184.PMC3378924.pdf
"192 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org INTRODUCTION Exercise is a common stimulus for asthma symptoms in asth - matic patients.",Non-OADS,/arxiv_data1/oa_pdf/6a/d9/aair-4-192.PMC3378925.pdf
2012 July;4(4):192-198. http://dx.doi.org/10.4168/aair.2012.4.4.192 pISSN 2092-7355 • eISSN 2092-7363 Purpose:   Exercise-induced  bronchoconstriction  (EIB) in patients  with asthma  occurs  more  frequently  in winter  than in summer.,Non-OADS,/arxiv_data1/oa_pdf/6a/d9/aair-4-192.PMC3378925.pdf
"Key Words:   Asthma;  bronchoconstriction;  exercise;  house  dust mite;  seasonThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6a/d9/aair-4-192.PMC3378925.pdf
2012 July;4(4):192-198.  http://dx.doi.org/10.4168/aair.2012.4.4.192AAIR  193 http://e-aair.orgchange in association with changes in temperature and humid - ity.,OADS,/arxiv_data1/oa_pdf/6a/d9/aair-4-192.PMC3378925.pdf
"2012 July;4(4):192-198.  http://dx.doi.org/10.4168/aair.2012.4.4.192Volume 4, Number 4, July 2012 194 http://e-aair.orgcurve.",Non-OADS,/arxiv_data1/oa_pdf/6a/d9/aair-4-192.PMC3378925.pdf
"2012 July;4(4):192-198.  http://dx.doi.org/10.4168/aair.2012.4.4.192AAIR  195 http://e-aair.orgterval [CI] =3.06-121.51, P=0.002) in season and 38.40 (6.17- 239.22, P=0.000) in moderate or severe methacholine-AHR.",Non-OADS,/arxiv_data1/oa_pdf/6a/d9/aair-4-192.PMC3378925.pdf
"2012 July;4(4):192-198.  http://dx.doi.org/10.4168/aair.2012.4.4.192Volume 4, Number 4, July 2012 196 http://e-aair.orgwith asthma who are sensitized to pollen.12,13 Therefore, our pa - tients that were sensitized to pollen seemed to show an inverse  correlation with EIA, unlike those sensitized to HDMs.",OADS,/arxiv_data1/oa_pdf/6a/d9/aair-4-192.PMC3378925.pdf
"2012 July;4(4):192-198.  http://dx.doi.org/10.4168/aair.2012.4.4.192AAIR  197 http://e-aair.orgincreased prevalence during low-temperature seasons, while  EIB showed an apparent increase in prevalence.",Non-OADS,/arxiv_data1/oa_pdf/6a/d9/aair-4-192.PMC3378925.pdf
"2012 July;4(4):192-198.  http://dx.doi.org/10.4168/aair.2012.4.4.192Volume 4, Number 4, July 2012 198 http://e-aair.org27.",Non-OADS,/arxiv_data1/oa_pdf/6a/d9/aair-4-192.PMC3378925.pdf
"199 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org INTRODUCTION Aspirin-exacerbated respiratory disease (AERD) is character - ized by asthma, the presence of polyps in nasal passages, and  sensitivity to aspirin and other non-steroidal anti-inflammato - ry drugs (NSAIDs).1 Although previous research has attributed  AERD pathophysiology to inhibition of the cyclooxygenase-2  (COX-2) pathway, resulting in decreased synthesis of prostaglan - din E 2 (PGE 2) and overproduction of cys-leukotrienes (cysLTs),2  recent reports have suggested that several genes may play a  predisposing role, implicating other pathways in AERD patho - genesis; these include major histocompatibility complex (MHC),  class II, DP beta 1 ( HLA-DPB1 ), solute carrier family 6 (neu - rotransmitter transporter, betaine/GABA) member 12 (SL - C6A12), complementary component 6 (C6), D-tyrosyl-tRNA WDR46  is a Genetic Risk Factor for Aspirin-Exacerbated  Respiratory Disease in a Korean Population Charisse Flerida A. Pasaje,1 Joon Seol Bae,1 Byung-Lae Park,2 Hyun Sub Cheong,2 Jeong-Hyun Kim,1 Soo-Taek Uh,3  Choon-Sik Park,4* Hyoung Doo Shin1,2* 1Department of Life Science, Sogang University, Seoul, Korea 2Department of Genetic Epidemiology, SNP Genetics Inc., Seoul, Korea 3Division of Allergy and Respiratory Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea 4Division of Allergy and Respiratory Medicine & Genome Research Center for Allergy and Respiratory Diseases, Soonchunhyang University Bucheon Hospital,  Bucheon, Korea deacylase (DTD1), and emilin/multimerin domain-containing  protein 2 (EMID2).3-7 The MHC, a group of genes that determines the immune re - sponse to pathogens, is central to the activation of the innate Original Article Allergy Asthma Immunol Res.",Non-OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
"2012 July;4(4):199-205. http://dx.doi.org/10.4168/aair.2012.4.4.199 pISSN 2092-7355 • eISSN 2092-7363 Purpose:  The human WD repeat-containing protein 46  (WDR46 ; also known as C6orf11 ), located at the disease-relevant centromere side of the  class II major histocompatibility complex region, is hypothesized to be associated with risk of aspirin-exacerbated respiratory disease (AERD) as well  as a decline in forced expiratory volume in the first second (FEV1), an important diagnostic marker of asthma.",Non-OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
"Key Words:  Aspirin exacerbated respiratory disease; WDR46; FEV1; haplotype; single-nucleotide polymorphismThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
"2012 July;4(4):199-205.  http://dx.doi.org/10.4168/aair.2012.4.4.199Volume 4, Number 4, July 2012 200 http://e-aair.orgimmune system.",Non-OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
"Selection and genotyping of single-nucleotide polymorphisms Using the tagging approach, candidate single-nucleotide poly - morphisms (SNPs) in WDR46  were screened from the Interna - tional HapMap database (version release #27; http://www.hap - map.org) based on linkage disequilibrium (LD) status in the  Asian population (Han Chinese and Japanese) and location  within the gene.",OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
"Statistical analyses The association between differences in genotype frequency  distribution of WDR46  variation and the risk of AERD and air - way obstruction was analyzed according to previous methods.7  The statistical power of single associations was determined us - ing the Power for Genetic Association Analyses software,17 and  multiple testing corrections were calculated using the effective  number of independent marker loci (Meff), that accounts for  the eigenvalue spectral decomposition (SpD) of all of the geno - types represented in the correlation matrix extracted from the  SNPSpD program.18 Furthermore, functional analyses of WDR46   SNPs were carried out in silico using the UTRScan program19  and the European Molecular Biology Laboratory-European  Bioinformatics Institute (EMBL-EBI) splice site prediction soft - ware (http://www.ebi.ac.uk/asd-srv/wb.cgi?method =2).",OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
2012 July;4(4):199-205.  http://dx.doi.org/10.4168/aair.2012.4.4.199AAIR  201 http://e-aair.orgTable 1.,Non-OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
"2012 July;4(4):199-205.  http://dx.doi.org/10.4168/aair.2012.4.4.199Volume 4, Number 4, July 2012 202 http://e-aair.orgFunctional analyses in silico   Functional estimation of SNPs in intronic regions of WDR46   revealed that none of the analyzed variants act as branch point  sites for alternative splicing (data not shown).",Non-OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
"2012 July;4(4):199-205.  http://dx.doi.org/10.4168/aair.2012.4.4.199AAIR  203 http://e-aair.orgin the regulation of gene expression by mediating translation  efficiency and mRNA stability.19 Thus, the results of our in silico   analyses suggest that the relevance of the significant SNP,  rs463260G >A, in AERD susceptibility may be a manifestation  of cis-regulated gene expression.",Non-OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
"2012 July;4(4):199-205.  http://dx.doi.org/10.4168/aair.2012.4.4.199Volume 4, Number 4, July 2012 204 http://e-aair.orgguideline: aspirin provocation tests for diagnosis of aspirin hyper - sensitivity.",Non-OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
2012 July;4(4):199-205.  http://dx.doi.org/10.4168/aair.2012.4.4.199AAIR  205 http://e-aair.orgSupplementary Table 1.,Non-OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
*Data taken from the International HapMap database (version: release #28; http://www.hapmap.org).,OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
*FASTA sequence taken from National Center for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov).,OADS,/arxiv_data1/oa_pdf/72/2e/aair-4-199.PMC3378926.pdf
"206 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org INTRODUCTION Many studies have demonstrated that air pollution is a major  factor in the pathogenesis of respiratory inflammation.1 The  most abundant air pollutants in the atmosphere of urban areas  are nitrogen dioxide, ozone, and inhalant particulate matter.",Non-OADS,/arxiv_data1/oa_pdf/be/43/aair-4-206.PMC3378927.pdf
2012 July;4(4):206-213. http://dx.doi.org/10.4168/aair.2012.4.4.206 pISSN 2092-7355 • eISSN 2092-7363 Purpose:   Recent  studies  have  reported  that Asian  sand  dust (ASD)  has a potential  risk of aggravating  airway  inflammation.,Non-OADS,/arxiv_data1/oa_pdf/be/43/aair-4-206.PMC3378927.pdf
"Key Words:   Asian  sand  dust;  airway  inflammation;  mucinThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/be/43/aair-4-206.PMC3378927.pdf
2012 July;4(4):206-213.  http://dx.doi.org/10.4168/aair.2012.4.4.206AAIR  207 http://e-aair.orgThis study was conducted to investigate the effects of ASD on  the expression of inflammatory cytokines and MUC5AC in  BALF and lung tissue from an allergic murine model.,OADS,/arxiv_data1/oa_pdf/be/43/aair-4-206.PMC3378927.pdf
"2012 July;4(4):206-213.  http://dx.doi.org/10.4168/aair.2012.4.4.206Volume 4, Number 4, July 2012 208 http://e-aair.org450 nm for OVA-specific IgE was measured using a microplate  reader (Hitachi U-2000, Tokyo, Japan).",OADS,/arxiv_data1/oa_pdf/be/43/aair-4-206.PMC3378927.pdf
2012 July;4(4):206-213.  http://dx.doi.org/10.4168/aair.2012.4.4.206AAIR  209 http://e-aair.org4 (11.5±0.8 pg/mL) than in group 1 (9.3 ±0.3 pg/mL) ( P<0.05).,Non-OADS,/arxiv_data1/oa_pdf/be/43/aair-4-206.PMC3378927.pdf
"2012 July;4(4):206-213.  http://dx.doi.org/10.4168/aair.2012.4.4.206Volume 4, Number 4, July 2012 210 http://e-aair.orgImmunohistochemical staining The number of IL-4-positive cells was higher in groups 2, 3,  and 4 than in group 1.",Non-OADS,/arxiv_data1/oa_pdf/be/43/aair-4-206.PMC3378927.pdf
"2012 July;4(4):206-213.  http://dx.doi.org/10.4168/aair.2012.4.4.206AAIR  21 1 http://e-aair.orgit was significantly higher in group 3 (7.4 ±5.3) and group 4  (25.8±3.7) (P<0.05), particularly in group 4 (Fig.",OADS,/arxiv_data1/oa_pdf/be/43/aair-4-206.PMC3378927.pdf
"2012 July;4(4):206-213.  http://dx.doi.org/10.4168/aair.2012.4.4.206Volume 4, Number 4, July 2012 212 http://e-aair.orgmany related diseases after it is phagocytized by macrophages.18  ASD can not only aggravate lung disease, but it may also cause  changes in, and the adaptation and development of, various re - spiratory cells.",Non-OADS,/arxiv_data1/oa_pdf/be/43/aair-4-206.PMC3378927.pdf
2012 July;4(4):206-213.  http://dx.doi.org/10.4168/aair.2012.4.4.206AAIR  213 http://e-aair.orgREFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/be/43/aair-4-206.PMC3378927.pdf
"214 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org INTRODUCTION The prevalence of asthma and allergic disease has increased  substantially during the past three or four decades.1,2 Although  it has been stabilized or has decreased in most high-prevalence  countries (such as English-speaking countries) since 2000, its  prevalence is still increasing in population-dense countries in  Africa, Latin America and parts of Asia.3,4 Overall, the global  burden of asthma is continuing to rise.",Non-OADS,/arxiv_data1/oa_pdf/f3/6e/aair-4-214.PMC3378928.pdf
2012 July;4(4):214-221. http://dx.doi.org/10.4168/aair.2012.4.4.214 pISSN 2092-7355 • eISSN 2092-7363 Purpose:   Live/killed  mycobacteria  and culture  supernatants  can suppress  asthmatic  reactions.,Non-OADS,/arxiv_data1/oa_pdf/f3/6e/aair-4-214.PMC3378928.pdf
"Key Words:   Ag85  complex;  asthma;  MPB70;  mycobacteria;  38-kDa  proteinThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f3/6e/aair-4-214.PMC3378928.pdf
"2012 July;4(4):214-221.  http://dx.doi.org/10.4168/aair.2012.4.4.214AAIR  215 http://e-aair.orgThe antigen 85 complex (Ag85) is a major constituent of the  secreted proteins of M. tuberculosis  and BCG that can induce  interferon (IFN)- γ secretion from Th1 cells.14 38-kDa protein is  also actively secreted from M. tuberculosis15 and stimulates IFN- γ  secretion.16 MPB70, another protein that induces IFN- γ produc - tion, is a major secreted protein of BCG but is only secreted in  small quantities from M. tuberculosis .17 This study aimed to de - termine which of the enriched secretory proteins of mycobac - teria have therapeutic effects on asthma.",Non-OADS,/arxiv_data1/oa_pdf/f3/6e/aair-4-214.PMC3378928.pdf
"2012 July;4(4):214-221.  http://dx.doi.org/10.4168/aair.2012.4.4.214Volume 4, Number 4, July 2012 216 http://e-aair.orgLung function tests Airway responsiveness to methacholine was measured using  the OCP3000 body plethysmograph, as described previously.21  Briefly, the animals inhaled PBS aerosol and then progressively  doubled concentrations of methacholine (starting from 3.125  mg/mL and increasing to 100 mg/mL at 24-hour after the final  ovalbumin inhalation challenge).",Non-OADS,/arxiv_data1/oa_pdf/f3/6e/aair-4-214.PMC3378928.pdf
"2012 July;4(4):214-221.  http://dx.doi.org/10.4168/aair.2012.4.4.214AAIR  217 http://e-aair.orgvalues for the BCG, 4 μg Ag85, and 4 μg 38-kDa protein groups  were not significantly different than those for the normal con - trol group.",OADS,/arxiv_data1/oa_pdf/f3/6e/aair-4-214.PMC3378928.pdf
"2012 July;4(4):214-221.  http://dx.doi.org/10.4168/aair.2012.4.4.214Volume 4, Number 4, July 2012 218 http://e-aair.orgneutrophils/lymphocytes in all treatment groups were not sig - nificantly different than those in the asthma control group.",Non-OADS,/arxiv_data1/oa_pdf/f3/6e/aair-4-214.PMC3378928.pdf
2012 July;4(4):214-221.  http://dx.doi.org/10.4168/aair.2012.4.4.214AAIR  219 http://e-aair.organisms.,OADS,/arxiv_data1/oa_pdf/f3/6e/aair-4-214.PMC3378928.pdf
"2012 July;4(4):214-221.  http://dx.doi.org/10.4168/aair.2012.4.4.214Volume 4, Number 4, July 2012 220 http://e-aair.orgBecause cytokine levels in the splenocyte culture supernatants  may not exactly reflect the local airway status, it would be better  to measure cytokine levels directly in the airways.",Non-OADS,/arxiv_data1/oa_pdf/f3/6e/aair-4-214.PMC3378928.pdf
2012 July;4(4):214-221.  http://dx.doi.org/10.4168/aair.2012.4.4.214AAIR  221 http://e-aair.org25.,Non-OADS,/arxiv_data1/oa_pdf/f3/6e/aair-4-214.PMC3378928.pdf
"222 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org INTRODUCTION Both inflammation and structural changes may occur in aller - gic rhinitis (AR), and chronic eosinophilic inflammation is re - lated to the development of remodeling.1 Remodeling is char - acterized by epithelial fragility, reticular basement membrane  thickening, and an increase in vascularity, the number of fibro - blasts, and interstitial collagen as well as mucous gland hyper - trophy.2 Remodeling appears to be less extensive in the nose  than in the lower airways because of the differences in the se - cretory activity of smooth muscle cells that are present in the  bronchi but not in the nose.",Non-OADS,/arxiv_data1/oa_pdf/31/2f/aair-4-222.PMC3378929.pdf
2012 July;4(4):222-230. http://dx.doi.org/10.4168/aair.2012.4.4.222 pISSN 2092-7355 • eISSN 2092-7363 Purpose:   Periostin  was originally  identified  as a secreted  factor  during  screening  of a mouse  osteoblastic  library.,Non-OADS,/arxiv_data1/oa_pdf/31/2f/aair-4-222.PMC3378929.pdf
"Key Words:   Airway  remodeling;  allergy;  eosinophils;  mice;  periostin  protein;  rhinitisThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/31/2f/aair-4-222.PMC3378929.pdf
"2012 July;4(4):222-230.  http://dx.doi.org/10.4168/aair.2012.4.4.222AAIR  223 http://e-aair.orginvolvement in stimulating metastatic growth of cancer cells by  promoting cell survival, invasion, and angiogenesis.5,13-17 How - ever, there have been only a few studies on periostin in relation  to allergy, despite the common features of extensive tissue re - modeling seen in both heart failure after myocardial infarction  and allergic inflammation of airways.",Non-OADS,/arxiv_data1/oa_pdf/31/2f/aair-4-222.PMC3378929.pdf
"2012 July;4(4):222-230.  http://dx.doi.org/10.4168/aair.2012.4.4.222Volume 4, Number 4, July 2012 224 http://e-aair.orgPreparation for histology The experimental mice were sacrificed and decapitated after  being anesthetized by an intraperitoneal injection of Zoletil®  (tiletamine/zolazepam; Virbac, Carros Cedex, France).",Non-OADS,/arxiv_data1/oa_pdf/31/2f/aair-4-222.PMC3378929.pdf
2012 July;4(4):222-230.  http://dx.doi.org/10.4168/aair.2012.4.4.222AAIR  225 http://e-aair.orgchemistry (Fig.,OADS,/arxiv_data1/oa_pdf/31/2f/aair-4-222.PMC3378929.pdf
"2012 July;4(4):222-230.  http://dx.doi.org/10.4168/aair.2012.4.4.222Volume 4, Number 4, July 2012 226 http://e-aair.orgpoints ( P<0.05).",OADS,/arxiv_data1/oa_pdf/31/2f/aair-4-222.PMC3378929.pdf
2012 July;4(4):222-230.  http://dx.doi.org/10.4168/aair.2012.4.4.222AAIR  227 http://e-aair.org A DB EC F Fig.,Non-OADS,/arxiv_data1/oa_pdf/31/2f/aair-4-222.PMC3378929.pdf
"2012 July;4(4):222-230.  http://dx.doi.org/10.4168/aair.2012.4.4.222Volume 4, Number 4, July 2012 228 http://e-aair.orgthelial tissue in the nasal mucosa was significantly thinner in  the KO group than in the OVA groups.",Non-OADS,/arxiv_data1/oa_pdf/31/2f/aair-4-222.PMC3378929.pdf
2012 July;4(4):222-230.  http://dx.doi.org/10.4168/aair.2012.4.4.222AAIR  229 http://e-aair.orginduced by repeated allergen exposure.,OADS,/arxiv_data1/oa_pdf/31/2f/aair-4-222.PMC3378929.pdf
"2012 July;4(4):222-230.  http://dx.doi.org/10.4168/aair.2012.4.4.222Volume 4, Number 4, July 2012 230 http://e-aair.org25.",Non-OADS,/arxiv_data1/oa_pdf/31/2f/aair-4-222.PMC3378929.pdf
"231 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org INTRODUCTION Allergic rhinitis (AR) is an inflammatory disease of the nasal  mucosa caused by an allergen-IgE interaction in sensitized in - dividuals; it is characterized by the clinical symptoms of sneez - ing, itching, congestion, rhinorrhea, and nasal blockage.1,2 Asth - ma is characterized by chronic inflammation of the lower air - ways and shares several characteristics with AR.3,4 In both con - ditions, an inflammatory response is triggered by similar factors  such as allergens, leading to the increased production and re - lease of inflammatory mediators, including interleukin (IL)-4,  IL-5, IL-13, granulocyte-macrophage colony-stimulating factor,  histamine, leukotrienes, prostaglandins, eotaxin, and thymus Expression and Roles of MMP-2, MMP-9, MMP-13, TIMP-1, and  TIMP-2 in Allergic Nasal Mucosa Sachiko Mori,1 Ruby Pawankar,1,2* Chika Ozu,1 Manabu Nonaka,1 Toshiaki Yagi,1 Kimihiro Okubo1 Departments of Otorhinolaryngology1, Pediatrics2, Nippon Medical School, Tokyo, Japan and activation-regulated chemokine, as well as the upregulation  of adhesion molecules common to both asthma and AR.",Non-OADS,/arxiv_data1/oa_pdf/3e/fb/aair-4-231.PMC3378930.pdf
"2012 July;4(4):231-239. http://dx.doi.org/10.4168/aair.2012.4.4.231 pISSN 2092-7355 • eISSN 2092-7363 Purpose:   Allergic  rhinitis  (AR) and asthma  share  many  characteristics,  but structural  changes  are observed  far less often  in AR.",Non-OADS,/arxiv_data1/oa_pdf/3e/fb/aair-4-231.PMC3378930.pdf
"Key Words:   Allergic  rhinitis;  MMP;  TIMP;  cell infiltration;  mast  cells;  eosinophilsThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3e/fb/aair-4-231.PMC3378930.pdf
"2012 July;4(4):231-239.  http://dx.doi.org/10.4168/aair.2012.4.4.231Volume 4, Number 4, July 2012 232 http://e-aair.orginvolve traversing capillary vessel walls and the interstitium, and  require degradation of extracellular matrix (ECM) proteins by  secreted matrix metalloproteinases (MMPs),7 although the pre - cise underlying mechanism is not fully understood.",Non-OADS,/arxiv_data1/oa_pdf/3e/fb/aair-4-231.PMC3378930.pdf
"2012 July;4(4):231-239.  http://dx.doi.org/10.4168/aair.2012.4.4.231AAIR  233 http://e-aair.orgtions of PLP-fixed specimens were cut at 4 μm thickness using a  cryostat (Sakura Finetek, Tokyo, Japan), mounted on silane- coated slides, air-dried for 30 minutes, and then fixed in 100%  acetone for 10 minutes.",Non-OADS,/arxiv_data1/oa_pdf/3e/fb/aair-4-231.PMC3378930.pdf
"2012 July;4(4):231-239.  http://dx.doi.org/10.4168/aair.2012.4.4.231Volume 4, Number 4, July 2012 234 http://e-aair.orgshowed no immunoreactivity for MMP-2, MMP-9, MMP-13,  TIMP-1, or TIMP-2.",Non-OADS,/arxiv_data1/oa_pdf/3e/fb/aair-4-231.PMC3378930.pdf
2012 July;4(4):231-239.  http://dx.doi.org/10.4168/aair.2012.4.4.231AAIR  235 http://e-aair.orgNumber of cells expressing MMPs and TIMPs at 12 hours post- NAC The numbers of cells staining positive for MMPs and TIMPs in  the allergic nasal mucosa of PAR patients at 12 hours post-NAC  are shown in Fig.,Non-OADS,/arxiv_data1/oa_pdf/3e/fb/aair-4-231.PMC3378930.pdf
"2012 July;4(4):231-239.  http://dx.doi.org/10.4168/aair.2012.4.4.231Volume 4, Number 4, July 2012 236 http://e-aair.orgHDM-exposed mucosa were higher than the respective ratios  in the control-exposed mucosa at 6 hours after NAC, but the ra - tios did not differ significantly (Table).",OADS,/arxiv_data1/oa_pdf/3e/fb/aair-4-231.PMC3378930.pdf
"2012 July;4(4):231-239.  http://dx.doi.org/10.4168/aair.2012.4.4.231AAIR  237 http://e-aair.orgalso called 72-kDa gelatinase (gelatinase A) and 92-kDa gelati - nase (gelatinase B), respectively.",OADS,/arxiv_data1/oa_pdf/3e/fb/aair-4-231.PMC3378930.pdf
"2012 July;4(4):231-239.  http://dx.doi.org/10.4168/aair.2012.4.4.231Volume 4, Number 4, July 2012 238 http://e-aair.orgexhibited much higher MMP-9 expression and lower TIMP ex - pression compared with the present levels in nasal mucosa.22  Although the MMP-9-to-TIMP ratio was high after NAC in the  present study, it was still lower than that in nasal polyps (data  not shown).",Non-OADS,/arxiv_data1/oa_pdf/3e/fb/aair-4-231.PMC3378930.pdf
2012 July;4(4):231-239.  http://dx.doi.org/10.4168/aair.2012.4.4.231AAIR  239 http://e-aair.org25.,Non-OADS,/arxiv_data1/oa_pdf/3e/fb/aair-4-231.PMC3378930.pdf
"240 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org INTRODUCTION Acute interstitial pneumonia (AIP), a rapidly progressive re - spiratory disease that affects patients with no pre-existing lung  disease, is a lethal lung disease with a mortality rate of about  50%.1 Unclassified interstitial pneumonia with fibrosis, which is  not classified as a disease entity under the classification of in - terstitial lung diseases in adults,1 shows clinical and radiologi - cal findings that are similar with those of AIP .",Non-OADS,/arxiv_data1/oa_pdf/59/07/aair-4-240.PMC3378931.pdf
2012 July;4(4):240-244. http://dx.doi.org/10.4168/aair.2012.4.4.240 pISSN 2092-7355 • eISSN 2092-7363 Several children presenting with mild symptoms of respiratory tract infection were diagnosed with unclassified interstitial pneumonia with fibrosis.,Non-OADS,/arxiv_data1/oa_pdf/59/07/aair-4-240.PMC3378931.pdf
"Key Words:  Interstitial pneumonia; family; fibrosis; respiratory tract infections; environmentThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/59/07/aair-4-240.PMC3378931.pdf
2012 July;4(4):240-244.  http://dx.doi.org/10.4168/aair.2012.4.4.240AAIR  241 http://e-aair.orghistory of cough and dyspnea.,Non-OADS,/arxiv_data1/oa_pdf/59/07/aair-4-240.PMC3378931.pdf
"2012 July;4(4):240-244.  http://dx.doi.org/10.4168/aair.2012.4.4.240Volume 4, Number 4, July 2012 242 http://e-aair.organtibiotics.",Non-OADS,/arxiv_data1/oa_pdf/59/07/aair-4-240.PMC3378931.pdf
2012 July;4(4):240-244.  http://dx.doi.org/10.4168/aair.2012.4.4.240AAIR  243 http://e-aair.orggressive lung fibrosis.,Non-OADS,/arxiv_data1/oa_pdf/59/07/aair-4-240.PMC3378931.pdf
"2012 July;4(4):240-244.  http://dx.doi.org/10.4168/aair.2012.4.4.240Volume 4, Number 4, July 2012 244 http://e-aair.orgthat interstitial pneumonia may be associated with viral infec - tions; however, more investigation is needed in the future.",Non-OADS,/arxiv_data1/oa_pdf/59/07/aair-4-240.PMC3378931.pdf
"245 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org INTRODUCTION Approximately 40% of patients with chronic urticaria (CU)  have functional autoantibodies against Fc εRIa or IgE on mast  cells and basophils.1 The same antibodies play a role in the  pathogenesis of urticarial vasculitis (UV),2 a subtype of CU (2%- 20% of cases) that is more common in women (60%-80%).3 Antihistamines and systemic steroids are the most common  drugs used in the treatment of CU, but the response to therapy  is often incomplete.4 In patients with UV or antihistamine-re - sistant or steroid-dependent CU, immunomodulators such as  cyclosporin A, sulfasalazine, and hydroxychloroquine have  been shown to be effective in randomized controlled trials.3  However, there are concerns regarding the safety of these alter - native treatment regimens.",Non-OADS,/arxiv_data1/oa_pdf/f1/e1/aair-4-245.PMC3378932.pdf
2012 July;4(4):245-247. http://dx.doi.org/10.4168/aair.2012.4.4.245 pISSN 2092-7355 • eISSN 2092-7363 Immune complexes are found in the circulation of 30%-75% of patients with urticarial vasculitis and much evidence supports the role of these im - mune complexes in the pathogenesis of urticarial vasculitis.,Non-OADS,/arxiv_data1/oa_pdf/f1/e1/aair-4-245.PMC3378932.pdf
"Key Words:  Plasmapheresis; treatment; urticarial vasculitisThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f1/e1/aair-4-245.PMC3378932.pdf
"2012 July;4(4):245-247.  http://dx.doi.org/10.4168/aair.2012.4.4.245Volume 4, Number 4, July 2012 246 http://e-aair.orgTo obtain further information on the nature of her CU, we per - formed an autologous serum skin test (ASST), which was posi - tive.",OADS,/arxiv_data1/oa_pdf/f1/e1/aair-4-245.PMC3378932.pdf
2012 July;4(4):245-247.  http://dx.doi.org/10.4168/aair.2012.4.4.245AAIR  247 http://e-aair.orgnology; Global Allergy and Asthma European Network; European  Dermatology Forum; World Allergy Organization.,Non-OADS,/arxiv_data1/oa_pdf/f1/e1/aair-4-245.PMC3378932.pdf
N Z Med J 2004;117. http://www.nzma.org.nz/ journal/117-1197/957/ 3.,Non-OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
http://socialreport.msd.govt.,Non-OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
N Z Med J 2007;120. http://www.nzma.,Non-OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
N Z Med J 2006;119. http://www.nzma.org.nz/journal/119-1245/2318/ 6.,Non-OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
N Z Med J 2007;120. http://www.nzma.org.nz/journal/120-1265/2800/ 7.,Non-OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
N Z Med J 2007;120. http://www.nzma.org.nz/journal/120-1248/2387/ 8.,Non-OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
N Z Med J2006;119. http://www.nzma.org.nz/journal/119-1245/2308/ 9.,Non-OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
N Z Med J 2007;120. http://www.nzmj.com/journal/120-1257/2607 10.,Non-OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
2006. http://www.stats.govt.nz/Census/ 2006CensusHomePage/QuickStats/AboutAPlace/SnapShot.aspx?,OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
2006. http://www.stats.govt.nz/browse_for_stats/ people_and_communities/geographic-areas/urban-rural-proﬁle/deﬁning-urban-rural-nz.aspx (accessed 27 Mar 2012).,Non-OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
2006. http://www.stats.govt.nz/Census/ 2006CensusHomePage/QuickStats/AboutAPlace/SnapShot.aspx?,OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
2006. http://www.stats.govt.nz/Census/2006CensusHomePage/ QuickStats/AboutAPlace/SnapShot.aspx?id¼2000060&type ¼ta&ParentID ¼1000013 (accessed 27 Mar 2012).,OADS,/arxiv_data1/oa_pdf/ea/13/bmjopen-2011-000799.PMC3378934.pdf
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5939a1.htm (accessed Dec 2011).,OADS,/arxiv_data1/oa_pdf/20/2a/bmjopen-2011-000219.PMC3378935.pdf
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5718a3.htm (accessed 15 Jun 2010).,OADS,/arxiv_data1/oa_pdf/20/2a/bmjopen-2011-000219.PMC3378935.pdf
2009. http://www.nielsen.com/content/corporate/us/en/search.html?,Non-OADS,/arxiv_data1/oa_pdf/20/2a/bmjopen-2011-000219.PMC3378935.pdf
http://www.idf.org/ diabetesatlas/5e/foreword (accessed Dec 2011).,Non-OADS,/arxiv_data1/oa_pdf/20/2a/bmjopen-2011-000219.PMC3378935.pdf
2010. http://data.euro.who.int/hfadb/ 18.,OADS,/arxiv_data1/oa_pdf/5d/db/bmjopen-2012-001050.PMC3378936.pdf
http://www.uemo.eu/ gp-in-europe/86-portugal.html 19.,Non-OADS,/arxiv_data1/oa_pdf/5d/db/bmjopen-2012-001050.PMC3378936.pdf
http://www.rxpgonline.,Non-OADS,/arxiv_data1/oa_pdf/5d/db/bmjopen-2012-001050.PMC3378936.pdf
http://www.emea.europa.eu/pdfs/human/press/pr/ 36234805en.pdf (accessed 17 Nov 2005).,Non-OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
"National Institute for Clinical Excellence, 2011. http://publications.nice.org.uk/donepezil-galantamine-rivastigmine-and-memantine-for-the-treatment- of-alzheimers-disease-ta217/guidance (accessed 23 Mar 2012).Figure 4 Behaviour and mood (NPI).",Non-OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
"Institute for Quality and Efﬁciency in Healthcare (IQWiG), 2009. https://www.iqwig.de/download/A05-19C_Executive_ Summary_Memantine_in_Alzheimers_disease.pdf (Translation of the executive summary of the ﬁnal report “Memantin bei AlzheimerDemenz”) (accessed 23 Mar 2012).",Non-OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
"Institute for Quality and Efﬁciency in Healthcare (IQWiG), 2011. https://www.iqwig.de/download/A10-06_Executive-summary_Responder_ analyses_on_memantine_in_Alzheimers_disease.pdf (accessed 23 Mar 2012).",Non-OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
"Institute for Quality and Efﬁciency in Healthcare (IQWiG), 2010. https://www.iqwig.de/memantine-in-alzheimer-s-disease- reliable.1079.en.html (accessed 23 Mar 2012).",Non-OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
"National Institute for Clinical Excellence, 2010. http://guidance.nice.org.uk/TA/WaveR111/1/AssessmentReport (accessed 23 Mar 2012).",Non-OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
http://www.medicine.ox.ac.uk/alois/ (accessed 23 Mar 2012).,Non-OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
"Cochrane Dementia and Cognitive Improvement Group (CDCIG), 2010:4. http://onlinelibrary.wiley.com/ o/cochrane/clabout/articles/DEMENTIA/frame.html (accessed 23 Mar 2012).",OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
"Forest Laboratories Clinical Trials Registry, 2008.http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?",Non-OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
"H. Lundbeck A/S, 2012. http://www.lundbecktrials.com/Data/PDFs/10112_Final% 20CTRS_28May2010.pdf (accessed 23 Mar 2012).",Non-OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
"Forest Laboratories, Inc, 2010. http://news.frx.",Non-OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
http://www.nice.org.uk/nicemedia/live/12248/51068/ 51068.pdf (accessed 17 Aug 2010).,Non-OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
"Forest Laboratories Clinical Trials Registry, 2005. http://www.forestclinicaltrials.com/CTR/CTRController/ CTRViewPdf?_ﬁle_id ¼scsr/SCSR_MEM-MD-51_ﬁnal.pdf (accessed 23 Mar 2012).",OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
"Forest Laboratories Clinical Trials Registry, 2009. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_ﬁle_id ¼scsr/SCSR_MEM-MD- 54_ﬁnal.pdf (accessed 23 Mar 2012).",OADS,/arxiv_data1/oa_pdf/c3/a8/bmjopen-2012-000917.PMC3378937.pdf
https://toronto.bixi.com/ (accessed 5 Nov 2012).3.,Non-OADS,/arxiv_data1/oa_pdf/6d/df/bmjopen-2012-001049.PMC3378939.pdf
http://www.melbournebikeshare.,Non-OADS,/arxiv_data1/oa_pdf/6d/df/bmjopen-2012-001049.PMC3378939.pdf
To view these ﬁles pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2012-000965).,Non-OADS,/arxiv_data1/oa_pdf/0d/81/bmjopen-2012-000965.PMC3378941.pdf
To view these ﬁles please visitthe journal online (http://dx.doi.org/10.1136/ bmjopen-2012-001148).,Non-OADS,/arxiv_data1/oa_pdf/8a/02/bmjopen-2012-001148.PMC3378942.pdf
http://www.dst.dk/en (accessed Mar 2012).,Non-OADS,/arxiv_data1/oa_pdf/8a/02/bmjopen-2012-001148.PMC3378942.pdf
"University of Ulster, 2005. http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf (accessed Mar 2012).",Non-OADS,/arxiv_data1/oa_pdf/8a/02/bmjopen-2012-001148.PMC3378942.pdf
1997. http://www.archive.ofﬁcial-documents.co.uk/document/doh/ newnhs/wpaper1.htm (accessed 2005).,Non-OADS,/arxiv_data1/oa_pdf/ea/3b/bmjopen-2012-001025.PMC3378943.pdf
http://www.bized.ac.uk/dataserv/ons/ onshistory.htm (accessed 2005).,OADS,/arxiv_data1/oa_pdf/ea/3b/bmjopen-2012-001025.PMC3378943.pdf
http://www.connectingforhealth.nhs.uk/ systemsandservices/sus (accessed 2005).,Non-OADS,/arxiv_data1/oa_pdf/ea/3b/bmjopen-2012-001025.PMC3378943.pdf
http://www.statistics.gov.uk/about/classiﬁcations/ icd10/default.asp (accessed 2005).,OADS,/arxiv_data1/oa_pdf/ea/3b/bmjopen-2012-001025.PMC3378943.pdf
http://www.advisorybodies.doh.,Non-OADS,/arxiv_data1/oa_pdf/ea/3b/bmjopen-2012-001025.PMC3378943.pdf
2001. http://www.doh.,Non-OADS,/arxiv_data1/oa_pdf/ea/3b/bmjopen-2012-001025.PMC3378943.pdf
http://cdu.mimas.ac.,Non-OADS,/arxiv_data1/oa_pdf/6e/d3/bmjopen-2011-000737.PMC3378944.pdf
http://www.bhf.org.uk/ publications/view-publication.aspx?ps ¼1001735 (accessed Feb 2012).,Non-OADS,/arxiv_data1/oa_pdf/6e/d3/bmjopen-2011-000737.PMC3378944.pdf
"Edinburgh: Scottish Government, 2010. http://www.scotland.gov.uk/Resource/Doc/ 315880/0100454.pdf (accessed 16 Jan 2012).",Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
2011. http://wales.gov.uk/docs/phhs/ publications/110329working2en.pdf (accessed 16 Jan 2012).,Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
"London: Department of Health, 2009. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_094397.pdf (accessed 16 Jan 2012).",OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
"Cardiff: Welsh Assembly Government, 2008. http://new.wales.gov.uk/dphhp/publication/research/health-gain-targets/child/childhealth-exec-e.pdf?lang ¼en (accessed 16 Jan 2012).",Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
http://www.ons.,Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
"Cardiff: Welsh Assembly Government, 2011. http://wales.gov.uk/docs/caecd/research/110328cypmonitoren.pdf (accessed 16 Jan 2012).",Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
http://www.ohri.ca/programs/ clinical_epidemiology/oxford.htm (accessed 16 Jan 2012).,Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
2011. http://www.neighbourhood.statistics.gov.uk/dissemination/Info.,Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
2010. http://www.poverty.org.uk/20/index.shtml (accessed 16 Jan 2012).,Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
"Statistical Bulletin .N e w p o r t :O f ﬁ c e for National Statistics, 2009. http://www.ons.gov.uk/ons/rel/child-health/ gestation-speciﬁc-infant-mortality-in-england-and-wales/2006/stb- gestation-speciﬁc-infant-mortality e2006.html (accessed 16 Jan 2012).",Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
"London: Department for Education and Skills, 2006. http://media.education.gov.uk/assets/ﬁles/pdf/t/teenage%20pregnancy%20%20%20accelerating%20the% 20strategy%20to%202010.pdf (accessed 16 Jan 2012).",Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
"Ireland: Institute of Public Health in Ireland, 2006. http://www.publichealth.ie/ ﬁles/ﬁle/Unequal_at_Birth.pdf (accessed 16 Jan 2012).",Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
"Alberta, Canada: Institute of Health Economics, 2008. http://www.ihe.ca/documents/IHE%20Report%20LowBirthWeight%20ﬁnal.pdf (accessed 16 Jan 2012).",Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
"London: The Stationary Ofﬁce Limited, 2009. http://www.publications.parliament.uk/pa/cm200809/cmselect/ cmhealth/286/286.pdf (accessed 16 Jan 2012).",Non-OADS,/arxiv_data1/oa_pdf/39/ab/bmjopen-2012-000964.PMC3378945.pdf
To view these ﬁles please visitthe journal online (http://dx.doi.org/10.1136/ bmjopen-2012-001124).,Non-OADS,/arxiv_data1/oa_pdf/9e/2e/bmjopen-2012-001124.PMC3378946.pdf
Competing interests All authors have completed t he Uniﬁed Competing Interest form at http://www.icmje.o rg/coi_disclosure.pdf (available on request from the corresponding author).,Non-OADS,/arxiv_data1/oa_pdf/9e/2e/bmjopen-2012-001124.PMC3378946.pdf
Data sharing statement The sequences reported in this paper have been deposited in the European Nucleotide Archive Sequence Read Archive understudy accession number ERP001413 (http://www.ebi.ac.,OADS,/arxiv_data1/oa_pdf/9e/2e/bmjopen-2012-001124.PMC3378946.pdf
http://www.eucast.org/ﬁleadmin/src/media/PDFs/ EUCAST_ﬁles/Disk_test_documents/ EUCAST_breakpoints_v_2.0_120101.pdf (accessed 20 Jan 2012).,OADS,/arxiv_data1/oa_pdf/9e/2e/bmjopen-2012-001124.PMC3378946.pdf
"Hui and others 244 E2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.or g/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/dc/ec/an004e091.PMC3379000.pdf
"Since the basic region ofEndolysosomes and HIV-1 Tat neurotoxicity E2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.or g/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.245",Non-OADS,/arxiv_data1/oa_pdf/dc/ec/an004e091.PMC3379000.pdf
"Hui and others 246 E2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.or g/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/dc/ec/an004e091.PMC3379000.pdf
"(B,D,F) HIV-1 Tat (100 nM) decreased significantly specific enzyme activity of ACP, Cat B and Cat D ( n54).Endolysosomes and HIV-1 Tat neurotoxicity E2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.or g/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.247",Non-OADS,/arxiv_data1/oa_pdf/dc/ec/an004e091.PMC3379000.pdf
"Hui and others 248 E2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.or g/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/dc/ec/an004e091.PMC3379000.pdf
"Although the underlying mechanisms whereby HIV-1 Tat elevates endolysosome pH are unknown, the arginine-rich domain of HIV-1 Tat between amino acid residues 49 and 57 could be responsible for HIV-1 Tat-induced elevation ofendolysosome pH because a series of other arginine-richpeptides including penetratin, an amino acid domain fromthe Antennapedia protein (sequences 43–58) of Drosophila , a flock house virus coat peptide (sequences 35–49) and oligo-arginines (R9) all have the ability to elevate endolysosomeEndolysosomes and HIV-1 Tat neurotoxicity E2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.or g/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.249",Non-OADS,/arxiv_data1/oa_pdf/dc/ec/an004e091.PMC3379000.pdf
"Hui and others 250 E2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.or g/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/dc/ec/an004e091.PMC3379000.pdf
"J Biol Chem 284:22736–22746.Endolysosomes and HIV-1 Tat neurotoxicity E2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.or g/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.251",Non-OADS,/arxiv_data1/oa_pdf/dc/ec/an004e091.PMC3379000.pdf
"Hui and others 252 E2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.or g/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/dc/ec/an004e091.PMC3379000.pdf
"The Illumina sequencing data was screened for novel or rare homoplasmic variants using the following criteria: (1) coverage for a position was greater than 500 , the called allele was not the 1http://www.phylotree.orgreference allele, (2) the% call at the variant position was >96%, and (3) the mutation had a reported incidence less than 1% in PhyloTree Build 12 (van Oven and Kayser, 2009), or in a total of 5,102 downloaded sequences from GenBank,or the mtDB-Human Mitochondrial Genome Database (Ingman and Gyllensten, 2006).",Non-OADS,/arxiv_data1/oa_pdf/62/03/fgene-03-00103.PMC3379031.pdf
2https://www.affymetrix.com/analysis/netaffx Frontiers in Genetics | Behavioral and Psychiatric Genetics June 2012 | Volume 3 | Article 103 | 4,Non-OADS,/arxiv_data1/oa_pdf/62/03/fgene-03-00103.PMC3379031.pdf
"In summary, there were seven novel mutations in Cohort 3: four novel mutations in the 10 con- trol subjects, one novel mutation in the four SZ subjects, one novel 3http://www.mitomap.org www.frontiersin.org June 2012 | Volume 3 | Article 103 | 5",Non-OADS,/arxiv_data1/oa_pdf/62/03/fgene-03-00103.PMC3379031.pdf
A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk.,OADS,/arxiv_data1/oa_pdf/62/03/fgene-03-00103.PMC3379031.pdf
The datasets used for the analyses described in this manuscript were obtained from the dbGaP found at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession num- bers (phs000017.v3.p1).,Non-OADS,/arxiv_data1/oa_pdf/62/03/fgene-03-00103.PMC3379031.pdf
The datasets used for the analyses described in this man- uscript were obtained from the database of Genotypes and Phenotypes (dbGaP) found at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number (phs000021.v3.p2).,OADS,/arxiv_data1/oa_pdf/62/03/fgene-03-00103.PMC3379031.pdf
"SUPPLEMENTARY MATERIAL The Supplementary Material for this article can be found online at http://www.frontiersin.org/Behavioral_and_Psychiatric_ Genetics/10.3389/fgene.2012.00103/abstract REFERENCES Amar, S., Shamir, A., Ovadia, O., Bla- naru, M., Reshef, A., Kremer, I., Rietschel, M., Schulze, T. G., Maier, W., Belmaker, R. H., Ebstein, R. P ., Agam, G., and Mishmar, D. (2007).",Non-OADS,/arxiv_data1/oa_pdf/62/03/fgene-03-00103.PMC3379031.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Nagali, E. et al.",Non-OADS,/arxiv_data1/oa_pdf/b8/7e/srep00443.PMC3379168.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and repr oduction in any medium, provided the  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/57/4c/TODENTJ-6-90.PMC3379539.pdf
"1http://www.millipore.com/techpublications/tech1/tn0087en00SEQUENCE ANNOTATION Protein coding sequences were identiﬁed using Glimmer v3 (Delcher et al., 2007 ), blastx searches of public protein databases (GenBank nr and env_nr), the IMG/M metagenome analysis sys-tem ( Markowitz et al., 2008 ) and the pedant software system 2.",OADS,/arxiv_data1/oa_pdf/8c/b7/fmicb-03-00208.PMC3379541.pdf
Six fosmids were positive for 16S 2http://pedant.gsf.de 3http://www-is.biotoul.fr/is.html www.frontiersin.org June 2012 | Volume 3 | Article 208 | 3,Non-OADS,/arxiv_data1/oa_pdf/8c/b7/fmicb-03-00208.PMC3379541.pdf
"SUPPLEMENTARY MATERIAL The Supplementary Material for this article can be found onlineat:http://www.frontiersin.org/T errestrial_Microbiology/10.3389/ fmicb.2012.00208/abstract T able S1 | Predicted RNA and protein encoding genes in thaumarchaeal fosmids 02j05, 05d18, 10c16, 19c08, and 22i07 .",Non-OADS,/arxiv_data1/oa_pdf/8c/b7/fmicb-03-00208.PMC3379541.pdf
"C/circlecopyrtThe Authors Journal compilation C/circlecopyrt2012 Biochemical Societywww.clinsci.org Clinical Science © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/19/cs1220349.PMC3379561.pdf
"C/circlecopyrtThe Authors Journal compilation C/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/19/cs1220349.PMC3379561.pdf
"Immunoﬂuorescent analysis of BeWo and JEG-3 cells BeWo and JEG-3 cells were ﬁxed in 4% paraform- aldehyde for 10 min prior to washes in PBS and C/circlecopyrtThe Authors Journal compilation C/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/19/cs1220349.PMC3379561.pdf
"From the 23 placentas, 13 C/circlecopyrtThe Authors Journal compilation C/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/19/cs1220349.PMC3379561.pdf
"Cellular localization of DEPTOR, mTOR, rictor and raptor in human placenta Immunoﬂuorescent analysis of the mTOR signalling components in human placental tissue sections revealed the cellular localization and distribution of each of the C/circlecopyrtThe Authors Journal compilation C/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/19/cs1220349.PMC3379561.pdf
"Pregnancy is associated with major C/circlecopyrtThe Authors Journal compilation C/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/19/cs1220349.PMC3379561.pdf
"The authors concluded that there were substantial differences of prenatal life events stress in the third trimester of pregnancy, as a function of educational C/circlecopyrtThe Authors Journal compilation C/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/19/cs1220349.PMC3379561.pdf
"In preterm C/circlecopyrtThe Authors Journal compilation C/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/19/cs1220349.PMC3379561.pdf
"Moreover, the impact of this treatment C/circlecopyrtThe Authors Journal compilation C/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/19/cs1220349.PMC3379561.pdf
"U.S.A. 103, 3938–3942 C/circlecopyrtThe Authors Journal compilation C/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/19/cs1220349.PMC3379561.pdf
"Placenta 30, 1002–1003 Received 27 July 2011/6 October 2011; accepted 13 October 2011 Published as Immediate Publication 13 October 2011, doi:10.1042/CS20110378 C/circlecopyrtThe Authors Journal compilation C/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/19/cs1220349.PMC3379561.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/9c/ea/1578.PMC3379574.pdf
"Corresponding author: Rachel Dankner, rdankner@gertner.health.gov.il.Received 9 August 2011 and accepted 12 March 2012.DOI: 10.2337/dc11-1513This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/DC11-1513/-/DC1.",Non-OADS,/arxiv_data1/oa_pdf/de/10/1538.PMC3379575.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/de/10/1538.PMC3379575.pdf
"NCT00000620, clinicaltrials.gov.This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-1827/-/DC1.",Non-OADS,/arxiv_data1/oa_pdf/b1/ea/1401.PMC3379577.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/b1/ea/1401.PMC3379577.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/4b/17/1429.PMC3379578.pdf
Spectrawere analyzed using LCModel software (version 6.2-1; http://s-provench-er.com) thatﬁts in vivo metabolite spectra using model resonances acquired under compa- rable scanning conditions from multiple compounds in standard phantom solu-tions (22).,OADS,/arxiv_data1/oa_pdf/4b/17/1429.PMC3379578.pdf
"Corresponding author: Deborah J. Wexler, dwexler@partners.org.Received 21 November 2011 and accepted 8 March 2012.DOI: 10.2337/dc11-2266This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-2266/-/DC1.",Non-OADS,/arxiv_data1/oa_pdf/e0/d8/1575.PMC3379579.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/e0/d8/1575.PMC3379579.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/7e/20/1585.PMC3379580.pdf
"NCT00856986, clinicaltrials.gov.This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-1928/-/DC1.",Non-OADS,/arxiv_data1/oa_pdf/5b/9e/1446.PMC3379583.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/5b/9e/1446.PMC3379583.pdf
Avail-able from http://www.ich.org/ ﬁleadmin/ Public_Web_Site/ICH_Products/Guidelines/Efﬁcacy/E6_R1/Step4/E6_R1__Guideline.,Non-OADS,/arxiv_data1/oa_pdf/5b/9e/1446.PMC3379583.pdf
Available from http://www.wma.net/en/30publications/10policies/ b3/index.html.,Non-OADS,/arxiv_data1/oa_pdf/5b/9e/1446.PMC3379583.pdf
Received 9 December 2011 and accepted 2 March 2012.DOI: 10.2337/dc11-2396This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-2396/-/DC1.,Non-OADS,/arxiv_data1/oa_pdf/dc/96/1519.PMC3379584.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/dc/96/1519.PMC3379584.pdf
(26) and at http://www.atsdr.,Non-OADS,/arxiv_data1/oa_pdf/dc/96/1519.PMC3379584.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/9e/bb/1406.PMC3379585.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/6b/2e/1466.PMC3379588.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/be/8f/1499.PMC3379589.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/b5/cb/1479.PMC3379590.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/a0/7c/1492.PMC3379591.pdf
"(22), using a publicly available SAS Macro (http://www.hsph.harvard.edu/faculty/donna-spiegelman/software/par/index.html).",OADS,/arxiv_data1/oa_pdf/a0/7c/1492.PMC3379591.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/0e/ea/1532.PMC3379592.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/29/2a/1556.PMC3379593.pdf
Available from http://apps.nccd.cdc.gov/DDTSTRS/NationalSurvData.,OADS,/arxiv_data1/oa_pdf/29/2a/1556.PMC3379593.pdf
Available from http://www.nhlbi.nih.gov/about/nhbpep/ nhbp_pd.htm.,OADS,/arxiv_data1/oa_pdf/29/2a/1556.PMC3379593.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/75/3a/1420.PMC3379595.pdf
"NCT00324350, clinicaltrials.gov.This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-2184/-/DC1.",Non-OADS,/arxiv_data1/oa_pdf/19/29/1525.PMC3379596.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/19/29/1525.PMC3379596.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/69/89/1552.PMC3379597.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/94/7d/1566.PMC3379598.pdf
Availablefrom http://www.cdc.gov/diabetes/pubs/ pdf/ndfs_2011.pdf.,Non-OADS,/arxiv_data1/oa_pdf/94/7d/1566.PMC3379598.pdf
Available from http://www.census.gov/ prod/2009pubs/p60-236.pdf.,OADS,/arxiv_data1/oa_pdf/94/7d/1566.PMC3379598.pdf
"Health insurance coverage: early release of estimates from the National Health Interview Survey, January-September 2010 [article online], 2011.Available from http://www.cdc.gov/nchs/ data/nhis/earlyrelea se/insur200903.htm.",OADS,/arxiv_data1/oa_pdf/94/7d/1566.PMC3379598.pdf
Available from http://www.cdc.gov/nchs/nhanes.htm.,OADS,/arxiv_data1/oa_pdf/94/7d/1566.PMC3379598.pdf
Available from http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf.Accessed 24 February 2011 28.,Non-OADS,/arxiv_data1/oa_pdf/94/7d/1566.PMC3379598.pdf
"NCT00683878, clinicaltrials.gov.This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-1693/-/DC1.",Non-OADS,/arxiv_data1/oa_pdf/c2/af/1473.PMC3379599.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/c2/af/1473.PMC3379599.pdf
Available from http://www.actos.,Non-OADS,/arxiv_data1/oa_pdf/c2/af/1473.PMC3379599.pdf
"Corresponding author: Eric Ravussin, eric.ravussin@pbrc.edu.Received 2 December 2011 and accepted 23 February 2012.DOI: 10.2337/dc11-2339This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-2339/-/DC1.",Non-OADS,/arxiv_data1/oa_pdf/52/5b/1605.PMC3379600.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/52/5b/1605.PMC3379600.pdf
"Corresponding author: Christie M. Ballantyne, cmb@bcm.tmc.edu.Received 15 October 2011 and accepted 5 March 2012.DOI: 10.2337/dc11-1957This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-1957/-/DC1.",Non-OADS,/arxiv_data1/oa_pdf/ac/eb/1513.PMC3379601.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/ac/eb/1513.PMC3379601.pdf
Users can downloadand subscribe to the podcast via iTunes at http://itunes.apple.com/us/podcast/ diabetes-core-update/id501572453.,Non-OADS,/arxiv_data1/oa_pdf/71/39/1397.PMC3379602.pdf
The app can be freely downloaded fromiTunes at http://itunes.apple.com/us/app/journals-american-diabetes/id52118 7781?mt=8.,Non-OADS,/arxiv_data1/oa_pdf/71/39/1397.PMC3379602.pdf
"Now, search-able PDF ﬁles of all articles dating back to theﬁrst issue in 1978 of Diabetes Care are accessible at http://care.diabetesjournals.",Non-OADS,/arxiv_data1/oa_pdf/71/39/1397.PMC3379602.pdf
Received 11 August 2011 and accepted 6 March 2012.DOI: 10.2337/dc11-1531This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-1531/-/DC1.,Non-OADS,/arxiv_data1/oa_pdf/1c/c8/1598.PMC3379603.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/1c/c8/1598.PMC3379603.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/78/75/1591.PMC3379604.pdf
"Corresponding author: Emily D. Williams, emily.d.williams@monash.edu.Received 26 July 2011 and accepted 1 March 2012.DOI: 10.2337/dc11-1410This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-1410/-/DC1.",Non-OADS,/arxiv_data1/oa_pdf/91/c9/1455.PMC3379605.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/91/c9/1455.PMC3379605.pdf
Available from http://www.ausstats.abs.gov.au/ausstats/free.nsf/0/A5561C69BF600637CA 256E20007B5DF1/$File/2039055001_2001.,Non-OADS,/arxiv_data1/oa_pdf/91/c9/1455.PMC3379605.pdf
Received 28 October 2011 and accepted 27 February 2012.DOI: 10.2337/dc11-2108This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-2108/-/DC1.,Non-OADS,/arxiv_data1/oa_pdf/64/b0/1485.PMC3379607.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/64/b0/1485.PMC3379607.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/7e/70/1462.PMC3379608.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/38/da/1413.PMC3379609.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/f0/ff/1572.PMC3379611.pdf
Available from http://www.cdc.gov/nchs/data_access/VitalStatsOnline.,OADS,/arxiv_data1/oa_pdf/f0/ff/1572.PMC3379611.pdf
Available from http://www.who.int/classi ﬁcations/icd/ICD-10_2nd_ed_ volume2.pdf.,Non-OADS,/arxiv_data1/oa_pdf/f0/ff/1572.PMC3379611.pdf
Received 13 December 2011 and accepted 9 March 2012.DOI: 10.2337/dc11-2420This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-2420/-/DC1.,Non-OADS,/arxiv_data1/oa_pdf/5f/8a/1482.PMC3379612.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/5f/8a/1482.PMC3379612.pdf
DOI: 10.2337/dc11-2060 This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-2060/-/DC1.,Non-OADS,/arxiv_data1/oa_pdf/99/df/1506.PMC3379613.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/99/df/1506.PMC3379613.pdf
"As the variance es- timation did not support collapse over sex groups (data not shown), we performed bivariate Cholesky s tructural equation models (SEMs) by sex using Mx soft- ware (http://www.psy.vu.nl/mxbib).",OADS,/arxiv_data1/oa_pdf/99/df/1506.PMC3379613.pdf
Available from http://www.idf.org/node/23563.,Non-OADS,/arxiv_data1/oa_pdf/99/df/1506.PMC3379613.pdf
Available from http://www.fda.gov/medWatch/report/DESK/advevnt.htm.,OADS,/arxiv_data1/oa_pdf/91/df/1436.PMC3379615.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/82/d9/1611.PMC3379616.pdf
"Corresponding author: Kyong Park, kypark@ynu.ac.kr.Received 2 November 2011 and accepted 11 March 2012.DOI: 10.2337/dc11-2136This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10 .2337/dc11-2136/-/DC1.",Non-OADS,/arxiv_data1/oa_pdf/f3/49/1544.PMC3379617.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/f3/49/1544.PMC3379617.pdf
"The CalCOFI group collected oceanographic metadataincluding temperature, salinity, pH, chlorophyllfluorescence, nutrients, oxygen, primary productionand phytoplankton and zooplankton biomass and biodiversity estimates (http://www.calcofi.org).",OADS,/arxiv_data1/oa_pdf/b9/fa/ismej2011201a.PMC3379637.pdf
"Each reference protein from all genomes,expressed sequence tags and viral metagenomics data sets was BLAST against a database of annotated proteins from NCBI (ftp://ftp.ncbi.nih.gov/pub/COG/ COG/ and ftp://ftp.ncbi.nih.gov/pub/COG/KOG/).",OADS,/arxiv_data1/oa_pdf/b9/fa/ismej2011201a.PMC3379637.pdf
"To view acopy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies the paper on The I SME Journal website (http://www.nature.com/ismej)Microbial metagenomics across an upwelling mosaic LZ Allen et al 1414 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/b9/fa/ismej2011201a.PMC3379637.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Supplementary Information accompanies the paper on Th e ISME Journal website (http://www.nature.com/ismej)B4galnt2 influences the intestinal microbiota F Staubach et al 1355 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/6e/b3/ismej2011204a.PMC3379640.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Supplementary Information accompanies the paper on The IS ME Journal website (http://www.nature.com/ismej)Primer choice for 16S taxonomic classification DAW Soergel et al 1444 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/69/1f/ismej2011208a.PMC3379642.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/ab/22/1659.PMC3379645.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/dd/eb/1869.PMC3379646.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/c3/0c/1860.PMC3379647.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/c7/63/1848.PMC3379648.pdf
Available from http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c7/63/1848.PMC3379648.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/20/a6/1895.PMC3379649.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/ca/fe/1719.PMC3379650.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/8b/57/1888.PMC3379651.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/b4/3f/1664.PMC3379652.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/fe/a6/e11.PMC3379653.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/60/81/e9.PMC3379654.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/46/b3/e8.PMC3379655.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/b8/7c/e7.PMC3379656.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/c9/04/1667.PMC3379657.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/89/0a/1879.PMC3379658.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/42/1a/1779.PMC3379659.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/93/4e/1700.PMC3379660.pdf
"See  http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.DIGESTS diabetes.diabetesjournals.org DIABETES, VOL.",Non-OADS,/arxiv_data1/oa_pdf/b7/49/1904.PMC3379661.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/54/a3/1801.PMC3379662.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/25/36/1726.PMC3379663.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/44/ed/1656.PMC3379664.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/bf/69/1691.PMC3379665.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/41/fe/1708.PMC3379666.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/04/41/1793.PMC3379667.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/8a/01/1742.PMC3379668.pdf
The transcription factor Onecut2 is a predicted target of miR-29a/b/c (http://www.targetscan.org) (35).,Non-OADS,/arxiv_data1/oa_pdf/8a/01/1742.PMC3379668.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/67/a3/1760.PMC3379669.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/e4/c6/1653.PMC3379670.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/64/07/1734.PMC3379671.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/ca/66/e6.PMC3379672.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/6e/fa/e10.PMC3379673.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/34/c4/1769.PMC3379675.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/c7/95/1831.PMC3379676.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/8d/c4/1838.PMC3379677.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/1e/2a/1752.PMC3379678.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/f6/1a/1661.PMC3379679.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/2b/c0/1680.PMC3379680.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/d8/f2/1669.PMC3379681.pdf
"We used fractional amplitude of LFFs, which is a reliable andconsistent index (23) to study intrinsic neuronal activity before and after3 months of SFA- or MUFA-enriched diet (http://resting-fmri.sourceforge.net).For statistical analysis, a one-way ANOVA was used to analyze the main effect of fat-enriched diet by using the difference between the normalized whole- brain fractional amplitude of LFF maps of the pre- and postmeasurement.APvalue of ,0.001 was considered statistically signi ﬁcant.",OADS,/arxiv_data1/oa_pdf/d8/f2/1669.PMC3379681.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/05/a9/1822.PMC3379682.pdf
Available from http://www.mesa-nhlbi.org/CACReference.,Non-OADS,/arxiv_data1/oa_pdf/05/a9/1822.PMC3379682.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/ee/e4/1814.PMC3379683.pdf
The Software Library (FSL 4.1) of the Functional MRI of the Brain (FMRIB) (http://www.fmrib.ox.ac.uk/fsl) was used for these analyses.,OADS,/arxiv_data1/oa_pdf/ee/e4/1814.PMC3379683.pdf
See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/24/32/1785.PMC3379684.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in an y medium, provided the original work is properly cited.1 Citation: Int J Qualitative Stud Health Well-being 2012, 7: 17726 - http://dx.doi.org/10.3402/qhw.v7i0.17726",Non-OADS,/arxiv_data1/oa_pdf/3b/26/QHW-7-17726.PMC3379790.pdf
2 (page number not for citation purpose)Citation: Int J Qualitative Stud Health Well-being 2012; 7:17726 - http://dx.doi.org/10.3402/qhw.v7i0.17726,Non-OADS,/arxiv_data1/oa_pdf/3b/26/QHW-7-17726.PMC3379790.pdf
"Being competent, ambivalent and creative at the same time The main theme consisted of three subthemes: being a digital native for better and for worse,knowing what’s healthy and sometimes doing it,Swedish adolescents and health promotion Citation: Int J Qualitative Stud Health Well-being 2012; 7:17726 - http://dx.doi.org/10.3402/qhw.v7i0.17726 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/3b/26/QHW-7-17726.PMC3379790.pdf
4 (page number not for citation purpose)Citation: Int J Qualitative Stud Health Well-being 2012; 7:17726 - http://dx.doi.org/10.3402/qhw.v7i0.17726,Non-OADS,/arxiv_data1/oa_pdf/3b/26/QHW-7-17726.PMC3379790.pdf
6:3 Someone I know has done it for about half aSwedish adolescents and health promotion Citation: Int J Qualitative Stud Health Well-being 2012; 7:17726 - http://dx.doi.org/10.3402/qhw.v7i0.17726 5 (page number not for citation purpose),Non-OADS,/arxiv_data1/oa_pdf/3b/26/QHW-7-17726.PMC3379790.pdf
6 (page number not for citation purpose)Citation: Int J Qualitative Stud Health Well-being 2012; 7:17726 - http://dx.doi.org/10.3402/qhw.v7i0.17726,Non-OADS,/arxiv_data1/oa_pdf/3b/26/QHW-7-17726.PMC3379790.pdf
"Thus, we conclude that, in our study the students were already quite well informed on many aspects ofhealth promotion, and they were able to prioritizeSwedish adolescents and health promotion Citation: Int J Qualitative Stud Health Well-being 2012; 7:17726 - http://dx.doi.org/10.3402/qhw.v7i0.17726 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/3b/26/QHW-7-17726.PMC3379790.pdf
8 (page number not for citation purpose)Citation: Int J Qualitative Stud Health Well-being 2012; 7:17726 - http://dx.doi.org/10.3402/qhw.v7i0.17726,Non-OADS,/arxiv_data1/oa_pdf/3b/26/QHW-7-17726.PMC3379790.pdf
"W omen’s Studies International Forum ,21(1), 111 /C1125.Swedish adolescents and health promotion Citation: Int J Qualitative Stud Health Well-being 2012; 7:17726 - http://dx.doi.org/10.3402/qhw.v7i0.17726 9 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/3b/26/QHW-7-17726.PMC3379790.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-CommercialLicense (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a4/14/nos112.PMC3379799.pdf
Tremor Other Hyperkinet Mov 2012;2: http://tremorjournal.org/article/view/47 * To whom correspondence should be addressed.,Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"These charts were reviewed by a fourth year neurologyresident (R.M.S), with special interest and training in MovementFreely available online Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services1",OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
Parkinson’s Disease and Essential Tremor Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services2,Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services3,Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"Co-occurrence of essential tremor and Parkinson’s disease: clinical study of a large kindred with autopsy findings.Parkinsonism Relat Disord 2003;9:225–231, http://dx.doi.org/10.1016/S1353- 8020(02)00057-3.2.Tan EK, Lee SS, Fook-Chong S, Lum SY.",OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"Parkinsonism Relat Disord 2007;13:67–76, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"Mov Disord 2008;23: 1602–1605, http://dx.doi.org/10.1002/mds.22161.",OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"Ann Neurol 1985;17:329–333, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"J Neurol Neurosurg Psychiatry 2009;80:423–425, http://dx.doi.org/10.1136/jnnp.2008.",Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"Ann Neurol 1997;41:222–229, http://dx.doi.org/10.1002/ ana.410410213.Table 1.Continued ETRPD (n518) ET (n 520) PD (n 530) Significance (p) UPDRS – finger tapping (mean ¡SD)51.1¡0.74– 1.5 ¡0.740.102 UPDRS – rigidity upper limb (mean ¡SD)51.1¡0.54– 1.4 ¡0.640.102 UPDRS – pull test (mean ¡SD) 0.5 ¡0.64– 0.2 ¡0.440.252 UPDRS total (mean ¡SD) 22.4 ¡14.84– 30.4 ¡17.640.142 Hoehn and Yahr score (mean ¡SD) 2.2 ¡0.7 – 2.0 ¡0.4 0.222 Schwab and England score (mean ¡SD) 91.8 ¡7.24– 87.9 ¡8.740.152 % are related to the available data; Statistical tests used:1ANOVA,2t-test, and3Chi-square.",Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
Parkinson’s Disease and Essential Tremor Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services4,Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"Mov Disord 2005;20:S172, http://dx.doi.org/10.1002/mds.20302.",OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"Mov Disord 2007;22:414–417, http://dx.doi.org/10.1002/ mds.21344.",OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"Brain 2007;130(Pt 12): 3297–3307, http://dx.doi.org/10.1093/brain/awm266.",Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"Neurology 2006;66:1756–1759, http://dx.doi.org/10.1212/01.wnl.0000218162.80315.b9.17.Louis ED, Honig LS, Vonsattel JP, Maraganore DM, Borden S, Moskowitz CB.",Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"Arch Neurol 2005;62:1004–1007, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"Arch Neurol 1991;48:1049–1051, http://dx.doi.org/10.1001/archneur.",Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"JN e u r a lT r a n s m 1986;67:1–14, http://dx.doi.org/10.1007/ BF01243355.Parkinson’s Disease and Essential Tremor Simo˜es RM, Constantino A, Gibadullina E, et al.",Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services5,Non-OADS,/arxiv_data1/oa_pdf/52/f5/tre-02-47-149-3.PMC3379814.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/46/7a/jir857.PMC3379837.pdf
"This is an Open Access article distributedunder the terms of the Creative Commons Attribution Non-Commercial License(http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.DOI: 10.1093/infdis/jis331 220JID 2012:206 (15 July) Mejia et al",Non-OADS,/arxiv_data1/oa_pdf/2e/02/jis331.PMC3379838.pdf
Maximum likelihood phylogenetic trees were constructed with PhyML ( http://www.atgc-montpellier.fr/phyml ) using HKY85 as the nucleotides substitution model with bootstrapping(Geneious Pro 5.1.4 software).,OADS,/arxiv_data1/oa_pdf/70/d2/jis337.PMC3379839.pdf
All human A(H1N1)pdm09 NA sequences containing date information (at least year/month) were downloaded from the National Center for Biotechnology Information in ﬂuenza virus resource [ 41](http://www.ncbi.nlm.nih.gov/genomes/FLU/ ) and GISAID ( http://www.gisaid.org ) and merged with the ones reported in this study (keeping only 1 per unique strain identi ﬁer).,OADS,/arxiv_data1/oa_pdf/70/d2/jis337.PMC3379839.pdf
"Summary of in ﬂuenza antiviral susceptibility surveillance ﬁndings, September2010 –March 2011. http://www.who.int/in ﬂuenza/gisrs_laboratory/ updates/antiviral_susceptibility_20110606/en/index.html .",OADS,/arxiv_data1/oa_pdf/70/d2/jis337.PMC3379839.pdf
Revised February 2010. http://www.who.int/csr/resources/publications/swine ﬂu/ h1n1_guidelines_pharmaceutical_mngt.pdf .,Non-OADS,/arxiv_data1/oa_pdf/70/d2/jis337.PMC3379839.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in an y medium, provided the original work is properly cited.1 Citation: Int J Qualitative Stud Health Well-being 2012, 7: 15471 - http://dx.doi.org/10.3402/qhw.v7i0.15471",Non-OADS,/arxiv_data1/oa_pdf/0f/7a/QHW-7-15471.PMC3379843.pdf
Ahlqwist & C. Sa ¨llfors 2 (page number not for citation purpose)Citation: Int J Qualitative Stud Health Well-being 2012; 7:15471 - http://dx.doi.org/10.3402/qhw.v7i0.15471,OADS,/arxiv_data1/oa_pdf/0f/7a/QHW-7-15471.PMC3379843.pdf
A coreLow back pain in adolescents Citation: Int J Qualitative Stud Health Well-being 2012; 7:15471 - http://dx.doi.org/10.3402/qhw.v7i0.15471 3 (page number not for citation purpose),Non-OADS,/arxiv_data1/oa_pdf/0f/7a/QHW-7-15471.PMC3379843.pdf
Ahlqwist & C. Sa ¨llfors 4 (page number not for citation purpose)Citation: Int J Qualitative Stud Health Well-being 2012; 7:15471 - http://dx.doi.org/10.3402/qhw.v7i0.15471,OADS,/arxiv_data1/oa_pdf/0f/7a/QHW-7-15471.PMC3379843.pdf
"The core category ‘‘mobilizing own resources,’’ the related categories labelled ‘‘coaching from the physiotherapist,’’ ‘‘seeking for information,’’ ‘‘compliance with physiotherapy’’ and ‘‘gaining energy from pain-free movements’’ and related subcategories describing how adolescents with LBP succeed in managing their main concern (gaining body conﬁdence) in daily life.Low back pain in adolescents Citation: Int J Qualitative Stud Health Well-being 2012; 7:15471 - http://dx.doi.org/10.3402/qhw.v7i0.15471 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/0f/7a/QHW-7-15471.PMC3379843.pdf
Ahlqwist & C. Sa ¨llfors 6 (page number not for citation purpose)Citation: Int J Qualitative Stud Health Well-being 2012; 7:15471 - http://dx.doi.org/10.3402/qhw.v7i0.15471,OADS,/arxiv_data1/oa_pdf/0f/7a/QHW-7-15471.PMC3379843.pdf
"Now I know that ifI do this I won’t hurt.’’ This quote clearly illustrateshow a teenager had the opportunity to learn to control the pain, rather than having the pain control everyday life.Low back pain in adolescents Citation: Int J Qualitative Stud Health Well-being 2012; 7:15471 - http://dx.doi.org/10.3402/qhw.v7i0.15471 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/0f/7a/QHW-7-15471.PMC3379843.pdf
Ahlqwist & C. Sa ¨llfors 8 (page number not for citation purpose)Citation: Int J Qualitative Stud Health Well-being 2012; 7:15471 - http://dx.doi.org/10.3402/qhw.v7i0.15471,OADS,/arxiv_data1/oa_pdf/0f/7a/QHW-7-15471.PMC3379843.pdf
"On the other hand, inadequateLow back pain in adolescents Citation: Int J Qualitative Stud Health Well-being 2012; 7:15471 - http://dx.doi.org/10.3402/qhw.v7i0.15471 9 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/0f/7a/QHW-7-15471.PMC3379843.pdf
Ahlqwist & C. Sa ¨llfors 10 (page number not for citation purpose)Citation: Int J Qualitative Stud Health Well-being 2012; 7:15471 - http://dx.doi.org/10.3402/qhw.v7i0.15471,Non-OADS,/arxiv_data1/oa_pdf/0f/7a/QHW-7-15471.PMC3379843.pdf
"Archives of Disease in Childhood ,88,1 2/C117.Low back pain in adolescents Citation: Int J Qualitative Stud Health Well-being 2012; 7:15471 - http://dx.doi.org/10.3402/qhw.v7i0.15471 11 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/0f/7a/QHW-7-15471.PMC3379843.pdf
"6,10–12 Here we report the presence of abnormal focal corticalhypermetabolism detected by 18F-deoxyglucose positron emissiontomography (PET) in a patient who met diagnostic criteria for documented PT.Freely available online Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services1",Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"15,16Sensory prediction of theHedera P PET in Psychogenic Tremor Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services2",Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"J Neurol 2007;254:569–574, http://dx.doi.org/10.1007/s00415-006-0348-z.",Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Lancet Neurol 2006;5:695–700, http://dx.doi.org/10.1016/S1474-4422(06)70523-3.",Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Mov Disord 2011;26: 2509–2515, http://dx.doi.org/10.1002/mds.23922.",OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
Corresponding areas of t he posterior parietal lobes showed no increased 18F-deoxyglucose uptake (arrows).PET in Psychogenic Tremor Hedera P Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services3,Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"C urr Opin Neurol 2009;22:430–436, http://dx.doi.org/10.1097/WCO.0b013e32832dc169.",Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Psychiatr Clin North Am 2011;34:621–641, http://dx.doi.org/ 10.1016/j.psc.2011.05.013.",OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Psychosom Med 2007;69:961–969, http://dx.doi.org/10.1097/PSY.0b013e31815b6c14.",Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Neurology 2006;67:2036–2038, http://dx.doi.org/10.1212/01.wnl.0000247275.68402.fc.",Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Park Relat Disord 2011;17:328–332, http://dx.doi.org/10.1016/j.parkreldis.2011.01.",OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Exp Brain Res 2003;153:239–245, http://dx.doi.org/10.1007/ s00221-003-1597-z.",Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Science 2009;324:811–813, http://dx.doi.org/10.1126/science.1169896.",Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Trends Cogn Sci 2009;13:411–419, http://dx.doi.",OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Prog Brain Res 2005;150:309–329, http://dx.doi.org/10.1016/S0079-6123(05)50023-2.",Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Cortex 2008;44:494–506, http://dx.doi.org/10.1016/j.cortex.2007.09.002.",OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
"Neuroimage 2009;47:1026–1037, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
org/10.1016/j.neuroimage.2009.05.023.Hedera P PET in Psychogenic Tremor Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services4,Non-OADS,/arxiv_data1/oa_pdf/f3/26/tre-02-50-441-1.PMC3379878.pdf
Tremor Other Hyperkinet Mov 2012;2: http://tremorjournal.org/ article/view/63 * To whom correspondence should be addressed.,Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"7A related issue is that additional neurological and medical signs that may have been regarded as unrelated to the premutation (e.g., peripheral neuropathy, hypertension, autonomic dysfunction) can be established as associated (or non-associated)Freely available online Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services1",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"The broader implications of FXTAS to neurodegenerative disease The spectrum of clinical involvement among individuals with FXTAS includes features of both parkinsonism 30–32and dementia,33,34Hagerman PJ Molecular Basis of FXTAS Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services2",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
Dysregulation of RNA processing is thought to lead to multiple forms of downstream cellular d ysregulation.Molecular Basis of FXTAS Hagerman PJ Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services3,Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
The broad challenge of defining the relationship between premuta- tion status and disease formation will only be met through the identification of the common and divergent mechanisms that underlieHagerman PJ Molecular Basis of FXTAS Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services4,Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Neurology 2005;65:299–301, http://dx.doi.org/10.1212/01.wnl.0000168900.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Hum Mol Genet 2001; 10:1449–1454, http://dx.doi.org/10.1093/hmg/10.14.1449.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Am J Hum Genet 2000;66:6–15, http://dx.doi.org/10.1086/302720.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Am J Hum Genet 2004;74:805–816, http://dx.doi.org/10.1086/ 386296.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Clin Genet 2011;80:214–225, http://dx.doi.org/10.1111/j.1399-0004.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"J Neurodev Disord 2011;3:211–224, http://dx.doi.org/10.1007/s11689-011-9084-5.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Am J Med Genet A 2008;146A:1009–1016, http://dx.doi.org/10.1002/ajmg.a.32060.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Eur J Hum Genet 2009;17:1359–1362, http://dx.doi.org/10.1038/ ejhg.2009.51.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Hum Genet 2012;131(4):581–589, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Biochem Soc Trans 2009;37:1281–1286, http://dx.doi.org/10.1042/ BST0371281.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Curr Opin Neurol 2007;20:572–576, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
1097/WCO.0b013e3282ef6064.Molecular Basis of FXTAS Hagerman PJ Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services5,Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"EMBO J 2010;29:1248–1261, http://dx.doi.org/10.1038/emboj.2010.21.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"J Cell Biol 2007;176:929–939, http://dx.doi.org/10.1083/jcb.200701005.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Neuron 2007;55:556–564, http://dx.doi.org/10.1016/ j.neuron.2007.07.020.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"PLoS Genet 2011;7:e1002102, http://dx.doi.org/10.1371/ journal.pgen.1002102.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Mol Cell Biol 2003;23:6857– 6875, http://dx.doi.org/10.1128/MCB.23.19.6857-6875.2003.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"J Cell Biol 2011;194:441–457, http://dx.doi.org/10.1083/jcb.201010027.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Curr Biol 2004;14:2162–2167, http://dx.doi.org/10.1016/j.cub.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Medicine (Baltimore) 2011;90:1–18, http://dx.doi.org/10.1097/MD.0b013e3182060469.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Science 2011;331:550–553, http://dx.doi.org/10.1126/ science.1191138.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Hum Mol Genet 2011;20:3079–3092, http://dx.doi.org/10.1093/ hmg/ddr211.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome.Biochem J 2010;429:545–552, http://dx.doi.org/10.1042/BJ20091960.28.Garcia-Arocena D, Yang JE, Brouwer JR, et al.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Hum Mol Genet 2010;19:299–312, http://dx.doi.org/10.1093/hmg/ddp497.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Am J Med Genet A 2008;146A:1543–1546, http://dx.doi.org/10.1002/ajmg.a.32342.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Parkinsonism Relat Disord 2009;15:156–159, http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Genet Med 2011;13:392–399, http://dx.doi.org/10.1097/GIM.0b013e3182064362.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Clin Genet 2009;76:471–476, http://dx.doi.org/10.1111/j.1399-0004.2009.01275.x.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"J Clin Psychiatry 2009;70:852–862, http://dx.doi.org/10.4088/JCP.08r04476.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Free Radic Res 2011;45:53–58, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Exp Neurol 2009;218:247–256, http://dx.doi.org/10.1016/j.expneurol.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Antioxid Redox Signal 2009;11:2135–2149, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Neuron 2011;70:1033–1053, http://dx.doi.org/10.1016/j.neuron.2011.06.003.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Hum Molec Genet 2011;20:64–79, http://dx.doi.org/ 10.1093/hmg/ddq432.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Hum Mol Genet 2010;19:196–208, http://dx.doi.org/10.1093/ hmg/ddp479.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Behav Neurosci 2009;123:1315–1324, http://dx.doi.org/10.1037/a0017616.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
Young adult female fragile X premutation carriers show age-and genetically-modulated cognitiveHagerman PJ Molecular Basis of FXTAS Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services6,Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Brain Cogn 2011;75:255–260, http://dx.doi.org/10.1016/j.bandc.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Neurobiol Dis 2011;42:85–98, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Results P r o b lC e l lD i f f e r 2012;54:255–269, http://dx.doi.org/10.1007/978-3-642- 21649-7_14.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Am J Med Genet 2000; 91: 144–152, http://dx.doi.org/10.1002/(SICI)1096- 8628(20000313)91:2 ,144::AID-AJMG14 .3.0.CO;2-V. 48.Goodlin-Jones BL, Tassone F, Gane LW, et al.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"J Dev Behav Pediatr 2004;25:392–398, http://dx.doi.org/10.1097/00004703-200412000-00002.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Biol Psychiatry 2011;70:859–865, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Am J Med Genet B Neuropsychiatr Genet 2003;121:119–127, http://dx.doi.org/10.1002/ajmg.b.20030.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"J Dev Behav Pediatr 2006;27:S137-S144, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Molec Autism 2010;1:12, http://dx.doi.org/10.1186/2040-2392-1-12.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"J Autism Dev Disord 2008;38:20–27, http://dx.doi.org/10.1007/s10803-007-0356-6.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Hum Reprod 2006;21:952–957, http://dx.doi.org/10.1093/ humrep/dei432.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Hum Genet 2005;117:376–382, http://dx.doi.org/10.1007/s00439-005- 1326-8.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Mov Disord 2010;25:1523–1524, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"J Neuropathol Exp Neurol 2011;70: 462–469, http://dx.doi.org/10.1097/NEN.0b013e31821d3194.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"J Neurodev Disord 2010;2:70–76, http://dx.doi.org/10.1007/s11689-010-9047-2.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Fragile X mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells.PLoS Genet 2010;6:e1000898, http://dx.doi.org/10.1371/journal.pgen.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Mov Disord 2011;26:1900–1906, http://dx.doi.org/10.1002/mds.23755.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"J Med Genet 2007;44:200–204, http://dx.doi.org/10.1136/jmg.2006.043950.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Arch Neurol 2009;66:244–249, http://dx.doi.org/10.1001/archneurol.2008.548.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"JAMA 2004;292:1685–1686, http://dx.doi.org/ 10.1001/jama.292.14.1685-b.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"FMR1 alleles in Parkinson’s disease: Relation to cognitive decline and hallucinations, a longitudinal study.J Geriatr Psychiatry Neurol 2007;20:89–92, http://dx.doi.org/10.1177/ 0891988706297737.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Frequency of FMR1 premutation in individuals with ataxia and/or tremor and/or parkinsonism.Genet Mol Res 2008;7:74–84, http://dx.doi.org/10.4238/vol7-1gmr357.",Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"Mov Disord 2005;20:230–233, http://dx.doi.org/10.1002/mds.",OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
20297.Molecular Basis of FXTAS Hagerman PJ Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services7,Non-OADS,/arxiv_data1/oa_pdf/ec/ea/tre-02-63-375-2.PMC3379894.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/83/5a/ceo-5-101.PMC3380109.pdf
"2: 101- 106, June 2012  http://dx.doi.org/10.3342/ceo.2012.5.2.101 Original Article INTRODUCTION In more than 90% of individuals, the superior and inferior can - aliculi merge to form a common canaliculus before entry into  the lacrimal sac (1).",Non-OADS,/arxiv_data1/oa_pdf/83/5a/ceo-5-101.PMC3380109.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4c/d1/ceo-5-107.PMC3380110.pdf
"2: 107- 111, June 2012  http://dx.doi.org/10.3342/ceo.2012.5.2.107",Non-OADS,/arxiv_data1/oa_pdf/4c/d1/ceo-5-107.PMC3380110.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/40/11/ceo-5-112.PMC3380111.pdf
"2: 112- 115, June 2012  http://dx.doi.org/10.3342/ceo.2012.5.2.112",Non-OADS,/arxiv_data1/oa_pdf/40/11/ceo-5-112.PMC3380111.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b3/d5/ceo-5-116.PMC3380112.pdf
"2: 116, June 2012  http://dx.doi.org/10.3342/ceo.2012.5.2.116 Erratum In the published article “The Listening Cube: A Three Dimensional Auditory Training Program” (2012;Suppl 1:S1- S5.",Non-OADS,/arxiv_data1/oa_pdf/b3/d5/ceo-5-116.PMC3380112.pdf
http://dx.doi.org/10.3342/ceo.2012.5.S1.S1.,OADS,/arxiv_data1/oa_pdf/b3/d5/ceo-5-116.PMC3380112.pdf
"5, Suppl 1: S1-S5, April 2012. http://dx.doi.org/10.3342/ceo.2012.5.S1.S1Erratum: Correction to Authors Names",Non-OADS,/arxiv_data1/oa_pdf/b3/d5/ceo-5-116.PMC3380112.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0c/84/ceo-5-57.PMC3380113.pdf
"2: 57- 61, June 2012  http://dx.doi.org/10.3342/ceo.2012.5.2.57 Original Article INTRODUCTION Universal newborn hearing screening (UNHS) is now performed  worldwide because of the significant harm of unidentified per - manent congenital hearing loss.",Non-OADS,/arxiv_data1/oa_pdf/0c/84/ceo-5-57.PMC3380113.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/32/43/ceo-5-62.PMC3380114.pdf
"2: 62- 67, June 2012  http://dx.doi.org/10.3342/ceo.2012.5.2.62 Original Article INTRODUCTION Cholesteatoma is defined by a keratinizing squamous epitheli - um in the middle ear cavities.",Non-OADS,/arxiv_data1/oa_pdf/32/43/ceo-5-62.PMC3380114.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1b/b4/ceo-5-68.PMC3380115.pdf
"2: 68- 73, June 2012  http://dx.doi.org/10.3342/ceo.2012.5.2.68 Original Article INTRODUCTION In everyday communications, the goal of speaking as well as  hearing is to communicate someone’s message in a manner that is intelligible to others.",Non-OADS,/arxiv_data1/oa_pdf/1b/b4/ceo-5-68.PMC3380115.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c7/64/ceo-5-74.PMC3380116.pdf
"2: 74- 80, June 2012  http://dx.doi.org/10.3342/ceo.2012.5.2.74 Original Article INTRODUCTION A perilymph fistula (PLF) is defined as an abnormal communi - cation between the inner ear fluids and the middle ear space (1).",Non-OADS,/arxiv_data1/oa_pdf/c7/64/ceo-5-74.PMC3380116.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ce/48/ceo-5-81.PMC3380117.pdf
"2: 81- 85, June 2012  http://dx.doi.org/10.3342/ceo.2012.5.2.81 Original Article INTRODUCTION Chronic otitis media with effusion (OME) is one of the most com - mon diseases of the childhood and it causes acquired hearing  loss in children (1).",Non-OADS,/arxiv_data1/oa_pdf/ce/48/ceo-5-81.PMC3380117.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f2/73/ceo-5-86.PMC3380118.pdf
"2: 86- 93, June 2012  http://dx.doi.org/10.3342/ceo.2012.5.2.86 Original Article INTRODUCTION Mesenchymal stem cells (MSCs) are undifferentiated cells, de - rived from bone marrow, and widely distributed in various tis - sues of the body.",Non-OADS,/arxiv_data1/oa_pdf/f2/73/ceo-5-86.PMC3380118.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)   which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/19/4c/ceo-5-94.PMC3380119.pdf
"2: 94- 100, June 2012  http://dx.doi.org/10.3342/ceo.2012.5.2.94 Original Article INTRODUCTION The glottis is the most commonly involved subsite of laryngeal cancer (1).",Non-OADS,/arxiv_data1/oa_pdf/19/4c/ceo-5-94.PMC3380119.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:167-180 Retinoid Metabolism and Diabetes Mellitus Eun-Jung Rhee1, Jorge Plutzky2 1Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea 2Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Retinoid acid is a metabolite of vitamin A and functions as an important factor in cell survival, differentiation and death.",Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
"Therefore, we want to briefly  review the recent research in retinoic acid metabolism and its  relationships with diabetes from the clinical and scientific per - spectives.Review Others http://dx.doi.org/10.4093/dmj.2012.36.3.167 pISSN 2233-6079 · eISSN 2233-6087",Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
"Diabetes Metab J 2012;36:167-180 http://e-dmj.org OVERVIEW OF RETINOIC ACID  METABOLISM Analogs of retinol, with or without biological activity, are called  retinoids.",Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
"169Retinoid and diabetes mellitus Diabetes Metab J 2012;36:167-180 http://e-dmj.org RAR γ is highly expressed in the skin and RAR γ-null mice dis - play some defects associated with vitamin A deficiency, which  can be rescued by RA treatment, indicating that RAR γ medi - ates some of the retinoid functions in vivo  [22,23].",Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
"Diabetes Metab J 2012;36:167-180 http://e-dmj.org RETINOID METABOLISM AND DIABETES- EVIDENCE FROM HUMAN STUDIES The association of retinoid metabolism and insulin sensitivity,  obesity and metabolism has been studied in humans.",Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
"171Retinoid and diabetes mellitus Diabetes Metab J 2012;36:167-180 http://e-dmj.org erodimers (for example, thyroid receptors, vitamin D recep - tors), the ligand-induced transcriptional activities of RXR are  suppressed.",Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
Diabetes Metab J 2012;36:167-180 http://e-dmj.org increases pancreatic glucokinase activity and mRNA levels in  the insulinoma cell line and primary rat pancreatic islets [52].,Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
"173Retinoid and diabetes mellitus Diabetes Metab J 2012;36:167-180 http://e-dmj.org erance by suppressing both CD4+ and CD8+ T effector cells,  while promoting Treg cell expansion.",Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
Diabetes Metab J 2012;36:167-180 http://e-dmj.org they made lipophyllic extract (LE) from rat liver and they  found that LE synergized with insulin to induce Gck mRNA  expression in primary hepatocytes.,Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
"175Retinoid and diabetes mellitus Diabetes Metab J 2012;36:167-180 http://e-dmj.org studies are based on post-treatment data obtained from pa - tients treated with isotretinoin, a 13-cis retinoic acid, for acne,  and etretinate, a synthetic retinoid, for psoriasis.",Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
"Diabetes Metab J 2012;36:167-180 http://e-dmj.org RA treatment induced the expression of RAR and PPAR β/δ  target genes involved in regulation of lipid homeostasis, fos - tering weight loss.",Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
177Retinoid and diabetes mellitus Diabetes Metab J 2012;36:167-180 http://e-dmj.org REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
Diabetes Metab J 2012;36:167-180 http://e-dmj.org type 2 (non-insulin-dependent) adult diabetic patients.,Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
179Retinoid and diabetes mellitus Diabetes Metab J 2012;36:167-180 http://e-dmj.org 50.,Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
Diabetes Metab J 2012;36:167-180 http://e-dmj.org 311-6.,Non-OADS,/arxiv_data1/oa_pdf/90/df/dmj-36-167.PMC3380120.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a9/f7/dmj-36-181.PMC3380121.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:181-189 Leptin in Relation to the Lipodystrophy-Associated  Metabolic Syndrome Christos S. Mantzoros1,2 1Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center,  2Section of Endocrinology, Boston V A Healthcare System, Harvard Medical School, Boston, MA, USA Leptin, an adipocyte-secreted hormone, regulates energy homeostasis as well as reproductive, neuroendocrine, immune and  metabolic functions.",Non-OADS,/arxiv_data1/oa_pdf/a9/f7/dmj-36-181.PMC3380121.pdf
"Leptin admin - istration has been demonstrated to successfully treat obesity  and its complications in individuals with congenital leptin de - ficiency, and thus leptin is available on a compassionate basis Review Obesity and Metabolic Syndrome http://dx.doi.org/10.4093/dmj.2012.36.3.181 pISSN 2233-6079 · eISSN 2233-6087",Non-OADS,/arxiv_data1/oa_pdf/a9/f7/dmj-36-181.PMC3380121.pdf
182Mantzoros C S. Diabetes Metab J 2012;36:181-189 http://e-dmj.org for these patients [5-7].,Non-OADS,/arxiv_data1/oa_pdf/a9/f7/dmj-36-181.PMC3380121.pdf
"183Leptin in relation to the lipodystrophy-associated metabolic syndrome Diabetes Metab J 2012;36:181-189 http://e-dmj.org HALS Abnormal fat distribution, called the HALS, is associated with  dyslipidemia, insulin resistance, and other metabolic compli - cations [38,39].",Non-OADS,/arxiv_data1/oa_pdf/a9/f7/dmj-36-181.PMC3380121.pdf
184Mantzoros C S. Diabetes Metab J 2012;36:181-189 http://e-dmj.org Similar results have been demonstrated in studies of patients  with HALS.,Non-OADS,/arxiv_data1/oa_pdf/a9/f7/dmj-36-181.PMC3380121.pdf
185Leptin in relation to the lipodystrophy-associated metabolic syndrome Diabetes Metab J 2012;36:181-189 http://e-dmj.org assessment of efficacy and side effects.,Non-OADS,/arxiv_data1/oa_pdf/a9/f7/dmj-36-181.PMC3380121.pdf
186Mantzoros C S. Diabetes Metab J 2012;36:181-189 http://e-dmj.org vational and interventional studies in humans.,Non-OADS,/arxiv_data1/oa_pdf/a9/f7/dmj-36-181.PMC3380121.pdf
187Leptin in relation to the lipodystrophy-associated metabolic syndrome Diabetes Metab J 2012;36:181-189 http://e-dmj.org Beirn Community Programs for Clinical Research on AIDS  (CPCRA); International Network for Strategic Initiatives in  Global HIV Trials (INSIGHT).,Non-OADS,/arxiv_data1/oa_pdf/a9/f7/dmj-36-181.PMC3380121.pdf
188Mantzoros C S. Diabetes Metab J 2012;36:181-189 http://e-dmj.org highly active antiretroviral therapy.,Non-OADS,/arxiv_data1/oa_pdf/a9/f7/dmj-36-181.PMC3380121.pdf
"189Leptin in relation to the lipodystrophy-associated metabolic syndrome Diabetes Metab J 2012;36:181-189 http://e-dmj.org ner in mouse GT1-7 hypothalamic, CC muscle and AML12  liver cell lines.",Non-OADS,/arxiv_data1/oa_pdf/a9/f7/dmj-36-181.PMC3380121.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-190.PMC3380122.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:190-198 Reactive Oxygen and Nitrogen Species in Pathogenesis  of Vascular Complications of Diabetes Seok Man Son Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Korea Macrovascular and microvascular diseases are currently the principal causes of morbidity and mortality in subjects with diabe - tes.",Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-190.PMC3380122.pdf
However it is now known that physiological free radicals  superoxide and nitric oxide are relatively harmless species that Review Complications http://dx.doi.org/10.4093/dmj.2012.36.3.190 pISSN 2233-6079 · eISSN 2233-6087,Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-190.PMC3380122.pdf
191Oxidative stress and diabetic vascular diseases Diabetes Metab J 2012;36:190-198 http://e-dmj.org are able to initiate or mediate many enzyme- and gene-depen - dent reactions in both physiological and pathophysiological  processes.,Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-190.PMC3380122.pdf
192Son SM Diabetes Metab J 2012;36:190-198 http://e-dmj.org regulated NAD(P)H oxidase and endothelial NO synthase in  human blood vessels from subjects with type 2 diabetes [9].,Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-190.PMC3380122.pdf
193Oxidative stress and diabetic vascular diseases Diabetes Metab J 2012;36:190-198 http://e-dmj.org been reported in diabetic animals and in human subjects with  diabetes [14].,Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-190.PMC3380122.pdf
"194Son SM Diabetes Metab J 2012;36:190-198 http://e-dmj.org synthesis collagen of vascular smooth muscle and increases  production of matrix metalloproteinases, which may also lead  to an increased tendency for plaque destabilization and rup - ture [21,24].",Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-190.PMC3380122.pdf
"195Oxidative stress and diabetic vascular diseases Diabetes Metab J 2012;36:190-198 http://e-dmj.org thologies such as cardiovascular diseases, inflammation, and  aging cannot be successfully inhibited by the traditional anti - oxidants vitamin C or vitamin E which are unable to react with  superoxide [36,37].",Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-190.PMC3380122.pdf
"196Son SM Diabetes Metab J 2012;36:190-198 http://e-dmj.org andmito-Q, which are selectively taken up into mitochondria  should be searched further [45,46].",Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-190.PMC3380122.pdf
197Oxidative stress and diabetic vascular diseases Diabetes Metab J 2012;36:190-198 http://e-dmj.org drial superoxide overproduction activates the hexosamine  pathway and induces plasminogen activator inhibitor-1 ex - pression by increasing Sp1 glycosylation.,Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-190.PMC3380122.pdf
198Son SM Diabetes Metab J 2012;36:190-198 http://e-dmj.org heart failure.,Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-190.PMC3380122.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/90/e1/dmj-36-199.PMC3380123.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:199-206 Post-Renal Transplant Diabetes Mellitus in Korean  Subjects: Superimposition of Transplant-Related  Immunosuppressant Factors on Genetic and Type 2  Diabetic Risk Factors Hyun Chul Lee Department of Internal Medicine, Y onsei University College of Medicine, Seoul, Korea Postrenal transplantation diabetes mellitus (PTDM), or new-onset diabetes after organ transplantation, is an important chronic  transplant-associated complication.",Non-OADS,/arxiv_data1/oa_pdf/90/e1/dmj-36-199.PMC3380123.pdf
"Among the established risk factors  for the development of cardiovascular events in transplant re - cipients, attention and research has focused on abnormal glu -Sulwon Lecture 2011 Pathophysiology http://dx.doi.org/10.4093/dmj.2012.36.3.199 pISSN 2233-6079 · eISSN 2233-6087",Non-OADS,/arxiv_data1/oa_pdf/90/e1/dmj-36-199.PMC3380123.pdf
200Lee HC Diabetes Metab J 2012;36:199-206 http://e-dmj.org cose homeostasis in kidney transplant recipients.,Non-OADS,/arxiv_data1/oa_pdf/90/e1/dmj-36-199.PMC3380123.pdf
"201Risk factors of post-renal transplant diabetes mellitus  Diabetes Metab J 2012;36:199-206 http://e-dmj.org casian kidney transplant recipients such as African-Ameri - cans, Hispanics, and Koreans are at greater risk of developing  PTDM.",Non-OADS,/arxiv_data1/oa_pdf/90/e1/dmj-36-199.PMC3380123.pdf
"202Lee HC Diabetes Metab J 2012;36:199-206 http://e-dmj.org of insulin on OGTT, representing insulin secretory function,  was significantly lower in the PTDM group than in the NGT  group.",Non-OADS,/arxiv_data1/oa_pdf/90/e1/dmj-36-199.PMC3380123.pdf
"203Risk factors of post-renal transplant diabetes mellitus  Diabetes Metab J 2012;36:199-206 http://e-dmj.org sion of the Down’s syndrome candidate region-1 (DSCR1), an  endogenous calcineurin inhibitor, and subsequent calcineurin  inhibition significantly reduced GSIS in cells expressing the  R325 but not the W325 variant, suggesting that differing sus - ceptibility to CsA may be due to different interactions with  calcineurin.",Non-OADS,/arxiv_data1/oa_pdf/90/e1/dmj-36-199.PMC3380123.pdf
204Lee HC Diabetes Metab J 2012;36:199-206 http://e-dmj.org Glycosuria and hyperglycaemia after kidney transplantation.,Non-OADS,/arxiv_data1/oa_pdf/90/e1/dmj-36-199.PMC3380123.pdf
205Risk factors of post-renal transplant diabetes mellitus  Diabetes Metab J 2012;36:199-206 http://e-dmj.org 30.,Non-OADS,/arxiv_data1/oa_pdf/90/e1/dmj-36-199.PMC3380123.pdf
206Lee HC Diabetes Metab J 2012;36:199-206 http://e-dmj.org associations between CCL5 gene polymorphisms and post- transplantational diabetes mellitus in Korean renal allograft  recipients.,Non-OADS,/arxiv_data1/oa_pdf/90/e1/dmj-36-199.PMC3380123.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3c/7e/dmj-36-207.PMC3380124.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:207-210 The Role of Cortisol in the Pathogenesis of the  Metabolic Syndrome  In-Kyung Jeong Division of Endocrinology & Metabolism, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea Corresponding author:  In-Kyung Jeong Division of Endocrinology & Metabolism, Department of Internal Medicine,  Kyung Hee University Hospital at Gangdong, Kyung Hee University School  of Medicine, 892 Dongnam-ro, Gangdong-gu, Seoul 134-727, Korea E-mail: jik1016@dreamwiz.comMetabolic syndrome (MetS) is a constellation of metabolic de - rangements that includes insulin resistance, hyperglycemia,  hypertension, reduced high density lipoprotein cholesterol  (HDL-C), elevated triglycerides, and abdominal obesity.",Non-OADS,/arxiv_data1/oa_pdf/3c/7e/dmj-36-207.PMC3380124.pdf
More Editorial Obesity and Metabolic Syndrome http://dx.doi.org/10.4093/dmj.2012.36.3.207 pISSN 2233-6079 · eISSN 2233-6087,Non-OADS,/arxiv_data1/oa_pdf/3c/7e/dmj-36-207.PMC3380124.pdf
"208Jeong I-K Diabetes Metab J 2012;36:207-210 http://e-dmj.org recently, salivary cortisol measurements have been used [24].",Non-OADS,/arxiv_data1/oa_pdf/3c/7e/dmj-36-207.PMC3380124.pdf
"209The role of cortisol in the pathogenesis of the metabolic syndrome Diabetes Metab J 2012;36:207-210 http://e-dmj.org betes, atherosclerosis, and cancer.",Non-OADS,/arxiv_data1/oa_pdf/3c/7e/dmj-36-207.PMC3380124.pdf
"210Jeong I-K Diabetes Metab J 2012;36:207-210 http://e-dmj.org PJ, Walker BR.",Non-OADS,/arxiv_data1/oa_pdf/3c/7e/dmj-36-207.PMC3380124.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:211-221 Effects of Aerobic Exercise Intensity on Abdominal and  Thigh Adipose Tissue and Skeletal Muscle Attenuation  in Overweight Women with Type 2 Diabetes Mellitus Ji Y eon Jung1,*, Kyung Ah Han1,2,*, Hee Jung Ahn1, Hwi Ryun Kwon1, Jae Hyuk Lee2, Kang Seo Park2, Kyung Wan Min1,2 1Diabetes Center, Eulji General Hospital, Seoul, 2Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea Background:  We investigated the effects of exercise intensity on abdominal and mid-thigh adipose tissue, attenuation of skeletal  muscle, and insulin sensitivity in overweight women with type 2 diabetes mellitus (T2DM).",Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
"[5] also re - ported that among diabetic obese subjects who performed  moderate intensity aerobic exercise for 14 weeks, 14% showed  a decrease in visceral fat without significant changes in body Original Article Clinical Care/Education http://dx.doi.org/10.4093/dmj.2012.36.3.211 pISSN 2233-6079 · eISSN 2233-6087",Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
Diabetes Metab J 2012;36:211-221 http://e-dmj.org weight.,Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
"213Effects of exercise intensity on regional fat and muscle  Diabetes Metab J 2012;36:211-221 http://e-dmj.org KITT=0.693/t1/2×100 (%/min) Exercise intervention The control group (CG) did not participate in the exercise  program and education regarding walking exercises, accord - ing to American Diabetes Association (ADA) guidelines [15],  was given during the initial meeting.",Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
Diabetes Metab J 2012;36:211-221 http://e-dmj.org upper margin of the patella and greater trochanter that falls  within 0 to +100 Hounsfield units was classified as thigh total  muscle.,Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
215Effects of exercise intensity on regional fat and muscle  Diabetes Metab J 2012;36:211-221 http://e-dmj.org Table 1.,Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
Diabetes Metab J 2012;36:211-221 http://e-dmj.org DISCUSSION Abdominal fat has been identified as an independent risk fac - tor for development of cardiovascular disease [19].,Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
217Effects of exercise intensity on regional fat and muscle  Diabetes Metab J 2012;36:211-221 http://e-dmj.org concentration and adrenaline secretion due to exercise.,Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
"Diabetes Metab J 2012;36:211-221 http://e-dmj.org tion rises during vigorous intensity exercise, and stimulates li - polysis in visceral fat.",Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
"219Effects of exercise intensity on regional fat and muscle  Diabetes Metab J 2012;36:211-221 http://e-dmj.org tal mid-thigh skeletal muscle and normal density muscle was  significantly higher in the vigorous intensity exercise group  compared to the control group, but low density muscle was  not significantly different among the groups after 12 weeks.",Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
Diabetes Metab J 2012;36:211-221 http://e-dmj.org ty on abdominal visceral fat and body composition.,Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
221Effects of exercise intensity on regional fat and muscle  Diabetes Metab J 2012;36:211-221 http://e-dmj.org 30.,Non-OADS,/arxiv_data1/oa_pdf/05/29/dmj-36-211.PMC3380125.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d1/f0/dmj-36-222.PMC3380126.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:222-229 Influence of the Duration of Diabetes on the Outcome  of a Diabetes Self-Management Education Program  Seung-Hyun Ko1, Sin-Ae Park1, Jae-Hyoung Cho1, Sun-Hye Ko1, Kyung-Mi Shin1, Seung-Hwan Lee1, Ki-Ho Song1,  Y ong-Moon Park2, Yu-Bae Ahn1 1Division of Endocrinology & Metabolism, Department of Internal Medicine, 2Department of Preventive Medicine, The Catholic University of Korea  College of Medicine, Seoul, Korea Background:  Diabetes education and lifestyle modification are critical components in controlling blood glucose levels of people  with type 2 diabetes.",Non-OADS,/arxiv_data1/oa_pdf/d1/f0/dmj-36-222.PMC3380126.pdf
We have previously reported the long-term beneficial ef - fects of structured intensive diabetes education programs on Original Article Clinical Care/Education http://dx.doi.org/10.4093/dmj.2012.36.3.222 pISSN 2233-6079 · eISSN 2233-6087,Non-OADS,/arxiv_data1/oa_pdf/d1/f0/dmj-36-222.PMC3380126.pdf
223Diabetes duration influence on self-management program Diabetes Metab J 2012;36:222-229 http://e-dmj.org glycemic control and lifestyle changes.,Non-OADS,/arxiv_data1/oa_pdf/d1/f0/dmj-36-222.PMC3380126.pdf
"Diabetes Metab J 2012;36:222-229 http://e-dmj.org patient clinic, the physician reviewed their SMBG data and  lifestyle behaviors by asking questions and encouraged the pa - tients to maintain their improved lifestyle behaviors.",Non-OADS,/arxiv_data1/oa_pdf/d1/f0/dmj-36-222.PMC3380126.pdf
225Diabetes duration influence on self-management program Diabetes Metab J 2012;36:222-229 http://e-dmj.org variates for the multivariate model.,OADS,/arxiv_data1/oa_pdf/d1/f0/dmj-36-222.PMC3380126.pdf
"Diabetes Metab J 2012;36:222-229 http://e-dmj.org had scores greater than or equal to four for dietary habits, phys - ical activity, and SMBG, respectively.",Non-OADS,/arxiv_data1/oa_pdf/d1/f0/dmj-36-222.PMC3380126.pdf
227Diabetes duration influence on self-management program Diabetes Metab J 2012;36:222-229 http://e-dmj.org between the two groups (Table 1).,Non-OADS,/arxiv_data1/oa_pdf/d1/f0/dmj-36-222.PMC3380126.pdf
Diabetes Metab J 2012;36:222-229 http://e-dmj.org servation period.,Non-OADS,/arxiv_data1/oa_pdf/d1/f0/dmj-36-222.PMC3380126.pdf
"229Diabetes duration influence on self-management program Diabetes Metab J 2012;36:222-229 http://e-dmj.org on self-care, metabolic control, and emotional well-being.",Non-OADS,/arxiv_data1/oa_pdf/d1/f0/dmj-36-222.PMC3380126.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-230.PMC3380127.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:230-236 Glycemic Effects of Once-a-Day Rapid-Acting Insulin  Analogue Addition on a Basal Insulin Analogue in  Korean Subjects with Poorly Controlled Type 2  Diabetes Mellitus Eun Y eong Choe*, Y ong-ho Lee*, Byung-Wan Lee, Eun-Seok Kang, Bong Soo Cha, Hyun Chul Lee  Division of Endocrinology and Metabolism, Department of Internal Medicine, Y onsei University College of Medicine, Seoul, Korea Background:  The present study investigates the efficacy in glycemic control by adding once-a-day glulisine to glargine as a basal  plus regimen and factors influencing glycemic control with the basal plus regimen in Korean subjects with type 2 diabetes.",Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-230.PMC3380127.pdf
Original Article Clinical Care/Education http://dx.doi.org/10.4093/dmj.2012.36.3.230 pISSN 2233-6079 · eISSN 2233-6087,Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-230.PMC3380127.pdf
"231Response to rapid acting insulin Diabetes Metab J 2012;36:230-236 http://e-dmj.org However, little information is currently available regarding the  effects of adding once-a-day glulisine (rapid-acting insulin an - alogue) to glargine as a basal plus regimen in Korean patients  with T2DM.",Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-230.PMC3380127.pdf
Diabetes Metab J 2012;36:230-236 http://e-dmj.org those variables.,Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-230.PMC3380127.pdf
"233Response to rapid acting insulin Diabetes Metab J 2012;36:230-236 http://e-dmj.org were 63.2±9.8 and 14.8±9.4 years, respectively.",Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-230.PMC3380127.pdf
Diabetes Metab J 2012;36:230-236 http://e-dmj.org levels were not significantly different between the two groups.,Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-230.PMC3380127.pdf
"235Response to rapid acting insulin Diabetes Metab J 2012;36:230-236 http://e-dmj.org DISCUSSION Little controversy remains regarding early intensive glycemic  control with basal insulin-based combination of OADs or  short-acting insulin to prevent or delay diabetic complications  [1,3,12].",Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-230.PMC3380127.pdf
"Diabetes Metab J 2012;36:230-236 http://e-dmj.org consisted of poorly controlled Korean patients who had a lon - ger duration of diabetes (>10 years) and predominantly fea - tured an insulin secretory defect over insulin resistance, the  results may not be applicable to other ethnic groups with  T2DM, especially when the major etiologic factor is insulin  resistance.",Non-OADS,/arxiv_data1/oa_pdf/ec/86/dmj-36-230.PMC3380127.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/06/fa/dmj-36-237.PMC3380128.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:237-244 Metabolic Syndrome versus Framingham Risk Score  for Association of Self-Reported Coronary Heart  Disease: The 2005 Korean Health and Nutrition  Examination Survey Hye Mi Kang, Dong-Jun Kim Department of Internal Medicine, Inje University College of Medicine, Goyang, Korea  Background:  Several studies in Western populations have indicated that metabolic syndrome (MetS) is inferior to the Framing - ham risk score (FRS) in predicting coronary heart disease (CHD).",Non-OADS,/arxiv_data1/oa_pdf/06/fa/dmj-36-237.PMC3380128.pdf
"However, there has been no study Original Article Epidemiology http://dx.doi.org/10.4093/dmj.2012.36.3.237 pISSN 2233-6079 · eISSN 2233-6087",Non-OADS,/arxiv_data1/oa_pdf/06/fa/dmj-36-237.PMC3380128.pdf
Diabetes Metab J 2012;36:237-244 http://e-dmj.org examining the predictability of MetS vs. FRS with regard to  CHD in Korea.,Non-OADS,/arxiv_data1/oa_pdf/06/fa/dmj-36-237.PMC3380128.pdf
"239Metabolic syndrome, Framingham risk score, and CHD Diabetes Metab J 2012;36:237-244 http://e-dmj.org RESULTS Table 1 summarizes the comparison of clinical characteristics  in both genders of the study population.",Non-OADS,/arxiv_data1/oa_pdf/06/fa/dmj-36-237.PMC3380128.pdf
Diabetes Metab J 2012;36:237-244 http://e-dmj.org  Table 2 summarizes the data concerning clinical character - istics according to self- reported coronary heart disease in each  sex.,Non-OADS,/arxiv_data1/oa_pdf/06/fa/dmj-36-237.PMC3380128.pdf
"241Metabolic syndrome, Framingham risk score, and CHD Diabetes Metab J 2012;36:237-244 http://e-dmj.org terminants for CHD.",Non-OADS,/arxiv_data1/oa_pdf/06/fa/dmj-36-237.PMC3380128.pdf
Diabetes Metab J 2012;36:237-244 http://e-dmj.org be explained by the fact that age was not included in the NCEP- ATP III criteria for MetS.,Non-OADS,/arxiv_data1/oa_pdf/06/fa/dmj-36-237.PMC3380128.pdf
"243Metabolic syndrome, Framingham risk score, and CHD Diabetes Metab J 2012;36:237-244 http://e-dmj.org ciation conference on scientific issues related to definition.",Non-OADS,/arxiv_data1/oa_pdf/06/fa/dmj-36-237.PMC3380128.pdf
Diabetes Metab J 2012;36:237-244 http://e-dmj.org American Heart Association; World Heart Federation; Inter - national Atherosclerosis Society; International Association for  the Study of Obesity.,Non-OADS,/arxiv_data1/oa_pdf/06/fa/dmj-36-237.PMC3380128.pdf
Available from: http://knhanes.cdc.go.kr  (updated 2006 Jul 8).,OADS,/arxiv_data1/oa_pdf/06/fa/dmj-36-237.PMC3380128.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d6/d7/dmj-36-245.PMC3380129.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:245-250 The Association between Midnight Salivary Cortisol  and Metabolic Syndrome in Korean Adults  Yun-Mi Jang, Eun Jung Lee, Dong Lim Kim, Suk Kyeong Kim, Kee-Ho Song Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea Background:  The common characteristics of metabolic syndrome (MetS) and Cushing’s syndrome suggest that excess cortisol  may be involved in the pathogenesis of MetS.",Non-OADS,/arxiv_data1/oa_pdf/d6/d7/dmj-36-245.PMC3380129.pdf
Original Article Obesity and Metabolic Syndrome http://dx.doi.org/10.4093/dmj.2012.36.3.245 pISSN 2233-6079 · eISSN 2233-6087,Non-OADS,/arxiv_data1/oa_pdf/d6/d7/dmj-36-245.PMC3380129.pdf
"Diabetes Metab J 2012;36:245-250 http://e-dmj.org  It has been convincingly demonstrated in adults and chil - dren that an elevated midnight salivary cortisol level is an ex - cellent surrogate for increased midnight serum cortisol, which  means disruption of diurnal variation in the diagnosis of Cush - ing’s syndrome [9-13].",Non-OADS,/arxiv_data1/oa_pdf/d6/d7/dmj-36-245.PMC3380129.pdf
247Increased salivary cortisol in metabolic syndrome Diabetes Metab J 2012;36:245-250 http://e-dmj.org RESULTS General subject characteristics  Table 1 shows a comparison of the characteristics of those with  and without MetS.,Non-OADS,/arxiv_data1/oa_pdf/d6/d7/dmj-36-245.PMC3380129.pdf
"Diabetes Metab J 2012;36:245-250 http://e-dmj.org Logistic regression analysis between midnight salivary  cortisol levels and MetS A univariate regression analysis revealed that high midnight  salivary cortisol concentrations (100 to 150 ng/dL) were relat - ed to increased odds for MetS (odds ratio [OR], 6.0; 95% con - fidence interval [CI], 1.8 to 44.3; P=0.001) compared to low  midnight salivary cortisol concentrations (<50 ng/dL) (Table  3).",Non-OADS,/arxiv_data1/oa_pdf/d6/d7/dmj-36-245.PMC3380129.pdf
"249Increased salivary cortisol in metabolic syndrome Diabetes Metab J 2012;36:245-250 http://e-dmj.org tors along with decreased vasodilator production, as some  studies have shown that reduced nitric oxide production or  bioavailability contributes to cortisol-induced hypertension  [30].",Non-OADS,/arxiv_data1/oa_pdf/d6/d7/dmj-36-245.PMC3380129.pdf
Diabetes Metab J 2012;36:245-250 http://e-dmj.org midnight serum cortisol as screening tests for Cushing’s syn - drome.,Non-OADS,/arxiv_data1/oa_pdf/d6/d7/dmj-36-245.PMC3380129.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b2/e8/dmj-36-251.PMC3380130.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:251-252 Impact of HbA1c Criterion on the Detection of Subjects  with Increased Risk for Diabetes among Health Check-Up   Recipients in Korea ( Diabetes Metab J  2012;36:151-6) Sung Hee Choi1,2 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul,  2Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea Corresponding author:  Sung Hee Choi Department of Internal Medicine, Seoul National University Bundang  Hospital, Seoul National University College of Medicine, 166 Gumi-ro,  Bundang-gu, Seongnam 463-707, Korea Email: drshchoi@snu.ac.krHemoglobin A1c (A1c) has been investigated as a target for  treatment of diabetes.",Non-OADS,/arxiv_data1/oa_pdf/b2/e8/dmj-36-251.PMC3380130.pdf
"This is an interesting  and important result in terms of providing proper methods  for diagnosis of diabetes in the Korean population, in spite of Letter http://dx.doi.org/10.4093/dmj.2012.36.3.251 pISSN 2233-6079 · eISSN 2233-6087",Non-OADS,/arxiv_data1/oa_pdf/b2/e8/dmj-36-251.PMC3380130.pdf
252Choi SH Diabetes Metab J 2012;36:251-252 http://e-dmj.org the retrospective data from routine health care of Kim et al.,OADS,/arxiv_data1/oa_pdf/b2/e8/dmj-36-251.PMC3380130.pdf
"D I A B E T E S  & M E T A B O L I S M  J O U R N A L This is an Open Access article distributed under the terms of the Creative Commons At - tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/59/46/dmj-36-253.PMC3380131.pdf
"Copyright © 2012 Korean Diabetes Association  http://e-dmj.orgDiabetes Metab J 2012;36:253 Impact of HbA1c Criterion on the Detection of Subjects  with Increased Risk for Diabetes among Health Check-Up   Recipients in Korea ( Diabetes Metab J  2012;36:151-6) Hong-Kyu Kim, Sung-Jin Bae, Jaewon Choe Health Screening and Promotion Center, Asan Medical Center, Seoul, Korea Corresponding author:  Hong-Kyu Kim Health Promotion Center, Asan Medical Center, 88 Olympic-ro 43-gil,  Songpa-gu, Seoul 138-736, Korea E-mail: hkkim0801@amc.seoul.krThank you for your interest and comments on our study, “Im - pact of HbA1c criterion on the detection of subjects with in - creased risk for diabetes among health check-up recipients in  Korea” published in Diabetes & Metabolism Journal  2012;36; 151-6.",Non-OADS,/arxiv_data1/oa_pdf/59/46/dmj-36-253.PMC3380131.pdf
Available from: http://www.ngsp.,Non-OADS,/arxiv_data1/oa_pdf/59/46/dmj-36-253.PMC3380131.pdf
org/docs/methods.pdf (updated 2012 Jun 1).Response http://dx.doi.org/10.4093/dmj.2012.36.3.253 pISSN 2233-6079 · eISSN 2233-6087,OADS,/arxiv_data1/oa_pdf/59/46/dmj-36-253.PMC3380131.pdf
This change makes the1http://www.mitofood.eu .,Non-OADS,/arxiv_data1/oa_pdf/9a/d3/12263_2011_Article_262.PMC3380190.pdf
2http://www.bioclaims.eu .400 Genes Nutr (2012) 7:399–404 123,Non-OADS,/arxiv_data1/oa_pdf/9a/d3/12263_2011_Article_262.PMC3380190.pdf
http://www.phenol-explorer.eu/ .,Non-OADS,/arxiv_data1/oa_pdf/9a/d3/12263_2011_Article_262.PMC3380190.pdf
http://www.researchdiets.com/pdf/Product% 20Sheets/phytoestrogens_3%20page.pdf0 5 10 15 200102030 Body mass Lean mass Fat massStart of feeding BIOsd Age (weeks)Body mass and composition (gram) Fig.,Non-OADS,/arxiv_data1/oa_pdf/9a/d3/12263_2011_Article_262.PMC3380190.pdf
http://www.nal.usda.,Non-OADS,/arxiv_data1/oa_pdf/9a/d3/12263_2011_Article_262.PMC3380190.pdf
"Mu OPIOID RECEPTOR AND OPIOID TOLERANCE Theμopioid receptor (MOR), a member of the G-protein cou- pled receptor superfamily, is the primary receptor responsible for 1http://microrna.sanger.ac.uk/sequences www.frontiersin.org June 2012 | Volume 3 | Article 1 10 | 1",Non-OADS,/arxiv_data1/oa_pdf/23/a0/fgene-03-00110.PMC3380223.pdf
"Furthermore, downregulating let-7 with speciﬁc LNA-modiﬁedantisense oligodeoxynucleot ides (LNA-let-7-AS) was found to increase MOR expression in SH-SY5Y cells, a human neuroblas-toma cell line, suggesting that (1) MOR is a target of let-7; (2)expression of MOR is under constitutive suppression by let-7.T a b l e1|M i c r o R N At a r g e t sp r edicted by miRanda (http://www.microrna.org/microrna/getGeneForm.do) and rankedaccording to the alignment scores.",OADS,/arxiv_data1/oa_pdf/23/a0/fgene-03-00110.PMC3380223.pdf
They proposed a transitional nucleation model in which a transitionalnucleation state determines the binding of miRs to nucleation 2http://www.targetscan.org/bulge mRNAs.,Non-OADS,/arxiv_data1/oa_pdf/23/a0/fgene-03-00110.PMC3380223.pdf
"He and Wang Let-7 microRNAs and opioid tolerance T able 2 |T op 100 predicted targets of let-7 miRNAs ranked by total context score (T argetScan 6.0, http://www.targetscan.org/.)",OADS,/arxiv_data1/oa_pdf/23/a0/fgene-03-00110.PMC3380223.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.RHEUMATOLOGYRheumatology 2012;51:1208 /C1501215 doi:10.1093/rheumatology/ker526 Advance Access publication 15 February 2012CLINICAL SCIENCE",Non-OADS,/arxiv_data1/oa_pdf/83/b4/ker526.PMC3380246.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.RHEUMATOLOGYRheumatology 2012;51:1161 /C1501165 doi:10.1093/rheumatology/kes002 Advance Access publication 15 February 2012 BASIC SCIENCE",Non-OADS,/arxiv_data1/oa_pdf/1e/09/kes002.PMC3380247.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution- Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"2 (page number not for citation purpose)Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"On the other hand, withinHow young men understand intimate partner violence in Ecuador Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"4 (page number not for citation purpose)Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"On gettingHow young men understand intimate partner violence in Ecuador Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"6 (page number not for citation purpose)Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"(Interview 5)How young men understand intimate partner violence in Ecuador Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"8 (page number not for citation purpose)Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"Further, theHow young men understand intimate partner violence in Ecuador Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049 9 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
Available from: http://www.who.int/violence_injury_prevention/ publications/violence/9789241564007_eng.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"10 (page number not for citation purpose)Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
Available from: http://www.un.org/womenwatch/daw/ public/w2000/08-52641_Women2000_SP_FIN.pdf [cited 7 Dec2011].,Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"Men Masc 2008; 10: 538 /C156.How young men understand intimate partner violence in Ecuador Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049 11 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"12 (page number not for citation purpose)Citation: Glob Health Action 2012, 5: 18049 - http://dx.doi.org/10.3402/gha.v5i0.18049",Non-OADS,/arxiv_data1/oa_pdf/b9/ec/GHA-5-18049.PMC3380270.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution- Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Food & Nutrition Research 2012.",Non-OADS,/arxiv_data1/oa_pdf/18/57/FNR-56-17549.PMC3380274.pdf
5617549 - http://dx.doi.org/10.3402/fnr.v56i0.17549,Non-OADS,/arxiv_data1/oa_pdf/18/57/FNR-56-17549.PMC3380274.pdf
"2 (page number not for citation purpose)Citation: Food & Nutrition Research 2012, 56: 17549 - http://dx.doi.org/10.3402/fnr.v56i0.17549",Non-OADS,/arxiv_data1/oa_pdf/18/57/FNR-56-17549.PMC3380274.pdf
"A second set of experiments wasperformed to determine the recovery effect of nWPI orpWPI hydrolysates on pre-stimulated Caco-2 cells.Cells were exposed to 0.25 mM H 2O2for 1 h. H 2O2 was removed, cells were washed twice with MEM, and nWPI or pWPI hydrolysates were added and cellsWhey protein decreases inflammation Citation: Food & Nutrition Research 2012, 56: 17549 - http://dx.doi.org/10.3402/fnr.v56i0.17549 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/18/57/FNR-56-17549.PMC3380274.pdf
"4 (page number not for citation purpose)Citation: Food & Nutrition Research 2012, 56: 17549 - http://dx.doi.org/10.3402/fnr.v56i0.17549",Non-OADS,/arxiv_data1/oa_pdf/18/57/FNR-56-17549.PMC3380274.pdf
"The * symbol identiﬁes extra peaks found in pWPH hydrolysates and arrows indicate differences in the relative abundances of peptides as a result of pressure treatment ( /C27, higher abundance, /C1, lower abundance in pWPI hydrolysates relative to nWPI hydrolysates).Whey protein decreases inflammation Citation: Food & Nutrition Research 2012, 56: 17549 - http://dx.doi.org/10.3402/fnr.v56i0.17549 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/18/57/FNR-56-17549.PMC3380274.pdf
"6 (page number not for citation purpose)Citation: Food & Nutrition Research 2012, 56: 17549 - http://dx.doi.org/10.3402/fnr.v56i0.17549",Non-OADS,/arxiv_data1/oa_pdf/18/57/FNR-56-17549.PMC3380274.pdf
"( j) Native WPI, ( I) Pressurized WPI.Whey protein decreases inflammation Citation: Food & Nutrition Research 2012, 56: 17549 - http://dx.doi.org/10.3402/fnr.v56i0.17549 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/18/57/FNR-56-17549.PMC3380274.pdf
"8 (page number not for citation purpose)Citation: Food & Nutrition Research 2012, 56: 17549 - http://dx.doi.org/10.3402/fnr.v56i0.17549",Non-OADS,/arxiv_data1/oa_pdf/18/57/FNR-56-17549.PMC3380274.pdf
"Vilela RM, Lands LC, Chan HM, Azadi B, Kubow S. High hydrostatic pressure enhances whey protein digestibility toWhey protein decreases inflammation Citation: Food & Nutrition Research 2012, 56: 17549 - http://dx.doi.org/10.3402/fnr.v56i0.17549 9 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/18/57/FNR-56-17549.PMC3380274.pdf
"10 (page number not for citation purpose)Citation: Food & Nutrition Research 2012, 56: 17549 - http://dx.doi.org/10.3402/fnr.v56i0.17549",Non-OADS,/arxiv_data1/oa_pdf/18/57/FNR-56-17549.PMC3380274.pdf
"The material, produced by Novamont (http://www.novamont.com/), is compostable, i.e., biodegradable and disintegrable under composting conditions and meet the compostability requirements of the EN 13432 (2000).",Non-OADS,/arxiv_data1/oa_pdf/df/0e/fmicb-03-00225.PMC3380294.pdf
"Available at: http://www.gazzettaufﬁciale.biz/atti/ 2003/20030035/03A01462.htm Kasuya, K., Takagi, K., Ishiwatari, S., Y oshida, Y., and Doi, Y.",Non-OADS,/arxiv_data1/oa_pdf/df/0e/fmicb-03-00225.PMC3380294.pdf
Available at: http://www.plasticseurope.,Non-OADS,/arxiv_data1/oa_pdf/df/0e/fmicb-03-00225.PMC3380294.pdf
"‘‘Winscape’’ (http://www.rationalcraft.com/Winscape.html) can be considered as another implementation of SR, as it can convince participants that a flat monitor on a wall, which shows a video streamof distant landscape, is a real window.",Non-OADS,/arxiv_data1/oa_pdf/bb/06/srep00459.PMC3380296.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/bb/06/srep00459.PMC3380296.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Suzuki, K., Wakisaka, S. & Fujii, N. Substitutional Reality System: A Novel Experimental Platform for Experiencing Alternative Reality.",Non-OADS,/arxiv_data1/oa_pdf/bb/06/srep00459.PMC3380296.pdf
"Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreportsCompeting financial interests: This work was supported by the Programme for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry by the Bio-oriented Technology Research Advancement Institution (BRAIN), JAPAN.",Non-OADS,/arxiv_data1/oa_pdf/42/33/srep00233.PMC3380406.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Matsumoto, M. et al.",Non-OADS,/arxiv_data1/oa_pdf/42/33/srep00233.PMC3380406.pdf
Transfor-mants were selected on synthetic complete media (SC) lacking 1http://abrc.osu.edutryptophan (Trp) and uracil (Ura).,OADS,/arxiv_data1/oa_pdf/ba/d7/fpls-03-00124.PMC3380418.pdf
"Domain–domain interaction was themost important feature, followed by the similarity scores basedon GO function and process annotations, and the topological 2ftp://ftp.arabidopsis.org/home/tair/Microarrays/analyzed_data/ 3http://atted.jp/help/coex_cal.shtml Frontiers in Plant Science | Plant Physiology June 2012 | Volume 3 | Article 124 | 4",OADS,/arxiv_data1/oa_pdf/ba/d7/fpls-03-00124.PMC3380418.pdf
"Particularly, three-node 4http://www.arabidopsis.org/tools/bulk/go/index.jsp FIGUR E 5 | Network diagrams of our ﬁnal protein interaction network (without the Cub hubs) (A), AraNet ( Lee et al., 2010 ) co-function links (B), PAIR DB ( Lin et al., 2011 ) co-function links (C), and a union of the protein interaction, AraNet, and PAIR DB links (D) visualized byCytoscape.",OADS,/arxiv_data1/oa_pdf/ba/d7/fpls-03-00124.PMC3380418.pdf
SUPPLEMENTARY MATERIAL The Supplementary Material for this article can be found online at:http://www.frontiersin.org/Plant_Physiology/10.3389/fpls.2012.00124/abstract T able S1 | A list of 414 proteins that were tested in the ﬁrst mbSUS assays.,Non-OADS,/arxiv_data1/oa_pdf/ba/d7/fpls-03-00124.PMC3380418.pdf
Publications policy and guidance 2004; Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4071443.,Non-OADS,/arxiv_data1/oa_pdf/2c/66/TOCMJ-6-72.PMC3380419.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2c/66/TOCMJ-6-72.PMC3380419.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare that they have no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/a9/6f/srep00460.PMC3380441.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Fu, F. et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/6f/srep00460.PMC3380441.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.European Journal of Heart Failure (2012) 14, 782–790 doi:10.1093/eurjhf/hfs083",Non-OADS,/arxiv_data1/oa_pdf/d8/0d/hfs083.PMC3380546.pdf
2009; Available from: http://www.hesonline.nhs.uk (accessed August 2010).,Non-OADS,/arxiv_data1/oa_pdf/d8/0d/hfs083.PMC3380546.pdf
2010; available from: http://www.dh.gov.uk (accessed August 2010).,OADS,/arxiv_data1/oa_pdf/d8/0d/hfs083.PMC3380546.pdf
2008; available from: http://www.nice.org.uk/ (accessed August 2010).,Non-OADS,/arxiv_data1/oa_pdf/d8/0d/hfs083.PMC3380546.pdf
"Retrieved December 23, 2010, from http://www.houstonisd.org/ Ialongo, N. S., Poduska, J. M., Werthamer, L., & Kellam, S. (2001).",Non-OADS,/arxiv_data1/oa_pdf/bc/61/10488_2011_Article_383.PMC3381118.pdf
"0098-311-6248238: e-mail, mosharraf@dnt.mui.ac.irReceived February 15, 2012 / Last Revison May 2, 2012 / Accepted May 7, 2012 ⓒ2012 The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative CommonsAttribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproductionin any medium, provided the original work is properly cited.http://dx.doi.org/10.4047/jap.2012.4.2.103 ORIGINAL ARTICLE J Adv Prosthodont 2012;4:103-8",Non-OADS,/arxiv_data1/oa_pdf/dc/d2/jap-4-103.PMC3381201.pdf
"However, there are not enough clinical studieshttp://dx.doi.org/10.4047/jap.2012.4.2.109 Complication rates and patient satisfaction with  removable dentures Hakan Bilhan, DDS, PhD, Ozge Erdogan, DDS, PhD, Selen Ergin, DDS, PhD, Melahat Celik, DDS, PhD, Gokcen Ates, DDS, PhD, Onur Geckili*, DDS, PhD Department of Prosthodontics, Faculty of Dentistry, Istanbul University, Istanbul, Turkey PURPOSE.",Non-OADS,/arxiv_data1/oa_pdf/1f/c4/jap-4-109.PMC3381202.pdf
"90 212 414 20 20/30256: e-mail, geckili@istanbul.edu.trReceived February 28, 2012 / Last Revison May 4, 2012 / Accepted May 9, 2012 ⓒ2012 The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative CommonsAttribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproductionin any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1f/c4/jap-4-109.PMC3381202.pdf
"82 55 360 5130: e-mail, cmjeong@pusan.ac.krReceived August 24, 2011 / Last Revison November 18, 2011 / AcceptedNovember 21, 2011 ⓒ2012 The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative CommonsAttribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproductionin any medium, provided the original work is properly cited.http://dx.doi.org/10.4047/jap.2012.4.2.116 CASE REPORT J Adv Prosthodont 2012;4:116-20",Non-OADS,/arxiv_data1/oa_pdf/8d/85/jap-4-116.PMC3381203.pdf
"00919950547337: e-mail, aporwal2000@gmail.comReceived July 27, 2011 / Last Revison February 17, 2012 / Accepted March 21, 2012 ⓒ2012 The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative CommonsAttribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproductionin any medium, provided the original work is properly cited.http://dx.doi.org/10.4047/jap.2012.4.2.61 ORIGINAL ARTICLE J Adv Prosthodont 2012;4:61-71",Non-OADS,/arxiv_data1/oa_pdf/2a/62/jap-4-61.PMC3381204.pdf
"Anterior teeth width was measured from distalcontact point of 13 to distal contact point of 23 in maxilla andhttp://dx.doi.org/10.4047/jap.2012.4.2.72 Golden proportion assessment between maxillary and mandibular teeth on Indian population Naveen Gopi Chander1*, MDS, DNB, Vaikunth Vijay Kumar2, MDS, Vedantham Rangarajan3, MDS  1Department of Prosthodontics, SRM Dental College, Ramapuram, Chennai, India, 2Department of Prosthodontics, Priyadarshini Dental College, Chennai, India, 3Department of Prosthodontics, Sri Venkateshwara Dental College, Chennai, India PURPOSE.",Non-OADS,/arxiv_data1/oa_pdf/d1/12/jap-4-72.PMC3381205.pdf
"91 98407 49441: e-mail, drgopichander@gmail.comReceived October 6, 2011 / Last Revison February 17, 2012 / Accepted February20, 2012 ⓒ2012 The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative CommonsAttribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproductionin any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d1/12/jap-4-72.PMC3381205.pdf
"Denzir-M �(Dentronic AB) is an exam-http://dx.doi.org/10.4047/jap.2012.4.2.76 Clinical performance and failures of zirconia-based fixed partial dentures: a review literature Premwara Triwatana, BSc, DDS, MS, Noppavan Nagaviroj, DDS, MSc, Chantana Tulapornchai*, DDS, MSc Department of Prosthodontics, Faculty of Dentistry, Mahidol University, Bangkok, Thailand PURPOSE.",Non-OADS,/arxiv_data1/oa_pdf/39/1c/jap-4-76.PMC3381206.pdf
"114: e-mail, dtctl@mahidol.ac.thReceived December 5, 2011 / Last Revison March 13, 2012 / Accepted March 20,2012 ⓒ2012 The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative CommonsAttribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproductionin any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/39/1c/jap-4-76.PMC3381206.pdf
"So it is all more impor-http://dx.doi.org/10.4047/jap.2012.4.2.84 Effect of alginate chemical disinfection on bacterial count over gypsum cast Satheesh B. Haralur*, MDS, Omir S. Al-Dowah, BDS, Naif S. Gana, BDS, Abdullah Al-Hytham, MSc Department of Prosthodontics, College of Dentistry, King Khalid University, Kingdom of Saudi Arabia PURPOSE.",Non-OADS,/arxiv_data1/oa_pdf/ea/99/jap-4-84.PMC3381207.pdf
"966 555835386: e-mail, hb_satheesh@yahoo.comReceived December 26, 2011 / Last Revison January 19, 2012 / AcceptedFebruary 21, 2012 ⓒ2012 The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative CommonsAttribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproductionin any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ea/99/jap-4-84.PMC3381207.pdf
"55 16 3602 4046: e-mail, rtiossi@yahoo.comReceived January 26, 2012 / Last Revison May 2, 2012 / Accepted May 7, 2012 ⓒ2012 The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative CommonsAttribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproductionin any medium, provided the original work is properly cited.http://dx.doi.org/10.4047/jap.2012.4.2.89 ORIGINAL ARTICLE J Adv Prosthodont 2012;4:89-92",Non-OADS,/arxiv_data1/oa_pdf/42/bb/jap-4-89.PMC3381208.pdf
"Therefore, it is important to evaluate the effectof different light curing units or different thicknesses of zirconiahttp://dx.doi.org/10.4047/jap.2012.4.2.93 Comparison of light transmittance in different  thicknesses of zirconia under various light curing units Isil Cekic-Nagas*, DDS, PhD, Ferhan Egilmez, DDS, PhD, Gulfem Ergun, DDS, PhD Department of Prosthodontics, Faculty of Dentistry, Gazi University, Ankara, Turkey PURPOSE.",Non-OADS,/arxiv_data1/oa_pdf/d8/c9/jap-4-93.PMC3381209.pdf
"90 312 203 41 91: e-mail, isilcekic@gazi.edu.trReceived February 3, 2012 / Last Revison May 2, 2012 / Accepted May 4, 2012 ⓒ2012 The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative CommonsAttribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproductionin any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d8/c9/jap-4-93.PMC3381209.pdf
"4Improvements have also been reported in chewing efficiency and bite force, resulting in a greater dis-tribution of occlusal forces over the denture bearing tissues,http://dx.doi.org/10.4047/jap.2012.4.2.97 An investigation into the effect of denture adhesives on incisal bite force of complete denture wearers using pressure transducers - a clinical study Pawan Kalra1, BDS, MDS, Ramesh Nadiger2, BDS, MDS, Farhan Khalid Shah3*, BDS, MDS 1Department of Prosthodontics, Harsarandas Dental College, Ghaziabad, India, 2Department of Prosthodontics, SDM College of Dental Sciences, Dharwad, India, 3Department of Prosthodontics, College of Dentistry, King Khalid University, Abha, Saudi Arabia PURPOSE.",Non-OADS,/arxiv_data1/oa_pdf/6b/96/jap-4-97.PMC3381210.pdf
"966542609929: e-mail, drfarhanshah@yahoo.com   Received February 5, 2012 / Last Revison May 2, 2012 / Accepted May 15, 2012 ⓒ2012 The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative CommonsAttribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproductionin any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6b/96/jap-4-97.PMC3381210.pdf
"CTA is an associative learning paradigm; by means of CTA, organisms learn to avoid a Th e Role of Protein Phosphorylation  in the Gustatory Cortex and Amygdala  During Taste Learning Chinnakkaruppan Adaikkan1,2 and Kobi Rosenblum1,2* 1Sagol Department of Neurobiology, 2Center for Gene Manipulation in the Brain, Faculty for Science,  University of Haifa, Haifa 31905, Israelhttp://dx.doi.org/10.5607/en.2012.21.2.37Exp Neurobiol.",Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
"Key words:  taste, insular cortex, amygdala, phosphorylation, translation regulation, ERK-MAPK This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
"38 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Chinnakkaruppan Adaikkan and Kobi Rosenblum novel food substance (conditioned stimulus, CS) associated with  delayed poisoning (unconditioned stimulus, US) [1-3].",Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
"39 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Phosphorylation and Taste Learning AMY , particularly in the CeA, has been shown to impair CTA  memory [38], and CREB mutant mice have also been found to be impaired in CTA memory [39], which suggests that the activity of CREB is vital for CTA memory formation.",Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
40 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Chinnakkaruppan Adaikkan and Kobi Rosenblum routes of protein degradation.,OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
"41 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Phosphorylation and Taste Learning As in the IC, novel taste learning activates ERKI/II in the  LA also [29].",Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
"42 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Chinnakkaruppan Adaikkan and Kobi Rosenblum subunits of PKA in mice, and phar macological studies using PKA  inhibitors have shown that the blockage of PKA activity in the IC or the AMY impaired long-term but not short-term CTA memory [85-88].",OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
43 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Phosphorylation and Taste Learning transgenic mice with genetically inhibited calcineurin showed  improved CTA memory and enhanced resistance to CTA extinction [109].,Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
44 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Chinnakkaruppan Adaikkan and Kobi Rosenblum the downstream signaling cascade that leads to activation of  learning-related protein changes [95].,OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
"45 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Phosphorylation and Taste Learning IC of discrete clusters of neurons, which responded selectively  to different taste modalities [143-145].",Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
46 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Chinnakkaruppan Adaikkan and Kobi Rosenblum 10.,Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
47 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Phosphorylation and Taste Learning and visceral inputs to the amygdala of the rat: conditioned  taste aversion and induction of c-fos-like immunoreactivity.,Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
48 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Chinnakkaruppan Adaikkan and Kobi Rosenblum 59.,Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
49 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Phosphorylation and Taste Learning Learn Mem 18:529-533.,Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
50 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Chinnakkaruppan Adaikkan and Kobi Rosenblum (2008) Control of the establishment of aversive memory by  calcineurin and Zif268.,Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
51 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.37Phosphorylation and Taste Learning campus.,Non-OADS,/arxiv_data1/oa_pdf/20/0b/en-21-37.PMC3381211.pdf
"Activation of the AMPK complex requires AMP-Activated Protein Kinase (AMPK) and  Energy-Sensing in the Brain Santosh Ramamurthy1,4 and Gabriele Ronnett1,2,3,4,5* Departments of 1Neuroscience, 2Neurology, and 3Biological Chemistry, 4Center for Metabolism and Obesity Research,  Th e Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA, 5Daegu Gyeongbuk Institute of  Science and Technology (DGIST), Daegu 711-873, Koreahttp://dx.doi.org/10.5607/en.2012.21.2.52Exp Neurobiol.",Non-OADS,/arxiv_data1/oa_pdf/40/5e/en-21-52.PMC3381212.pdf
"Key words:  5’-adenosine monophosphate-activated kinase, AMPK, energy balance, neuronal metabolism, stroke, feeding behavior This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/40/5e/en-21-52.PMC3381212.pdf
"53 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.52AMPK in the Brain phosphorylation of the α subunit at threonine-172 (T172) in the  kinase loop by one of two identified upstream kinases, LKB1 (Liver kinase B1/serine threonine kinase 11) or CaMKKβ (Ca 2+/ calmodulin-dependent kinase kinase β) (Fig.",Non-OADS,/arxiv_data1/oa_pdf/40/5e/en-21-52.PMC3381212.pdf
54 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.52Santosh Ramamurthy and Gabriele Ronnett carnitne palmitoyltransferase-1 stimulator and demonstrated its  ability to reduce food intake and body weight in mice [17-19].,Non-OADS,/arxiv_data1/oa_pdf/40/5e/en-21-52.PMC3381212.pdf
55 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.52AMPK in the Brain AMPK inhibitor compound C was able protect neurons from  tributyltin toxicity.,OADS,/arxiv_data1/oa_pdf/40/5e/en-21-52.PMC3381212.pdf
56 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.52Santosh Ramamurthy and Gabriele Ronnett development [63].,Non-OADS,/arxiv_data1/oa_pdf/40/5e/en-21-52.PMC3381212.pdf
57 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.52AMPK in the Brain Nat Cell Biol 13:1016-1023.,OADS,/arxiv_data1/oa_pdf/40/5e/en-21-52.PMC3381212.pdf
58 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.52Santosh Ramamurthy and Gabriele Ronnett 26.,Non-OADS,/arxiv_data1/oa_pdf/40/5e/en-21-52.PMC3381212.pdf
59 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.52AMPK in the Brain 43.,Non-OADS,/arxiv_data1/oa_pdf/40/5e/en-21-52.PMC3381212.pdf
60 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.52Santosh Ramamurthy and Gabriele Ronnett (2011) Nuclear translocation of AMPK-alpha1 potentiates  striatal neurodegeneration in Huntington ’ s disease.,Non-OADS,/arxiv_data1/oa_pdf/40/5e/en-21-52.PMC3381212.pdf
"In primary neuronal cultures, newly formed neurons undergo a series of extensive morphological changes as they mature, including neurite Diff erential Expressions of Synaptogenic  Markers between Primary Cultured Cortical and  Hippocampal Neurons Yun-Gi Kim1 and Y oung-Il Lee2* Departments of 1NanoBio Medical Science, 2Anatomy, College of Medicine, Dankook University, Cheonan 330-714, Koreahttp://dx.doi.org/10.5607/en.2012.21.2.61Exp Neurobiol.",Non-OADS,/arxiv_data1/oa_pdf/24/8d/en-21-61.PMC3381213.pdf
"TEL: 82-41-550-3855, FAX: 82-41-556-6461e-mail: anat104@dku.edu Copyright © Experimental Neurobiology 2012. www.enjournal.orgThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Primary dissociated neuronal cultures are widely used research to ols to investigate of pathological mechanisms and to treat var ious  central and peripheral nervous system problems including trauma and degenerative neuronal diseases.",Non-OADS,/arxiv_data1/oa_pdf/24/8d/en-21-61.PMC3381213.pdf
"62 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.61Yun-Gi Kim and Y oung-Il Lee sprouting and outgrowth, neurite branching, and establishment  of synaptogenesis.",OADS,/arxiv_data1/oa_pdf/24/8d/en-21-61.PMC3381213.pdf
63 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.61Diff erential Expressions of Synaptogenic Markers in Primary Cultured Neuron with ice-cold 70% ethanol for 10 min and washed with DPBS 3  times for 5 min.,OADS,/arxiv_data1/oa_pdf/24/8d/en-21-61.PMC3381213.pdf
64 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.61Yun-Gi Kim and Y oung-Il Lee neurons (data not shown).,OADS,/arxiv_data1/oa_pdf/24/8d/en-21-61.PMC3381213.pdf
65 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.61Diff erential Expressions of Synaptogenic Markers in Primary Cultured Neuron especially under high magnifi  cations.,Non-OADS,/arxiv_data1/oa_pdf/24/8d/en-21-61.PMC3381213.pdf
66 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.61Yun-Gi Kim and Y oung-Il Lee on non-coated cover slips and clumped heavily (data not shown).,Non-OADS,/arxiv_data1/oa_pdf/24/8d/en-21-61.PMC3381213.pdf
67 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.61Diff erential Expressions of Synaptogenic Markers in Primary Cultured Neuron 15.,Non-OADS,/arxiv_data1/oa_pdf/24/8d/en-21-61.PMC3381213.pdf
"Therefore, it is crucial to determine Neurochemical Properties of Dental Primary  Aff erent Neurons Hue Vang1+, Gehoon Chung1+, Hyun Y eong Kim1, Seok-Beom Park2,  Sung Jun Jung3, Joong-Soo Kim1 and Seog Bae Oh1* 1National Research Laboratory for Pain, Dental Research Institute and Department of Neurobiology and Physiology,  School of Dentistry, Seoul National University, Seoul 110-749, 2Department of Physiology, College of Medicine,  Kangwon National University, Chuncheon 200-701, 3Department of Physiology, School of Medicine,  Hanyang University, Seoul 133-791, Koreahttp://dx.doi.org/10.5607/en.2012.21.2.68Exp Neurobiol.",Non-OADS,/arxiv_data1/oa_pdf/7b/a9/en-21-68.PMC3381214.pdf
"Key words:  nociceptor, trigeminal ganglion, tooth pain, peripherin, NF200, ATF3 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7b/a9/en-21-68.PMC3381214.pdf
69 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.68Non-Nociceptive Neurons in Dental Pulp whether dental primary aff  erent neurons are purely nociceptors or  not in order to understand the sensory system of oral cavity.,Non-OADS,/arxiv_data1/oa_pdf/7b/a9/en-21-68.PMC3381214.pdf
"70 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.68Hue Vang, et al.",OADS,/arxiv_data1/oa_pdf/7b/a9/en-21-68.PMC3381214.pdf
71 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.68Non-Nociceptive Neurons in Dental Pulp possibility.,Non-OADS,/arxiv_data1/oa_pdf/7b/a9/en-21-68.PMC3381214.pdf
"72 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.68Hue Vang, et al.",OADS,/arxiv_data1/oa_pdf/7b/a9/en-21-68.PMC3381214.pdf
"73 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.68Non-Nociceptive Neurons in Dental Pulp non-nociceptive large myelinated neurons, which might serve as  mechanotransducers that detect movement of dentinal fluid.",Non-OADS,/arxiv_data1/oa_pdf/7b/a9/en-21-68.PMC3381214.pdf
"74 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.68Hue Vang, et al.",OADS,/arxiv_data1/oa_pdf/7b/a9/en-21-68.PMC3381214.pdf
"Th  ese reports suggest that inhibition of Ih Capsaicin Blocks the Hyperpolarization-Activated  Inward Currents via TRPV1 in the Rat Dorsal  Root Ganglion Neurons Jiyeon Kwak * Department of Physiology and Biophysics, Inha University College of Medicine, Incheon 402-752, Koreahttp://dx.doi.org/10.5607/en.2012.21.2.75 Exp Neurobiol.",OADS,/arxiv_data1/oa_pdf/30/b7/en-21-75.PMC3381215.pdf
"Key words:  capsaicin, DRG neuron, hyperpolarization-activated cation current, rat This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/30/b7/en-21-75.PMC3381215.pdf
76 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.75Jiyeon Kwak may be responsible for the peripheral analgesia [9].,Non-OADS,/arxiv_data1/oa_pdf/30/b7/en-21-75.PMC3381215.pdf
78 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.75Jiyeon Kwak (Fig.,Non-OADS,/arxiv_data1/oa_pdf/30/b7/en-21-75.PMC3381215.pdf
80 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.75Jiyeon Kwak not involved in the inhibition of Ih in our experiment condition.,Non-OADS,/arxiv_data1/oa_pdf/30/b7/en-21-75.PMC3381215.pdf
82 www.enjournal.org http://dx.doi.org/10.5607/en.2012.21.2.75Jiyeon Kwak 24.,Non-OADS,/arxiv_data1/oa_pdf/30/b7/en-21-75.PMC3381215.pdf
1www.unos.org/ 2http://www.eurotransplant.nl/ www.frontiersin.org June 2012 | Volume 3 | Article 168 | 1,Non-OADS,/arxiv_data1/oa_pdf/69/5f/fimmu-03-00168.PMC3381218.pdf
"Therefore, it is necessary to understand the impact of 3http://clinicaltrials.gov www.frontiersin.org June 2012 | Volume 3 | Article 168 | 5",Non-OADS,/arxiv_data1/oa_pdf/69/5f/fimmu-03-00168.PMC3381218.pdf
"For each subject and each session, 2http://icatb.sourceforge.net/four ROIs were identiﬁed: the PCC, the left later parietal cor- tex (LPC), the right later parietal cortex (RPC), and the mPFC.",OADS,/arxiv_data1/oa_pdf/06/5f/fpsyg-03-00206.PMC3381220.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.Q J Med 2012; 105:641–648 doi:10.1093/qjmed/hcs031 Advance Access Publication 29 February 2012",Non-OADS,/arxiv_data1/oa_pdf/af/a5/hcs031.PMC3381221.pdf
[http://www.cdc.gov/nchs/icd.htm] Accessed 11 January2012.,Non-OADS,/arxiv_data1/oa_pdf/af/a5/hcs031.PMC3381221.pdf
"Database URL: http://www.MuteinDB.org ............................................................................................................................... ............................................................................................................................... ............................... Introduction One of nature’s fundamental mechanisms to create genetic diversity in living organisms is the creation of mutants,which, in turn, leads to evolution.",OADS,/arxiv_data1/oa_pdf/84/db/bas028.PMC3381223.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creative-commons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/84/db/bas028.PMC3381223.pdf
"In this article, we present the novel database MuteinDB (http://www.MuteinDB.org).",Non-OADS,/arxiv_data1/oa_pdf/84/db/bas028.PMC3381223.pdf
"The PubMed ID or the digital object identifier (DOI, http://crossref.org) of the publications are given and directly linked to PubMed or to the webpageassociated with the digital object identifier, respectively.Additionally, the EC number is provided and linked to thecomprehensive enzyme database BRENDA ( Figure 2 F–H).",OADS,/arxiv_data1/oa_pdf/84/db/bas028.PMC3381223.pdf
The CreZOO (http://www.crezoo.org/) is the European virtual repository of Cre and other targeted conditional driver strains.,Non-OADS,/arxiv_data1/oa_pdf/2f/3f/bas029.PMC3381224.pdf
"CreZOO is being developed in the context of the CREATE consortium (http://www.creline.org/), a core of major European and international mouse database holders and research groups involved in conditional mutagenesis.",Non-OADS,/arxiv_data1/oa_pdf/2f/3f/bas029.PMC3381224.pdf
"Database URL: http://www.crezoo.org/; alternative URL: http://www.e-mouse.org/ ............................................................................................................................... ............................................................................................................................... ............................... Introduction The detailed knowledge gained through sequencing the mouse and human genomes has provided a comprehensive picture of gene arrangement and composition, revealing the startling genetic similarities between mouse and man(1).",Non-OADS,/arxiv_data1/oa_pdf/2f/3f/bas029.PMC3381224.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2f/3f/bas029.PMC3381224.pdf
"Given the importance of this powerful Cre-recombinase mouse system and in the context of the CREATE(Coordination of resources for conditional expression ofmutated mouse alleles) Coordination Action (http://www.creline.org/), a European CreZOO (http://www.crezoo.org/) has been created in an attempt to bring togetherexisting and new Cre driver strains created and main-tained in Europe, their complete characterization, andadequate coverage of cell and tissue types in whichthey are active.",Non-OADS,/arxiv_data1/oa_pdf/2f/3f/bas029.PMC3381224.pdf
Alexander Fleming Institute (http://www.fleming.gr/).Database design and implementation CreZOO is a J2EE application built around a PostgreSQL database that consists of 66 tables.,OADS,/arxiv_data1/oa_pdf/2f/3f/bas029.PMC3381224.pdf
The CreZOO application is hosted in a Glassfish 2.1 server and itssource code is available under the GNU general public li-cense at Githubs public repository (https://github.com/bioit/ crezoo).,OADS,/arxiv_data1/oa_pdf/2f/3f/bas029.PMC3381224.pdf
"Overall, gene/promoter and allelic nomenclature is as- signed according to rules and guidelines for mouse genesand strains given by MGI [( 8) http://www.informatics.jax .org/mgihome/nomen/strains.shtml] and based on GeneOntology (GO) [( 9) http://www.geneontology.org] and international nomenclature standards.",Non-OADS,/arxiv_data1/oa_pdf/2f/3f/bas029.PMC3381224.pdf
"CreZOO, staying up to date with the use of structured vocabularies for transgenic mouse descriptions, is planningto collaborate with EMAP (http://www.emouseatlas.org/ emap/home.html) ( 8) to best characterize mouse develop- mental stages and temporal Cre or other targeted condi-tional expression, thus enabling its users to detect the desired developmental stage via simple keyword(s) search and to eventually make developmental stage as- signment as simple as possible.",Non-OADS,/arxiv_data1/oa_pdf/2f/3f/bas029.PMC3381224.pdf
CreZOO taking into account the necessity for database interoperability and combinational data from different resources ( 9) has already developed web services and is contributing itsdata to the Cre8 portal (http://www.creline.org/search_cre_mice).,OADS,/arxiv_data1/oa_pdf/2f/3f/bas029.PMC3381224.pdf
"Participat- ing databases (CreZOO/EU [http://www.crezoo.org/], MGI’sRecombinase/USA [http://www.informatics.jax.org/recom-binase.shtml] and Cre-X-Mice/Canada [http://nagy.mshri.on.ca/cre_new/index.php]) are exchanging/contributingseven agreed datafields to the cre8 portal, thus fulfilling the urgent need on the production and expansion of an international creZOO to complement the conditionalmouse alleles currently being generated worldwide.",Non-OADS,/arxiv_data1/oa_pdf/2f/3f/bas029.PMC3381224.pdf
"1NIF, http://neuinfo.orgNIFSTD DESIGN PRINCIPLES As originally proposed in Bug et al.",Non-OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
"Based on the 2BFO, http://www.ifomis.org/bfo 3BFO manual, http://www.ifomis.org/bfo/manual www.frontiersin.org June 2012 | Volume 3 | Article 111 | 1",Non-OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
"OWL 4OWL, http://www.w3.org/TR/owl-ref/ 5DIG Group, http://dl.kr.org/dig/ 6OWL 2 Primer, http://www.w3.org/TR/owl2-primer/2 provides improved ontological features such as deﬁning prop- erty chain rules to enable transitivity across object properties, specifying reﬂexivity, asymmetry, and disjointness between object properties, richer data-types, qualiﬁed cardinality restrictions, and enhanced annotation capabilities.",Non-OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
"(2006), OntoQuest generates an OWL-compliant relational schema for NIFSTD ontologies and implements various graph search algorithms for navigating, path ﬁnding, hierarchy exploration, and term searching in ontological 7OWL format, http://purl.org/nif/ontology/nif.owl 8Protégé Ontology Editor, http://protege.stanford.edu/ 9NIFSTD in NCBO BioPortal, http://bioportal.bioontology.org/ontologies/40510 10NIFSTD SPARQL endpoint, http://ontology.neuinfo.org/sparql-endpoint.html T able 1 |The NIFSTD OWL modules and corresponding community sources from which they were built.",OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
"As we worked through the process of adopting CogPO, we needed to make sure that the upper-level 11OntoQuest, http://ontology.neuinfo.org/ontoquest-service.htmlclasses in CogPO were BFO compliant and derivable under the same foundational layers of NIFSTD, and the properties were extended from OBO-RO.",OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
"12Ontology Design Pattern: Normalization,http://ontologydesignpatterns.org/wiki/ Submissions:Normalization www.frontiersin.org June 2012 | Volume 3 | Article 111 | 3",Non-OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
"Based on where the relations are asserted, there are two kinds of relations that exist in NIFSTD: one that are within a same module, i.e., intra-modular relations, 13PubMed, http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0006431/and the other that is inter-modular, cross-domain relations that exist as a separate, isolated module between two independent modules.",OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
The umbrella ﬁle nif.owl at http://purl.org/nif/ontology/nif.owl always imports the current versions of the NIFSTD modules.,OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
All other versions after the 1.0 release can be accessed from the NIF ontology archive at http://ontology.neuinfo.org/NIF/Archive/.,OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
"The release note should include a version number, version speciﬁc major changes, major hierarchical changes, newly added module(s), and other technical changes Update NIFSTD (production) This step involves updating the NIFSTD OWL modules in the production server that are pointing to the Persistent URLs (PURL; http://purl.org) Update NeuroLex Wiki A new release of NIFSTD should be followed by the updates in NeuroLex wiki which will reﬂect the implemented additions/changes of the NIFSTD contents merged with the previous iteration Update OntoQuest A major release of NIFSTD should be followed by an update in OntoQuest production version Update BioPortal A major release of NIFSTD should be followed by an update in BioPortal production version Frontiers in Genetics | Bioinformatics and Computational Biology June 2012 | Volume 3 | Article 111 | 6",Non-OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
"The NIF portal provides simultaneous search across three major sources of information: (1) The NIF Registry; a catalog of 14International Neuroinformatics Coordinating Facility, http://incf.org>4500 resources (databases, tools, materials, services) categorized according to the NIF Resource module and annotated with key- words derived from other NIFSTD modules; (2) The NIF Data Federation: Deep access to the contents of >150 databases; and (3) NIF Literature: Abstracts of Pub Med and full text of open access articles.",OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
Available at: http://dx.doi.org/10.1038/npre.2009.,Non-OADS,/arxiv_data1/oa_pdf/86/57/fgene-03-00111.PMC3381282.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Tan, X. et al.",Non-OADS,/arxiv_data1/oa_pdf/5d/1e/srep00466.PMC3381290.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/21/db/srep00467.PMC3381291.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Qin, C. et al.",Non-OADS,/arxiv_data1/oa_pdf/21/db/srep00467.PMC3381291.pdf
"The rapidly decreasing cost and 1http://www.onekp.com/increasing output from “next generation” sequencing ( Mardis, 2008 ;Schuster, 2008 ) now allows a different strategy, in which diverse species can be selected for study based on phylogeneticposition and biological traits of interest.",Non-OADS,/arxiv_data1/oa_pdf/5a/24/fpls-03-00137.PMC3381292.pdf
"Repositories within USDA ’s NPGS can be searched at http://www.ars-grin.gov/npgs/index.html, and BGCI’sPlantSearch 4has the capability to draw upon over 500,000 records in botanic gardens across the globe.",OADS,/arxiv_data1/oa_pdf/5a/24/fpls-03-00137.PMC3381292.pdf
2http://arboretum.harvard.edu/plants/plant-inventory/ 3http://arboretum.harvard.edu/plants/collection-researcher/ 4http://www.bgci.org/plant_search.php Frontiers in Plant Science |Plant Evolution and Development June 2012 |Volume 3 |Article 137 |4,Non-OADS,/arxiv_data1/oa_pdf/5a/24/fpls-03-00137.PMC3381292.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/b0/43/thnov02p0553.PMC3381344.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/55/91/thnov02p0589.PMC3381345.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/e5/2e/thnov02p0577.PMC3381346.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/22/e8/thnov02p0541.PMC3381347.pdf
"To view a copy of this license, visit http://creativecommons .org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)Overexpressed hPTTG1 activates GEF-H1 to promote Metastasis YC Liao et al 3097 Oncogene",Non-OADS,/arxiv_data1/oa_pdf/f3/fb/onc2011476a.PMC3381367.pdf
Motion artifacts were examined using an artifact detection toolbox (ART) (http://www.nitrc.org/projects/artifact_detect/).,OADS,/arxiv_data1/oa_pdf/67/a7/fnhum-06-00169.PMC3381445.pdf
Connectivity analyses were conducted using the CONN-fMRI functional connectivity toolbox for SPM (ver 12) (http://web.mit.edu/swg/software.htm).,OADS,/arxiv_data1/oa_pdf/67/a7/fnhum-06-00169.PMC3381445.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 759Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.759 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):759-764, 2012 Anti-Cyclic Citrullinated Peptide Antibodies and   Joint Involvement in Behçet’s Disease Sung Bin Cho,1 Ju Hee Lee,1 Keun Jae Ahn,1 Byung Gi Bae,1 Taegyun Kim,1  Yong-Beom Park,2 Soo-Kon Lee,2 Kwang Hoon Lee,1 and Dongsik Bang1 1Department of Dermatology and Cutaneous Biology Research Institute, 2Division of Rheumatology, Department of Internal Medicine, Institute for Immunology and Immunologic Diseases,  BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/47/c6/ymj-53-759.PMC3381466.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  We aimed to determine the prevalence of anti-cyclic citrullinated pep - tide (anti-CCP) antibodies in a large group of Korean patients with Behçet’s dis - ease (BD), with and without joint involvement, and to compare these findings with  the prevalences of anti-CCP antibodies in patients with rheumatoid arthritis (RA)  and systemic lupus erythematosus (SLE).",Non-OADS,/arxiv_data1/oa_pdf/47/c6/ymj-53-759.PMC3381466.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 760Joint involvement in BD was defined as joint symptoms of  both arthralgia and arthritis without joint deformities.,Non-OADS,/arxiv_data1/oa_pdf/47/c6/ymj-53-759.PMC3381466.pdf
Anti-CCP and Behçet’s Disease Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 761years and age range 12-67 years).,Non-OADS,/arxiv_data1/oa_pdf/47/c6/ymj-53-759.PMC3381466.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 762Several studies have attempted to establish the frequency  of positive anti-CCP antibody tests in BD, though findings  have varied.6,9-12 Kwok, et al.9 reported that one of three BD  patients had positive anti-CCP tests; while Sghiri, et al.10 re- ported one among five, and another study reported none in  four.11 Koca, et al.6 reported that one patient out of 46 BD  patients (2.2%) and three of the 46 patients (6.5%) tested  positive for anti-CCP and IgM RF, respectively.",Non-OADS,/arxiv_data1/oa_pdf/47/c6/ymj-53-759.PMC3381466.pdf
Anti-CCP and Behçet’s Disease Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 7634.,Non-OADS,/arxiv_data1/oa_pdf/47/c6/ymj-53-759.PMC3381466.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 764lupus erythematosus.,Non-OADS,/arxiv_data1/oa_pdf/47/c6/ymj-53-759.PMC3381466.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 772Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.772 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):772-780, 2012 Predictors of Postoperative Mortality of Ruptured Abdominal  Aortic Aneurysm: A Retrospective Clinical Study Sang Dong Kim, Jeong Kye Hwang, Sun Cheol Park, Ji Il Kim, In Sung Moon,   Jang Sang Park, and Sang Seob Yun Division of Vascular and Endovascular Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/4d/46/ymj-53-772.PMC3381467.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Despite significant improvements in surgery, anesthesia, and postopera - tive critical care, the postoperative mortality rate of ruptured abdominal aortic aneu - rysm (RAAA) has remained at 40% to 50% for several decades.",Non-OADS,/arxiv_data1/oa_pdf/4d/46/ymj-53-772.PMC3381467.pdf
"Postoperative Mortality of RAAA Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 773disease (IHD), diabetes mellitus (DM), hypertension, stroke,  chronic renal failure (CRF), chronic obstructive pulmonary  disease (COPD)], serum creatinine, hemoglobin, shock,  pulse rate, and time from ER to operation room (OR).",Non-OADS,/arxiv_data1/oa_pdf/4d/46/ymj-53-772.PMC3381467.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 774HUO (mL) was 107.76±57.16, and the operation time (min)  was 294.12±68.23 (Table 1 and 2).",OADS,/arxiv_data1/oa_pdf/4d/46/ymj-53-772.PMC3381467.pdf
"Postoperative Mortality of RAAA Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 775ative factors, intraoperative transfusion was statistically sig - nificant (p=0.031) (Table 2).",Non-OADS,/arxiv_data1/oa_pdf/4d/46/ymj-53-772.PMC3381467.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 776On multivariate analysis of the association of the 2-day  mortality and factors found to be significant on univariate  analysis, preoperative shock ( p=0.049), postoperative ino - tropic support ( p=0.002) and postoperative MOF ( p=0.001)  were statistically significant (Table 4).",Non-OADS,/arxiv_data1/oa_pdf/4d/46/ymj-53-772.PMC3381467.pdf
"Postoperative Mortality of RAAA Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 7772-day and 30-day mortality rates, and analyzed these sepa - rately.",Non-OADS,/arxiv_data1/oa_pdf/4d/46/ymj-53-772.PMC3381467.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 778been many efforts to decrease the postoperative mortality  of RAAA.2-4,6,14,20-22 Kim, et al.,2 Scarcello, et al.4 and Beah,  et al.14 asserted that operations should be performed as soon  as possible before preoperative cardiac arrest develops.",Non-OADS,/arxiv_data1/oa_pdf/4d/46/ymj-53-772.PMC3381467.pdf
"Postoperative Mortality of RAAA Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 779nani F, et al.",Non-OADS,/arxiv_data1/oa_pdf/4d/46/ymj-53-772.PMC3381467.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 78025.,Non-OADS,/arxiv_data1/oa_pdf/4d/46/ymj-53-772.PMC3381467.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 729Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.729 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):729-733, 2012 Differential Diagnosis of Complex Renal Cysts Based on Lesion  Size along with the Bosniak Renal Cyst Classification Hyun Ho Han,1 Kyung Hwa Choi,1 Young Taik Oh,2 Seung Choul Yang,1 and Woong Kyu Han1 1Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul; 2Department of Diagnostic Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/7e/24/ymj-53-729.PMC3381468.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  To identify size criteria for complex cystic renal masses that can distin - guish renal cell carcinoma from benign cysts supplementing the Bosniak classifi - cation.",Non-OADS,/arxiv_data1/oa_pdf/7e/24/ymj-53-729.PMC3381468.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 730est diameter).,Non-OADS,/arxiv_data1/oa_pdf/7e/24/ymj-53-729.PMC3381468.pdf
"Differential Diagnosis of the Complex Renal Cystic Mass Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 731category III, and 29 of 32 cases (90.1%) in category IV .",Non-OADS,/arxiv_data1/oa_pdf/7e/24/ymj-53-729.PMC3381468.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 732between the size of a cystic renal tumor - not solid - and the  possibility of cancer.,Non-OADS,/arxiv_data1/oa_pdf/7e/24/ymj-53-729.PMC3381468.pdf
Differential Diagnosis of the Complex Renal Cystic Mass Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 733cases.,Non-OADS,/arxiv_data1/oa_pdf/7e/24/ymj-53-729.PMC3381468.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 820Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.820 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):820-824, 2012 Magnetic Resonance Arthrographic Dissection of Posterolateral  Corner of the Knee: Revealing the Meniscofibular Ligament Young Han Lee,1 Ho-Taek Song,1 Sungjun Kim,1 Sung-Jae Kim,2 and Jin-Suck Suh1 1Department of Radiology, Research Institute of Radiological Science, Medical Convergence Research Institute,  and Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul; 2Department of Orthopedic Surgery and Arthroscopic Surgery Unit, Yonsei University College of Medicine, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/05/e0/ymj-53-820.PMC3381469.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  To evaluate meniscofibular ligament (MFibL) at the posterolateral cor - ner of the knee joint on the magnetic resonance arthrography (MRA) with 70°  knee flexion.",Non-OADS,/arxiv_data1/oa_pdf/05/e0/ymj-53-820.PMC3381469.pdf
Meniscofibular Ligament in MR Arthrography Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 821ance.,Non-OADS,/arxiv_data1/oa_pdf/05/e0/ymj-53-820.PMC3381469.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 8223D GRE images, reviewer 1 identified the MFibL in 94.7%  (n=18/19) by scale 2 and 5.3% (n=1/19) by scale 1, whereas  reviewer 2 identified the MFibL in 89.5% (n=17/19) by scale  2 and 10.5% (n=2/19) by scale 1 (kappa=0.642, p=0.003).",Non-OADS,/arxiv_data1/oa_pdf/05/e0/ymj-53-820.PMC3381469.pdf
"Meniscofibular Ligament in MR Arthrography Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 823The MRA with knee flexion was performed in a way  similar to the arthroscopic posture which consists of a fluid  capsular distention, knee flexion, and mild external rota - tion.",Non-OADS,/arxiv_data1/oa_pdf/05/e0/ymj-53-820.PMC3381469.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 8245.,Non-OADS,/arxiv_data1/oa_pdf/05/e0/ymj-53-820.PMC3381469.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 734Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.734 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):734-741, 2012 Five-Year Follow-Up Results of a Randomized Controlled Trial  Comparing Bipolar Plasmakinetic and Monopolar Transurethral  Resection of the Prostate  Chang-Ying Xie,2* Guang-Bin Zhu,1,2* Xing-Huan Wang,1 and Xiang-Bin Liu2 1Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei; 2Department of Urology, Daqing Oilfields General Hospital, Daqing, Heilongjiang, China.",Non-OADS,/arxiv_data1/oa_pdf/36/b4/ymj-53-734.PMC3381470.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  To report the 5-year follow-up results of a randomized controlled trial   comparing bipolar transurethral resection of the prostate (TURP) with standard  monopolar TURP for the treatment of benign prostatic obstruction (BPO).",Non-OADS,/arxiv_data1/oa_pdf/36/b4/ymj-53-734.PMC3381470.pdf
RCT Comparing Bipolar PK-TURP and M-TURP of the Prostate Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 735prostate-specific antigen (PSA) level.,Non-OADS,/arxiv_data1/oa_pdf/36/b4/ymj-53-734.PMC3381470.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 736cal analysis was based on the principles of intention to treat  and performed using SPSS software version 17.0.,OADS,/arxiv_data1/oa_pdf/36/b4/ymj-53-734.PMC3381470.pdf
RCT Comparing Bipolar PK-TURP and M-TURP of the Prostate Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 737Table 3.,Non-OADS,/arxiv_data1/oa_pdf/36/b4/ymj-53-734.PMC3381470.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 738group and in 4 patients (3.6%) in the PK-TURP group  (p=0.373).,Non-OADS,/arxiv_data1/oa_pdf/36/b4/ymj-53-734.PMC3381470.pdf
RCT Comparing Bipolar PK-TURP and M-TURP of the Prostate Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 739bin was significantly higher in the M-TURP group than in  the PK-TURP group.,Non-OADS,/arxiv_data1/oa_pdf/36/b4/ymj-53-734.PMC3381470.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 740here was in agreement with the previously reported 3 to  14.5% retreatment rate.3   In conclusion, to the best of our knowledge, our study is  the only RCT to compare PK-TURP with standard TURP  that includes 5 years of follow-up data.",Non-OADS,/arxiv_data1/oa_pdf/36/b4/ymj-53-734.PMC3381470.pdf
RCT Comparing Bipolar PK-TURP and M-TURP of the Prostate Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 741lar) versus conventional (monopolar) transurethral resection of the  prostate.,Non-OADS,/arxiv_data1/oa_pdf/36/b4/ymj-53-734.PMC3381470.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 825Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.825 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):825-833, 2012 Diffusion-Weighted MR Imaging before and after Contrast  Enhancement with Superparamagnetic Iron Oxide   for Assessment of Hepatic Metastasis  Hana Kim,1 Jeong-Sik Yu,1 Dae Jung Kim,2 Jae-Joon Chung,1 Joo Hee Kim,1 and Ki Whang Kim3 1Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul; 2Department of Radiology, CHA Bundang Medical Center, CHA University, Seongnam; 3Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/0e/72/ymj-53-825.PMC3381471.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  The purpose of our study was to validate diffusion-weighted MRI (DWI)  before and after superparamagnetic iron oxide (SPIO) injection for assessment of  hepatic metastases.",Non-OADS,/arxiv_data1/oa_pdf/0e/72/ymj-53-825.PMC3381471.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 826for informed consent from individual patients.,Non-OADS,/arxiv_data1/oa_pdf/0e/72/ymj-53-825.PMC3381471.pdf
"DWI MR with SPIO for Assesment of Hepatic Metastasis Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 827Two observers (10 years and 2 years of experience in ab - dominal imaging, respectively) independently reviewed sev - en different imaging sets consisted of SPIO-T2*wI, three  pre-DWI with different b-factors (50, 400, 800 s/mm2) and  three SPIO-DWI with different b-factors (50, 400, 800 s/ mm2), and scored the individual arrow-indicated lesions ac - cording to the 5-point confidence scale (1, no distinguish - able abnormal signals from background parenchyma; 2,  poorly defined abnormal signals but not well distinguished  from background parenchyma; 3, poorly defined but well  distinguished from background parenchyma; 4, well defined  with marginal blurring; 5, well defined with sharp margin).",OADS,/arxiv_data1/oa_pdf/0e/72/ymj-53-825.PMC3381471.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 828es except SPIO-DWI using a b-factor of 50 s/mm2 (observer  1, p=0.200; observer 2, p=0.430) (Fig.",Non-OADS,/arxiv_data1/oa_pdf/0e/72/ymj-53-825.PMC3381471.pdf
"DWI MR with SPIO for Assesment of Hepatic Metastasis Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 8291.3±1.0 cm) in the right hepatic lobe including two caudate  lobe lesions and 28 lesions (mean size±standard deviation,  1.9±1.3 cm) in the left hepatic lobe.",Non-OADS,/arxiv_data1/oa_pdf/0e/72/ymj-53-825.PMC3381471.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 830DISCUSSION When dealing with contrast-enhanced hepatic MRI, SPIO  reduces the signal intensity of normal liver parenchyma in a  manner dependent on the phagocytic effect of Kupffer cells,  resulting in an increase of lesion-to-liver contrast in cases of  hepatic malignancy and, therefore, SPIO-enhanced MRI has  been thought to be one of the best imaging tools in the as - sessment of hepatic metastases.11-13 DWI creates image con -p<0.05) or without statistical significance (b-factors of 400  and 800 s/mm2 by observer 2, p>0.3) (Table 2).",Non-OADS,/arxiv_data1/oa_pdf/0e/72/ymj-53-825.PMC3381471.pdf
DWI MR with SPIO for Assesment of Hepatic Metastasis Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 831Table 2.,Non-OADS,/arxiv_data1/oa_pdf/0e/72/ymj-53-825.PMC3381471.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 832with the SPIO-T2*wI in the present study.,Non-OADS,/arxiv_data1/oa_pdf/0e/72/ymj-53-825.PMC3381471.pdf
"DWI MR with SPIO for Assesment of Hepatic Metastasis Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 833S, et al.",Non-OADS,/arxiv_data1/oa_pdf/0e/72/ymj-53-825.PMC3381471.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 794Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.794 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):794-800, 2012 Evaluation of Postoperative Range of Motion and Functional  Outcomes after Cruciate-Retaining and Posterior-Stabilized   High-Flexion Total Knee Arthroplasty Chang Wook Han, Ick Hwan Yang, Woo Suk Lee, Kwan Kyu Park, and Chang Dong Han Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/4b/47/ymj-53-794.PMC3381472.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  The purpose of this study was to compare postoperative range of motion  and functional outcomes among patients who received high-flexion total knee ar - throplasty using cruciate-retaining (CR-Flex) and posterior-stabilized (PS-Flex)  type prostheses.",Non-OADS,/arxiv_data1/oa_pdf/4b/47/ymj-53-794.PMC3381472.pdf
"Comparison between CR-Flex and PS-Flex TKA Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 795single surgeon using Nexgen high-flexion prostheses (Zim - mer, Warsaw, IL, USA).",Non-OADS,/arxiv_data1/oa_pdf/4b/47/ymj-53-794.PMC3381472.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 796Anteroposterior and lateral fluoroscopically assisted ra - diographs, as well as a skyline patellar radiograph, were ob - tained preoperatively and postoperatively with the patient  standing and in a supine position.",Non-OADS,/arxiv_data1/oa_pdf/4b/47/ymj-53-794.PMC3381472.pdf
Comparison between CR-Flex and PS-Flex TKA Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 797tive ROM was expected for patients with older age as well  as for those with better preoperative ROM (Table 2).,Non-OADS,/arxiv_data1/oa_pdf/4b/47/ymj-53-794.PMC3381472.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 798during joint motion while preserving the longevity of the  prosthesis.,Non-OADS,/arxiv_data1/oa_pdf/4b/47/ymj-53-794.PMC3381472.pdf
"Comparison between CR-Flex and PS-Flex TKA Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 799ditt, et al.,25 using a new scoring system based on functional  performance during specific high-flexion activities, reported  that patients with CR knees showed better functional out - comes than patients with PS knees during specific high- flexion activities such as squatting, kneeling and gardening.",Non-OADS,/arxiv_data1/oa_pdf/4b/47/ymj-53-794.PMC3381472.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 800Orthop Relat Res 1996:107-17.,Non-OADS,/arxiv_data1/oa_pdf/4b/47/ymj-53-794.PMC3381472.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 834Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.834 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):834-841, 2012 Capsaicin-Induced Apoptosis of FaDu Human Pharyngeal  Squamous Carcinoma Cells Thanh-Do Le,1* Dong Chun Jin,1* Se Ra Rho,1 Myung Su Kim,1 Rina Yu,2 and Hoon Yoo1 1Department of Pharmacology and Dental Therapeutics, School of Dentistry, Chosun University, Gwangju; 2Department of Food Science and Nutrition, University of Ulsan, Ulsan, Korea.",Non-OADS,/arxiv_data1/oa_pdf/48/f2/ymj-53-834.PMC3381473.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  To investigate the anti-tumor effect of capsaicin on human pharyngeal  squamous carcinoma cells (FaDu).",Non-OADS,/arxiv_data1/oa_pdf/48/f2/ymj-53-834.PMC3381473.pdf
"Capsaicin-Induced Apoptosis of FaDu Carcinoma Cells Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 835Polymerase chain reaction (PCR) primers were purchased  from Bioneer (Daejeon, Korea).",Non-OADS,/arxiv_data1/oa_pdf/48/f2/ymj-53-834.PMC3381473.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 836tal RNA was then isolated using gene plate from RNAture  (Irvine, CA, USA).",OADS,/arxiv_data1/oa_pdf/48/f2/ymj-53-834.PMC3381473.pdf
Capsaicin-Induced Apoptosis of FaDu Carcinoma Cells Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 837(data not shown).,Non-OADS,/arxiv_data1/oa_pdf/48/f2/ymj-53-834.PMC3381473.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 838Flow cytometric analysis Apoptotic cell death in FaDu cells was further confirmed  by analyzing the sub-G 1 DNA content using flow cytome - try.,OADS,/arxiv_data1/oa_pdf/48/f2/ymj-53-834.PMC3381473.pdf
"Capsaicin-Induced Apoptosis of FaDu Carcinoma Cells Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 839of caspase-3 was found to increase proportionally with the  exposure time to capsaicin, suggesting that the cytochrome  c release into the cytosol induced the apoptotic response by  activating caspase-3, probably through an autocatalytic  mechanism mediated by caspase-9.",Non-OADS,/arxiv_data1/oa_pdf/48/f2/ymj-53-834.PMC3381473.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 840capsaicin dose for the oral cancer chemoprevention is un - clear at this point and remains to be answered in future in - vestigation.,Non-OADS,/arxiv_data1/oa_pdf/48/f2/ymj-53-834.PMC3381473.pdf
Capsaicin-Induced Apoptosis of FaDu Carcinoma Cells Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 841in HT-29 human colon cancer cells.,Non-OADS,/arxiv_data1/oa_pdf/48/f2/ymj-53-834.PMC3381473.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 685Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.685 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):685-690, 2012 The Relationship between Coronary Artery Calcification and  Renal Function in Nondialyzed Patients Jae Hyun Chang,1 Ji Yoon Sung,1 Ji Yong Jung,1 Hyun Hee Lee,1 Wookyung Chung,1  Yon Mi Sung,2 and Sejoong Kim1,3 1Departments of Internal Medicine and 2Radiology, Gachon University of Medicine and Science, Incheon; 3Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.",Non-OADS,/arxiv_data1/oa_pdf/34/43/ymj-53-685.PMC3381474.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Coronary artery calcification (CAC) has been described in individuals  with chronic kidney disease (CKD), and its presence is associated with an in - creased risk of cardiovascular death.",Non-OADS,/arxiv_data1/oa_pdf/34/43/ymj-53-685.PMC3381474.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 686sified using the eGFR and proteinuria data.14 Stage 1 or 2  CKD was defined as proteinuria with eGFR ≥60 mL/min/  1.73 m2.,OADS,/arxiv_data1/oa_pdf/34/43/ymj-53-685.PMC3381474.pdf
CAC & Renal Function in CKD Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 687stage 1 or 2 CKD and 70.0% with stage 3 or 4 CKD.,Non-OADS,/arxiv_data1/oa_pdf/34/43/ymj-53-685.PMC3381474.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 688Stage 3 or 4 CKD (n=31) Stage 3 or 4 CKD (n=10)Stage 3 or 4 CKD (n=21)Stage 3 or 4 CKD (n=10)Stage 3 or 4 CKD (n=21)Stage 1 or 2 CKD (n=77) Stage 1 or 2 CKD (n=77)No CKD (n=762)Stage 1 or 2 CKD (n=22)Stage 1 or 2 CKD (n=55)No CKD (n=762) ProteinuriaNo proteinuriaNo CKD (n=118)No CKD (n=644)All patients DiabetesNo diabetes0% 0%0%20% 20%20%40% 40%40%60% 60%60%80% 80%80%100% 100%100% CAC scores     0    1-100    101-400    >400CBA Fig.,Non-OADS,/arxiv_data1/oa_pdf/34/43/ymj-53-685.PMC3381474.pdf
"CAC & Renal Function in CKD Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 689nondiabetic stratum.11 Two other studies reported positive  relationships between CKD and CAC, yet both investiga - tions studied individuals with diabetes exclusively.22,23 In- creased CAC scores in CKD patients with diabetes may re - flect end-organ damage caused by multiple metabolic  derangements.",Non-OADS,/arxiv_data1/oa_pdf/34/43/ymj-53-685.PMC3381474.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 690the Dallas Heart Study.,Non-OADS,/arxiv_data1/oa_pdf/34/43/ymj-53-685.PMC3381474.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 870Letter to the Editorhttp://dx.doi.org/10.3349/ymj.2012.53.4.870 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):870-872, 2012 Clinical Usefulness of a Rapid Antigen Test in Patients   with 2009 H1N1 Influenza Jeong-Hwan Hwang,1 Ju-Hyung Lee,2,3 Cheon-Hyeon Kim,4 and Chang-Seop Lee1,3 Departments of 1Internal Medicine, 2Preventive Medicine and 3Research Institute of Clinical Medicine,  Chonbuk National University Medical School, Jeonju; 4Division of Zoonoses, Jeollabukdo Institute of Health & Environmental Research, Imsil, Korea.",Non-OADS,/arxiv_data1/oa_pdf/7c/8d/ymj-53-870.PMC3381475.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.We read with interest the article by Choi, et al.1 (RA1), entitled “The clinical use - fulness of the SD bioline influenza antigen test for detecting the 2009 influenza A  (H1N1) virus.” In this study, the authors explained that the rapid antigen test  (RA T) cannot be recommended for general use in all patients with influenza-like  illnesses because of its low sensitivity.",Non-OADS,/arxiv_data1/oa_pdf/7c/8d/ymj-53-870.PMC3381475.pdf
Clinical Usefulness of Rapid Antigen Test  Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 871pandemic (H1N1) 2009 virus.,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/ymj-53-870.PMC3381475.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 872REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/7c/8d/ymj-53-870.PMC3381475.pdf
Available from URL: http://www.who.int/csr/resources/ publications/swineflu/h1n1_use_antivirals_20090820/en/.,OADS,/arxiv_data1/oa_pdf/7c/8d/ymj-53-870.PMC3381475.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 849Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.849 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):849-855, 2012 Anococcygeal Raphe Revisited: A Histological Study Using   Mid-Term Human Fetuses and Elderly Cadavers Yusuke Kinugasa,1 Takashi Arakawa,2 Hiroshi Abe,3 Shinichi Abe,4  Baik Hwan Cho,5 Gen Murakami,6 and Kenichi Sugihara7 1Division of Colon and Rectal Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan; 2Arakawa Clinic of Proctology, Tokyo, Japan;  3Department of Anatomy, Akita University School of Medicine, Akita, Japan; 4Oral Health Science Center hrc8, Tokyo Dental College, Chiba, Japan.",Non-OADS,/arxiv_data1/oa_pdf/12/6e/ymj-53-849.PMC3381476.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  We recently demonstrated the morphology of the anococcygeal liga - ment.",Non-OADS,/arxiv_data1/oa_pdf/12/6e/ymj-53-849.PMC3381476.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 850years) without macroscopic tumor in the abdomen and pel - vis.,Non-OADS,/arxiv_data1/oa_pdf/12/6e/ymj-53-849.PMC3381476.pdf
"Anatomy of the Anococcygeal Raphe Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 851RESULTS   Observations in elderly specimens At the midsagittal area on the dorsal side of the anal canal,  the anococcygeal ligament was identified as a thick connec - tive tissue band irrespective of whether the EAS was well- developed (Fig.",Non-OADS,/arxiv_data1/oa_pdf/12/6e/ymj-53-849.PMC3381476.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 852layer of the anorectum showed positive immunohistochem - ical findings for smooth muscle actin.,Non-OADS,/arxiv_data1/oa_pdf/12/6e/ymj-53-849.PMC3381476.pdf
Anatomy of the Anococcygeal Raphe Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 853sistently observed.,Non-OADS,/arxiv_data1/oa_pdf/12/6e/ymj-53-849.PMC3381476.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 854tor ani sling, a fascia connects the rectum and presacral pa - rietal fascia (reviewed by García-Armengol, et al.27).",Non-OADS,/arxiv_data1/oa_pdf/12/6e/ymj-53-849.PMC3381476.pdf
Anatomy of the Anococcygeal Raphe Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 85522.,Non-OADS,/arxiv_data1/oa_pdf/12/6e/ymj-53-849.PMC3381476.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 753Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.753 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):753-758, 2012 Clinical Features of Fitz-Hugh-Curtis Syndrome   in the Emergency Department Je Sung You,1 Min Joung Kim,1 Hyun Soo Chung,1 Yong Eun Chung,2 Incheol Park,1  Sung Phil Chung,1 Seungho Kim,1 and Hahn Shick Lee1   Departments of 1Emergency Medicine and 2Diagnostic Radiology, Yonsei University College of Medicine, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/3a/ed/ymj-53-753.PMC3381477.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Fitz-Hugh-Curtis Syndrome (FHCS) is a clinical entity characterized by  inflammation of the liver capsule associated with genital tract infection.",Non-OADS,/arxiv_data1/oa_pdf/3a/ed/ymj-53-753.PMC3381477.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 754ed endocervical swab specimens for detection of C. tracho - matis  was performed using the polymerase chain reaction  (PCR) nucleic acid amplification technique and nucleic acid  hybridization by the Roche COBAS® AmplicorTM (Roche  Diagnostics, Mannheim, Germany).",OADS,/arxiv_data1/oa_pdf/3a/ed/ymj-53-753.PMC3381477.pdf
"Fitz-Hugh-Curtis Syndrome in the Emergency Department Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 75520 of the 82 patients were lost to follow-up for reasons in - cluding discharged against medical advice (n=9), transfer to  another hospital due to lack of beds in the ward (n=6), and  change of medical facility due to location (n=5).",Non-OADS,/arxiv_data1/oa_pdf/3a/ed/ymj-53-753.PMC3381477.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 756left upper abdomen by perisplenitis as the main symptom  of FHCS.14 Although the results of pelvic examination are  subjective and somewhat dependent on a physician’s exper - tise, cervical motion tenderness and adnexal tenderness  may suggest underlying PID.",Non-OADS,/arxiv_data1/oa_pdf/3a/ed/ymj-53-753.PMC3381477.pdf
Fitz-Hugh-Curtis Syndrome in the Emergency Department Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 757female patients of childbearing age with right upper ab - dominal pain.,Non-OADS,/arxiv_data1/oa_pdf/3a/ed/ymj-53-753.PMC3381477.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 758Cleve Clin J Med 2004;71:233-9.,Non-OADS,/arxiv_data1/oa_pdf/3a/ed/ymj-53-753.PMC3381477.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 856Case Reporthttp://dx.doi.org/10.3349/ymj.2012.53.4.856 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):856-858, 2012 A Case of Acute Disseminated Encephalomyelitis   Associated with Hepatitis C Virus Infection Jae Eun Sim,1 Jun-Bum Lee,1 Yu Na Cho,1 Sang Hyun Suh,2 Ja Kyung Kim,3 and Kyung-Yul Lee1 Departments of 1Neurology, Severance Institute for Vascular and Metabolic Research, 2Radiology, and 3Internal Medicine,  Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/0e/ae/ymj-53-856.PMC3381478.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Acute disseminated encephalomyelitis (ADEM) is a monophasic autoimmune de - myelinating disease of the central nervous system, which typically follows acute  viral or bacterial infection or vaccination.",Non-OADS,/arxiv_data1/oa_pdf/0e/ae/ymj-53-856.PMC3381478.pdf
ADEM Associated with HCV Infection Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 857and then reduced to 10 mg per week.,Non-OADS,/arxiv_data1/oa_pdf/0e/ae/ymj-53-856.PMC3381478.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 858REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/0e/ae/ymj-53-856.PMC3381478.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 691Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.691 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):691-700, 2012 Antidiabetic Effects of Corni Fructus  Extract  in Streptozotocin-Induced Diabetic Rats Dawei Gao,1 Qingwang Li,1 Zhengrong Gao,2 and Lixin Wang1  1Department of Biological Engineering, College of Environmental and Chemical Engineering, Yanshan University, Qinhuangdao; 2Department of Surgery, Beijing Ditan Hospital, Beijing, China.",Non-OADS,/arxiv_data1/oa_pdf/5b/67/ymj-53-691.PMC3381479.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Diabetes is the leading cause of end-stage renal failure.",Non-OADS,/arxiv_data1/oa_pdf/5b/67/ymj-53-691.PMC3381479.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 692Chemical Co., ursolic acid standards from Yousi Biotech - nology Inc. (Shanghai, China), streptozotocin from Sigma  Chemicals Co. (St. Louis, MO, USA), glucose analyzer  (GT-1640) and strips from Arkray Inc. (Kyoto, Japan), and  Corni Fructus  from Chang Hai Traditional Chinese Medi - cine Ltd. (Qinhuangdao, China).",OADS,/arxiv_data1/oa_pdf/5b/67/ymj-53-691.PMC3381479.pdf
"Antidiabetic Effects of Corni Fructus Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 693oxide dismutase (SOD) using commercial kits according to  the manufacturer’s instructions (Nanjing Jiancheng Bioengi - neering Co., Nanjing, China).",Non-OADS,/arxiv_data1/oa_pdf/5b/67/ymj-53-691.PMC3381479.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 694Fructus  were analyzed using one-way ANOV A, followed by  the Scheffe test.",Non-OADS,/arxiv_data1/oa_pdf/5b/67/ymj-53-691.PMC3381479.pdf
Antidiabetic Effects of Corni Fructus Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 695el at 2 hours (Group IV and V).,Non-OADS,/arxiv_data1/oa_pdf/5b/67/ymj-53-691.PMC3381479.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 696Influence on renal histology In PAS-stained images of glomeruli at the end of the 40- day treatment period (Fig.,Non-OADS,/arxiv_data1/oa_pdf/5b/67/ymj-53-691.PMC3381479.pdf
Antidiabetic Effects of Corni Fructus Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 697Expression levels of PPARγ in kidneys The protein was isolated from one quarter of the kidney tis - sues of treated rats and expression levels of PPARγ were de - termined by Western blotting.,Non-OADS,/arxiv_data1/oa_pdf/5b/67/ymj-53-691.PMC3381479.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 698betic rats.,Non-OADS,/arxiv_data1/oa_pdf/5b/67/ymj-53-691.PMC3381479.pdf
"Antidiabetic Effects of Corni Fructus Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 699rums G, et al.",Non-OADS,/arxiv_data1/oa_pdf/5b/67/ymj-53-691.PMC3381479.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 700sequences of the diabetic status on the oxidant/antioxidant bal - ance.,Non-OADS,/arxiv_data1/oa_pdf/5b/67/ymj-53-691.PMC3381479.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 801Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.801 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):801-805, 2012 Existence of a Neuropathic Pain Component in Patients   with Osteoarthritis of the Knee Seiji Ohtori, Sumihisa Orita, Masaomi Yamashita, Tetsuhiro Ishikawa, Toshinori Ito,   Tomonori Shigemura, Hideki Nishiyama, Shin Konno, Hideyuki Ohta, Masashi Takaso, Gen Inoue,   Yawara Eguchi, Nobuyasu Ochiai, Shunji Kishida, Kazuki Kuniyoshi, Yasuchika Aoki, Gen Arai,   Masayuki Miyagi, Hiroto Kamoda, Miyako Suzkuki, Junichi Nakamura, Takeo Furuya,   Gou Kubota, Yoshihiro Sakuma, Yasuhiro Oikawa, Masahiko Suzuki, Takahisa Sasho,   Koichi Nakagawa, Tomoaki Toyone, and Kazuhisa Takahashi Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.",Non-OADS,/arxiv_data1/oa_pdf/7d/d4/ymj-53-801.PMC3381480.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Pain from osteoarthritis (OA) is generally classified as nociceptive (in - flammatory).",Non-OADS,/arxiv_data1/oa_pdf/7d/d4/ymj-53-801.PMC3381480.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 802of NP in the knees of OA patients using painDETECT, and  to evaluate the relationship between NP and stage of OA.",Non-OADS,/arxiv_data1/oa_pdf/7d/d4/ymj-53-801.PMC3381480.pdf
Neuropathic Pain in OA Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 80373 (79.3%) as unlikely NP .,Non-OADS,/arxiv_data1/oa_pdf/7d/d4/ymj-53-801.PMC3381480.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 804Some authors have reported that joint pain arises mainly  from free nerve endings that exist in the capsule or in the  synovium,19-21 whereas others have reported innervation of  the osteochondral junction in human knee OA samples and  indicated a possible contribution of the subchondral area to  OA knee pain.22,23 Regarding the mechanism of NP in knee  OA, it is highly possible that NP occurs in association with  damage to nerves innervating subchondral bone because of  its weight-bearing surface in late stage OA.",Non-OADS,/arxiv_data1/oa_pdf/7d/d4/ymj-53-801.PMC3381480.pdf
2008. http://www.cdc.gov/arthritis/osteoarthritis.htm.,Non-OADS,/arxiv_data1/oa_pdf/7d/d4/ymj-53-801.PMC3381480.pdf
Neuropathic Pain in OA Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 805pain.,Non-OADS,/arxiv_data1/oa_pdf/7d/d4/ymj-53-801.PMC3381480.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 806Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.806 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):806-811, 2012 Parent-Reported Symptoms of Attention Deficit Hyperactivity  Disorder in Children with Intermittent Exotropia   before and after Strabismus Surgery Seung Ah Chung,1,2 Yoon Hee Chang,1 Soolienah Rhiu,2 Helen Lew,3 and Jong Bok Lee2  1Department of Ophthalmology, Ajou University School of Medicine, Suwon;  2Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul;  3Department of Ophthalmology, CHA University College of Medicine, Bundang CHA Hospital, Seongnam, Korea.",Non-OADS,/arxiv_data1/oa_pdf/17/dc/ymj-53-806.PMC3381481.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  To investigate the symptoms of attention deficit hyperactivity disorder  (ADHD) as reported by parents in children with intermittent exotropia [X(T)] and  to determine whether strabismus surgery for X(T) affects ADHD symptoms.",Non-OADS,/arxiv_data1/oa_pdf/17/dc/ymj-53-806.PMC3381481.pdf
Symptoms of ADHD with Exotropia after Strabismus Surgery Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 807learning disability or ADHD were also excluded to elimi - nate potential bias.,Non-OADS,/arxiv_data1/oa_pdf/17/dc/ymj-53-806.PMC3381481.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 808without the ADHD trait (Table 1).,Non-OADS,/arxiv_data1/oa_pdf/17/dc/ymj-53-806.PMC3381481.pdf
"Symptoms of ADHD with Exotropia after Strabismus Surgery Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 809found that children, who were monitored up to a mean age  of 20.3 years, with exotropia were 3.1 times more likely to  develop a psychiatric disorder.",Non-OADS,/arxiv_data1/oa_pdf/17/dc/ymj-53-806.PMC3381481.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 810with a clinical diagnosis of ADHD are warranted.,Non-OADS,/arxiv_data1/oa_pdf/17/dc/ymj-53-806.PMC3381481.pdf
Symptoms of ADHD with Exotropia after Strabismus Surgery Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 811teacher.,Non-OADS,/arxiv_data1/oa_pdf/17/dc/ymj-53-806.PMC3381481.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 863Case Reporthttp://dx.doi.org/10.3349/ymj.2012.53.4.863 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):863-865, 2012 Oral Muscle Relaxant May Induce Immediate Allergic Reactions  Gyu-Young Hur,1 Eui Kyung Hwang,2 Jae-Young Moon,1 Young-Min Ye,2  Jae-Jeong Shim,1 Hae-Sim Park,2 and Kyung-Ho Kang1 1Department of Internal Medicine, Korea University College of Medicine, Seoul;  2Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.",Non-OADS,/arxiv_data1/oa_pdf/f1/18/ymj-53-863.PMC3381482.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Eperisone and afloqualone act by relaxing both skeletal and vascular smooth  muscles to improve circulation and suppress pain reflex.",Non-OADS,/arxiv_data1/oa_pdf/f1/18/ymj-53-863.PMC3381482.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 864dyspnea and angioedema after taking painkillers, including  eperisone and meloxicam, to treat back pain.",Non-OADS,/arxiv_data1/oa_pdf/f1/18/ymj-53-863.PMC3381482.pdf
"Oral Muscle Relaxant Induced Allergic Reactions Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 865tions, all practitioners should bear in mind that oral muscle  relaxants could cause drug-induced anaphylactic reactions.",Non-OADS,/arxiv_data1/oa_pdf/f1/18/ymj-53-863.PMC3381482.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 812Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.812 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):812-819, 2012 Mixed Echoic Thyroid Nodules on Ultrasound:   Approach to Management Yu-Mee Sohn,1 Jung Hyun Yoon,2 Hee Jung Moon,3 Eun-Kyung Kim,3 and Jin Young Kwak3 1Department of Radiology, Kyung Hee University Hospital, College of Medicine, Kyung Hee University, Seoul; 2Department of Radiology, CHA Bundang Medical Center, CHA University College of Medicine, Seongnam; 3Department of Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/77/39/ymj-53-812.PMC3381483.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  To evaluate malignancy risk according to ultrasound (US) features and  size change on follow-up US in mixed echoic thyroid nodules and to suggest man - agement guidelines thereof.",Non-OADS,/arxiv_data1/oa_pdf/77/39/ymj-53-812.PMC3381483.pdf
Mixed Echoic Thyroid Nodules on Ultrasound Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 813cords.,Non-OADS,/arxiv_data1/oa_pdf/77/39/ymj-53-812.PMC3381483.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 814ule.,Non-OADS,/arxiv_data1/oa_pdf/77/39/ymj-53-812.PMC3381483.pdf
"Mixed Echoic Thyroid Nodules on Ultrasound Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 815or patient request (n=71), growth at follow-up US (n=26),  suspicious US features (n=25) and newly developed suspi - cious features with decreased size at follow-up US (n=5).",Non-OADS,/arxiv_data1/oa_pdf/77/39/ymj-53-812.PMC3381483.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 816ular or microlobulated margins,17,20,30,34-38 hypoechogenici - ty,17,20,29,30,34,37,38 marked hypoechogenicity,20,29 taller than wide  shape,17,20,39 microcalcification,17,20,30,36-38,40-42 solid composi - tion17,36-38,43 and intratumoral vascularity.17,30,34,43 US findings  are also important for the discrimination of mixed echoic  thyroid nodules.",Non-OADS,/arxiv_data1/oa_pdf/77/39/ymj-53-812.PMC3381483.pdf
"Mixed Echoic Thyroid Nodules on Ultrasound Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 817nodule was, the lower the likelihood of cancer with statisti - cal significance.",Non-OADS,/arxiv_data1/oa_pdf/77/39/ymj-53-812.PMC3381483.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 818Management of Thyroid Nodules.,Non-OADS,/arxiv_data1/oa_pdf/77/39/ymj-53-812.PMC3381483.pdf
Mixed Echoic Thyroid Nodules on Ultrasound Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 819tion and its association with thyroid carcinoma.,Non-OADS,/arxiv_data1/oa_pdf/77/39/ymj-53-812.PMC3381483.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 701Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.701 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):701-707, 2012 The Influence of Diabetes Mellitus on Short-Term Outcomes   of Patients with Bleeding Peptic Ulcers Atsuhiko Murata,1 Shinya Matsuda,1 Kazuaki Kuwabara,2 Yukako Ichimiya,1  Yoshihisa Fujino,1 and Tatsuhiko Kubo1 1Department of Preventive Medicine and Community Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; 2Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.",Non-OADS,/arxiv_data1/oa_pdf/ca/1c/ymj-53-701.PMC3381484.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Little information is available on the influence of diabetes mellitus on the  short-term clinical outcomes of patients with bleeding peptic ulcers.",Non-OADS,/arxiv_data1/oa_pdf/ca/1c/ymj-53-701.PMC3381484.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 702ternational Classification of Diseases and Injuries (ICD)- 10th.,Non-OADS,/arxiv_data1/oa_pdf/ca/1c/ymj-53-701.PMC3381484.pdf
"Diabetes Mellitus and Outcomes of Bleeding Ulcers Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 703and additional factors related to LOS, such as causes of  bleeding peptic ulcers, age, gender, hospital type, use of am - bulance transportation, use of a proton pump inhibitor, anti - platelet and anticoagulation drugs, and endoscopic hemosta - sis and salvage surgery during hospitalization.",Non-OADS,/arxiv_data1/oa_pdf/ca/1c/ymj-53-701.PMC3381484.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 704with the in-hospital mortality within 30 days are demon - strated in Table 3.,Non-OADS,/arxiv_data1/oa_pdf/ca/1c/ymj-53-701.PMC3381484.pdf
Diabetes Mellitus and Outcomes of Bleeding Ulcers Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 705crease of in-hospital mortality and LOS may be explained  by several factors.,Non-OADS,/arxiv_data1/oa_pdf/ca/1c/ymj-53-701.PMC3381484.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 706tients minimizes any bias due to differences in the bleeding  conditions of bleeding peptic ulcers, because almost all the  patients were considered to be in a temporary hemostatic  condition (in other words, almost all the patients were in  the same condition at the baseline).",Non-OADS,/arxiv_data1/oa_pdf/ca/1c/ymj-53-701.PMC3381484.pdf
Diabetes Mellitus and Outcomes of Bleeding Ulcers Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 707base to determine the impact of hospital volume on compliance  with clinical practice guidelines.,Non-OADS,/arxiv_data1/oa_pdf/ca/1c/ymj-53-701.PMC3381484.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 781Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.781 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):781-787, 2012 Acute Appendicitis in Children with Acute Leukemia:  Experiences of a Single Institution in Korea Eun Young Kim,1 Jae Wook Lee,2 Nak-Gyun Chung,2 Bin Cho,2 Hack-Ki Kim,2 and Jae Hee Chung1 1Department of Surgery, Yeouido St. Mary’ s Hospital, College of Medicine, The Catholic University of Korea, Seoul; 2Department of Pediatrics, Seoul St. Mary’ s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/a4/8f/ymj-53-781.PMC3381485.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Acute appendicitis has been reported to be relatively rare in pediatric  leukemia patients but there is no official data for this in Korea.",Non-OADS,/arxiv_data1/oa_pdf/a4/8f/ymj-53-781.PMC3381485.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 782period of neutropenia that occurred after intensive chemo - therapy: 3 and 1 patients developed acute appendicitis dur - ing the period of neutropenia that occurred after consolida - tion chemotherapy and reinduction chemotherapy following  post-transplantation relapse, respectively (Table 1).",Non-OADS,/arxiv_data1/oa_pdf/a4/8f/ymj-53-781.PMC3381485.pdf
"Acute Appendicitis in Children with Acute Leukemia Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 783cal wound infection was observed in 1 patient, and this re - sponded well to supportive care (Table 2).",Non-OADS,/arxiv_data1/oa_pdf/a4/8f/ymj-53-781.PMC3381485.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 784gins with periumbilical pain that migrates to the right lower  quadrant (RLQ).,Non-OADS,/arxiv_data1/oa_pdf/a4/8f/ymj-53-781.PMC3381485.pdf
Acute Appendicitis in Children with Acute Leukemia Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 785cecal wall of 39 mm in length was present.,Non-OADS,/arxiv_data1/oa_pdf/a4/8f/ymj-53-781.PMC3381485.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 786when perforation has occurred and the patient has an ANC  of 0×109/L, surgical treatment may improve overall surviv - al without incurring significant complications.",Non-OADS,/arxiv_data1/oa_pdf/a4/8f/ymj-53-781.PMC3381485.pdf
Acute Appendicitis in Children with Acute Leukemia Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 787the neutropenic patient: characterization and differentiation with  abdominal CT. Radiology 2003;226:668-74.,Non-OADS,/arxiv_data1/oa_pdf/a4/8f/ymj-53-781.PMC3381485.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 788Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.788 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):788-793, 2012 Transdermal Fentanyl for Chronic Low Back Pain Seiji Ohtori, Gen Inoue, Sumihisa Orita, Yawara Eguchi, Nobuyasu Ochiai, Shunji Kishida,  Masashi Takaso, Yasuchika Aoki, Kazuki Kuniyoshi, Junichi Nakamura, Tetsuhiro Ishikawa, Gen Arai,  Masayuki Miyagi, Hiroto Kamoda, Miyako Suzuki, Tomoaki Toyone, and Kazuhisa Takahashi Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.",Non-OADS,/arxiv_data1/oa_pdf/89/91/ymj-53-788.PMC3381486.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Chronic low back pain is a common clinical problem.",Non-OADS,/arxiv_data1/oa_pdf/89/91/ymj-53-788.PMC3381486.pdf
Transdermal Fentanyl for LBP Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 789Demographic characteristics Table 1 shows patient demographic characteristics.,Non-OADS,/arxiv_data1/oa_pdf/89/91/ymj-53-788.PMC3381486.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 790was considered statistically significant.,OADS,/arxiv_data1/oa_pdf/89/91/ymj-53-788.PMC3381486.pdf
"Transdermal Fentanyl for LBP Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 791The most common adverse events were constipation, nau - sea, itching, and somnolence.",Non-OADS,/arxiv_data1/oa_pdf/89/91/ymj-53-788.PMC3381486.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 792ed with less constipation compared with sustained-release  morphine.,Non-OADS,/arxiv_data1/oa_pdf/89/91/ymj-53-788.PMC3381486.pdf
Transdermal Fentanyl for LBP Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 793scription medication dependence and neuropsychologic function.,Non-OADS,/arxiv_data1/oa_pdf/89/91/ymj-53-788.PMC3381486.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 873Erratumhttp://dx.doi.org/10.3349/ymj.2012.53.4.873 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):873-873, 2012 Erratum to “The First Case of Familial Mediterranean Fever  Associated with Renal Amyloidosis in Korea”   by Koo KY , et al.",Non-OADS,/arxiv_data1/oa_pdf/fc/5c/ymj-53-873.PMC3381487.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 748Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.748 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):748-752, 2012 Predicting Factors of Breakthrough Infection   in Children with Primary Vesicoureteral Reflux Hyeon Chan Jang, Yoo Jun Park, and Jae Shin Park Department of Urology, Catholic University of Daegu, School of Medicine, Daegu, Korea.",Non-OADS,/arxiv_data1/oa_pdf/e6/14/ymj-53-748.PMC3381488.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Many pediatric urologists still favor using prophylactic antibiotics to treat chil - dren with vesicoureteral reflux (VUR).",Non-OADS,/arxiv_data1/oa_pdf/e6/14/ymj-53-748.PMC3381488.pdf
"Predicting Factors of Breakthrough Infection in V esicoureteral Reflux Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 749tation, gender, age, VUR grade, laterality, presence of intra - renal reflux, class of antibiotic drug, and presence of  abnormal renal scan by DMSA.",Non-OADS,/arxiv_data1/oa_pdf/e6/14/ymj-53-748.PMC3381488.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 750nal scan detected by DMSA are at increased risk of break - through infection in patients with VUR.,Non-OADS,/arxiv_data1/oa_pdf/e6/14/ymj-53-748.PMC3381488.pdf
Predicting Factors of Breakthrough Infection in V esicoureteral Reflux Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 751still need prospective data collected in a standardized fash - ion to be able to draw further conclusions.,Non-OADS,/arxiv_data1/oa_pdf/e6/14/ymj-53-748.PMC3381488.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 75216.,Non-OADS,/arxiv_data1/oa_pdf/e6/14/ymj-53-748.PMC3381488.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 842Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.842 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):842-848, 2012 Fluoxetine Protects against Big Endothelin-1 Induced   Anti-Apoptosis by Rescuing Kv1.5 Channels in Human  Pulmonary Arterial Smooth Muscle Cells FeiFeng Dai, ZhiFu Mao, Jun Xia, ShaoPing Zhu, and ZhiYong Wu Department of Cardiothoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.",Non-OADS,/arxiv_data1/oa_pdf/b9/78/ymj-53-842.PMC3381489.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Pulmonary Kv channels are thought to play a crucial role in the regulation  of cell proliferation and apoptosis.",Non-OADS,/arxiv_data1/oa_pdf/b9/78/ymj-53-842.PMC3381489.pdf
"Fluoxetine Rescues Kv1.5 Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 843ShangHai, China), and fluoxetine (F; Sigma-Aldrich, Shang - Hai, China) with and without ET-1 separately for 72 hours.",Non-OADS,/arxiv_data1/oa_pdf/b9/78/ymj-53-842.PMC3381489.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 844as 100%, and the results for the ET -1, F with or without ET -1  groups were expressed as a percentage of the value from the  Blank group.",OADS,/arxiv_data1/oa_pdf/b9/78/ymj-53-842.PMC3381489.pdf
Fluoxetine Rescues Kv1.5 Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 845(Fig.,Non-OADS,/arxiv_data1/oa_pdf/b9/78/ymj-53-842.PMC3381489.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 846the fluoxetine treatment group in contrast with the ET-1 in - duced group (4.85±0.3852 vs. 1.1±0.1634, p<0.001).",Non-OADS,/arxiv_data1/oa_pdf/b9/78/ymj-53-842.PMC3381489.pdf
"Fluoxetine Rescues Kv1.5 Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 847stages was decreased, paralleling with the downregulation  of Kv1.5 channels.",Non-OADS,/arxiv_data1/oa_pdf/b9/78/ymj-53-842.PMC3381489.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 848ulation of pulmonary artery smooth muscle cell proliferation and  apoptosis: pharmacotherapeutic implications.,Non-OADS,/arxiv_data1/oa_pdf/b9/78/ymj-53-842.PMC3381489.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 866Letter to the Editorhttp://dx.doi.org/10.3349/ymj.2012.53.4.866 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):866-869, 2012 Re: Microalbuminuria in Normal Korean Children  Francois Cachat and Hassib Chehade Department of Pediatrics, Division of Pediatric Nephrology University Hospital, Lausanne, Switzerland.",Non-OADS,/arxiv_data1/oa_pdf/93/76/ymj-53-866.PMC3381490.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Dear Sir,  We read with much interest the article of Kwak, et al.1 The authors report nor - mal reference values of urinary albumin excretion (expressed as an albumin/creati - nine ratio) in a normal population of normal children/adolescents aged 1 month to  19 years old.",Non-OADS,/arxiv_data1/oa_pdf/93/76/ymj-53-866.PMC3381490.pdf
Re: Microalbuminuria in Normal Korean Children  Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 867REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/93/76/ymj-53-866.PMC3381490.pdf
"Francois Cachat and Hassib Chehade Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 868Although there were 7 children with more than 97 percen - tile of body mass index (BMI), we did not observe any sig - nificant difference in microalbumin/creatinine ratio.",Non-OADS,/arxiv_data1/oa_pdf/93/76/ymj-53-866.PMC3381490.pdf
Re: Microalbuminuria in Normal Korean Children  Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 869bourg L. Which creatinine and cystatin C equations can be reliably  used in children?,Non-OADS,/arxiv_data1/oa_pdf/93/76/ymj-53-866.PMC3381490.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 680Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.680 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):680-684, 2012 Comparison between Measured and Calculated Length   of Side Branch Ostium in Coronary Bifurcation   Lesions with Intravascular Ultrasound Hyeon Min Ryu,1* Byeong-Keuk Kim,2* Jung-Sun Kim,2 Young-Guk Ko,2  Donghoon Choi,2 Yangsoo Jang,2,3 and Myeong-Ki Hong2,3 1Division of Cardiology, Gumi CHA University Medical Center, Gumi; 2Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul;  3Division of Cardiology, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/7e/18/ymj-53-680.PMC3381491.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Accurate evaluation of side branch (SB) ostium could be critical to the  treatment of bifurcation lesions.",Non-OADS,/arxiv_data1/oa_pdf/7e/18/ymj-53-680.PMC3381491.pdf
"Measurement of Side Branch Ostium Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 681mg nitroglycerin using a motorized transducer pullback sys - tem (0.5 mm/s) and a commercial scanner (Boston Scientific  Corp./Scimed, Natrick, MA, USA), comprising a rotating 30-  or 40-MHz transducer within a 2.9- or 3.2-Fr imaging sheath.",Non-OADS,/arxiv_data1/oa_pdf/7e/18/ymj-53-680.PMC3381491.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 682was obtained from the trigonometric function as follows: SB  diameter/sin (angle between distal MV and SB).13 The corre - lation between the directly measured and calculated values of  SBOL was then evaluated.,OADS,/arxiv_data1/oa_pdf/7e/18/ymj-53-680.PMC3381491.pdf
Measurement of Side Branch Ostium Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 683ber of patients was relatively small.,Non-OADS,/arxiv_data1/oa_pdf/7e/18/ymj-53-680.PMC3381491.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 68410.,Non-OADS,/arxiv_data1/oa_pdf/7e/18/ymj-53-680.PMC3381491.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 765Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.765 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):765-771, 2012 Permissive Hypotension in Extremely Low   Birth Weight Infants (≤1000 gm)  So Yoon Ahn, Eun Sun Kim, Jin Kyu Kim, Jeong Hee Shin, Se In Sung, Ji Mi Jung,   Yun Sil Chang, and Won Soon Park  Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/f7/e9/ymj-53-765.PMC3381492.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  We performed this study to evaluate the safety of permissive hypoten - sion management in extremely low birth weight infants (ELBWIs).",Non-OADS,/arxiv_data1/oa_pdf/f7/e9/ymj-53-765.PMC3381492.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 766permissive hypotension group (P group; MAP <gestational  age with signs of good perfusion and no intervention), and  3) a treated hypotension group (T group; MAP <gestational  age and intervention including volume pushes, vasopres - sors or corticosteroids).",Non-OADS,/arxiv_data1/oa_pdf/f7/e9/ymj-53-765.PMC3381492.pdf
Permissive Hypotension in ELBWIs Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 767were significantly lower in the T group than the other two  groups.,Non-OADS,/arxiv_data1/oa_pdf/f7/e9/ymj-53-765.PMC3381492.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 768compared to the other two groups, and higher in the P group  than the N group.",Non-OADS,/arxiv_data1/oa_pdf/f7/e9/ymj-53-765.PMC3381492.pdf
"Permissive Hypotension in ELBWIs Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 769dence of cerebral palsy, hearing loss, or developmental de - lay, defined as Bayley score MDI or PDI <75 (Table 4).",Non-OADS,/arxiv_data1/oa_pdf/f7/e9/ymj-53-765.PMC3381492.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 770hypotension was symptomatic or not and whether these ad - verse outcomes resulted from symptomatic hypotension it - self or the side-effects of treatments such as fluid replace - ment and vasopressor agents.,Non-OADS,/arxiv_data1/oa_pdf/f7/e9/ymj-53-765.PMC3381492.pdf
Permissive Hypotension in ELBWIs Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 7719.,Non-OADS,/arxiv_data1/oa_pdf/f7/e9/ymj-53-765.PMC3381492.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 723Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.723 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):723-728, 2012 Recurrent Varicoceles: Causes and Treatment Using Angiography  and Magnification Assisted Subinguinal Varicocelectomy Kyung Hyun Moon,1 Suk Ju Cho,2 Kun Suk Kim,3 Seonghun Park,4 and Sungchan Park1 1Department of Urology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan; 2Department of Anesthesiology and Pain Medicine, Jeju National University College of Medicine, Jeju National Universtiy Hospital, Jeju; 3Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul; 4School of Mechanical Engineering, Pusan National University, Busan, Korea.",Non-OADS,/arxiv_data1/oa_pdf/54/e6/ymj-53-723.PMC3381493.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  To investigate the causes of varicocele recurrence and assess the use of  embolization and subinguinal varicocelectomy in its treatment in patients with angi - ography and subinguinal varicocelectomy.",Non-OADS,/arxiv_data1/oa_pdf/54/e6/ymj-53-723.PMC3381493.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 724W A, USA).",Non-OADS,/arxiv_data1/oa_pdf/54/e6/ymj-53-723.PMC3381493.pdf
Causes and Treatment of Recurrent V aricocele Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 725(Fig.,Non-OADS,/arxiv_data1/oa_pdf/54/e6/ymj-53-723.PMC3381493.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 726cocele after surgical repair involves the ISVs.12,13 Redun - dancies of the gonadal veins confined to the region in or  near the inguinal canal appear to be responsible for the ma - jority of post-surgical persistent or recurrent varicocele.14  Macroscopic inguinal or subinguianl varicocelectomy per - formed without optical magnification may miss smaller in - ternal spermatic veins that may later dilate and cause recur - rence.10 The use of microscope magnification allows to  identify the testicular artery, lymphatics, and small venous  channels, which assists in the preservation of arterial and  lymphatic vessels, and also allows to completely ligate the  spermatic veins, which in turn minimizes the risk of postop - erative complications.",Non-OADS,/arxiv_data1/oa_pdf/54/e6/ymj-53-723.PMC3381493.pdf
Causes and Treatment of Recurrent V aricocele Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 727appropriate in a limited number of recurrent varicoceles pa - tients with patent ISVs.,Non-OADS,/arxiv_data1/oa_pdf/54/e6/ymj-53-723.PMC3381493.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 728cele.,Non-OADS,/arxiv_data1/oa_pdf/54/e6/ymj-53-723.PMC3381493.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 708Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.708 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):708-714, 2012 Removal of Kidney Stones by Extracorporeal Shock Wave  Lithotripsy Is Associated with Delayed Progression   of Chronic Kidney Disease  Dong Eun Yoo, Seung Hyeok Han, Hyung Jung Oh, Seung Jun Kim, Dong Ho Shin,   Mi Jung Lee, Tae-Hyun Yoo, Shin-Wook Kang, and Kyu Hun Choi Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/62/c8/ymj-53-708.PMC3381494.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  This study aimed to elucidate whether stone removal by extracorporeal  shock wave lithotripsy (ESWL) is associated with delayed chronic kidney disease  (CKD) progression.",Non-OADS,/arxiv_data1/oa_pdf/62/c8/ymj-53-708.PMC3381494.pdf
ESWL in CKD Patients with Nephrolithiasis Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 709twice before the diagnosis of nephrolithiasis to confirm that  patients had CKD.,Non-OADS,/arxiv_data1/oa_pdf/62/c8/ymj-53-708.PMC3381494.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 710compared with the use of Mann-Whitney U test for continu - ous variables and Fisher’s exact test for categorical variables.,Non-OADS,/arxiv_data1/oa_pdf/62/c8/ymj-53-708.PMC3381494.pdf
ESWL in CKD Patients with Nephrolithiasis Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 711before ESWL and for 2.3 years after ESWL.,Non-OADS,/arxiv_data1/oa_pdf/62/c8/ymj-53-708.PMC3381494.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 712success and failure groups (Table 2).,Non-OADS,/arxiv_data1/oa_pdf/62/c8/ymj-53-708.PMC3381494.pdf
ESWL in CKD Patients with Nephrolithiasis Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 713nied by focal sites of parenchymal and subcapsular hemor - rhage.14 Tubules also show features similar to the tears seen  in the vessel walls.,Non-OADS,/arxiv_data1/oa_pdf/62/c8/ymj-53-708.PMC3381494.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 7143.,Non-OADS,/arxiv_data1/oa_pdf/62/c8/ymj-53-708.PMC3381494.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 715Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.715 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):715-722, 2012 The Clinical Characteristics of Steroid Responsive Nephrotic  Syndrome of Children according to the Serum   Immunoglobulin E Levels and Cytokines You Sook Youn,1 Han Hyuk Lim,2 and Jae Ho Lee2 1Department of Pediatrics, Deajeon St. Mary’ s Hospital, The Catholic University of Korea, Daejeon; 2Department of Pediatrics, Chungnam National University School of Medicine, Daejeon, Korea.",Non-OADS,/arxiv_data1/oa_pdf/90/e1/ymj-53-715.PMC3381495.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  The nephrotic syndrome (NS) is characterized by the favorable response  to glucocorticoid therapy and the development of NS may be associated with dys - functional immune systems.",Non-OADS,/arxiv_data1/oa_pdf/90/e1/ymj-53-715.PMC3381495.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 716national Study of Kidney Disease in Children.16 Five healthy  children (1 boy and 4 girls, aged 6 to 8 years) were includ - ed as normal control group.",Non-OADS,/arxiv_data1/oa_pdf/90/e1/ymj-53-715.PMC3381495.pdf
The Clinical and Cytokine Characteristics of Steroid Responsive Nephrotic Syndrome Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 717and 5 girls) who had normal IgE levels and 20 patients (14  boys and 6 girls) who had high IgE levels.,Non-OADS,/arxiv_data1/oa_pdf/90/e1/ymj-53-715.PMC3381495.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 718The serum levels of IL-5 were higher also in the nephrot - ic phase patient than those of remission phase of NS  (p=0.051) and controls ( p=0.028), but there were no signifi - cant differences between the patients with remission phase  and control group ( p=0.858) (Fig.",Non-OADS,/arxiv_data1/oa_pdf/90/e1/ymj-53-715.PMC3381495.pdf
The Clinical and Cytokine Characteristics of Steroid Responsive Nephrotic Syndrome Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 719Fig.,Non-OADS,/arxiv_data1/oa_pdf/90/e1/ymj-53-715.PMC3381495.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 720pathic NS are driven toward the Th2 phenotype.13  IL-4 is the most important Th2 cytokine which mediates  IgE synthesis.24 In NS, IL-4 can act on glomerular visceral  epithelial cells by binding IL-4 receptor, and plays a role in  glomerular permeability.25 This suggests that, regardless of  atopy, IL-4 may be one of the cytokines associated with the  pathogenesis of proteinuria and also be a predictive factor  for disease severity in NS.",Non-OADS,/arxiv_data1/oa_pdf/90/e1/ymj-53-715.PMC3381495.pdf
The Clinical and Cytokine Characteristics of Steroid Responsive Nephrotic Syndrome Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 721REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/90/e1/ymj-53-715.PMC3381495.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 7222006;17:2731-41.,Non-OADS,/arxiv_data1/oa_pdf/90/e1/ymj-53-715.PMC3381495.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 671Review Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.671 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):671-679, 2012 Leptin as a Modulator of Neuroendocrine Function in Humans Sami M. Khan,1 Ole-Petter R. Hamnvik,1-3 Mary Brinkoetter,1,2 and Christos S. Mantzoros1,2 1Division of Endocrinology, Diabetes & Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; 2Section of Endocrinology, Boston VA Healthcare System, Boston, MA; 3Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’ s Hospital, Harvard Medical School, Boston, MA, USA.",Non-OADS,/arxiv_data1/oa_pdf/34/68/ymj-53-671.PMC3381496.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Leptin, a peptide hormone secreted by adipocytes in proportion of the amount of  energy stored in fat, plays a central role in regulating human energy homeostasis.",Non-OADS,/arxiv_data1/oa_pdf/34/68/ymj-53-671.PMC3381496.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 672the hypothalamus,27,28 kidneys, lungs,29 lymphocytes,28,30-32  adipose tissue,21,33,34 prostate, ovaries, liver, small intestines,  and heart.16,35 There are at least six isoforms of the murine  leptin receptor,36 whereas in humans, only four alternatively  spliced isoforms have been described.37,38 The ObRb recep - tor, the long form of the leptin receptor, is considered the  active leptin receptor and is highly expressed in the hypo - thalamus, including in nuclei associated with body weight  control.29 Circulating leptin levels in humans Leptin levels in the blood stream display a circadian pattern  such that leptin concentration is at the lowest point between  early afternoon and mid-afternoon and is at its highest point  between midnight and early morning.39,40 Furthermore,  leptin secretion appears to be pulsatile.11 Though the pulsa - tility of leptin secretion is similar in obese and in lean indi - viduals, the amplitude of leptin pulses is greater among  obese individuals.11 Several factors contribute to the inter-individual variabili - ty of leptin levels in humans, including gender and total  body fat mass.41 Leptin levels display sexual dimorphism,  with women having higher levels than men even after con - trolling for adiposity.42 Sex hormones such as testosterone43  and estrogen44,45 explain some of the gender variation in  leptin levels.",Non-OADS,/arxiv_data1/oa_pdf/34/68/ymj-53-671.PMC3381496.pdf
"Neuroendocrine Functions of Leptin Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 673mice express Kiss1 mRNA to a lesser degree than do their  wild-type counterparts.67 The expression of Kiss1 mRNA is  partially restored with the administration of exogenously  administered leptin67 whereas exogenously administered  kisspeptin to rodents that are relatively leptin deficient stim - ulates the secretion of GnRH71 and increases levels of LH,  follicle-stimulating hormone,72,73 and testosterone.73 Popula - tions of neurons with leptin receptors in brain regions such  as the hypothalamic ventral premammillary nucleus and the  preoptic region have been found in close proximity to both  Kiss1 and GnRH neurons.74 Although leptin’s initiation of  puberty in mice requires a functional ventral premammilla - ry nucleus, this does not appear to require the action of  Kiss1 mRNA expressing neurons.75 THYROID AXIS Similar to leptin, thyroid-stimulating hormone (TSH) has a  pulsatile and circadian pattern of secretion, and we have  found that both hormones have similar circadian patterns.76  In congenitally leptin-deficient individuals, we have ob - served that TSH secretion is disorganized.76 It has also been  reported that leptin-deficient children exhibit an increase in  triiodothyronine (T3) and thyroxine (T4), though not in TSH,  after leptin therapy in an uncontrolled interventional study;49  however, one boy, one man, and two women, all of whom  had congenital leptin-deficiency, demonstrated normal thy - roid function whether or not they were undergoing leptin  replacement.50  In rodents, leptin deficient ob/ob  mice demonstrate much  more pronounced thyroid disorders, including hypothalamic  hypothyroidism since birth.77 Similarly, fasting decreases se - rum levels of T4 in mice, though this effect can be amelio - rated through leptin administration.6 Leptin regulates thyro - tropin-releasing hormone levels by increasing pro-TRH  gene expression in neurons in the paraventricular nucleus of  the hypothalamus,78 probably through the central melano - cortin system.79 Leptin also stimulates the expression of pro - hormone convertases 1 and 2, which cleave pro-TRH in or - der to produce TRH in the paraventricular nucleus.80 To directly test the role of leptin in regulating thyroid func - tion in humans, we administered leptin in the context of a ran - domized, placebo controlled interventional study involving  fasting of normal-weight men for 72 hours.",Non-OADS,/arxiv_data1/oa_pdf/34/68/ymj-53-671.PMC3381496.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 674leptin gene demonstrate normal growth velocity in child - hood48,49 although their final height is decreased due to the  lack of pubertal growth spurt.83 We have proposed on the  basis of the above and other experimental data from our  own physiology studies in humans that leptin may regulate  growth hormone’s ability to stimulate the secretion of insu - lin-like growth factor 1 (IGF-1) as well as the corresponding  binding proteins in the periphery as opposed to acting di - rectly on pituitary secretion of growth hormone itself.84  We have shown by studying a group of normal-weight  men who became truly hypoleptinemic through prolonged  fasting that leptin administration tends to restore total IGF-1  levels, which are decreased due to caloric deprivation.7 In  normal weight women, though, we found that leptin re - placement did not significantly normalize IGF-1 levels.8  Again, this was interpreted as illustrative of leptin having a  threshold for neuroendocrine regulation as the men’s leptin  levels dropped below 3 ng/mL whereas the women’s aver - age leptin level did not.81 Similarly, administering leptin to  euleptinemic subjects undergoing a 6-month-long mild hy - pocaloric diet did not appear to alter levels of the circulat - ing levels of IGF-1 or other hormones in the IGF axis.82 ADRENAL AXIS In vitro  evidence indicates that corticotropin-releasing hor - mone is released in response to leptin in a dose-dependent  manner10 and suggests that leptin decreases the secretion of  corticosterone from cells of rat adrenal cortex.85 Additionally,  leptin decreases the degree to which stress increases ACTH  and corticosterone levels.86 On the basis of very small and non-randomized studies, it  has been suggested that the adrenal axis of individuals with  mutated leptin or leptin receptor genes may not be signifi - cantly impaired.26,48,49 Similarly, leptin administration in a  group of men who became hypoleptinemic in response to  fasting for 72 hours did not appear to have a major effect on  cortisol secretion.7 Likewise, leptin administration did not  attenuate significantly the activation of the adrenal axis in a  similar study of fasting women.8 In contrast, in the context  of a larger randomized placebo-controlled study, we found  that women with hypothalamic amenorrhea who were hy - percortisolemic did experience a statistically significant de - crease in cortisol levels after they were treated with replace - ment doses of metreleptin.87 Along the same lines, we have  reported that there appears to be an inverse relationship be -which caloric deprivation altered TSH secretion patterns and  levels.7 In contrast to men, in whom significant hypolepti - nemia was induced (levels less than 2-3 ng/mL), similarly  pronounced effects of leptin administration were not seen in  a similar study on normal-weight women8 in whom leptin  levels were decreased but remained within normal limits.",Non-OADS,/arxiv_data1/oa_pdf/34/68/ymj-53-671.PMC3381496.pdf
"Neuroendocrine Functions of Leptin Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 675teocalcin, two bone formation markers.54 More definitive  results in terms of changes in overall or regional bone min - eral content or density were reported in the nine-month long  randomized placebo-controlled study.87 In this study, six  women underwent nine months of double-blind leptin ad - ministration and then elected to receive an additional year of  open-label leptin administration; these women experienced  significant gains in bone mineral content and density.87 Anorexia nervosa Anorexia nervosa is associated with hypoleptinemia.53 Among  amenorrheic anorexic women with who have gained weight,  circulating leptin levels are higher in those whose menses  had resumed than in those who had remained amenorrheic.93  Unfortunately, there may be mild weight and/or fat loss with  leptin replacement in lean women,54,92 which may be a po - tential reason not to administer leptin to anorexic women.",Non-OADS,/arxiv_data1/oa_pdf/34/68/ymj-53-671.PMC3381496.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 676related to pituitary-adrenal function.,Non-OADS,/arxiv_data1/oa_pdf/34/68/ymj-53-671.PMC3381496.pdf
Neuroendocrine Functions of Leptin Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 6772009;56:425-33.,Non-OADS,/arxiv_data1/oa_pdf/34/68/ymj-53-671.PMC3381496.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 678hormone messenger ribonucleic acid in neurons of the hypotha - lamic paraventricular nucleus.,Non-OADS,/arxiv_data1/oa_pdf/34/68/ymj-53-671.PMC3381496.pdf
Neuroendocrine Functions of Leptin Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 679and pituitary function in male and female hypoleptinemic lipo - dystrophic patients.,Non-OADS,/arxiv_data1/oa_pdf/34/68/ymj-53-671.PMC3381496.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 742Original Articlehttp://dx.doi.org/10.3349/ymj.2012.53.4.742 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):742-747, 2012 Carriage Rates and Serogroups of Neisseria meningitidis  among  Freshmen in a University Dormitory in Korea  Areum Durey,1* Song-Mee Bae,2* Hye-Jin Lee,3 So-Yun Nah,1 Mijeong Kim,1  Ji Hyeon Baek,1 Yeon-Ho Kang,2 Moon-Hyun Chung,1 and Jin-Soo Lee1 Departments of 1Internal Medicine and 3Infection Control Service, Inha University Hospital, Incheon;  2Division of Bacterial Respiratory Infections, Centers for Infectious Diseases, National Institute of Health,  Korea Centers for Disease Control and Prevention, Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/08/9d/ymj-53-742.PMC3381497.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Neisseria meningitidis  is a leading cause of bacterial meningitis in  young adults.",Non-OADS,/arxiv_data1/oa_pdf/08/9d/ymj-53-742.PMC3381497.pdf
Carriage of N. meningitidis  in Freshmen Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 743erator took a posterior pharyngeal swab behind the uvula.,Non-OADS,/arxiv_data1/oa_pdf/08/9d/ymj-53-742.PMC3381497.pdf
"For the detec - tion and identification of serogroups A, B, C, Y , W135, a  multiplex PCR was performed simultaneously with oligo - nucleotides in the siaD gene (serogroups B, C, Y, and  W135) and in a gene cassette of orf-2 required for the bio - synthesis of the capsule of serogroup A.4 For the detection  and identification of serogroups 29E, X, and Z, the ctrA  gene, exclusive to meningococci and forming part of the  capsule biosynthesis locus, was chosen as the PCR target  according to the methods described by Bennett, et al.5 PorA genosubtyping Amplification of the porA  gene by PCR and sequencing of  the porA  variable regions (VR1 and VR2) were performed  as described by Sacchi, et al.6 All nucleotide sequences for  each VR were aligned with reference to both the nucleotide  and the corresponding amino acid sequences through a  Web-accessible PorA database (http://neisseria.org/nm/typ - ing/pora) and defined subtype families.",OADS,/arxiv_data1/oa_pdf/08/9d/ymj-53-742.PMC3381497.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 744followed up, 4.4% (4/90) acquired carriage and 95.6%  (86/90) remained as noncarriers one month later.",Non-OADS,/arxiv_data1/oa_pdf/08/9d/ymj-53-742.PMC3381497.pdf
Carriage of N. meningitidis  in Freshmen Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 745A number of risk factors have been shown to be associat - ed with meningococcal carriage.,Non-OADS,/arxiv_data1/oa_pdf/08/9d/ymj-53-742.PMC3381497.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 746meningococcal serogroup B is unable to stimulate a protec - tive immune response.22 Other alternatives for meningococ - cal outer membrane protein (OMP)-based vaccines have  been investigated to prevent meningococcal disease, re - gardless of their serogroup.23 The PorA OMP , characterized  by genosubtyping of the VR1 and VR2 of the porA  gene, is  highly immunogenic and is considered to be an important  component in protein-based vaccines against meningococ - cal disease.",Non-OADS,/arxiv_data1/oa_pdf/08/9d/ymj-53-742.PMC3381497.pdf
Carriage of N. meningitidis  in Freshmen Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 747for Neisseria meningitidis carriage in a school during a communi - ty outbreak of meningococcal infection.,Non-OADS,/arxiv_data1/oa_pdf/08/9d/ymj-53-742.PMC3381497.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 859Case Reporthttp://dx.doi.org/10.3349/ymj.2012.53.4.859 pISSN: 0513-5796, eISSN: 1976-2437         Yonsei Med J 53(4):859-862, 2012 Cerebral Salt Wasting Treated with Fludrocortisone   in a 17-Year-Old Boy Min Jeong Choi,1 Yoon Su Oh,1 Se Jin Park,2 Ji Hong Kim,1 and Jae Il Shin1 1The Institute of Kidney Disease, Department of Pediatrics, Yonsei University College of Medicine, Severance Children’ s Hospital, Seoul; 2Department of Pediatrics, Ajou University School of Medicine, Ajou University Hospital, Suwon, Korea.",Non-OADS,/arxiv_data1/oa_pdf/f2/37/ymj-53-859.PMC3381498.pdf
"© Copyright: Yonsei University College of Medicine 2012 This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/  licenses/by-nc/3.0) which permits unrestricted non- commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Cerebral salt wasting is characterized by inappropriate natriuresis and volume con - traction with associated cerebral pathology.",Non-OADS,/arxiv_data1/oa_pdf/f2/37/ymj-53-859.PMC3381498.pdf
"Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 860from the laboratory test were as follows: antidiuretic hor - mone (ADH) level of 5.55 pg/mL, renin level of 3.48 ng/mL/ hr, aldosterone level of 154.2 pg/mL, and a cortisol level of  164.94 ng/mL.",Non-OADS,/arxiv_data1/oa_pdf/f2/37/ymj-53-859.PMC3381498.pdf
"Cerebral Salt Wasting Treated with Fludrocortisone Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 861requirements in the first few months of life, usually 0.1-0.3  mg daily in two divided doses but occasionally up to 0.4  mg daily, and often require sodium supplementation (sodi - um chloride, 1-3 g) in addition to the mineralocorticoid.3  Older infants and children are typically maintained with a  0.05-0.1 mg dose of fludrocortisones.3 Our patient demon - strated that fludrocortisone administration was effective for  CSW treatment and refractory hyponatremia after intracra - nial surgery.",Non-OADS,/arxiv_data1/oa_pdf/f2/37/ymj-53-859.PMC3381498.pdf
Yonsei Med J   http://www.eymj.org   Volume 53   Number 4   July 2012 8624.,Non-OADS,/arxiv_data1/oa_pdf/f2/37/ymj-53-859.PMC3381498.pdf
The 128-bp sequence of the aberrant CEP290  exon that is included into the mutant CEP290 mRNA was  analyzed for the presence of exonic splice enhancer motifs  using the ESE finder 3.0 program (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home).,OADS,/arxiv_data1/oa_pdf/13/93/mtna20123a.PMC3381589.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/13/93/mtna20123a.PMC3381589.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Molecular Therapy: Nucleic Acids website (http://www.nature.com/mtna)",Non-OADS,/arxiv_data1/oa_pdf/e2/4e/mtna20125a.PMC3381590.pdf
Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)Molecular Therapy–Nucleic Acids is an open-access  journal published by Nature Publishing Group.,Non-OADS,/arxiv_data1/oa_pdf/88/46/mtna20113a.PMC3381593.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/88/46/mtna20113a.PMC3381593.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Molecular Therapy: Nucleic Acids website (http://www.nature.com/mtna)",Non-OADS,/arxiv_data1/oa_pdf/6d/c7/mtna201110a.PMC3381594.pdf
Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)Molecular Therapy–Nucleic Acids is an open-access  journal published by Nature Publishing Group.,Non-OADS,/arxiv_data1/oa_pdf/9d/c3/mtna20115a.PMC3381595.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/9d/c3/mtna20115a.PMC3381595.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)",Non-OADS,/arxiv_data1/oa_pdf/15/2f/mtna20117a.PMC3381596.pdf
"Some LNA oligonucleotides sequences are hepato- toxic,6 but other LNA antisense compounds of the same length  and pattern of modifications can be quite nontoxic: LNA anti-sense gapmers to survivin and hypoxia-inducible factor-1α  have been dosed in human clinical  trials above 4 mg/kg  weekly for as long as over a year with an acceptable safety  profile (http://webcast.aacr.org/portal/p/2011annual552).",Non-OADS,/arxiv_data1/oa_pdf/ea/0e/mtna20118a.PMC3381597.pdf
"The first human phase I safety and tolerability clinical trial of SPC5001 opened 18 May 2011, but was terminated 4 October 2011 (http://clinicaltrials.gov/show/NCT01350960).",Non-OADS,/arxiv_data1/oa_pdf/ea/0e/mtna20118a.PMC3381597.pdf
"Constrained sugars have become accepted as the next generation in development of antisense therapeutics to the  point that in 2010 Isis adopted a constrained sugar, IScEt,  for its upcoming antisense programs (http://www.isispharm.com/Antisense-Technology/Antisense-Drug- Discovery- Platform/Medicinal-Chemistry.htm).",Non-OADS,/arxiv_data1/oa_pdf/ea/0e/mtna20118a.PMC3381597.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)",Non-OADS,/arxiv_data1/oa_pdf/11/ed/mtna20114a.PMC3381598.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/48/06/mtna20111a.PMC3381599.pdf
Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)Molecular Therapy: Nucleic Acids is an open-access  journal published by Nature Publishing Group.,Non-OADS,/arxiv_data1/oa_pdf/f0/4f/mtna20116a.PMC3381600.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/f0/4f/mtna20116a.PMC3381600.pdf
We focused on  the 20 mRNAs most enriched in MVs as compared to cells of origin (Supplementary Table S1) and performed exten- sive analysis of 3′ UTR sequences of these mRNAs using a  multiple alignment program (Clustal W2-http://www.clustal.,OADS,/arxiv_data1/oa_pdf/dd/87/mtna20112a.PMC3381601.pdf
"To test this hypothesis, we performed miRNA database search (http://www.mirbase.",OADS,/arxiv_data1/oa_pdf/dd/87/mtna20112a.PMC3381601.pdf
The mFold web server (http://mfold.rna.albany.edu/?q=mfold) search predicted that this  25-nt putative zipcode sequence can assume a stem-loop  configuration.,OADS,/arxiv_data1/oa_pdf/dd/87/mtna20112a.PMC3381601.pdf
"5 The 3′ UTR sequences of the top enriched 20  genes were aligned using the multiple sequence alignment  tool ClustalW (Clustal W2-http://www.clustal.org/) under the  following conditions: fast alignment method, gap open 10, gap  extend 0.2, and DNA weight matrix ClustalW.",Non-OADS,/arxiv_data1/oa_pdf/dd/87/mtna20112a.PMC3381601.pdf
miRNA targeting sequences  within the 25-nt putative MV zipcode were checked using miRBase (http://www.mirbase.org/).,OADS,/arxiv_data1/oa_pdf/dd/87/mtna20112a.PMC3381601.pdf
"The microarray data have been deposited in NCBI’s Gene  Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) with GEO series accession number GSE35444.",OADS,/arxiv_data1/oa_pdf/dd/87/mtna20112a.PMC3381601.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)",Non-OADS,/arxiv_data1/oa_pdf/dd/87/mtna20112a.PMC3381601.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)",Non-OADS,/arxiv_data1/oa_pdf/07/82/mtna20121a.PMC3381603.pdf
"This is an Open Access article distributedunder the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non- commercial use, distribution, and reproduction in any medium, provided the originalwork is properly cited.DOI: 10.1093/cid/cis359 VACCINES CID 2012:55 (15 July) 259",Non-OADS,/arxiv_data1/oa_pdf/f7/84/cis359.PMC3381637.pdf
"This is an Open Access article distributed underthe terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non- commercial use, distribution, and reproduction in any medium, provided the originalwork is properly cited.DOI: 10.1093/cid/cis383 Effects of rhIL-7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients CID 2012:55 (15 July) 291",Non-OADS,/arxiv_data1/oa_pdf/2e/7c/cis383.PMC3381639.pdf
"The study was approved by ethics committees or institutional review boards of all participating in-stitutions in France, Italy, United States, and Canada and was registered in the EudraCT database ( http://eudract.emea.eu/ ; protocol 2006 –00624-20A) and at clinicaltrials.gov (NCT0047732), IND 100538, and CTA 9427-C2666/1-21C.",Non-OADS,/arxiv_data1/oa_pdf/2e/7c/cis383.PMC3381639.pdf
"This is an Open Access article distribu-ted under the terms of the Creative Commons AttributionNon-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided theoriginal work is properly cited.DOI: 10.1093/cid/cis399 310CID 2012:55 (15 July) CORRESPONDENCE",Non-OADS,/arxiv_data1/oa_pdf/3e/78/cis399.PMC3381640.pdf
Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)Molecular Therapy–Nucleic Acids is an open-access  journal published by Nature Publishing Group.,Non-OADS,/arxiv_data1/oa_pdf/05/bb/mtna20128a.PMC3381641.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/05/bb/mtna20128a.PMC3381641.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)",Non-OADS,/arxiv_data1/oa_pdf/29/cf/mtna201211a.PMC3381642.pdf
"This work is   licensed under the Creative Commons Attribution-Noncommercial-No   Derivative Works 3.0 Unported License.To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)",Non-OADS,/arxiv_data1/oa_pdf/7c/ae/mtna20129a.PMC3381643.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/be/94/evs025.PMC3381671.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/f2/evs027.PMC3381672.pdf
Materials and Methods Preparation of Data Polymorphism data were retrieved from GenBank http:// www.ncbi.nlm.nih.gov/Genbank or in case of Arabidopsis thaliana downloaded from http://walnut.usc.edu/2010 .,OADS,/arxiv_data1/oa_pdf/6d/f2/evs027.PMC3381672.pdf
"(2008) aEGP: http://egp.gs.washington.edu and PGA: http://pga.gs.washington.edu , August 2010.Gossmann et al.",Non-OADS,/arxiv_data1/oa_pdf/6d/f2/evs027.PMC3381672.pdf
Supplementary Material Supplementary ﬁgures S1 and S2 a r ea v a i l a b l ea t Genome Biology and Evolution online ( http://www.gbe.,Non-OADS,/arxiv_data1/oa_pdf/6d/f2/evs027.PMC3381672.pdf
Available from: http://www.mobot.org/mobot/research/ apweb/ .,Non-OADS,/arxiv_data1/oa_pdf/6d/f2/evs027.PMC3381672.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/db/c7/evs035.PMC3381673.pdf
All genomes were obtained from the UCSC Genome Bioinformatics data- base ( http://genome.ucsc.edu/ ).,OADS,/arxiv_data1/oa_pdf/db/c7/evs035.PMC3381673.pdf
2009 ) and the Ensembl human database ( http://www.ensembl.,OADS,/arxiv_data1/oa_pdf/db/c7/evs035.PMC3381673.pdf
Extraction of Primate-Shared and Rodent-Shared HCNSs We applied a sliding window analysis to UCSC pairwise noncoding alignments of human–marmoset and mouse– rat ( http://genome.ucsc.edu/ ).,OADS,/arxiv_data1/oa_pdf/db/c7/evs035.PMC3381673.pdf
SNP Detection We downloaded human single nucleotide polymorphism (SNP) data from the Hapmap database ( http://hapmap.ncbi.,OADS,/arxiv_data1/oa_pdf/db/c7/evs035.PMC3381673.pdf
nlm.nih.gov/ ) and mouse SNP data from NCBI dbSNP build 128 ( http://www.ncbi.nlm.nih.gov/SNP ).,OADS,/arxiv_data1/oa_pdf/db/c7/evs035.PMC3381673.pdf
Gene Ontology Analysis We looked for signiﬁcantly enriched gene categories in pri-mate and rodent LHF genes in the Gene Ontology (GO) da- tabase ( http://www.geneontology.org/ )(Ashburner et al.,OADS,/arxiv_data1/oa_pdf/db/c7/evs035.PMC3381673.pdf
The assignment of GO terms and the test for statis- tical enrichment of those terms were performed with GO-stat using goa_human and mgi GO gene associationdatabase ( http://gostat.wehi.edu.au/ )(Beissbarth and Speed 2004 ).,OADS,/arxiv_data1/oa_pdf/db/c7/evs035.PMC3381673.pdf
"Statistical analysis(one-sample t-test, two tailed) was conducted using the R package ( http://www.r-project.org ).",OADS,/arxiv_data1/oa_pdf/db/c7/evs035.PMC3381673.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ac/6e/evs039.PMC3381674.pdf
Multiple sequence alignment was conducted by ClustalW2 (http://www.ebi.ac.uk/T ools/msa/clustalw2/ ) and a neighbor- joining tree was constructed using MEGA5 ( Tamura et al.,OADS,/arxiv_data1/oa_pdf/ac/6e/evs039.PMC3381674.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0c/61/evs040.PMC3381675.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/da/07/evs042.PMC3381676.pdf
Materials and Methods Genome Assembly Paired-end shotgun sequence reads were downloaded fromthe NCBI Trace Archive repository ( ftp://ftp.ncbi.nih.gov/ pub/TraceDB/ ).,OADS,/arxiv_data1/oa_pdf/da/07/evs042.PMC3381676.pdf
Transmembrane domainsin each candidate ORF were predicted using TMHMM Serverversion 2.0 ( http://www.cbs.dtu.dk/services/TMHMM/ ).,OADS,/arxiv_data1/oa_pdf/da/07/evs042.PMC3381676.pdf
"Supplementary Material Supplementary text ,ﬁgures 1 –5, and table 1 are available at Genome Biology and Evolution online ( http://www.gbe.",Non-OADS,/arxiv_data1/oa_pdf/da/07/evs042.PMC3381676.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5f/ae/evs043.PMC3381677.pdf
"Sequence Alignment of Orthologous Genes An entire data set of orthologous genes (one-to-oneorthologous groups in supplementary table S1 ,Supplemen- tary Material online, which were almost equivalent to the core genes) was prepared by clustering using DomClust ( Uchiyama 2006 )a n dR E C O G( http://mbgd.genome.ad.jp/RECOG/ ).",OADS,/arxiv_data1/oa_pdf/5f/ae/evs043.PMC3381677.pdf
Supplementary Material Supplementary ﬁgure S1 and tables S1–S7 are available at Genome Biology and Evolution online ( http://www.gbe.,OADS,/arxiv_data1/oa_pdf/5f/ae/evs043.PMC3381677.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4c/17/evs044.PMC3381678.pdf
A draft of the stickleback genome has been available since February 2006 on the Universityof California—Santa Cruz (UCSC) genome browser(http://genome.ucsc.edu ).,OADS,/arxiv_data1/oa_pdf/4c/17/evs044.PMC3381678.pdf
"Similarly, the L2 clade is represented by the sole Maui family, whereas the zebra ﬁsh genomecontains more than 40 L2-related families (based on the an-notations of the zebra ﬁsh genome at http://genome.ucsc.e- du) and the lizard has 17 families ( Novick et al.",OADS,/arxiv_data1/oa_pdf/4c/17/evs044.PMC3381678.pdf
"Available from: http://www.girinst.org/repbase/update Kapitonov VV, Tempel S, Jurka J.",OADS,/arxiv_data1/oa_pdf/4c/17/evs044.PMC3381678.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e3/74/evs045.PMC3381679.pdf
"Finally, 3,571 elephant con- tigs had a signiﬁcant similarity to at least one of the follow- ing genomic/transcript databases: human, mouse, cow,opossum, platypus, and chicken but did not map to thelow coverage (2 /C2) African elephant draft genome assembly (http://www.broadinstitute.org ).",OADS,/arxiv_data1/oa_pdf/e3/74/evs045.PMC3381679.pdf
"In ad- dition, in order to maximize the use of all currently available elephant genomic data, elephant transcripts were down-loaded from Ensembl, and elephant genomic data werefetched from http://www.broadinstitute.org/science/projects/ mammals-models/elephant/elephant , February 2009.",OADS,/arxiv_data1/oa_pdf/e3/74/evs045.PMC3381679.pdf
"To supplement the transcript data provided by Ensembl, we also included the human and mouse contig data fromGenBank and full mRNA data sets from the mammalian gene collection (MGC, http://mgc.nci.nih.gov/ ;Temple et al.",OADS,/arxiv_data1/oa_pdf/e3/74/evs045.PMC3381679.pdf
"All sequences, BLAT results, and annotation tables were stored in a MySQL database ( http://www.mysql.com ).",OADS,/arxiv_data1/oa_pdf/e3/74/evs045.PMC3381679.pdf
Supplementary Material Supplementary ﬁgure S1 and data sets S1–S6 are available atGenome Biology and Evolution online ( http://www.gbe.,OADS,/arxiv_data1/oa_pdf/e3/74/evs045.PMC3381679.pdf
"Available from: http://www.repeatmasker.org Soares MJ, Konno T, Alam SMK.",Non-OADS,/arxiv_data1/oa_pdf/e3/74/evs045.PMC3381679.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/ 3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e1/88/evs046.PMC3381680.pdf
2002 ;http://www.stats.ox.ac.uk/ ;mcvean/LDhat ).,Non-OADS,/arxiv_data1/oa_pdf/e1/88/evs046.PMC3381680.pdf
"Hotspot Detection To identify windows with recombination rates signiﬁcantly higher than mean background rates, that is, recombinationhotspots, we used the sequenceLDhot program ( Fearnhead 2006 ;http://www.maths.lancs.ac.uk/ ;fearnhea/Hotspot/ ).",Non-OADS,/arxiv_data1/oa_pdf/e1/88/evs046.PMC3381680.pdf
Supplementary Material Supplementary tables S1 and S2 are available at Genome Biology and Evolution online ( http://www.gbe.,Non-OADS,/arxiv_data1/oa_pdf/e1/88/evs046.PMC3381680.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4b/a7/aws074.PMC3381719.pdf
Data were monitored and analysed online and re-analy-zed ofﬂine using the WinLTP software (http://www.ltp-program.com).,OADS,/arxiv_data1/oa_pdf/4b/a7/aws074.PMC3381719.pdf
"Available from: http://mouse.brain-map.org (march 2012, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/4b/a7/aws074.PMC3381719.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a0/68/aws115.PMC3381720.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c2/38/aws128.PMC3381722.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/ad/aws143.PMC3381726.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/2d/53/srep00470.PMC3381803.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Shadbolt, P. et al.",Non-OADS,/arxiv_data1/oa_pdf/2d/53/srep00470.PMC3381803.pdf
"Moreover, PAGAN-generated alignments of noisy next-generation sequencing (NGS)sequences are accurate enough for the use of RNA-seq data inevolutionary analyses.Availability: PAGAN is written in C++, licensed under the GPL and its source code is available at http://code.google.com/p/pagan-msa.Contact: ari.loytynoja@helsinki.ﬁ Supplementary information: Supplementary data are available at Bioinformatics online.",OADS,/arxiv_data1/oa_pdf/02/54/bts198.PMC3381962.pdf
http://www.onekp.com).,Non-OADS,/arxiv_data1/oa_pdf/02/54/bts198.PMC3381962.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/02/54/bts198.PMC3381962.pdf
Theadditional features implemented in PAGAN are explained in detail in theSupplementary Material.2.2 Comparison of methods for alignment extension The test data for alignment extension were simulated using phylogenetic trees based on the Ensembl/UCSC tree (http://tinyurl.com/ensembltree;Fig.,OADS,/arxiv_data1/oa_pdf/02/54/bts198.PMC3381962.pdf
"Available at http://www.ebi.ac.uk/goldman-srv/simNGS/ Matsen,F.",Non-OADS,/arxiv_data1/oa_pdf/02/54/bts198.PMC3381962.pdf
"The enhanced EventMine outperforms the highest ranked systemsfrom the BioNLP’09 shared task, and from the GENIA and InfectiousDiseases subtasks of the BioNLP’11 shared task.Availability: The improved version of EventMine, incorporating the CR system and DA methods, is available at: http://www.nactem.ac.uk/EventMine/.Contact: makoto.miwa@manchester.ac.uk Received on December 12, 2011; revised on March 20, 2012; accepted on April 18, 2012 1 INTRODUCTION The focus of text mining systems in biomedicine has recently shifted from extracting named entities of biological relevance to recognizingrelations and events.",Non-OADS,/arxiv_data1/oa_pdf/a2/3f/bts237.PMC3381963.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/a2/3f/bts237.PMC3381963.pdf
"Sherman1,†, Da Wei Huang1, Robert Stephens2, Michael W. Baseler3, H. Clifford Lane4and Richard A. Lempicki1,∗ 1Laboratory of Immunopathogenesis and Bioinformatics,2Advanced Biomedical Computing Center,3Clinical Services Program, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA and 4Laboratory of Immuno-regulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA Associate Editor: Martin Bishop ABSTRACT Summary: The database for annotation, visualization and integrated discovery (DAVID), which can be freely accessed athttp://david.abcc.ncifcrf.gov/, is a web-based online bioinformaticsresource that aims to provide tools for the functional interpretationof large lists of genes/proteins.",OADS,/arxiv_data1/oa_pdf/26/cb/bts251.PMC3381967.pdf
"DAVID-WS (webservice) has been developed to automate user tasks by providingstateful web services to access DAVID programmatically without theneed for human interactions.Availability: The web service and sample clients (written in Java, Perl, Python and Matlab) are made freely available under the DAVIDLicense at http://david.abcc.ncifcrf.gov/content.jsp?ﬁle=WS.html.Contact: xiaoli.jiao@nih.gov; rlempicki@nih.gov Received on February 6, 2012; revised on March 24, 2012; accepted on April 23, 2012 1 INTRODUCTION The database for annotation, visualization and integrated discovery (DA VID) bioinformatics resources (Dennis et al.",OADS,/arxiv_data1/oa_pdf/26/cb/bts251.PMC3381967.pdf
2 SERVER IMPLEMENTATION The implementation of DA VID-WS adheres to current W3C (http://www.w3.org/) standards including Extensible MarkupLanguage (XML)-based languages such as Simple Object AccessProtocol (SOAP) and Web Service Deﬁnition Language (WSDL).,OADS,/arxiv_data1/oa_pdf/26/cb/bts251.PMC3381967.pdf
The server is implemented in Java using Apache Axis2 (http://axis.apache.org/axis2/java/core) to call DA VID functional © The Author(s) 2012.,OADS,/arxiv_data1/oa_pdf/26/cb/bts251.PMC3381967.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/26/cb/bts251.PMC3381967.pdf
4 PERFORMANCE TESTING We used Apache Jmeter (http://jakarta.apache.org/jmeter/) to conﬁgure test plans and perform load testing for DA VID-WS.,OADS,/arxiv_data1/oa_pdf/26/cb/bts251.PMC3381967.pdf
"The analytical tools include a variety ofgraph theoretic and geometric tools that summarize the distributionof the numbers of edges per face, areas, perimeters, anglesof Delaunay triangle edges (anglograms), Gabriel graphs, nearestneighbor graphs, minimal spanning trees, Ulam trees, Pitteway tests,circumcircles and convexhulls, as well as spatial statistics (Clark–Evans Nearest Neighborhood and Variance to Mean Ratio) andexport functions for standard relationships (Lewis’s Law, Desch’s Lawand Aboav–Weaire Law).Availability: Ka-me: a Voronoi image analyzer is available as an executable with documentation and sample applications from theBioQUEST Library (http://bioquest.org/downloads/kame_1.0.rar).Contact: noppadon.khiripet@nectec.or.th Received on October 25, 2011; revised on April 5, 2012; accepted on April 24, 2012 Important recent work in computational biology (Bock et al ., 2010; Gibson et al.",Non-OADS,/arxiv_data1/oa_pdf/d0/27/bts253.PMC3381968.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/d0/27/bts253.PMC3381968.pdf
workshops in mathematical biology offered by the BioQUEST Curriculum Consortium (http://bioquest.org).,Non-OADS,/arxiv_data1/oa_pdf/d0/27/bts253.PMC3381968.pdf
"The software is available online from http://code.google.com/p/bitseq/, version 0.4 was used forgenerating results presented in this article.Contact: glaus@cs.man.ac.uk, antti.honkela@hiit.ﬁ or m.rattray@shefﬁeld.ac.ukSupplementary information: Supplementary data are available at Bioinformatics online.",OADS,/arxiv_data1/oa_pdf/6b/94/bts260.PMC3381971.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/6b/94/bts260.PMC3381971.pdf
"Two other mem- bers of this family (At1g18690 and At1g74380) are expressed at very low levels in all tissues that were examined (http://www.weigelworld.org/resources/microarray/AtGenExpress/; Schmid et al., 2005) and are therefore unlikely to contribute sig- niﬁcantly to XyG biosynthesis.",Non-OADS,/arxiv_data1/oa_pdf/ab/9f/fpls-03-00134.PMC3382260.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Supplementary Information accompanies the paper on the Mol ecular Psychiatry website (http://www.nature.com/mp)Genetic interaction in ADHD M Jain et al 747 Molecular Psychiatry",Non-OADS,/arxiv_data1/oa_pdf/76/e7/mp201159a.PMC3382263.pdf
Materials and methods Plant material Plants of S. arachnoideum L. at different stages of development were obtained from a commercial company (http://kaktusiarnia.pl/index1.html ) in northern Poland.,OADS,/arxiv_data1/oa_pdf/3a/84/709_2011_Article_297.PMC3382269.pdf
"Outcome The primary outcome was self-report of depressive symp- toms as measured by the short version of the Mood and Feelings Questionnaire (MFQ) [ 2,34](http://devepi.mc.",Non-OADS,/arxiv_data1/oa_pdf/50/ed/127_2011_Article_422.PMC3382270.pdf
Avalible from  http://www.bic.mni.mcgill.ca/brainweb/  [27] C.A.,Non-OADS,/arxiv_data1/oa_pdf/b8/5e/TOBEJ-6-56.PMC3382289.pdf
http://www.ia.unc.edu/MSseg/  [33] A.C. Evans et al.,Non-OADS,/arxiv_data1/oa_pdf/b8/5e/TOBEJ-6-56.PMC3382289.pdf
http://www.ia.unc.edu/MSseg/results_table.php   [45] B.A.,Non-OADS,/arxiv_data1/oa_pdf/b8/5e/TOBEJ-6-56.PMC3382289.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and repr oduction in any medium, provided the  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b8/5e/TOBEJ-6-56.PMC3382289.pdf
Available at http://www.esrf.eu/UsersAndScience/ Experiments/TBS/SciSoft.,Non-OADS,/arxiv_data1/oa_pdf/fe/b5/ncomms1839.PMC3382302.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/fe/b5/ncomms1839.PMC3382302.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Bentov, S. et al.",Non-OADS,/arxiv_data1/oa_pdf/fe/b5/ncomms1839.PMC3382302.pdf
"TEV- At17b induced visible symptoms in the ecotype in which it was evolved, L er-0, includ- ing stunting, etching, and leaf malformation (Agudelo-Romero 1http://babelomics.bioinfo.cipf.es 2http://evolution.genetics.washington.edu/phylip.html www.frontiersin.org June 2012 | Volume 3 | Article 229 | 3",Non-OADS,/arxiv_data1/oa_pdf/41/2a/fmicb-03-00229.PMC3382383.pdf
SUPPLEMENTARY MATERIAL The Supplementary Material for this article can be found online at http://www.frontiersin.org/Virology/10.3389/fmicb.2012.00229/ abstract Figure S1 | Examples of symptoms induced byTEV- At17b on the different A. thaliana ecotypes used in this study.,Non-OADS,/arxiv_data1/oa_pdf/41/2a/fmicb-03-00229.PMC3382383.pdf
http://archives.citypaper.net/articles/032196/arti- cle038.shtml (accessed March 21–28).,Non-OADS,/arxiv_data1/oa_pdf/56/60/fpsyg-03-00210.PMC3382412.pdf
"Excellent and very recent reviews on the topic are available 1According to the Department of Health Statistics and Health Information Systems, World Health Organization (WHO), (http://www.who.int/healthinfo/survey/ageingdefnolder/en/index.html), “Most developed world countries have accepted the chronological age of 65 years as a deﬁnition of “elderly” or older person,” although this concept does not adapt well to every country or population.",Non-OADS,/arxiv_data1/oa_pdf/91/80/fphys-03-00218.PMC3382417.pdf
2008. http://www.acgme.org/acWebsite/downloads/RRC_progReq/440_general_surgery_01012008.pdf (accessed 5 Jan 2010).8.,Non-OADS,/arxiv_data1/oa_pdf/f3/97/qhc-2011-000603.PMC3382446.pdf
2008. http://www.ahrq.gov/downloads/pub/advances2/vol2/Advances-Deis_82.pdf (accessed 14 Jul 2009).,OADS,/arxiv_data1/oa_pdf/f3/97/qhc-2011-000603.PMC3382446.pdf
2008. http://www.moh.govt.nz/moh.nsf/UnidPrint/MH236?,Non-OADS,/arxiv_data1/oa_pdf/f3/97/qhc-2011-000603.PMC3382446.pdf
2005. http://webmm.ahrq.gov (accessed Jun 2010).,OADS,/arxiv_data1/oa_pdf/f3/97/qhc-2011-000603.PMC3382446.pdf
2005. http://www.cdha.nshealth.ca/defaultnc.aspx?,Non-OADS,/arxiv_data1/oa_pdf/f3/97/qhc-2011-000603.PMC3382446.pdf
http://www12.statcan.ca/census-recensement/2006/as-sa/97-557/pdf/ 97-557-XIE2006001.pdf .,OADS,/arxiv_data1/oa_pdf/2f/0b/10823_2011_Article_9157.PMC3382634.pdf
Ottawa .http://www.statcan.gc.ca/daily-quotidien/080402/ dq080402a-eng.htm .,Non-OADS,/arxiv_data1/oa_pdf/2f/0b/10823_2011_Article_9157.PMC3382634.pdf
"In addition, theauthors acknowledge financial support from the Department of AnimalScience, Cornell University and Higher Education for Development through a US –Mexico Training, Internships, Exchanges and Scholarships grant ( http://tiesmexico.cals.cornell.edu/ ).",Non-OADS,/arxiv_data1/oa_pdf/04/51/11250_2011_Article_49.PMC3382636.pdf
"Unpublished MS thesis, Cornell University.http://tiesmexico.cals.cornell.edu/research/documents/victor_ absalon_masters_thesis.pdf Aguilar-Pérez, C., Ku-Vera, J., Centurión-Castro, F., Garnsworthy, P. C., 2009.",Non-OADS,/arxiv_data1/oa_pdf/04/51/11250_2011_Article_49.PMC3382636.pdf
http://tiesmexico.cals.cornell.,Non-OADS,/arxiv_data1/oa_pdf/04/51/11250_2011_Article_49.PMC3382636.pdf
"In addition, the authors acknowledge financial support from the Department of Animal Science, Cornell University and Higher Education for Devel-opment through a US –Mexico Training, Internships, Exchanges and Scholarships grant ( http://tiesmexico.cals.cornell.edu/ ).",Non-OADS,/arxiv_data1/oa_pdf/f7/55/11250_2011_Article_50.PMC3382639.pdf
"http://tiesmexico.cals.cornell.edu/research/ documents/victor_absalon_masters_thesis.pdf Absalón-Medina, V. A., Blake, R. W., Fox, D. G., Juárez-Lagunes, F. I., Nicholson, C. F., Canudas-Lara, E. G., Rueda-Maldonado, B. L., 2011.",Non-OADS,/arxiv_data1/oa_pdf/f7/55/11250_2011_Article_50.PMC3382639.pdf
http://tiesmexico.cals.,Non-OADS,/arxiv_data1/oa_pdf/f7/55/11250_2011_Article_50.PMC3382639.pdf
Clin ExpRheumatol 19(4 Suppl 23):S158–S162 13.http://www.sgk.gov.tr/wps/portal/en 14.http://en.wikipedia.org/wiki/Health_care_in_Turkey 15.http://www.euro.who.int/__data/assets/pdf_ﬁle/0007/96415/e79838.,Non-OADS,/arxiv_data1/oa_pdf/5e/a6/296_2011_Article_1894.PMC3382642.pdf
pdf 16.http://www.tuik.gov.tr 17.,Non-OADS,/arxiv_data1/oa_pdf/5e/a6/296_2011_Article_1894.PMC3382642.pdf
Scrubber (http://www.biologic.com.au ) was utilized for data pro- cessing and analysis.,OADS,/arxiv_data1/oa_pdf/43/f6/10822_2011_Article_9521.PMC3382646.pdf
"(cited 2011 June 23), available at: http://www.cialca.org/files/files/Student% 20Thesis/PaulCox-SouthKivu.pdf .Cox, T.P., 2011.",Non-OADS,/arxiv_data1/oa_pdf/85/b8/11250_2011_Article_61.PMC3382655.pdf
"World Animal Review, 77,26–37 (cited 2010 March 16), available at: http://www.fao.org/ docrep/V1650T/v1650T0d.htm .",Non-OADS,/arxiv_data1/oa_pdf/85/b8/11250_2011_Article_61.PMC3382655.pdf
"(cited 2011 June 20),available at: http://www.biomedcentral.com/1471-2458/11/261/ abstract/.",OADS,/arxiv_data1/oa_pdf/85/b8/11250_2011_Article_61.PMC3382655.pdf
"In: Tropentag, 14 –16 Sep. 2010, ETH Zurich, Switzerland, Book of Abstracts, p. 392(cited 2011 June 20), available at: http://www.tropentag.de/2010/ abstracts/full/491.pdf .",Non-OADS,/arxiv_data1/oa_pdf/85/b8/11250_2011_Article_61.PMC3382655.pdf
"210, (Centro Internacional de Agricultura Tropical (CIAT), Nairobi, Kenya), 36 pp (cited 2011 June 22), available at: http://www.ciat.cgiar.org/ourprograms/ Agrobiodiversity/forages/Pages/Publications.aspx .",Non-OADS,/arxiv_data1/oa_pdf/85/b8/11250_2011_Article_61.PMC3382655.pdf
"International Journal for Rural Development, 45(1), 40 –42 (cited 2011 April 2), available at: http://www.rural21.com/uploads/media/Small_ healthy_highyielding_01.pdf .",Non-OADS,/arxiv_data1/oa_pdf/85/b8/11250_2011_Article_61.PMC3382655.pdf
"(cited 2011 June 22), available at: http://www.ciat.",Non-OADS,/arxiv_data1/oa_pdf/85/b8/11250_2011_Article_61.PMC3382655.pdf
http://www.ambrosiainfo.de/53223897640d5c602/ index.html .,Non-OADS,/arxiv_data1/oa_pdf/55/04/484_2011_Article_468.PMC3382656.pdf
"IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012http://dx.doi.org/10.4110/in.2012.12.2.41 pISSN 1598-2629    eISSN 2092-6685 41REVIEW ARTICLE Received on February 2, 2012.",Non-OADS,/arxiv_data1/oa_pdf/38/9a/in-12-41.PMC3382663.pdf
"CC This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org/licenses/by-nc/3.0) wh ich permits unrestricted non-commercial use, distribu- tion, and reproduction in any medium, provid ed the original work  is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/38/9a/in-12-41.PMC3382663.pdf
42 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012active states may improve neuronal survival by releasing neu- rotrophic factors or by removing excess glutamate from the  extracellular space (3).,Non-OADS,/arxiv_data1/oa_pdf/38/9a/in-12-41.PMC3382663.pdf
"43 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012emerging as a new target for drug development (32,33).",Non-OADS,/arxiv_data1/oa_pdf/38/9a/in-12-41.PMC3382663.pdf
44 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/38/9a/in-12-41.PMC3382663.pdf
"45 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012the footpad, cutaneous inflammation appears in minutes to  hours and peaks within 5 ∼8 hours.",Non-OADS,/arxiv_data1/oa_pdf/38/9a/in-12-41.PMC3382663.pdf
"46 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012ACKNOWLEDGEMENTS This work was supported by the National Research Founda- tion (NRF) grants funded by the Ministry of Education,  Science and Technology (MEST) of Korean government  (2011-0028240).",Non-OADS,/arxiv_data1/oa_pdf/38/9a/in-12-41.PMC3382663.pdf
47 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 201231.,Non-OADS,/arxiv_data1/oa_pdf/38/9a/in-12-41.PMC3382663.pdf
"IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012http://dx.doi.org/10.4110/in.2012.12.2.48 pISSN 1598-2629    eISSN 2092-6685REVIEW ARTICLE 48Received on February 3, 2012.",Non-OADS,/arxiv_data1/oa_pdf/af/77/in-12-48.PMC3382664.pdf
"CC This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org/licenses/by-nc/3.0) wh ich permits unrestricted non-commercial use, distribu- tion, and reproduction in any medium, provid ed the original work  is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/77/in-12-48.PMC3382664.pdf
"49 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012ruses is well-characterized in the evidence of immune system  recognition and the presence of inflammatory components  during the neuropathological changes (5), there are only a  few studies describing the role of CD4＋ helper T cell (Th)  subsets, in particular the CD4＋CD25＋Foxp3＋ T r e g ,  d u r i n g   the progression of an infection caused by neurotrophic vi- ruses (6).",Non-OADS,/arxiv_data1/oa_pdf/af/77/in-12-48.PMC3382664.pdf
"50 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012type-I interferons (IFN), IFN- α and IFN-β (28).",Non-OADS,/arxiv_data1/oa_pdf/af/77/in-12-48.PMC3382664.pdf
"51 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012onstrated that TLR2-deficient m ice have a blunted cytokine re- sponse and these mice are much less susceptible to normally  lethal HSV1-induced encephalitis (47), which suggests that in-duction of inflammatory cytokin es through TLR2 may lead to  en ceph alitis (47).",Non-OADS,/arxiv_data1/oa_pdf/af/77/in-12-48.PMC3382664.pdf
52 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012mounted rapidly within the CNS against both self and exoge- nous antigens in the face of an antigenic challenge.,Non-OADS,/arxiv_data1/oa_pdf/af/77/in-12-48.PMC3382664.pdf
53 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/af/77/in-12-48.PMC3382664.pdf
54 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012burden may generate inflammatory mediators that sub- sequently alter the permeability of the BBB to allow free virus   and/or virus-infected leukocytes to enter the CNS.,Non-OADS,/arxiv_data1/oa_pdf/af/77/in-12-48.PMC3382664.pdf
55 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 20122004.,Non-OADS,/arxiv_data1/oa_pdf/af/77/in-12-48.PMC3382664.pdf
"56 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012Chapgier A, Plancoulaine S, Titeux M, Cognet C, von Bernuth  H, Ku CL, Casrouge A, Zhang XX, Barreiro L, Leonard J,  Hamilton C, Lebon P, H éron B, Vall ée L, Quintana-Murci L,  Hovnanian A, Rozenberg F, Vivier E, Geissmann F, Tardieu M, Abel L, Casanova JL: TLR3 deficiency in patients with her- pes simplex encephalitis.",Non-OADS,/arxiv_data1/oa_pdf/af/77/in-12-48.PMC3382664.pdf
"57 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012Bauhofer O, T âche V, Hjertner B, McNeilly F, van Gennip  HG, McCullough KC, Summerfield A: Interaction of classical  swine fever virus with dendritic cells.",Non-OADS,/arxiv_data1/oa_pdf/af/77/in-12-48.PMC3382664.pdf
"IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012http://dx.doi.org/10.4110/in.2012.12.2.58 pISSN 1598-2629    eISSN 2092-6685ORIGINAL ARTICLE 58Received on March 16, 2012.",Non-OADS,/arxiv_data1/oa_pdf/04/c0/in-12-58.PMC3382665.pdf
"CC This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org/licenses/by-nc/3.0) wh ich permits unrestricted non-commercial use, distribu- tion, and reproduction in any medium, provid ed the original work  is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/04/c0/in-12-58.PMC3382665.pdf
"59 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012dence supports WT1 as a promising target for hematological  malignancies, and various clin ical trials have demonstrated  the feasibility of this approach (3,9-15).",Non-OADS,/arxiv_data1/oa_pdf/04/c0/in-12-58.PMC3382665.pdf
60 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012sec.,Non-OADS,/arxiv_data1/oa_pdf/04/c0/in-12-58.PMC3382665.pdf
61 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/04/c0/in-12-58.PMC3382665.pdf
62 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012 Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/04/c0/in-12-58.PMC3382665.pdf
63 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012DISCUSSION Recent advances in immunotherapy have opened the possibil- ities of further eradication of post-chemotherapy residual leu- kemia by targeting leukemia-associated antigens of WT1 (25).,Non-OADS,/arxiv_data1/oa_pdf/04/c0/in-12-58.PMC3382665.pdf
64 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012(2010-0008762).,Non-OADS,/arxiv_data1/oa_pdf/04/c0/in-12-58.PMC3382665.pdf
65 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 201225.,Non-OADS,/arxiv_data1/oa_pdf/04/c0/in-12-58.PMC3382665.pdf
"IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012http://dx.doi.org/10.4110/in.2012.12.2.66 pISSN 1598-2629    eISSN 2092-6685BRIEF COMMUNICATION 66Received on March 10, 2012.",Non-OADS,/arxiv_data1/oa_pdf/af/fe/in-12-66.PMC3382666.pdf
"CC This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org/licenses/by-nc/3.0) wh ich permits unrestricted non-commercial use, distribu- tion, and reproduction in any medium, provid ed the original work  is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/fe/in-12-66.PMC3382666.pdf
67 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012Table I.  EY-6-induced CRT expression on the tumor cell surface.,Non-OADS,/arxiv_data1/oa_pdf/af/fe/in-12-66.PMC3382666.pdf
68 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012 Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/af/fe/in-12-66.PMC3382666.pdf
69 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012cells directly as well as induce the tumor antigen specific im- munity to evoke complete tumor cell elimination.,Non-OADS,/arxiv_data1/oa_pdf/af/fe/in-12-66.PMC3382666.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 377 Korean J Urol 2012;53:377-385www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.377 Review Article Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for  Erectile Dysfunction Hyun Hwan Sung, Sung Won Lee Department of Urology, Samsung Medical Center, Sung kyunkwan University School of Medicine, Seoul, Korea Oral phosphodiesterase type 5 (PDE5) inhibito rs have provided non-invasive, effective,  and well-tolerated treatments for patients with erectile dysfunction (ED).",Non-OADS,/arxiv_data1/oa_pdf/c2/0f/kju-53-377.PMC3382685.pdf
"Key Words:  Chronic; Erectile dysfunction ; Phosphodiesterase 5 inhibitors This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 12 March, 2012 accepted 19 April, 2012 Corresponding Author: Sung Won LeeDepartment of Urology, Samsung Medical Center, Sungkyunkwan  University School of Medicine, 81  Irwon-ro, Gangnam-gu, Seoul 135-710, Korea TEL: +82-2-3410-3559 FAX: +82-2-3410-3027E-mail: drswlee@skku.edu INTRODUCTION Erectile dysfunction (ED) is a chronic condition defined as  the consistent inabil ity to maintain a su fficient erection for  satisfactory sexual function.",Non-OADS,/arxiv_data1/oa_pdf/c2/0f/kju-53-377.PMC3382685.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 386 Korean J Urol 2012;53:386-390www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.386 Urological Oncology Clinical Outcomes of Bosniak Category IIF Complex Renal Cysts in  Korean Patients Jong Ho Hwang, Chang Ki Lee1, Ho Song Yu1, Kang Su Cho1, Young Deuk Choi1, Won Sik Ham1 Department of Urology, Sahmyook Medical Center, Seoul, 1Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea Purpose:  To assess the clinical reliability of th e Bosniak IIF category and to determine  the proper radiologic follow-up duration an d intervals for category IIF complex renal  cysts.",Non-OADS,/arxiv_data1/oa_pdf/47/38/kju-53-386.PMC3382686.pdf
"Key Words:  Carcinoma; Cysts; Disease pr ogression; Kidney; Renal cell This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 19 February, 2012 accepted 19 April, 2012 Corresponding Author: Won Sik HamDepartment of Urology, Yonsei University College of Medicine, 50  Yonsei-ro, Seodaemun-gu, Seoul  120-752, KoreaTEL: +82-2-2228-2313 FAX: +82-2-312-2538 E-mail: uroham@yuhs.ac INTRODUCTION  Renal cysts are common lesions.",Non-OADS,/arxiv_data1/oa_pdf/47/38/kju-53-386.PMC3382686.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 391 Korean J Urol 2012;53:391-395www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.391 Urological Oncology Preoperative Clinical Factors for Diagnosis of Incidental Prostate  Cancer in the Era of Tissue-Ablative Surgery for Benign Prostatic Hyperplasia: A Korean Multi-Center Review Changhee Yoo, Cheol Young Oh, Se Joong Kim1, Sun Il Kim1, Young Sig Kim2, Jong Yeon Park3,  Do Hwan Seong4, Yun Seob Song5, Won Jae Yang5, Hyun Chul Chung6, In Rae Cho7, Sung Yong Cho7,  Sang Hyeon Cheon3, Sungjoon Hong8, Jin Seon Cho Department of Urology, Hallym Universi ty College of Medicine, Chuncheon, 1Department of Urology, Ajou University School of Medicine,  Suwon, 2Department of Urology, National Health Insurance Corporation Ilsan Hospital, Goyang, 3Department of Urology, University of  Ulsan College of Medicine, Ulsan, 4Department of Urology, Inha University School of Medicine, Incheon, 5Department of Urology,  Soonchunhyang University College of Medicine, Cheonan, 6Department of Urology, Yonsei University Wonju College of Medicine, Wonju,  7Department of Urology, Inje University College of Medicine, Gimhae, 8Department of Urology, Yonsei University College of Medicine,  Busan, Korea Purpose:  To identify potential predictive factors of incidental prostate cancer (IPca) in  patients considering tissue-ablation treatmen t for benign prostatic hyperplasia (BPH).",Non-OADS,/arxiv_data1/oa_pdf/23/f4/kju-53-391.PMC3382687.pdf
"Key Words:  Prostate neoplasms; Prostatic hy perplasia; Transu rethral resection of  prostate This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 21 November, 2011 accepted 30 March, 2012 Corresponding Author: Jin Seon Cho Department of Urology, Hallym  University Sacred Heart Hospital,  Hallym University College of Medicine, 22 Gwanpyeong-ro, 170beon-gil,  Dongan-gu, Anyang 431-796, Korea TEL: +82-31-380-3851FAX: +82-31-380-3852 E-mail: js315@hallym.or.kr INTRODUCTION Transurethral resection of the prostate (TURP) is a stand- ard surgical treatment for symptomatic benign prostatic hyperplasia (BPH).",Non-OADS,/arxiv_data1/oa_pdf/23/f4/kju-53-391.PMC3382687.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 396 Korean J Urol 2012;53:396-400www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.396 Urological Oncology Tumor Establishment Features of Orthotopic Murine Bladder  Cancer Models Jin Seok Lee, Min Ho Bae, Sung Ho Choi, Sang Hun Lee, Young Sam Cho, Heung Jae Park,  Chil Hun Kwon, Kwan Joong Joo Department of Urology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea Purpose:  Animal tumor models are important fo r the evaluation of novel therapeutic  modalities.",Non-OADS,/arxiv_data1/oa_pdf/3c/f8/kju-53-396.PMC3382688.pdf
"Key Words:  Animal models; Intravesical admini stration; Urinary bladder neoplasms  This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 27 March, 2012 accepted 25 April, 2012 Corresponding Author: Kwan Joong JooDepartment of Urology, Kangbuk  Samsung Hospital, Sungkyunkwan University School of Medicine, 29  Saemunan-ro, Jongno-gu, Seoul  110-746, KoreaTEL: +82-2-2001-2241 FAX: +82-2-2001-2247 E-mail: urojoo@dreamwiz.com INTRODUCTION The gold standard of treatment  for patients with non-mus- cle-invasive bladder cancer is transurethral resection.",Non-OADS,/arxiv_data1/oa_pdf/3c/f8/kju-53-396.PMC3382688.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 401 Korean J Urol 2012;53:401-404www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.401 Robotics/Laparoscopy Use of Cystoscopic Tattooing in Laparoscopic Partial Cystectomy Bong Ki Kim, Mi Ho Song, Hee Jo Yang, Doo Sang Kim, Nam Kyu Lee, Youn Soo Jeon Department of Urology, Soonchunhyang University Cheonan Hospita l, Soonchunhyang University College of Medicine, Cheonan, Korea Purpose:  During laparoscopic partial cystectomy (LPC), lesion identi fication is essen- tial to help to determine the appropriate bladder incisions requir ed to maintain ad- equate resection margins.",Non-OADS,/arxiv_data1/oa_pdf/69/b5/kju-53-401.PMC3382689.pdf
"Key Words:  Cystectomy; Cystoscopy; Laparoscopy; Tattooing This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 2 April, 2012 accepted 4 May, 2012 Corresponding Author: Youn Soo Jeon Department of Urology,  Soonchunhyang University Cheonan Hospital, Soonchunhyang University  College of Medicine, 31  Suncheonhyang 6-gil, Dongnam-gu, Cheonan 330-930, Korea TEL: +82-41-570-2277 FAX: +82-41-574-6248E-mail: ysurol@schmc.ac.kr INTRODUCTION Partial cystectomy is an excellent method for bladder  preservation.",Non-OADS,/arxiv_data1/oa_pdf/69/b5/kju-53-401.PMC3382689.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 405 Korean J Urol 2012;53:405-409www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.405 Voiding Dysfunction A Predictive Factor in Overactive Bladder Symptoms Improvement  after Combined Anterior Vaginal Wall Prolapse Repair: A Pilot Study Dong Min Lee, Young Woo Ryu, Yong Taec Lee, Seung Hyun Ahn, June Hyun Han, Seung Hee Yum Department of Urology, KEPCO Medical Foundation, Hanil General Hospital, Seoul, Korea Purpose:  We aimed to determine whether a preoperative urodynamic parameter is a  valuable predictor for the persistence of OAB symptoms after the AVP repair.",Non-OADS,/arxiv_data1/oa_pdf/59/4d/kju-53-405.PMC3382690.pdf
"Key Words:  Pelvic organ prolapse; Urinary bladder, overactive This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 31 January, 2012 accepted 25 April, 2012 Corresponding Author: Seung Hee YumDepartment of Urology, KEPCO Medical Foundation, Han-il General  Hospital, 308, Uicheon-ro,  Dobong-gu, Seoul 132-703, KoreaTEL: +82-2-901-3159 FAX: +82-2-901-3467 E-mail: urohee@hanmail.net INTRODUCTION Pelvic organ prolapse (POP) is often accompanied by the  overactive bladder (OAB) symptoms including urinary fre-quency, urgency andincontine nce.",Non-OADS,/arxiv_data1/oa_pdf/59/4d/kju-53-405.PMC3382690.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 410 Korean J Urol 2012;53:410-413www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.410 Voiding Dysfunction Is Increased Prostatic Urethral Angle Related to Lower Urinary  Tract Symptoms in Males with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms?",Non-OADS,/arxiv_data1/oa_pdf/45/28/kju-53-410.PMC3382691.pdf
"Key Words:  BPH; LUTS; Prostate; Urethra This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 15 December, 2011 accepted 16 February, 2012 Corresponding Author: Jae Shin ParkDepartment of Urology, Catholic  University of Daegu, School of  Medicine, 33 Duryugongwon-ro 17-gil, Nam-gu, Daegu 705-718,  Korea TEL: +82-53-650-4662FAX: +82-53-623-4660 E-mail: jspark@cu.ac.kr INTRODUCTION Benign prostatic hyperplasia (BPH) is one of the most com- mon problems faced by aging men and can be associated with bothersome lower urinar y tract symptoms (LUTS).",Non-OADS,/arxiv_data1/oa_pdf/45/28/kju-53-410.PMC3382691.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 414 Korean J Urol 2012;53:414-418www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.414 Voiding Dysfunction Clinical Usefulness of Corticotropin Releasing Hormone Testing in  Subclinical Cushing’s Syndrome for Predicting Cortisol Replacement after Adrenalectomy Masahiro Inoue, Hisamitsu Ide, Koji Kurihara, Tatsuro Koseki, Jingsong Yu, Toshiyuki China,  Keisuke Saito, Shuji Isotani, Satoru Muto, Shigeo Horie Department of Urology, Teikyo University School of Medicine, Tokyo, Japan Purpose:  The purpose of this study was to investigate the clinical and hormonal features  of patients with incidentally discovered ad renal adenomas in relation to corticotropin  releasing hormone (CRH) testing and the clinical outcome of adrenalectomy.",Non-OADS,/arxiv_data1/oa_pdf/0d/60/kju-53-414.PMC3382692.pdf
"Key Words:  Adrenalectomy; Corticotropin-relea sing hormone; Cushing syndrome This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 25 October, 2011 accepted 1 December, 2011 Corresponding Author: Shigeo Horie Department of Urology, Teikyo  University School of Medicine, 2-11-1  Kaga, Itabashi-ku, Tokyo 173-8605, Japan TEL: +81-3-3964-2497 FAX: +81-3-3964-8934E-mail: shorie@med.teikyo-u.ac.jp INTRODUCTION Subclinical Cushing 's syndrome (SCS) is defined as auton- omous cortisol secretion in patients who do not have the typical signs and symptoms of hypercortisolism.",Non-OADS,/arxiv_data1/oa_pdf/0d/60/kju-53-414.PMC3382692.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 419 Korean J Urol 2012;53:419-423www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.419 Voiding Dysfunction Preventive Effect of Tamsulosin on Postoperative Urinary  Retention Mohammadreza Mohammadi-Fallah, Sepehr Hamedanchi, Ali Tayyebi-Azar Urology, Nephrology & Kidney Transplant Research Center, Department of Urology, Imam Medical Center, Urmia University of Medica l  Sciences, Urmia, Iran Purpose:  To investigate the prophylactic effect  of Tamsulosin, a super-selective al- pha-1a adrenergic blocking agent, on the de velopment of urinary retention in men un- dergoing elective in guinal herniorrhaphy.",Non-OADS,/arxiv_data1/oa_pdf/76/83/kju-53-419.PMC3382693.pdf
"Key Words:  Adrenergic alpha-Anta gonists; Herniorrhaphy ; Tamsulosin; Urinary  retention This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 21 February, 2012 accepted 30 April, 2012 Corresponding Author: Sepehr Hamedanchi Department of Urology, Imam Medical Center, Ershad Blvd, Urmia University  of Medical Sciences, Urmia, Iran TEL: +98-914-441-2600FAX: +98-441-346-9935 E-mail: sepehrhamedanchi@ yahoo.com INTRODUCTION Postoperative urinary retent ion (POUR) is a common and  potentially serious morbidity wi th a reported incidence of  3 to 25% [1].",Non-OADS,/arxiv_data1/oa_pdf/76/83/kju-53-419.PMC3382693.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 424 Korean J Urol 2012;53:424-430www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.424 Urolithiasis Predictive Factors of the Outcome of Extracorporeal Shockwave  Lithotripsy for Ureteral Stones Ji W oong Choi, Phil Hyun Song, Hyun Tae Kim Department of Urology, Yeungnam University College of Medicine, Daegu, Korea Purpose:  Extracorporeal Shock Wave Lithotripsy (ESWL) has shown successful out- comes for ureteral stones.",Non-OADS,/arxiv_data1/oa_pdf/bc/47/kju-53-424.PMC3382694.pdf
"Key Words:  Lithotripsy; Treatment outcome; Ureteral calculi This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 5 January, 2012 accepted 2 April, 2012 Corresponding Author: Hyun Tae KimDepartment of Urology, Yeungnam University College of Medicine, 170  Hyeonchung-ro, Nam-gu, Daegu  705-717, KoreaTEL: +82-53-620 –3693 FAX: +82-53-627 –5535 E-mail: htkim-1212@hanmail.net INTRODUCTION Extracorporeal shockwave lithotripsy (ESWL) has been  considered as a first-line treatment for ureteral stones for the past 20 years [1].",Non-OADS,/arxiv_data1/oa_pdf/bc/47/kju-53-424.PMC3382694.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 431 Korean J Urol 2012;53:431-434www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.431 Pediatric Urology Effect of Preputial Type on Bacterial Colonization and Wound  Healing in Boys Undergoing Circumcision Hüseyin Tarhan, Ilker Akarken, Osman Koca, I şık Ozgü, Ferruh Zorlu Department of Urology, Tepecik Training  and Research Hospital, Izmir, Turkey Purpose:  In this study, we evaluated the effect of  preputial type on bacterial colonization  and wound healing in boys  undergoing circumcision.",Non-OADS,/arxiv_data1/oa_pdf/6c/64/kju-53-431.PMC3382695.pdf
"Key Words:  Bacterial colonization; Circumcisio n; Preputium; Urinary infection;  Urinary pathogens This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 27 November, 2011 accepted 24 April, 2012 Corresponding Author: Hüseyin Tarhan Department of Urology, Tepecik Training and Research Hospital, 126/7  sok.",Non-OADS,/arxiv_data1/oa_pdf/6c/64/kju-53-431.PMC3382695.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 435 Korean J Urol 2012;53:435-437www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.435 Case Report Impalement Injury of the Urinary Bladder: A Case Report Jun Morita, Michio Naoe, Takehiko Nakasato, Yoshio Ogawa Department of Urology, Showa Universi ty School of Medicine, Tokyo, Japan Impalement injury of the urinary bladder, especially secondary to  rectal impalement,  is extremely rare.",Non-OADS,/arxiv_data1/oa_pdf/df/13/kju-53-435.PMC3382696.pdf
"Key Words:  Bladder injuries; Rupt ure; Urinary bladder This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 8 March, 2011 accepted 31 October, 2011 Corresponding Author: Jun MoritaDepartment of Urology, Showa University School of Medicine, 1-5-8,  Hatanodai, Shinagawa-ku, Tokyo  142-8666, JapanTEL: +81-3-3784-8560 FAX: +81-3-3784-1400 E-mail: moritajun@hotmail.co.jp FIG.",Non-OADS,/arxiv_data1/oa_pdf/df/13/kju-53-435.PMC3382696.pdf
"Korean Journal of Urology ⒸThe Korean Urological Association, 2012 438 Korean J Urol 2012;53:438-440www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.6.438 Case Report Synchronous Urothelial Carcinoma of the Bladder and Urachal  Adenoma with Subsequent Malignant Transformation David Pan1, Yeng Kwang Tay1, Scott Donnellan1,2 1Department of Urology, Monash Medical  Centre, Southern Health, Victoria, 2Cabrini Health, Malvern, Melbourne, Australia Malignant transformation of urachal adenoma is exceedingly rare, with intestinal met- aplasia as the most common contributing me chanism.",Non-OADS,/arxiv_data1/oa_pdf/a9/02/kju-53-438.PMC3382697.pdf
"Key Words:  Synchronous; Transformation; Urachal adenocarcinoma; Urachal adenoma;  Urothelial carcinoma This is an Open Access article distributed under the te rms of the Creative Commons Attribution Non-Commercial  License (http://creativecommons.org /licenses/by-nc/3.0) which permit s unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original work is properly cited.Article History: received 3 October, 2011 accepted 7 November, 2011 Corresponding Author: David PanDepartment of Urology, Monash  Medical Centre, Southern Health, 865  Centre Road, East Bentleigh, 3165, Victoria, Australia TEL: +61-3-9928-8643 FAX: +61-3-9928-8361E-mail: dpan1111@yahoo.com.au Malignant transformation of a urachal adenoma into an ad- enocarcinoma is exceedingly rare .",Non-OADS,/arxiv_data1/oa_pdf/a9/02/kju-53-438.PMC3382697.pdf
"http://dx.doi.org/10.3345/kjp.2012.55.6.185 Korean J Pediatr 2012;55(6):185-192 eISSN 1738-1061 • pISSN 2092-7258Review article 185Ambient air pollution and allergic diseases in children The prevalence of allergic diseases has increased worldwide, a  phenomenon that can be largely attributed to environmental effects.",Non-OADS,/arxiv_data1/oa_pdf/f5/2d/kjped-55-185.PMC3382698.pdf
"Key words: Air pollution, Asthma, Allergy, Child, Oxidative stress,  EpigeneticsByoung-Ju Kim, MD, PhD1, Soo-Jong Hong,  MD, PhD2 1Department of Pediatrics, Inje University Haeundae  Paik Hospital, Busan, 2Department of Pediatrics,  Childhood Asthma Atopy Center, Research Center  for Standardization of Allergic Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Received: 20 February 2012, Accepted: 19 March 2012 Corresponding author: Soo-Jong Hong, MD, PhD  Department of Pediatrics, Childhood Asthma and Atopy Cen - ter, Research Center for Standardization of Allergic Diseases, Asan Medical Center, University of Ulsan College of Medi - cine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea Tel: +82-2-3010-3379, Fax: +82-2-473-3725E-mail: sjhong@amc.seoul.kr Copyright © 2012 by The Korean Pediatric Society This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f5/2d/kjped-55-185.PMC3382698.pdf
Korean J Pediatr  2012;55(6):185-192 • http://dx.doi.org/10.3345/kjp.2012.55.6.185     187 (air pollution) interactions in order to identify children vulnerable to  air pollution.,Non-OADS,/arxiv_data1/oa_pdf/f5/2d/kjped-55-185.PMC3382698.pdf
Real-time air quality and periodic data can be found on at http://www.airkorea.or.kr.,Non-OADS,/arxiv_data1/oa_pdf/f5/2d/kjped-55-185.PMC3382698.pdf
"Korean J Pediatr  2012;55(6):185-192 • http://dx.doi.org/10.3345/kjp.2012.55.6.185     189 studies consistently showed that PM can cause asthma and allergy in  children14,16,25,26).",Non-OADS,/arxiv_data1/oa_pdf/f5/2d/kjped-55-185.PMC3382698.pdf
"Korean J Pediatr  2012;55(6):185-192 • http://dx.doi.org/10.3345/kjp.2012.55.6.185     191 Pediatricians need to understand the harmful effects of air pollution  and integrate this knowledge into managing allergic diseases,  including enhancement of patient education.",Non-OADS,/arxiv_data1/oa_pdf/f5/2d/kjped-55-185.PMC3382698.pdf
Available from: http://www.who.int/ceh/publications/atlas/en/.,Non-OADS,/arxiv_data1/oa_pdf/f5/2d/kjped-55-185.PMC3382698.pdf
http://dx.doi.org/10.3345/kjp.2012.55.6.193 Korean J Pediatr 2012;55(6):193-201 eISSN 1738-1061 • pISSN 2092-7258Review article 193Effects of probiotics on the prevention of atopic der - matitis Atopic dermatitis (AD) is an immune disorder that is becoming  increasingly prevalent throughout the world.,Non-OADS,/arxiv_data1/oa_pdf/4c/fb/kjped-55-193.PMC3382699.pdf
"Key words: Probiotics, Dermatitis, Atopic, Prevention, Immunomo - dulation, Immune systemNam Y eun Kim, MS, Geun Eog Ji, PhD Department of Food and Nutrition, Research Institute  of Human Ecology, Seoul National University College of Human Ecology, Seoul, Korea Received: 13 February 2012, Accepted: 27 February 2012 Corresponding author: Geun Eog Ji, PhD  Department of Food and Nutrition, Seoul National University College of Human Ecology, 1, Gwanak-ro, Gwanak-gu, Seoul 152-742, Korea Tel: +82-2-880-8749, Fax: +82-2-884-0305E-mail: geji@snu.ac.kr Copyright © 2012 by The Korean Pediatric Society This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4c/fb/kjped-55-193.PMC3382699.pdf
Korean J Pediatr  2012;55(6):193-201 • http://dx.doi.org/10.3345/kjp.2012.55.6.193     195 Table 1.,Non-OADS,/arxiv_data1/oa_pdf/4c/fb/kjped-55-193.PMC3382699.pdf
"Korean J Pediatr  2012;55(6):193-201 • http://dx.doi.org/10.3345/kjp.2012.55.6.193     197 period reduced the extent and the severity of atopic eczema, which  was accompanied by the reduction of serum cluster of differentiation  (CD)4 and urine eosinophilic protein X39).",Non-OADS,/arxiv_data1/oa_pdf/4c/fb/kjped-55-193.PMC3382699.pdf
"Korean J Pediatr  2012;55(6):193-201 • http://dx.doi.org/10.3345/kjp.2012.55.6.193     199 actions of regulatory network41) such as Tregs and inducible  Tregs (Th3, Tr1) as well as Foxp3+.",OADS,/arxiv_data1/oa_pdf/4c/fb/kjped-55-193.PMC3382699.pdf
Available from: http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf.,Non-OADS,/arxiv_data1/oa_pdf/4c/fb/kjped-55-193.PMC3382699.pdf
Korean J Pediatr  2012;55(6):193-201 • http://dx.doi.org/10.3345/kjp.2012.55.6.193     201 disease in the infant.,Non-OADS,/arxiv_data1/oa_pdf/4c/fb/kjped-55-193.PMC3382699.pdf
http://dx.doi.org/10.3345/kjp.2012.55.6.202 Korean J Pediatr 2012;55(6):202-205 eISSN 1738-1061 • pISSN 2092-7258Original article 202Epidemiology of Kawasaki disease in infants 3  months of age and younger Purpose:  This study investigated the epidemiology of Kawasaki disease  (KD) in infants ≤3-month-old.,Non-OADS,/arxiv_data1/oa_pdf/9a/5b/kjped-55-202.PMC3382700.pdf
"Key words: Kawasaki disease, Coronary artery dilatation, Coronary  aneurysm, Epidemiology, InfantEun Jung Lee, MD1, Yong Won Park, MD2,  Young Mi Hong, MD3, Joon Sung Lee, MD1, Ji  Whan Han, MD1 1Department of Pediatrics, The Catholic University  of Korea School of Medicine, Seoul, 2Department of  Pediatrics, Inje University College of Medicine, Seoul,  3Department of Pediatrics, Ewha Womans University  School of Medicine, Seoul, Korea Received: 15 September 2011, Revised: 15 November 2011 Accepted: 27 December 2011Corresponding author: Ji Whan Han, MDDepartment of Pediatrics, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea School of Medicine, 271 Cheonbo-ro, Uijeongbu 480-717 , KoreaTel: +82-31-820-3580, Fax: +82-31-821-3108E-mail: han59@catholi.ac.kr Copyright © 2012 by The Korean Pediatric Society This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9a/5b/kjped-55-202.PMC3382700.pdf
Korean J Pediatr  2012;55(6):202-205  • http://dx.doi.org/10.3345/kjp.2012.55.6.202     203 diagnosed within the 9-year period from January 2000 to December  2008 in all hospitals that have pediatric residency programs6-11).,Non-OADS,/arxiv_data1/oa_pdf/9a/5b/kjped-55-202.PMC3382700.pdf
Korean J Pediatr  2012;55(6):202-205  • http://dx.doi.org/10.3345/kjp.2012.55.6.202     205 older.,Non-OADS,/arxiv_data1/oa_pdf/9a/5b/kjped-55-202.PMC3382700.pdf
http://dx.doi.org/10.3345/kjp.2012.55.6.206 Korean J Pediatr 2012;55(6):206-211 eISSN 1738-1061 • pISSN 2092-7258Original article 206Prevalence and risk factors for vitamin D deficiency  in children with iron deficiency anemia Purpose:  The increasing prevalence of breast feeding has led to  concerns about vitamin D deficiency (VDD) and iron deficiency  anemia (IDA) in children.,Non-OADS,/arxiv_data1/oa_pdf/39/c9/kjped-55-206.PMC3382701.pdf
"Key words: Vitamin D deficiency, Iron deficiency anemia, ChildJung Won Yoon, MD, Sung Woo Kim, MD,  Eun Gyong Yoo, MD, Moon Kyu Kim, MD Department of Pediatrics, CHA Bundang Medical  Center, CHA University, Seongnam, Korea Received: 5 May 2011, Revised: 9 September 2011 Accepted: 30 November 2011Corresponding author: Moon Kyu Kim, MDDepartment of Pediatrics, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam 463-712, KoreaTel: +82-31-780-5235, Fax: +82-31-780-5239E-mail: mkkim929@gmail.com Copyright © 2012 by The Korean Pediatric Society This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/39/c9/kjped-55-206.PMC3382701.pdf
Korean J Pediatr  2012;55(6):206-211  • http://dx.doi.org/10.3345/kjp.2012.55.6.206     207 VDD and nutritional rickets in children and adolescents from the  United States5-10) and other countries11-14).,Non-OADS,/arxiv_data1/oa_pdf/39/c9/kjped-55-206.PMC3382701.pdf
"Korean J Pediatr  2012;55(6):206-211  • http://dx.doi.org/10.3345/kjp.2012.55.6.206     209 currently or had recently been breastfed, and 97% of the subjects  who were VDD had been breastfed.",Non-OADS,/arxiv_data1/oa_pdf/39/c9/kjped-55-206.PMC3382701.pdf
Korean J Pediatr  2012;55(6):206-211  • http://dx.doi.org/10.3345/kjp.2012.55.6.206     211 exclusive breast-feeding and maternal anemia in a Mexican cohort.,Non-OADS,/arxiv_data1/oa_pdf/39/c9/kjped-55-206.PMC3382701.pdf
Available from:  http://kosis.kr.,Non-OADS,/arxiv_data1/oa_pdf/39/c9/kjped-55-206.PMC3382701.pdf
"http://dx.doi.org/10.3345/kjp.2012.55.6.212 Korean J Pediatr 2012;55(6):212-214 eISSN 1738-1061 • pISSN 2092-7258Case report 212Pulmonary hypertension due to obstructive sleep  apnea in a child with Rubinstein-Taybi syndrome Rubinstein-Taybi syndrome (RTS) is characterized by peculiar facies,  mental retardation, broad thumbs, and great toes.",Non-OADS,/arxiv_data1/oa_pdf/db/97/kjped-55-212.PMC3382702.pdf
"Key words: Rubinstein-Taybi syndrome, Obstructive sleep apnea,  Pulmonary hypertensionHyung Soon Choi, MD1, Jeong Jin Yu, MD2,  Y oung-Hwue Kim, MD2, Jae-Kon Ko, MD2, In- Sook Park, MD2 1Department of Pediatrics, Kosin University Gospel  Hospital, Busan, 2Division of Pediatric Cardiology,  Department of Pediatrics, University of Ulsan College  of Medicine, Seoul, Korea Received: 17 May 2011, Revised: 5 September 2011 Accepted: 30 November 2011Corresponding author: Jeong Jin Yu, MD Division of Pediatric Cardiology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medi - cine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea Tel: +82-2-3010-3924, Fax: +82-2-473-3725E-mail: pediatrist@medimail.co.kr Copyright © 2012 by The Korean Pediatric Society This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/db/97/kjped-55-212.PMC3382702.pdf
Korean J Pediatr  2012;55(6):212-214  • http://dx.doi.org/10.3345/kjp.2012.55.6.212     213 right ventricular dilatation (Fig.,Non-OADS,/arxiv_data1/oa_pdf/db/97/kjped-55-212.PMC3382702.pdf
http://dx.doi.org/10.3345/kjp.2012.55.6.215 Korean J Pediatr 2012;55(6):215-218 eISSN 1738-1061 • pISSN 2092-7258Case report 215A case of bilateral submandibular gland mucoceles in  a 16-month-old child Mucoceles are common benign cystic lesions of the oral cavity that  develop following extravasation or retention of mucous material from the major or minor salivary glands.,Non-OADS,/arxiv_data1/oa_pdf/31/b6/kjped-55-215.PMC3382703.pdf
"Key words: Mucocele, Submandibular gland, ChildHye Jung Choi, MD1, Seoung Geun Kim, MD1,  Jong Duk Kim, MD2, Jun Hyeng Kim, MD2, Jun  Hyen Kim, MD3, Sung Mi Kim, MD1 Departments of 1Pediatrics, 2Radiology, and 3General  surgery, Busan St. Mary's Medical Center, Busan, Korea Received: 7 August 2011, Revised: 19 October 2011 Accepted: 30 November 2011Corresponding author: Sung Mi Kim, MDDepartment of Pediatrics, Busan St. Mary's Medical Center, 25-14, Yongho-ro, 232beon-gil, Nam-gu, Busan, KoreaTel: +82-51-933-7984, Fax: +82-51-936-7531E-mail: ksm7090@hanmail.net Copyright © 2012 by The Korean Pediatric Society This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/31/b6/kjped-55-215.PMC3382703.pdf
Korean J Pediatr  2012;55(6):215-218 • http://dx.doi.org/10.3345/kjp.2012.55.6.215     217 The cyst was totally excised with the submandibular and sublingual  glands via the external cervical approach (Fig.,Non-OADS,/arxiv_data1/oa_pdf/31/b6/kjped-55-215.PMC3382703.pdf
"Please join me in welcoming Liz to  the JGP and Rockefeller University  Press family!Introducing Elizabeth M. Adler, JGP Executive Editor Edward N. Pugh Jr., Editor The Journal of General Physiology © 2012 Pugh  This article is distributed under the terms of an Attribution–Noncommercial– Share Alike–No Mirror Sites license for the first six months after the publication date (see  http://www.rupress.org/terms).",Non-OADS,/arxiv_data1/oa_pdf/74/7e/JGP_201210843.PMC3382717.pdf
"After six months it is available under a Creative Commons  License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at  http://creativecommons.org/licenses/by-nc-sa/3.0/).",Non-OADS,/arxiv_data1/oa_pdf/74/7e/JGP_201210843.PMC3382717.pdf
© 2012 Jadey and Auerbach  This article is distributed under the terms of an Attribution– Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publi- cation date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"After six months it is available under a  Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,  as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).The Journal of General Physiology",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
QUB software was used to digitize and analyze the currents (http://www.qub.buffalo.edu).,OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1038/ nature07462 Brams, M., E.A.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1074/jbc.M110.188730 Brams, M., A. Pandya, D. Kuzmin, R. van Elk, L. Krijnen, J.L.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1371/journal.pbio.1001034 Burnham, K.P., and D.R.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1016/j.bpj.2010.05.008 Celie, P.H., I.E.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"225:1335– 1345. http://dx.doi.org/10.1126/science.6382611 Del Castillo, J., and B. Katz.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1098/rspb.1957.0016 Fenwick, M.K., and R.E.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"285:12334– 12343. http://dx.doi.org/10.1074/jbc.M109.086371 Fersht, A.R., R.J. Leatherbarrow, and T.N.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1021/bi00393a013 Grosman, C., and A. Auerbach.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi .org/10.1085/jgp.115.5.621 Grosman, C., and A. Auerbach.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1038/35001586 Gupta, S., and A. Auerbach.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1016/j.bpj.2010.12.3727 Hansen, S.B., G. Sulzenbacher, T. Huxford, P. Marchot, P. Taylor,  and Y. Bourne.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1038/27692 Auerbach, A.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/ 10.1113/jphysiol.2009.182774 Auerbach, A.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1371/journal.pone.0002515 Bafna, P.A., A. Jha, and A. Auerbach.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi .org/10.1074/jbc.M807152200 Berg, O.G., and P.H.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
14:131– 160. http://dx.doi.org/10.1146/annurev.bb.14.060185.001023,Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi .org/10.1085/jgp.201110752 Purohit, P., and A. Auerbach.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1085/ jgp.200509438 Qin, F. 2004.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1016/S0006-3495(04) 74217-4 Qin, F., A. Auerbach, and F. Sachs.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"264:375– 383. http://dx.doi.org/10.1098/rspb.1997.0054 Robert, A., N. Armstrong, J.E.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1016/j.bcp.2009.06.098 Talley, T.T., M. Harel, R.E.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1038/298272a0 Ulens, C., A. Akdemir, A. Jongejan, R. van Elk, S. Bertrand, A.  Perrakis, R. Leurs, A.B.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"52:2372– 2383. http://dx.doi.org/10.1021/jm801400g Unwin, N. 2005.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi .org/10.1016/j.jmb.2004.12.031 Zhang, Y., J. Chen, and A. Auerbach.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
http://dx.doi .org/10.1529/biophysj.105.067215determinants for interaction of partial agonists with acetylcho line binding protein and neuronal alpha7 nicotinic acetylcholine   receptor.,Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1038/emboj .2009.227 Hilf, R.J., and R. Dutzler.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1016/ S0006-3495(86)83693-1 Jackson, M.B., K. Imoto, M. Mishina, T. Konno, S. Numa, and B.  Sakmann.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1016/j.bpj.2010.01.025 Jha, A., P. Purohit, and A. Auerbach.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1016/j.bpj.2009.02.030 Jin, R., T.G.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi.org/10.1038/ nn1091 Jones, M.V., P. Jonas, Y. Sahara, and G.L.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"16:306– 320. http://dx.doi.org/10.1016/0022-5193(67)90011-2 Lape, R., D. Colquhoun, and L.G.",OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
"http://dx.doi .org/10.1038/nature07923 Nayak, T.K., P.G.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/JGP_201210801.PMC3382718.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publi- cation date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"After six months it is available under a  Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,  as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).The Journal of General Physiology",Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
The programs KielPatch  and bownhill  are  available at http://www.zbm.uni-kiel.de/aghansen/software.html.,Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi .org/10.1085/jgp.200910266 Apetrei, A., A. Asandei, Y.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"42:173– 180. http://dx.doi.org/10.1007/s10863-010-9273-z Bainbridge, G., I. Gokce, and J.H.",Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1016/ S0014-5793(98)00761-3 Bainbridge, G., H. Mobasheri, G.A.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1006/jmbi.1997.1474 Bredin, J., N. Saint, M. Malléa, E. Dé, G. Molle, J.-M. Pagès, and  V. Simonet.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1042/0264-6021: 3630521 Caceci, M.S., and W.P.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1038/358727a0 Danelon, C., T. Brando, and M. Winterhalter.",Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/ 10.1074/jbc.M305434200 Delcour, A.H. 2009.",Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1016/S0006-3495 (94)80461-8 FitzHugh, R. 1983.",Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
http://dx.doi.org/10.1016/0025-5564(83) 90028-7(8) Sidedness of k OB According to Figs.,OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1111/j.1432-1033.1969.tb00601.x Garavito, R.M., and J.P. Rosenbusch.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/ 10.1146/annurev.ph.53.030191.002013 Hansen, U.P., M. Keunecke, and R. Blunck.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1085/jgp.114.4.551 Heinemann, S.H., and F.J. Sigworth.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1016/ S0006-3495(91)82087-2 Hoenger, A., J.M.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1006/jmbi.1993.1520 James, C.E., K.R.",Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1371/journal.pone.0005453 Korchev, Y.E., C.L.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"15:1845– 1849. http://dx.doi.org/10.1016/S0731-7085(96)02033-X Mahendran, K.R., C. Chimerel, T. Mach, and M. Winterhalter.",Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1007/ s00249-009-0495-0 Mahendran, K.R., E. Hajjar, T. Mach, M. Lovelle, A. Kumar, I.  Sousa, E. Spiga, H. Weingart, P. Gameiro, M. Winterhalter, and M. Ceccarelli.",Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1021/jp911485k Mahendran, K.R., M. Kreir, H. Weingart, N. Fertig, and M.  Winterhalter.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/ 10.1177/1087057109357791 Montal, M., and P. Mueller.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/ 10.1073/pnas.69.12.3561 Mortimer, P.G., and L.J.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1093/jac/32.2.195 Müller, D.J., and A. Engel.",Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1006/jmbi.1998.2359Nikaido, H. 2003.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/ 10.1038/nrmicro1994 Phale, P.S., T. Schirmer, A. Prilipov, K.-L. Lou, A. Hardmeyer, and  J.P. Rosenbusch.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1007/s00232- 011-9368-4 Riessner, T. 1998.",Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1007/s00232-003-0641-z Schroeder, I., and U.P.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1007/s00232-006-0858-8 Schroeder, I., and U.P.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/ 10.1085/jgp.200709802 Schroeder, I., and U.P.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi .org/10.1007/s00232-009-9183-3 Sigworth, F.J. 1985.",Non-OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1016/S0006-3495(85)83968-0 Tran, Q.T., K.R.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1074/jbc.M110 .143305 Wang, S., E.H. McDonnell, F.A.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/10.1007/s002320001057 Yamashita, E., M.V.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
"http://dx.doi.org/ 10.1038/emboj.2008.137 Yellen, G. 1984.",OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
http://dx.doi.org/10.1085/jgp.84.2.157,OADS,/arxiv_data1/oa_pdf/5f/44/JGP_201210776.PMC3382719.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publi- cation date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"After six months it is available under a  Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,  as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).The Journal of General Physiology",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
Online supplemental material is avail - able at http://www.jgp.org/cgi/content/full/jgp.201110766/DC1.,Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/S0896-6273(00)80143-9 Armstrong, C.M.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi .org/10.1021/bi800642m Cabani, S., P. Gianni, V. Mollica, and L. Lepori.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1007/BF00646936 Callenberg, K.M., O.P.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1371/journal.pone.0012722 Catterall, W.A.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi .org/10.1146/annurev.bi.55.070186.004513 Catterall, W.A.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/0166-2236(86)90004-4 Chang, G., R.H. Spencer, A.T. Lee, M.T.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"282:2220– 2226. http://dx.doi.org/10.1126/science.282.5397.2220 Choe, S., K.A.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1126/science .1101373 Dan, N., and S.A. Safran.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/S0006-3495(98)74059-7 Dolinsky, T.J., J.E.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1093/nar/gkh381 Dolinsky, T.J., P. Czodrowski, H. Li, J.E.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
http://dx.doi.org/10.1093/nar/gkm276detail of the lipid headgroups into our membrane  model.,Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/j.bpj.2009.07.006 Kim, K.S., J. Neu, and G. Oster.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/S0006-3495(98)77672-6 Kleinschmidt, J.H., and L.K.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/S0022-2836 (02)01071-9 Krepkiy, D., M. Mihailescu, J.A.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi .org/10.1038/nature08542 Krivov, G.G., M.V.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1002/prot.22488 Lecar, H., H.P.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/S0006-3495(03)74708-0 Lee, M.C.S., L. Orci, S. Hamamoto, E. Futai, M. Ravazzola, and R.  Schekman.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/j.cell.2005.07.025 Lomize, M.A., A.L.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1093/ bioinformatics/btk023 Long, S.B., E.B.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1126/science.1116270 Long, S.B., X. Tao, E.B.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi .org/10.1038/nature06265 Luo, H., and S.C. Tucker.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1021/ja00150a042 MacCallum, J.L., W.F.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1085/jgp.200709745 MacCallum, J.L., W.F.D.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"101:110– 117. http://dx.doi.org/10.1016/j.bpj.2011.05.038 Mondal, S., G. Khelashvili, J. Shan, O.S.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/ j.bpj.2011.09.037 Moon, C.P., and K.G.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi .org/10.1073/pnas.1103979108 Morris, C.E., P.F.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/ 10.1007/978-1-59745-000-3_22 Murata, Y., H. Iwasaki, M. Sasaki, K. Inaba, and Y. Okamura.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1038/ nature03650Dorairaj, S., and T.W.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1073/ pnas.0610470104 Durell, S.R., Y.L.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1006/jsbi.1998.3962 Dzubiella, J., J.M.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"96:087802. http://dx.doi.org/10.1103/ PhysRevLett.96.087802 Freites, J.A., D.J.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1073/ pnas.0507618102 Grabe, M., H. Lecar, Y.N.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/ 10.1073/pnas.0408116101 Guy, H.R., and P. Seetharamulu.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/ S0006-3495(99)77257-7 Helfrich, W. 1973.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1038/nature03216 Hessa, T., S.H.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1038/nature06387 Hong, H., and L.K.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"24:1691– 1702. http://dx.doi.org/10.1002/jcc.10321 Itoh, T., K.S.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/ j.devcel.2005.11.005 Jeon, J., and G.A.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
130:185101. http://dx.doi.org/10.1063/1.3129863,Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1021/j100058a043 Sitkoff, D., N. BenTal, and B. Honig.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1021/jp952986i Snapp, E.L., R.S.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1083/jcb .200306020 Soubias, O., S.L.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi .org/10.1021/ja803599x Strandberg, E., S. Ozdirekcan, D.T.S.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1529/ biophysj.103.035402 Sukharev, S., M. Betanzos, C.S.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1038/35055559 Tang, Y., G. Cao, X. Chen, J. Yoo, A. Yethiraj, and Q. Cui.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi .org/10.1529/biophysj.106.085985 Tierney, K.J., D.E.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi .org/10.1529/biophysj.104.057943 Tiwari-Woodruff, S.K., C.T.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/S0006-3495(97) 78797-6 Ulmschneider, M.B., J.P. Ulmschneider, M.S.P.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/S0006-3495(02)73918-0 Vieira-Pires, R.S., and J.H.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"136:585– 592. http://dx.doi.org/10.1085/jgp.201010508 Vrljic, M., P. Strop, J.A.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1038/nsmb.1764 Wagoner, J.A., and N.A.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1073/ pnas.0608714103 Wee, C.L., A. Chetwynd, and M.S.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/S0006-3495(98)77904-4 Noda, M., S. Shimizu, T. Tanabe, T. Takai, T. Kayano, T. Ikeda, H.  Takahashi, H. Nakayama, Y. Kanaoka, N. Minamino, et al.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi .org/10.1038/312121a0 Ozdirekcan, S., D.T.S.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1021/bi0481242 Papazian, D.M., T.L.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1126/science.2441470 Parsegian, A.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1038/221844a0 Pathak, M.M., V. Yarov-Yarovoy, G. Agarwal, B. Roux, P. Barth, S.  Kohout, F. Tombola, and E.Y.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/j.neuron.2007.09.023 Perozo, E., A. Kloda, D.M.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1038/nsb827 Powell, M.J.D.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"7:155. http://dx.doi.org/10.1093/comjnl/7.2.155 Powl, A.M., J.N.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1021/ bi047338g Ramsey, I.S., M.M.",Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1038/nature04700 Ravazzola, M., and L. Orci.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi .org/10.1038/284066a0 Ruta, V., J. Chen, and R. MacKinnon.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi .org/10.1016/j.cell.2005.08.041 Sali, A., and T.L.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1126/science.1122352 Schmidt, D., Q.X.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1038/nature05416 Seoh, S.A., D. Sigg, D.M.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/ S0896-6273(00)80142-7 Shental-Bechor, D., S.J.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/j.tibs.2006.02.002 Shrake, A., and J.A.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
79:351– 371. http://dx.doi.org/10.1016/0022-2836(73)90011-9,Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1021/bi980809c Zhang, L., Y. Sato, T. Hessa, G. von Heijne, J.K. Lee, I. Kodama,  M. Sakaguchi, and N. Uozumi.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"82:041923. http://dx.doi.org/10.1103/PhysRevE.82.041923Weiss, T.M., P.C.A.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/ S0006-3495(03)74858-9 White, S.H.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
"http://dx.doi.org/10.1016/S0006-3495(78)85453-8 Wiggins, P., and R. Phillips.",OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
http://dx.doi.org/10.1038/nature07836,Non-OADS,/arxiv_data1/oa_pdf/39/10/JGP_201110766.PMC3382720.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publi- cation date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"After six months it is available under a  Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,  as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).The Journal of General Physiology",Non-OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
Online supplemental  material is available at http://www.jgp.org/cgi/content/full/jgp.201110749/DC1.,Non-OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/ 10.1126/science.1108595 Chen, J., J.S.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/ 10.1124/jpet.107.121467 Craven, K.B., and W.N.",Non-OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1085/jgp.200409178 Craven, K.B., and W.N.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi .org/10.1146/annurev.physiol.68.040104.134728 Decher, N., J. Chen, and M.C.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/ 10.1074/jbc.M313704200 Denyer, J.C., and H.F. Brown.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi .org/10.1038/272467a0 Flynn, G.E., K.D.",Non-OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi .org/10.1016/j.str.2007.04.008 Hackos, D.H., T.H.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1085/jgp.20028569 Harris, N.C., and A. Constanti.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1038/nature06410 Hille, B.",Non-OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
http://dx.doi.org/10.1085/jgp.200409187on the binding affinity to cAMP.,Non-OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1085/jgp.117.6.519 Barnes, S., and B. Hille.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"94:719– 743. http://dx.doi.org/10.1085/jgp.94.4.719 Bell, D.C., H. Yao, R.C.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1085/ jgp.200308918 Biel, M., C. Wahl-Schott, S. Michalakis, and X. Zong.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
http://dx.doi.org/10.1152/ physrev.00029.2008,Non-OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi .org/10.1085/jgp.200509430 Ulens, C., and S.A. Siegelbaum.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi .org/10.1016/S0896-6273(03)00753-0 Vemana, S., S. Pandey, and H.P.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1152/ ajpcell.00154.2008 Wang, J., S. Chen, M.F.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1016/S0896-6273 (02)00968-6 Webster, S.M., D. Del Camino, J.P. Dekker, and G. Yellen.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi .org/10.1038/nature02468 Wu, S., Z.V.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1016/j.bpj.2011.01.034 Xu, X., Z.V.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1074/jbc .M110.152033 Yang, J., Y.N.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/ 10.1016/0896-6273(95)90343-7 Zagotta, W.N., and S.A. Siegelbaum.",Non-OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"19:235– 263. http://dx.doi.org/10.1146/annurev.ne.19.030196.001315 Zagotta, W.N., N.B.",Non-OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi .org/10.1016/j.str.2007.04.012 Zhou, L., N.B.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1016/j.neuron.2004 .11.012 Zong, X., H. Zucker, F. Hofmann, and M. Biel.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi .org/10.1093/emboj/17.2.353Jan, L.Y., and Y.N.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"345:672. http://dx.doi.org/10.1038/345672a0 Kaupp, U.B., and R. Seifert.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1016/j.neuron.2010.05.022 Long, S.B., X. Tao, E.B.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi .org/10.1038/nature06265 Lopatin, A.N., E.N.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/ 10.1038/372366a0 Lyashchenko, A.K., and G.R.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/ 10.1085/jgp.200709868 Männikkö, R., F. Elinder, and H.P.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1038/ nature01038 Monod, J., J. Wyman, and J.P. Changeux.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1016/S0022-2836(65)80285-6 Paoletti, P., E.C.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi .org/10.1085/jgp.113.1.17 Prole, D.L., and G. Yellen.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1085/jgp.200609590 Richards, M.J., and S.E.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1021/bi001639i Robinson, R.B., and S.A. Siegelbaum.",Non-OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1146/annurev.physiol.65.092101.142734 Rosenbaum, T., and S.E.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
"http://dx.doi.org/10.1085/jgp.200308928 Shin, K.S., C. Maertens, C. Proenza, B.S.",OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
http://dx.doi.org/10.1016/S0896-6273(04)00083-2,OADS,/arxiv_data1/oa_pdf/24/69/JGP_201110749.PMC3382721.pdf
This article is distributed under the terms of an Attribution– Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publi- cation date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"After six months it is available under a  Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,  as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).The Journal of General Physiology",Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
Online supplemental material is available at http://www.jgp.org/cgi/content/full/jgp.201210796/DC1.,Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1038/283673a0 Brown, D.A., and A.A. Selyanko.",Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1111/ j.1476-5381.2009.00111.x Colquhoun, D. 1998.",Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1038/sj.bjp.0702164 Colquhoun, D., and B. Sakmann.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1529/ biophysj.103.038679 Delmas, P., and D.A.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1038/nrn1785 Dempster, J.",Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1113/jphysiol.2004 .080028 Etxeberria, A., P. Aivar, J.A.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1096/fj.07-9712com Gahwiler, B.H., and D.A.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi .org/10.1038/313577a0 Gamper, N., and M.S.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"8:921– 934. http://dx.doi.org/10.1038/nrn2257 Gibb, A.J., and D. Colquhoun.",Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"59:483– 504. http://dx.doi.org/10.1146/annurev.physiol.59.1.483 McCormack, K., L. Lin, L.E.",Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"63:1406– 1411. http://dx.doi.org/10.1016/S0006-3495(92)81703-4 Mullaney, I., M.W.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1126/science.280.5369.1596 Ruiz, M.L., and J.W.",Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"389:389– 392. http://dx.doi.org/10.1038/38744 Ruiz, M.L., and J.W.",Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1085/jgp.113.6.873 Rycroft, B.K., and A.J.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1523/JNEUROSCI .5612-10.2011 Selyanko, A.A., and D.A.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1016/ S0006-3495(99)76925-0 Selyanko, A.A., J.K. Hadley, and D.A.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1111/ j.1469-7793.2001.00015.x Shapiro, M.S., J.P. Roche, E.J.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi .org/10.1074/jbc.M111.336511 Suh, B.C., and B. Hille.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/ 10.1016/S0896-6273(02)00790-0 Suh, B.C., and B. Hille.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1038/nature10370 Harpsøe, K., P.K.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"31:10759– 10766. http://dx.doi.org/10.1523/JNEUROSCI.1509-11.2011 He, Y., M. Ruiz, and J.W.",Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1085/jgp.200810007 Hernandez, C.C., B. Falkenburger, and M.S.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1085/jgp.200910313 Hilgemann, D.W., S. Feng, and C. Nasuhoglu.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1126/stke.2001.111.re19 Horowitz, L.F., W. Hirdes, B.C.",Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1085/jgp.200509309 Jin, T., J.L.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1016/ 0896-6273(92)90277-K Li, Y., P. Langlais, N. Gamper, F. Liu, and M.S.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1074/jbc.M408410200 Li, Y., N. Gamper, D.W. Hilgemann, and M.S.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1523/JNEUROSCI.2597-05.2005 Liman, E.R., J. Tytgat, and P. Hess.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1016/ 0896-6273(92)90239-A Logothetis, D.E., V.I.",Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1007/s00424- 010-0828-y Main, M.J., J.E.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1523/JNEUROSCI.3231-04.2005 Zaika, O., C.C.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1016/ S0896-6273(03)00125-9Suh, B.C., T. Inoue, T. Meyer, and B. Hille.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/10.1126/science .1131163 Traynelis, S.F., L.P. Wollmuth, C.J.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
"http://dx.doi.org/ 10.1016/S0006-3495(99)77358-3 Wang, H.S., Z. Pan, W. Shi, B.S.",OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
http://dx.doi.org/10.1126/science.282 .5395.1890,Non-OADS,/arxiv_data1/oa_pdf/3c/a9/JGP_201210796.PMC3382723.pdf
This article is distributed under the terms of an Attribution– Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publi- cation date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"After six months it is available under a  Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,  as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).The Journal of General Physiology",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1152/jn.90263.2008 Fieni, F., V. Ghiaroni, R. Tirindelli, P. Pietra, and A. Bigiani.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"552:425– 436. http://dx.doi.org/10.1113/jphysiol.2003.052035 Frings, S. 2009a.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1007/s00359-008-0389-0 Frings, S., D. Reuter, and S.J.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1016/ S0301-0082(99)00027-1 Hartzell, C., I. Putzier, and J. Arreola.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/ 10.1146/annurev.physiol.67.032003.154341 Hengl, T., H. Kaneko, K. Dauner, K. Vocke, S. Frings, and F.  Möhrlen.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1023/A:1026548020851 Holy, T.E., C. Dulac, and M. Meister.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1016/ 0006-8993(96)00110-2 Kaneko, H., T. Nakamura, and B. Lindemann.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1523/ JNEUROSCI.2115-04.2004 Kim, S., L. Ma, and C.R.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"2:365. http://dx.doi.org/10.1038/ncomms1368 Kleene, S.J.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi .org/10.1093/chemse/bjn048 Lau, Y.E., and J.A.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1097/00001756- 200001170-00006 Leinders-Zufall, T., A.P.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1126/science.1102818We thank Stephan Frings (Heidelberg University, Heidelberg,  Germany) for providing guinea pig antibodies against TMEM16A and TMEM16B, Peter Mombaerts (Max Planck Institute of Bio-physics, Frankfurt, Germany) for providing OMP-GFP mice,   Johannes Reisert for helpful discussions, Simone Pifferi and Anna Boccaccio for comments on the manuscript, and all members of the laboratories for discussions.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1038/nn.2821 Boccaccio, A., and A. Menini.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1152/jn.00270.2007 Boccaccio, A., L. Lagostena, V. Hagen, and A. Menini.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1085/jgp.200609555 Boccaccio, A., C. Sagheddu, and A. Menini.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1038/ nature05404 Caputo, A., E. Caci, L. Ferrera, N. Pedemonte, C. Barsanti, E.  Sondo, U. Pfeffer, R. Ravazzolo, O. Zegarra-Moran, and L.J.V.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"322:590– 594. http://dx.doi.org/10.1126/science.1163518 Chamero, P., T.F.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1038/nature05997 Dauner, K., J. Lissmann, S. Jeridi, S. Frings, and F. Möhrlen.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1007/s00441-012-1324-9 Dean, D.M., A. Mazzatenta, and A. Menini.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
http://dx.doi.org/10.1007/s00359-004-0513-8,Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1113/ jphysiol.2010.194407 Schild, D., and D. Restrepo.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1016/j.cell .2008.09.003 Scudieri, P., E. Sondo, L. Ferrera, and L.J.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10 .1113/expphysiol.2011.058198 Shimazaki, R., A. Boccaccio, A. Mazzatenta, G. Pinato, M. Migliore,  and A. Menini.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1093/ chemse/bjj047 Spehr, M., H. Hatt, and C.H.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/ 10.1523/JNEUROSCI.5416-08.2009 Stephan, A.B., E.Y.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1523/JNEUROSCI.5546-08.2009 Tirindelli, R., M. Dibattista, S. Pifferi, and A. Menini.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi .org/10.1152/physrev.00037.2008 Touhara, K., and L.B.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1146/annurev.physiol.010908  .163209 Xiao, Q., K. Yu, P. Perez-Cornejo, Y. Cui, J. Arreola, and H.C. Hartzell.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1085/ jgp.200910265 Yang, Y.D., H. Cho, J.Y.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1038/nature07313 Zufall, F., K. Ukhanov, P. Lucas, E.R.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10 .1016/j.conb.2007.07.012Leinders-Zufall, T., T. Ishii, P. Mombaerts, F. Zufall, and T. Boehm.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1038/nn.2452 Liberles, S.D., L.F. Horowitz, D. Kuang, J.J. Contos, K.L.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1113/ jphysiol.2002.037119 Liman, E.R., and D.P.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1073/ pnas.96.10.5791 Ma, M. 2009.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"71:115– 140. http://dx.doi.org/10.1146/annurev.physiol.70.113006.100608 Pifferi, S., A. Boccaccio, and A. Menini.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1016/j.febslet.2006.03.086 Pifferi, S., M. Dibattista, and A. Menini.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1007/s00424-009-0684-9 Pifferi, S., M. Dibattista, C. Sagheddu, A. Boccaccio, A. Al Qteishat,  F. Ghirardi, R. Tirindelli, and A. Menini.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1113/ jphysiol.2009.176131 Pifferi, S., V. Cenedese, and A. Menini.",Non-OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/ 10.1093/chemse/bjq007 Reisert, J., and H. Zhao.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1085/jgp.201110645 Reisert, J., P.J.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi.org/10.1085/jgp.200308888 Reuter, D., K. Zierold, W.H.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"http://dx.doi .org/10.1038/nature08029 Ryba, N.J., and R. Tirindelli.",OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
http://dx.doi .org/10.1016/S0896-6273(00)80946-0,OADS,/arxiv_data1/oa_pdf/6d/53/JGP_201210780.PMC3382724.pdf
"WHO) http://www.who.int/neglected_diseases/ 2010report/en/, Accessed January 2012, , Geneva; 2011.",Non-OADS,/arxiv_data1/oa_pdf/ab/a9/srep00472.PMC3382734.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/ab/a9/srep00472.PMC3382734.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Nausch, N. et al.",Non-OADS,/arxiv_data1/oa_pdf/ab/a9/srep00472.PMC3382734.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/0a/e0/srep00473.PMC3382735.pdf
"To view a copyof this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Watanabe, M., Watanabe, D. & Kondo, S. Polyamine sensitivity of gap junctions is required for skin pattern formation in zebrafish.",Non-OADS,/arxiv_data1/oa_pdf/0a/e0/srep00473.PMC3382735.pdf
A complete list of all the peptides and proteins identiﬁed in this work for the species E. hyemale can be down- loaded from http://www.plantrhizome.org/peptides/.,OADS,/arxiv_data1/oa_pdf/13/cf/fpls-03-00131.PMC3382741.pdf
This project was supported by NSF grant IOS-1044821.SUPPLEMENTARY MATERIAL The Supplementary Materials for this article can be found online at http://www.frontiersin.org/Plant_Proteomics/10.3389/ fpls.2012.00131/abstract Figure S1 | Database search evaluation for Equisetum hyemale samples.,OADS,/arxiv_data1/oa_pdf/13/cf/fpls-03-00131.PMC3382741.pdf
"From all these observations, it became highly probable that Egfl7 affected the extravasation of immune cells from the *Correspondence to: Fabrice Soncin; Email: fabrice.soncin@ibl.fr Submitted: 12/06/11; Accepted: 12/07/11 http://dx.doi.org/10.4161/onci.18964OncoImmunology 1:3, 37 4  – G2012 Landes Bioscience 37 5  ; May/June 2012; 374 OncoImmunology Volume 1 Issue 3",Non-OADS,/arxiv_data1/oa_pdf/a3/74/onci-1-375.PMC3382845.pdf
Cancer Res 2011; 71:7176-86; PMID:22037871; http://dx.doi.org/10.1158/0008- 5472.CAN-11-1301 5.,Non-OADS,/arxiv_data1/oa_pdf/a3/74/onci-1-375.PMC3382845.pdf
EMBO J 2003; 22: 5700-11; PMID:14592969; http://dx.doi.org/10.1093/emboj/cdg549 6.,Non-OADS,/arxiv_data1/oa_pdf/a3/74/onci-1-375.PMC3382845.pdf
EMBO J2008; 27:1658-70; PMID:18497746; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a3/74/onci-1-375.PMC3382845.pdf
Hepatology 2009; 50:1839-50; PMID:19824075; http://dx.doi.org/10.1002/hep.23197 8.,Non-OADS,/arxiv_data1/oa_pdf/a3/74/onci-1-375.PMC3382845.pdf
J Cancer Res Clin Oncol 2010; 136:1737-43; PMID:20213100; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/a3/74/onci-1-375.PMC3382845.pdf
Genes Chromosomes Cancer 2008; 47:794-802; PMID:18521848; http://dx.doi.org/10.1002/gcc.20580 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/a3/74/onci-1-375.PMC3382845.pdf
"Additional studies are Correspondence to: Raphael Nemenoff; Email: Raphael.nemenoff@ucdenver.edu Submitted: 01/03/12; Accepted: 01/09/12 http://dx.doi.org/10.4161/onci.19309OncoImmunology 1:3, 40 403; May/June 2012; G2012 Landes Bioscience  – 402 OncoImmunology Volume 1 Issue 32",Non-OADS,/arxiv_data1/oa_pdf/33/e8/onci-1-403.PMC3382846.pdf
Cell 2005; 121:977-90; PMID: 15989949; http://dx.doi.org/10.1016/j.cell.2005.04.,OADS,/arxiv_data1/oa_pdf/33/e8/onci-1-403.PMC3382846.pdf
J Clin Oncol 2007; 25:1476-81; PMID:17442990; http://dx.doi.org/10.1200/JCO.2006.,Non-OADS,/arxiv_data1/oa_pdf/33/e8/onci-1-403.PMC3382846.pdf
Mol Pharmacol 2008; 73:709- 17; PMID:18055759; http://dx.doi.org/10.1124/mol.,Non-OADS,/arxiv_data1/oa_pdf/33/e8/onci-1-403.PMC3382846.pdf
Cell Metab 2007; 6:137-43; PMID:17681149; http://dx.doi.org/ 10.1016/j.cmet.2007.06.010 7.,OADS,/arxiv_data1/oa_pdf/33/e8/onci-1-403.PMC3382846.pdf
BMC Cancer 2010; 10:220; PMID:20487543; http://dx.doi.org/10.1186/ 1471-2407-10-2208.,Non-OADS,/arxiv_data1/oa_pdf/33/e8/onci-1-403.PMC3382846.pdf
Cell 2006; 124:263-6; PMID:16439202; http://dx.doi.org/10.1016/j.cell.2006.01.007 9.,OADS,/arxiv_data1/oa_pdf/33/e8/onci-1-403.PMC3382846.pdf
Purinergic Signal 2011; 7:231-41; PMID:21484085; http://dx.doi.org/10.1007/s11302- 011-9228-9 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/33/e8/onci-1-403.PMC3382846.pdf
"we used Ad5 or Ad5f35-pseudotyped adenovectors to transduce mouse bone marrow-derived Correspondence to: David M. Spencer; Email: dspencer@bcm.edu Submitted: 10/18/11; Accepted: 10/19/11 http://dx.doi.org/10.4161/onci.18482AUTHOR'S VIEW OncoImmunology 1:3, 361 –362; May/June 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 361",Non-OADS,/arxiv_data1/oa_pdf/a1/12/onci-1-362.PMC3382847.pdf
PLoS ONE 2011; 6:e18801; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/a1/12/onci-1-362.PMC3382847.pdf
Cancer Immunol Immunother 2007; 56: 1513-37; http://dx.doi.org/10.1007/s00262-007-0334-z 4.,Non-OADS,/arxiv_data1/oa_pdf/a1/12/onci-1-362.PMC3382847.pdf
Science 1993; 262:1019-24; PMID:7694365; http://dx.doi.org/10.1126/science.7694365 7.,OADS,/arxiv_data1/oa_pdf/a1/12/onci-1-362.PMC3382847.pdf
"We have previously shown that in the MUC1/interleukin-10 knockout (MUC1+/IL-10−/−) mouse model of human IBD and CACC, derived by crossing human MUC1 transgenic mouse (MUC1.tg) with the IL-10−/−mouse, MUC1 expression has a profound effect on the time of IBD occurrence, degree of inflammation, and progression to colon cancer.9In addition, we *Correspondence to: Olivera J. Finn; Email: OJFINN@pitt.edu Submitted: 10/31/11; Revised: 12/05/11; Accepted: 12/05/11 http://dx.doi.org/10.4161/onci.18950RESEARCH PAPER OncoImmunology 1:3, 263 –270; May/June 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 263",Non-OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
Nat Rev Gastroenterol Hepatol 2009; 6: 297-305; PMID:19404270; http://dx.doi.org/10.1038/ nrgastro.2009.44 3.,Non-OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
Gastroenterology 2011; 140:1807-16; PMID: 21530747; http://dx.doi.org/10.1053/j.gastro.2011.01.,Non-OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
Immunol Res 2011; 50:261-8; PMID:21717081; http://dx.doi.org/ 10.1007/s12026-011-8214-15.,Non-OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
Adv Immunol 2004; 82:249-93; PMID: 14975259; http://dx.doi.org/10.1016/S0065-2776(04) 82006-6 6.,Non-OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
Pancreas 2010; 39:510-5; PMID:20084048; http://dx.doi.org/10.1097/MPA.0b013e3181bd6501 13.,Non-OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
J Histochem Cytochem 2006; 54:1335-48; PMID:16924127; http://dx.doi.org/10.1369/jhc.5A6904.2006 14.,Non-OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
Biochemistry 2003; 42:13817-25; PMID:14636048; http://dx.doi.org/10.1021/bi035307017.,Non-OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
Cancer Cell 2004; 5:163-75; PMID:14998492; http://dx.doi.org/ 10.1016/S1535-6108(04)00020-0 22.,Non-OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
J Biol Chem 2004; 279:45721-7; PMID: 15322085; http://dx.doi.org/10.1074/jbc.M40802720023.,OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
J Biol Chem 2001; 276: 6191-9; PMID:11084045; http://dx.doi.org/10.1074/ jbc.M009449200 24.,OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
Acta Otolaryngol 2003; 123:524-31; PMID:12797589; http://dx.doi.org/10.1080/00016480310001268 25.,Non-OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
J Biol Chem 2011; 286:42248- 56; PMID:22021035; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/f5/2a/onci-1-263.PMC3382848.pdf
"Although the molecular machineries that ATM-mediated DNA damage res- ponses cause integrin- avβ3 upregulation Correspondence to: Masahisa Jinushi; Email: jinushiigm.hokudai.ac.jp Submitted: 12/15/11; Accepted: 12/19/11 http://dx.doi.org/10.4161/onci.19123OncoImmunology 1:3, 39  401; May/June 2012; G2012 Landes Bioscience 9 –AUTHOR'S VIEW www.landesbioscience.com OncoImmunology 399 999    99999  99  9",Non-OADS,/arxiv_data1/oa_pdf/b4/06/onci-1-400.PMC3382849.pdf
Science 2008; 319:1352-5; PMID: 18323444; http://dx.doi.org/10.1126/science.1140735 2.,Non-OADS,/arxiv_data1/oa_pdf/b4/06/onci-1-400.PMC3382849.pdf
Nature 2005; 436:1186-90; PMID:15995699; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/b4/06/onci-1-400.PMC3382849.pdf
Nat Cell Biol 2009; 11:973-9; PMID:19597488; http://dx.doi.org/10.1038/ncb1909 4.,OADS,/arxiv_data1/oa_pdf/b4/06/onci-1-400.PMC3382849.pdf
Nature 2007; 445: 656-60; PMID:17251933; http://dx.doi.org/10.1038/ nature055295.,Non-OADS,/arxiv_data1/oa_pdf/b4/06/onci-1-400.PMC3382849.pdf
Cell 2010; 143:355-66; PMID:21029859; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/b4/06/onci-1-400.PMC3382849.pdf
Cancer Discov 2011; 1:54-67; PMID:22039576; http://dx.doi.org/10.1158/ 2159-8274.CD-10-0028 7.,Non-OADS,/arxiv_data1/oa_pdf/b4/06/onci-1-400.PMC3382849.pdf
PMID:22094875; http://dx.doi.org/10.1158/ 0008-5472.CAN-11-20288.,Non-OADS,/arxiv_data1/oa_pdf/b4/06/onci-1-400.PMC3382849.pdf
Science 2006; 311:1141-6; PMID:16497931; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b4/06/onci-1-400.PMC3382849.pdf
Cell 2011; 145:92-103; PMID:21458669; http://dx.doi.org/10.1016/j.cell.,OADS,/arxiv_data1/oa_pdf/b4/06/onci-1-400.PMC3382849.pdf
Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/10.1016/j.cell.,OADS,/arxiv_data1/oa_pdf/b4/06/onci-1-400.PMC3382849.pdf
"The former results in an onto- genic process of “split T-cell tolerance, ” Correspondence to: Takemasa Tsuji and Sacha Gnjatic; Email: tsujit@mskcc.org and gnjatics@mskcc.org Submitted: 01/06/12; Accepted: 01/09/12 http://dx.doi.org/10.4161/onci.19310OncoImmunology 1:3, 40 406; May/June 2012; G2012 Landes Bioscience   – 404 OncoImmunology Volume 1 Issue 3  4",Non-OADS,/arxiv_data1/oa_pdf/b5/03/onci-1-405.PMC3382850.pdf
Adv Cancer Res 2006; 95:1-30; PMID:16860654; http://dx.doi.org/10.1016/ S0065-230X(06)95001-5 2.,Non-OADS,/arxiv_data1/oa_pdf/b5/03/onci-1-405.PMC3382850.pdf
Proc Natl Acad Sci U S A 2011; 108: 16723-8; PMID:21933959; http://dx.doi.org/10.1073/ pnas.1110814108 3.,OADS,/arxiv_data1/oa_pdf/b5/03/onci-1-405.PMC3382850.pdf
PLoS One 2011; 6:e23651; PMID:21858191; http://dx.doi.org/10.1371/journal.pone.0023651 4.,Non-OADS,/arxiv_data1/oa_pdf/b5/03/onci-1-405.PMC3382850.pdf
Blood 2005; 106:1008-11; PMID: 15840697; http://dx.doi.org/10.1182/blood-2005-02- 06075.,Non-OADS,/arxiv_data1/oa_pdf/b5/03/onci-1-405.PMC3382850.pdf
J Exp Med 1997; 185:833-41; PMID:9120389; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/b5/03/onci-1-405.PMC3382850.pdf
Cancer Res 2008; 68:893-900; PMID:18245492; http://dx.doi.org/10.1158/0008- 5472.CAN-07-3166 7.,Non-OADS,/arxiv_data1/oa_pdf/b5/03/onci-1-405.PMC3382850.pdf
J Immunol 2012; 188:111-21; PMID:22140254; http://dx.doi.org/10.4049/jimmunol.10026129.,Non-OADS,/arxiv_data1/oa_pdf/b5/03/onci-1-405.PMC3382850.pdf
J Exp Med 2004; 199:155-66; PMID:14734521; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b5/03/onci-1-405.PMC3382850.pdf
"Moreover, IDO activity in these co-cultures *Correspondence to: Kelvin P. Lee; Email: Kelvin.lee@roswellpark.org Submitted: 10/13/11; Revised: 11/09/11; Accepted: 11/11/11 http://dx.doi.org/10.4161/onci.18746OncoImmunology 1:3, 38 388; May/June 2012; G2012 Landes Bioscience  7–7AUTHOR'S VIEW www.landesbioscience.com OncoImmunology 387",Non-OADS,/arxiv_data1/oa_pdf/2d/08/onci-1-388.PMC3382851.pdf
Blood 2007; 109:5002-10; PMID:17311991; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/08/onci-1-388.PMC3382851.pdf
J Immunol 2011; 187:1243-53; PMID:21715687; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/2d/08/onci-1-388.PMC3382851.pdf
J Exp Med 2011; 208:1435-46; PMID: 21690252; http://dx.doi.org/10.1084/jem.20110040 6.,Non-OADS,/arxiv_data1/oa_pdf/2d/08/onci-1-388.PMC3382851.pdf
Nature 1988; 332:83-5; PMID:3258060; http://dx.doi.org/ 10.1038/332083a0 7.,OADS,/arxiv_data1/oa_pdf/2d/08/onci-1-388.PMC3382851.pdf
Haematologica 2008; 93:423-30; PMID: 18287134; http://dx.doi.org/10.3324/haematol.118979.,Non-OADS,/arxiv_data1/oa_pdf/2d/08/onci-1-388.PMC3382851.pdf
Eur J Immunol 1999; 29:3712-21; PMID:10556827; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2d/08/onci-1-388.PMC3382851.pdf
Nat Immunol 2004; 5:1134-42; PMID:15467723; http://dx.doi.org/10.1038/ni1124 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/2d/08/onci-1-388.PMC3382851.pdf
"In vitro experiments confirmed that several chemotherapeutic drugs induced expression of CXCL9, *Correspondence to: Jean-Pierre Abastado; Email: abastado@immunol.a-star.edu.sg Submitted: 11/18/11; Accepted: 11/18/11 http://dx.doi.org/10.4161/onci.18805OncoImmunology 1:3, 38 383; May/June 2012; G2012 Landes Bioscience 4 – 382 OncoImmunology Volume 1 Issue 32",Non-OADS,/arxiv_data1/oa_pdf/7c/20/onci-1-383.PMC3382852.pdf
Nat Chem Biol 2011; 7:335-9; PMID: 21587251; http://dx.doi.org/10.1038/nchembio.581 2.,OADS,/arxiv_data1/oa_pdf/7c/20/onci-1-383.PMC3382852.pdf
Curr Top Microbiol Immunol 2010; 344:1- 24; PMID:20512556; http://dx.doi.org/10.1007/ 82_2010_46 3.,Non-OADS,/arxiv_data1/oa_pdf/7c/20/onci-1-383.PMC3382852.pdf
Adv Exp Med Biol 2007; 604:67-86; PMID:17695721; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/7c/20/onci-1-383.PMC3382852.pdf
PLoS Biol 2011; 9: e1001162; PMID:21980263; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/7c/20/onci-1-383.PMC3382852.pdf
Nat Rev Clin Oncol 2011; 8:151-60; PMID: 21364688; http://dx.doi.org/10.1038/nrclinonc.2010.,OADS,/arxiv_data1/oa_pdf/7c/20/onci-1-383.PMC3382852.pdf
Semin Cancer Biol 2006; 16: 344-7; PMID:16914325; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/7c/20/onci-1-383.PMC3382852.pdf
Gut 2012; 61:427-38; PMID:21930732; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/7c/20/onci-1-383.PMC3382852.pdf
Nat Med 2011; 17:1094-100; PMID:21873989; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/7c/20/onci-1-383.PMC3382852.pdf
"The intrinsic characteristics ofNSCLC (which near-to-always is chemoresistant and associated with poor prognosis) and/or the type of therapy that isemployed to treat this malignancy (which near-to-always is based on cisplatin) may explain why two genes that affectthe immune response to dying cells fail to influence the clinical progression of NSCLC patients.IntroductionThere is ever expanding evidence suggesting that the escape fromimmune surveillance is a fundamental hallmark of cancer1,2andthat therapeutic interventions with cytotoxic compounds ortargeted anticancer agents are successful only when they re-establish an immune control on cancer growth.3-5Transplantableor primary murine cancers respond to chemotherapy withanthracyclins or oxaliplatin much more efficiently when theygrow in syngenic immunocompetent mice than in immunodefi-cient hosts.6,7In line with this finding, clinical studies revealedthat severe lymphopenia negatively affects the response of solidtumors to chemotherapy.8Moreover, while tumors growingon immunocompetent mice respond to chemotherapy withanthracyclins or oxaliplatin, tumors that grow on hosts lacking Tcells, important cytokines [such as interleukin 1β(IL-1β), IL-17Aand interferonc] or their receptors continue to proliferate in anunperturbed fashion.7,9,10Thus, at least in some settings, immunedefects are negative predictors of the response to chemotherapy.Successful chemotherapeutics can induce a type of tumor celldeath that is immunogenic,11-13implying that the patient’s dyingcancer cells function as a therapeutic vaccine, thereby eliciting anantitumor immune response that controls or eliminates the residual(chemotherapy-resistant) disease.5,14We have reported in the past*Correspondence to: Guido Kroemer; Email: kroemer@orange.frSubmitted: 11/05/11; Accepted: 11/07/11http://dx.doi.org/10.4161/onci.18684OncoImmunology 1:3, 271–278; May/June 2012;G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 271RESEARCHPAPER",Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013 2.,OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Nat Med 2011; 17:700-7; PMID:21552268; http://dx.doi.org/10.1038/nm.2366 Figure 2.,OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Nat Med 2011; 17:1094-100; PMID:21873989; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Nat Rev Clin Oncol 2011; 8:151-60; PMID:21364688; http://dx.doi.org/10.1038/nrclinonc.2010.223 6.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
J Exp Med 2005; 202:1691-701; PMID:16365148; http://dx.doi.org/10.1084/jem.20050915 7.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Cancer Res 2009; 69:5383-91; PMID:19549917; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Oncogene 2010; 29:482-91; PMID:19881547; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Immunol Rev 2011; 241:77-88; PMID:21488891; http://dx.doi.org/ 10.1111/j.1600-065X.2011.01006.x 14.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
N Engl J Med 2008; 358:2704-15; PMID:18565863; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Cell Death Differ 2008; 15:1499- 509; PMID:18464797; http://dx.doi.org/10.1038/cdd.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
EMBO J 2009; 28:578-90; PMID:19165151; http://dx.doi.org/10.1038/emboj.2009.1 18.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Cell Cycle 2009; 8: 3723-8; PMID:19855167; http://dx.doi.org/10.4161/ cc.8.22.10026 19.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347 20.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Immunol Rev 2007; 220: 47-59; PMID:17979839; http://dx.doi.org/10.1111/j.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Cell 2005; 123:321-34; PMID:16239148; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Sci Transl Med 2010; 2:63ra94; PMID:21178137; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
J Leukoc Biol 2009; 86:573-6; PMID:19414536; http://dx.doi.org/ 10.1189/jlb.1008585 25.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Nat Genet 2000; 25:187-91; PMID:10835634; http://dx.doi.org/ 10.1038/76048 26.,OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Respir Med 2006; 100: 892-6; PMID:16219455; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Clin Exp Immunol 2006; 143: 420-6; PMID:16487240; http://dx.doi.org/10.1111/j.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Am J Respir Crit Care Med 2007; 175: 360-6; PMID:17095747; http://dx.doi.org/10.1164/ rccm.200607-970OC 30.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Genes Immun 2010; 11: 374-83; PMID:20535134; http://dx.doi.org/10.1038/ gene.2010.31 31.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
N Engl J Med 2004; 350:351-60; PMID:14736927; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
N Engl J Med 2006; 355:983-91; PMID: 16957145; http://dx.doi.org/10.1056/NEJMoa060570 33.,OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
N Engl J Med 2008; 359:1367-80; PMID:18815398; http://dx.doi.org/10.1056/NEJMra0802714 35.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Cancer Res 2011; 71: 5412-22; PMID:21708957; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
J Pathol 2003; 201:268-77; PMID:14517844; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Cancer Res 2011; 71:5601-5; PMID:21846822; http://dx.doi.org/10.1158/0008-5472.CAN-11-1316 39.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Cancer Res 2010; 70:9538-43; PMID:21098713; http://dx.doi.org/10.1158/0008-5472.CAN-10-1003 40.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
J Clin Oncol 2008; 26: 4410-7; PMID:18802153; http://dx.doi.org/10.1200/ JCO.2007.15.0284 41.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Clin Cancer Res 2011; 17:5247-56; PMID:21659461; http://dx.doi.org/10.1158/1078- 0432.CCR-10-2805 42.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Oncogene 2011; Epub ahead of press; PMID:21892204; http://dx.doi.org/10.1038/onc.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Curr Opin Immunol 2008; 20:504-11; PMID:18573340; http://dx.doi.org/ 10.1016/j.coi.2008.05.007 44.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Oncogene 2011; 30:1147-58; PMID: 21151176; http://dx.doi.org/10.1038/onc.2010.500 45.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
Immunol Rev 2007; 220:22-34; PMID: 17979837; http://dx.doi.org/10.1111/j.1600-065X.,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
J Clin Oncol 2010; 28:35-42; PMID:19933916; http://dx.doi.org/10.1200/JCO.2009.23.2272 278 OncoImmunology Volume 1 Issue 3,Non-OADS,/arxiv_data1/oa_pdf/d1/40/onci-1-271.PMC3382853.pdf
"However, a direct demonstration of this *Correspondence to: Lars Zender; Email: Lars.Zender@helmholtz-hzi.de Submitted: 12/20/11; Accepted: 12/20/11 http://dx.doi.org/10.4161/onci.19128OncoImmunology 1:3, 39 398; May/June 2012; G2012 Landes Bioscience  –AUTHOR'S VIEW www.landesbioscience.com OncoImmunology 3977",Non-OADS,/arxiv_data1/oa_pdf/99/d9/onci-1-398.PMC3382854.pdf
Nature 2004; 432:307-15; PMID: 15549092; http://dx.doi.org/10.1038/nature03098 2.,Non-OADS,/arxiv_data1/oa_pdf/99/d9/onci-1-398.PMC3382854.pdf
Nat Med 2005; 11:920-2; PMID:16145569; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/99/d9/onci-1-398.PMC3382854.pdf
Nature 2011; 479:547-51; PMID: 22080947; http://dx.doi.org/10.1038/nature10599 4.,Non-OADS,/arxiv_data1/oa_pdf/99/d9/onci-1-398.PMC3382854.pdf
J Clin Invest 2007; 117:1137-46; PMID:17476343; http://dx.doi.org/10.1172/JCI314055.,Non-OADS,/arxiv_data1/oa_pdf/99/d9/onci-1-398.PMC3382854.pdf
"www.landesbioscience.com  OncoImmunology  355OncoImmunology 1:3, 355-337; May/June 2012; © 2012 Landes Bioscience EDITOR’S CA ORNER AUTH OR’S V IEW Invariant natural killer T cells reconstitution  and the control of leukemia relapse in pediatric  haploidentical hematopoietic stem cell  transplantation Giulia Casorati,* Claudia de Lalla and Paolo Dellabona Experimental immunology Unit; Division of Immunology; Transplantation and Infectious Diseases; San Raﬀaele Scienti/f_ic Institute; Milano, Italy Keywords:  NKT cells, CD1d, immunesurveillance, leukemia, immunotherapy *Correspondence to: Giulia Casorati; Email: casorati.giulia@hsr.it Submitted: 10/07/11; Revised: 10/11/11; Accepted: 10/13/11 http://dx.doi.org/10.4161/onci.18399CD1d-restricted invariant (i) NKT cells are innate-like, lipid-reactive T lymphocytes implicated in the control of infections,  cancer and autoimmunity.",Non-OADS,/arxiv_data1/oa_pdf/0d/4a/onci-1-355.PMC3382855.pdf
Annu Rev Immunol 2007; 25:297-336; PMID: 17150027; http://dx.doi.org/10.1146/annurev.immunol.,Non-OADS,/arxiv_data1/oa_pdf/0d/4a/onci-1-355.PMC3382855.pdf
N Engl J Med 1998; 339:1186-93; PMID:9780338; http://dx.doi.org/ 10.1056/NEJM199810223391702 3.,Non-OADS,/arxiv_data1/oa_pdf/0d/4a/onci-1-355.PMC3382855.pdf
Bone Marrow Transplant 2005; 35(Suppl 1):S53-7; PMID:15812532; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0d/4a/onci-1-355.PMC3382855.pdf
J Exp Med 2002; 195:637-41; PMID: 11877486; http://dx.doi.org/10.1084/jem.20011908 7.,Non-OADS,/arxiv_data1/oa_pdf/0d/4a/onci-1-355.PMC3382855.pdf
Eur J Immunol 2010; 40:1862-9; PMID: 20583031; http://dx.doi.org/10.1002/eji.2010403949.,Non-OADS,/arxiv_data1/oa_pdf/0d/4a/onci-1-355.PMC3382855.pdf
J Immunol 2011; 186:4490-9; PMID:21357532; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/0d/4a/onci-1-355.PMC3382855.pdf
J Clin Oncol 2007; 25: 862-8; PMID:17327607; http://dx.doi.org/10.1200/ JCO.2006.08.5787 www.landesbioscience.com OncoImmunology 357,Non-OADS,/arxiv_data1/oa_pdf/0d/4a/onci-1-355.PMC3382855.pdf
"Immunostimulatory agents given as monother- apy have been associated with consistent rates of tumor regression*Correspondence to: Guido Kroemer; Email: kroemer@orange.fr Submitted: 01/31/12; Accepted: 01/31/12 http://dx.doi.org/10.4161/onci.19549OncoImmunology 1:3, 306 –315; May/June 2012; G2012 Landes Bioscience 306 OncoImmunology Volume 1 Issue 3",Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cancer Cell 2005; 7:411-23; PMID:15894262; http://dx.doi.org/10.1016/j.ccr.2005.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cancer Res 2010; 70:7465-75; PMID:20841473; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Proc Natl Acad Sci U S A 2011; 108:10662-7; PMID:21670304; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri19365.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Nat Rev Drug Discov 2012; 11:215-33; PMID: 22301798; http://dx.doi.org/10.1038/nrd3626 6.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Science 2006; 313: 1960-4; PMID:17008531; http://dx.doi.org/10.1126/ science.1129139 8.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Clin Oncol 2011; 29: 610-8; PMID:21245428; http://dx.doi.org/10.1200/ JCO.2010.30.5425 9.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cancer Metastasis Rev 2011; 30:5-12; PMID:21249426; http://dx.doi.org/10.1007/s10555-011-9270-7 10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi.org/ 10.1038/nm1100 11.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Nat Rev Clin Oncol 2011; 8:577-85; PMID:21808266; http://dx.doi.org/10.1038/nrclinonc.2011.116 12.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466 13.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
N Engl J Med 1985; 313:1485-92; PMID:3903508; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Cancer Res 2008; 14:5610-8; PMID:18765555; http://dx.doi.org/10.1158/1078- 0432.CCR-08-0116 16.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cancer Metastasis Rev 2011; 30:83-95; PMID:21249423; http://dx.doi.org/10.1007/s10555-011-9281-4 17.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Nat Rev Immunol 2003; 3:630-41; PMID: 12974478; http://dx.doi.org/10.1038/nri1150 18.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Clin Oncol 2006; 24:3089-94; PMID:16809734; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Cancer Res 2011; 17: 4558-67; PMID:21558406; http://dx.doi.org/10.1158/ 1078-0432.CCR-10-322321.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Clin Oncol 2010; 28:1099-105; PMID:20100959; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
N Engl J Med 2011; 364: 2119-27; PMID:21631324; http://dx.doi.org/10.1056/ NEJMoa1012863 23.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116 24.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Nat Rev Immunol 2006; 6:383-93; PMID: 16622476; http://dx.doi.org/10.1038/nri1842 25.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Nat Rev Immunol 2007; 7:790-802; PMID:17853902; http://dx.doi.org/10.1038/nri2173 27.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cancer Immunol Immunother 2009; 58:553-66; PMID:18751701; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Natl Cancer Inst 1991; 83:932-7; PMID: 2067036; http://dx.doi.org/10.1093/jnci/83.13.932 30.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Proc Natl Acad Sci U S A 2005; 102:9571-6; PMID:15980149; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Immunother 2010; 33:672-83; PMID:20664359; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Blood 2011; 117:808-14; PMID:20971955; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cancer Res 2005; 65:1761-9; PMID:15753372; http://dx.doi.org/10.1158/0008-5472.CAN-04-3169 37.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Nat Med 2010; 16:1029-34; PMID:20693993; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Immunol 2010; 136: 338-47; PMID:20547105; http://dx.doi.org/10.1016/ j.clim.2010.04.013 41.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Exp Med 2008; 205:2673-82; PMID:18936238; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Eur J Immunol 2010; 40:1786-94; PMID: 20217862; http://dx.doi.org/10.1002/eji.200940132 43.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Science 2006; 314:126-9; PMID:16946036; http://dx.doi.org/10.1126/science.1129003 44.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Mol Ther 2011; 19:620-6; PMID:21157437; http://dx.doi.org/10.1038/mt.2010.272 46.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Nat Rev Cancer 2005; 5:615-25; PMID: 16034368; http://dx.doi.org/10.1038/nrc1669 www.landesbioscience.com OncoImmunology 313,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Clin Oncol 2011; 29:917- 24; PMID:21282551; http://dx.doi.org/10.1200/JCO.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
N Engl J Med 2008; 358:2698-703; PMID:18565862; http://dx.doi.org/10.1056/NEJMoa0800251 49.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Gene Ther 2005; 12:140-6; PMID: 15496961; http://dx.doi.org/10.1038/sj.gt.3302388 50.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Immunol 2011; 186:685-96; PMID: 21149604; http://dx.doi.org/10.4049/jimmunol.1001775 51.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Blood 2011; 118:4817-28; PMID:21849486; http://dx.doi.org/10.1182/blood-2011-04-348540 52.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Blood 2010; 116: 4099-102; PMID:20668228; http://dx.doi.org/10.1182/ blood-2010-04-281931 53.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
N Engl J Med 2011; 365: 725-33; PMID:21830940; http://dx.doi.org/10.1056/ NEJMoa1103849 54.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
N Engl J Med 1988; 319: 1676-80; PMID:3264384; http://dx.doi.org/10.1056/ NEJM198812223192527 56.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Trends Immunol 2005; 26:111-7; PMID:15668127; http://dx.doi.org/10.1016/j.it.2004.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Immunother 2010; 33:1-7; PMID:19952961; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Int J Cancer 1995; 63:205- 12; PMID:7591205; http://dx.doi.org/10.1002/ijc.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Biomed Pharmacother 1992; 46:473-84; PMID:1306361; http://dx.doi.org/ 10.1016/0753-3322(92)90005-R 61.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Blood 2006; 107:2409-14; PMID: 16304057; http://dx.doi.org/10.1182/blood-2005-06- 2399 62.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cancer Lett 1994; 85:39-46; PMID:7923100; http://dx.doi.org/ 10.1016/0304-3835(94)90236-4 67.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cancer Immunol Immunother 2010; 59:1325-34; PMID:20532883; http://dx.doi.org/10.1007/s00262- 010-0860-y 68.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Cancer Res 2011; 17:3134-45; PMID:21252159; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Cancer Res 2011; 17:4987-95; PMID:21690573; http://dx.doi.org/10.1158/1078-0432.CCR-11-020772.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Science 2002; 295:2097-100; PMID:11896281; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Curr Opin Immunol 2009; 21:525-30; PMID:19717293; http://dx.doi.org/10.1016/j.coi.2009.07.015 75.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Cancer Res 2011; 17:6287-97; PMID:21844012; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cytotherapy 2011; 13:98-107; PMID:20849361; http://dx.doi.org/10.3109/14653249.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Cancer Res 2010; 16:2646-55; PMID:20406835; http://dx.doi.org/10.1158/1078- 0432.CCR-10-0041 78.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Cancer Res 2010; 16:6122-31; PMID:20668005; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cancer Cell 2011; 20:755-67; PMID:22172721; http://dx.doi.org/10.1016/j.ccr.2011.10.019 82.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Mol Ther 2010; 18:843-51; PMID: 20179677; http://dx.doi.org/10.1038/mt.2010.24 85.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Clin Oncol 2005; 23:2346-57; PMID:15800326; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Hum Gene Ther 2008; 19:496-510; PMID:18444786; http://dx.doi.org/10.1089/hum.2007.0171 89.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449 90.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Lancet 2009; 373:673-83; PMID:19231634; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Invest Dermatol 2009; 129:2835-42; PMID:19554023; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Cancer Res 2010; 16:4892-8; PMID:20719934; http://dx.doi.org/10.1158/1078-0432.CCR-10-150793.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cancer Immunol Immunother 2011; 60:953-63; PMID:21431917; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Sci Transl Med 2011; 3:80ra34; PMID: 21525398; http://dx.doi.org/10.1126/scitranslmed.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Clin Oncol 2003; 21:884-90; PMID:12610189; http://dx.doi.org/10.1200/JCO.2003.08.023 96.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Cancer Biol Ther 2011; 11:450-6; PMID: 21258206; http://dx.doi.org/10.4161/cbt.11.5.14669 98.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Cancer Res 2006; 12:6106-15; PMID:17062687; http://dx.doi.org/10.1158/1078- 0432.CCR-06-1183 99.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Nat Med 2008; 14:1264-70; PMID:18978797; http://dx.doi.org/10.1038/nm.1882 100.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Immunol 2011; 138:255-65; PMID:21185787; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Blood 2003; 102:2004-13; PMID:12763934; http://dx.doi.org/10.1182/blood-2003-01-0095 103.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Clin Cancer Res 2007; 13:2392-9; PMID: 17438098; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
PLoS One 2009; 4:e4749; PMID: 19270751; http://dx.doi.org/10.1371/journal.pone.,OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
Blood 2011; 117:788-97; PMID: 21030558; http://dx.doi.org/10.1182/blood-2010-08- 299396 106.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
PMID:22160384; http://dx.doi.org/10.1182/ blood-2011-10-384388 107.,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
J Cancer 2011; 2:363- 8; PMID:21716717; http://dx.doi.org/10.7150/jca.2.363 www.landesbioscience.com OncoImmunology 315,Non-OADS,/arxiv_data1/oa_pdf/21/f7/onci-1-306.PMC3382856.pdf
"We documented *Correspondence to: Barbara Molon; Email: barbara.molon@unipd.it Submitted: 12/04/11; Revised: 12/09/11; Accepted: 12/14/11 http://dx.doi.org/10.4161/onci.19069OncoImmunology 1:3, 3 391; May/June 2012; G2012 Landes Bioscience    –89AUTHOR'S VIEW www.landesbioscience.com OncoImmunology 389",Non-OADS,/arxiv_data1/oa_pdf/2e/be/onci-1-390.PMC3382857.pdf
Nature 2011; 475:226-30; PMID: 21753853; http://dx.doi.org/10.1038/nature10169 2.,Non-OADS,/arxiv_data1/oa_pdf/2e/be/onci-1-390.PMC3382857.pdf
Eur J Immunol 2011; 41:1843-9; PMID:21480210; http://dx.doi.org/ 10.1002/eji.2010408686.,Non-OADS,/arxiv_data1/oa_pdf/2e/be/onci-1-390.PMC3382857.pdf
J Exp Med 2006; 203:2749-61; PMID:17116735; http://dx.doi.org/10.1084/jem.20060710 8.,Non-OADS,/arxiv_data1/oa_pdf/2e/be/onci-1-390.PMC3382857.pdf
PLoS ONE 2011; 6:e21214; PMID:21731676; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/2e/be/onci-1-390.PMC3382857.pdf
"Schijns and Apostolis Stathopoulos; Email: Virgil.schijns@wur.nl and tstath@hotmail.com Submitted: 09/30/11; Revised: 12/15/11; Accepted: 12/15/11 http://dx.doi.org/10.4161/onci.19068OncoImmunology 1:3, 298 –305; May/June 2012; G2012 Landes Bioscience 298 OncoImmunology Volume 1 Issue 3",Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Science 2006; 313: 1960-4; PMID:17008531; http://dx.doi.org/10.1126/ science.1129139 2.,OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177 4.,OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Eur J Cancer 1994; 30:1797-803; PMID:7880609; http://dx.doi.org/10.1016/0959-8049(94)E0159-2 6.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
"Int J Cancer 1997; 74:492-501; PMID: 9355970; http://dx.doi.org/10.1002/(SICI)1097-0215 (19971021)74:5 ,492::AID-IJC3 .3.0.CO;2-Z 7.",Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Nat Immunol 2002; 3:991-8; PMID: 12407406; http://dx.doi.org/10.1038/ni1102-991 8.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Immunity 2004; 21:137-48; PMID:15308095; http://dx.doi.org/10.1016/j.immuni.2004.07.017 9.,OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Proc Natl Acad Sci USA 1998; 95:7556-61; PMID:9636188; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936 13.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
J Clin Invest 2005; 115:3623-33; PMID:16308572; http://dx.doi.org/10.1172/JCI25947 14.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Cancer Cell 2005; 8:369-80; PMID:16286245; http://dx.doi.org/10.1016/j.ccr.,OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Clin Cancer Res 2007; 13:4345-54; PMID:17671115; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Nature 2001; 410:1107-11; PMID: 11323675; http://dx.doi.org/10.1038/35074122 17.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Annu Rev Immunol 2003; 21:335-76; PMID:12524386; http://dx.doi.org/10.1146/annurev.immunol.21.120601.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Expert Rev Vaccines 2011; 10:539-50; PMID: 21506650; http://dx.doi.org/10.1586/erv.11.21 19.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Br J Ophthalmol 2011; 95:890-2; PMID: 21378006; http://dx.doi.org/10.1136/bjo.2010.195800 21.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Cell Immunol 2000; 204:64-74; PMID: 11006019; http://dx.doi.org/10.1006/cimm.2000.1689 23.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Vaccine 2005; 23:5263-70; PMID:16081189; http://dx.doi.org/10.1016/j.vaccine.2005.06.024 24.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Int Immunol 2007; 19:297-304; PMID:17289655; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
J Immunother 2011; 34:264-9; PMID:21389872; http://dx.doi.org/10.1097/CJI.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Nat Immunol 2002; 3:499; PMID:12032557; http://dx.doi.org/10.1038/ni0602-499 27.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
J Neurooncol 2007; 85:133-48; PMID:17874037; http://dx.doi.org/10.1007/s11060-007-9400-9 28.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Nat Rev Immunol 2008; 8:59-73; PMID:18097448; http://dx.doi.org/10.1038/nri2216 30.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Cancer Invest 1984; 2:459-66; PMID:6509357; http://dx.doi.org/10.3109/ 07357908409048519 31.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
J Neurooncol 1994; 22:191-200; PMID: 7760095; http://dx.doi.org/10.1007/BF01052919 32.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Immunotherapy 2011; 3(Suppl): 42-4; PMID:21524170; http://dx.doi.org/10.2217/ imt.11.39 33.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Immunol Rev 2006; 213: 131-45; PMID:16972901; http://dx.doi.org/10.1111/ j.1600-065X.2006.00442.x 34.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Immunol Today 1991; 12:370-4; PMID:1958290; http://dx.doi.org/10.1016/ 0167-5699(91)90068-5 35.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
Clin Dev Immunol 2010; 296453; Epub; PMID:21437175; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
J Clin Invest 2010; 120:1285-97; PMID:20237413; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
J Neurooncol 1993; 15:97-112; PMID:8509824; http://dx.doi.org/10.1007/BF01053931 38.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
J Exp Med 2007; 204:1441-51; PMID:17535975; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
J Immunother 2011; 34:264- 9; PMID:21389872; http://dx.doi.org/10.1097/CJI.,Non-OADS,/arxiv_data1/oa_pdf/74/82/onci-1-298.PMC3382858.pdf
"More importantly, clus- tering was “clean ”(i.e., with complete Correspondence to: Daniel E. Speiser; Email: doc@dspeiser.ch Submitted: 10/03/11; Accepted: 10/07/11 http://dx.doi.org/10.4161/onci.18342OncoImmunology 1:3, 368 –370; May/June 2012; G2012 Landes Bioscience 368 OncoImmunology Volume 1 Issue 3",Non-OADS,/arxiv_data1/oa_pdf/f2/81/onci-1-369.PMC3382859.pdf
J Clin Invest 2011; 121:2350-60; PMID:21555851; http://dx.doi.org/10.1172/JCI46102 2.,Non-OADS,/arxiv_data1/oa_pdf/f2/81/onci-1-369.PMC3382859.pdf
Immunity 2007; 27:670-84; PMID:17950003; http://dx.doi.org/ 10.1016/j.immuni.2007.09.006 3.,OADS,/arxiv_data1/oa_pdf/f2/81/onci-1-369.PMC3382859.pdf
Int J Cancer 2011; 130:2607-17; PMID: 21796616; http://dx.doi.org/10.1002/ijc.26297 4.,Non-OADS,/arxiv_data1/oa_pdf/f2/81/onci-1-369.PMC3382859.pdf
Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-01165.,Non-OADS,/arxiv_data1/oa_pdf/f2/81/onci-1-369.PMC3382859.pdf
PLoS ONE 2011; 6:e17621; PMID:21408177; http://dx.doi.org/10.1371/journal.pone.0017621 6.,Non-OADS,/arxiv_data1/oa_pdf/f2/81/onci-1-369.PMC3382859.pdf
Nature 1993; 362:758-61; PMID: 8469287; http://dx.doi.org/10.1038/362758a0 7.,Non-OADS,/arxiv_data1/oa_pdf/f2/81/onci-1-369.PMC3382859.pdf
J Exp Med 1998; 188:2205-13; PMID: 9858507; http://dx.doi.org/10.1084/jem.188.12.22058.,OADS,/arxiv_data1/oa_pdf/f2/81/onci-1-369.PMC3382859.pdf
Nature 2006; 439:682-7; PMID:16382236; http://dx.doi.org/ 10.1038/nature04444 9.,OADS,/arxiv_data1/oa_pdf/f2/81/onci-1-369.PMC3382859.pdf
Nat Immunol 2011; 131:492-9; PMID:21739672; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/f2/81/onci-1-369.PMC3382859.pdf
"Our in vitro analyses also identified that the effects of dexamethasone on CD4+T-cell IL-2 *Correspondence to: David S. Ritchie; Email: david.ritchie@petermac.org Submitted: 11/17/11; Revised: 12/06/11; Accepted: 12/07/11 http://dx.doi.org/10.4161/onci.18963AUTHOR'S VIEW OncoImmunology 1:3, 371 –373; May/June 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 371",Non-OADS,/arxiv_data1/oa_pdf/25/16/onci-1-372.PMC3382860.pdf
Blood 2011; 118: 2970-5; PMID:21690557; http://dx.doi.org/10.1182/ blood-2011-04-348896 3.,Non-OADS,/arxiv_data1/oa_pdf/25/16/onci-1-372.PMC3382860.pdf
Blood 2001; 98:210-6; PMID: 11418482; http://dx.doi.org/10.1182/blood.V98.1.2104.,Non-OADS,/arxiv_data1/oa_pdf/25/16/onci-1-372.PMC3382860.pdf
Blood 2011; 117:1605-13; PMID:20978269; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/16/onci-1-372.PMC3382860.pdf
Blood 2011; 118:6465-6; PMID:22161851; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/25/16/onci-1-372.PMC3382860.pdf
Blood 2011; 117:1605-15; PMID:20978269; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/25/16/onci-1-372.PMC3382860.pdf
"AdV/DC become more mature phenoty- pically (increased CD83, CD86, HLA-DR) and have decreased secretion of IL-10 and increased IL-12p70.35-37AdV transduction has also been shown to result in increased expression of IFN a, *Correspondence to: Lisa H. Butterfield; Email: butterfieldl@upmc.edu Submitted: 10/05/11; Revised: 10/28/11; Accepted: 11/02/11 http://dx.doi.org/10.4161/onci.18628RESEARCH PAPER OncoImmunology 1:3, 287 –297; May/June 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 287",Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Supplemental Material Supplemental materials may be found here: http://www.landesbioscience.com/journals/oncoimmunology/article/18628/ References 1.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992;  http://dx.doi.org/10.1056/NEJMoa1003466 2.,OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
N Engl J Med 2011; 364: 2119- 27; PMID:21631324; http://dx.doi.org/10.1056/  NEJMoa1012863 3.,OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Nat Med 1998; 4:328-32; PMID:  9500607; http://dx.doi.org/10.1038/nm0398-328 6.,OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Clin Oncol 2008; 26:4973- 80; PMID:18809608;  http://dx.doi.org/10.1200/JCO.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Immunother 2004; 27:354-67; PMID:15314544;  http://dx.doi.org/10.1097/00002371-200409000-00004 8.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Nature 1998; 392:245-52;  PMID:9521319; http://dx.doi.org/10.1038/32588  10.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Curr Opin Immunol 1991;  3:361-72; PMID:1910616; http://dx.doi.org/10.1016/  0952-7915(91)90039-4 11.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Immunology 2004; 113:472-81; PMID:15554925;  http://dx.doi.org/ 10.1111/j.1365-2567.2004.01978.x 17.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Oncology  2005; 68:163-70; PMID:16006753; http://dx.doi.org/10.1159/000086770 20.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Immunother 2007; 30:  425-37; PMID:17457217; http://dx.doi.org/10.1097/  CJI.0b013e31802fd8e2 23.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Cancer Gene Ther 1999; 6:523-36; PMID:10608349; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Cancer Gene Ther 2005; 12:516-27; PMID:  15775996; http://dx.doi.org/10.1038/sj.cgt.7700818 25.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Arch  Dermatol 2002; 138:799-802; PMID:12056962;  http://dx.doi.org/10.1001/archderm.138.6.799 34.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Cancer Gene Ther 2006; 13:905-18; PMID:  16710345; http://dx.doi.org/10.1038/sj.cgt.7700961 35.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Immunother 2004;  27:191-200; PMID:15076136; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Cancer Immunol Immunother 2009; 58: 121-33; PMID:18488218; http://dx.doi.org/10.1007/  s00262-008-0533-2,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Blood 2005; 105:3824-32; PMID:15671441; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Blood 2010; 116:575-83; PMID:20430958; http://dx.doi.org/10.1182/blood- 2009-08-240325 41.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Immunother 2008; 31:294- 309; PMID:18317358; http://dx.doi.org/10.1097/CJI.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Cancer Gene Ther 2001; 8:361-70; PMID: 11477456; http://dx.doi.org/10.1038/sj.cgt.7700321 43.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Immunol Rev 2002; 188:22-32; PMID:12445278; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Gene Med 2006; 8:1208-22; PMID:16960915; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Exp Med 1994; 180:35-42; PMID:8006593; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Exp Med 1998; 188:1203-8; PMID:9743539; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Invest Dermatol 2001; 117:326-32; PMID:11511311; http://dx.doi.org/10.1046/j.1523-1747.2001.01408.x 53.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Invest Dermatol 2003; 121:308-14; PMID: 12880423; http://dx.doi.org/10.1046/j.1523-1747.2003.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Invest Dermatol 2003; 121:550-6; PMID:12925214; http://dx.doi.org/ 10.1046/j.1523-1747.2003.12413.x 58.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Arch Dermatol 1999; 135:417-22; PMID:10206048; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
"Eur J Immunol 1999; 29:602-7; PMID: 10064076; http://dx.doi.org/10.1002/(SICI)1521-4141 (199902)29:02 ,602::AID-IMMU602 .3.0.CO;2-Y 60.",Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Exp Med 2002; 196:619-28; PMID:12208877; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Proc Natl Acad Sci USA 2006; 103:11160-5; PMID:16847267; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Immunol 2009; 182: 6328-41; PMID:19414786; http://dx.doi.org/10.4049/ jimmunol.0801898 63.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
J Immunol 2009; 183:4895-903; PMID: 19801514; http://dx.doi.org/10.4049/jimmunol.0901459 64.,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Lancet 2000; 356:1795-9; PMID:11117911; http://dx.doi.org/10.1016/S0140- 6736(00)03231-1 68.,OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Nat Med 1999; 5:405-11; PMID:10202929; http://dx.doi.org/ 10.1038/7403 69.,OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
Clin Cancer Res 2007; 13:6796-806; PMID:18006782; http://dx.doi.org/10.1158/1078-0432.CCR-07-1909 www.landesbioscience.com OncoImmunology 297,Non-OADS,/arxiv_data1/oa_pdf/08/51/onci-1-287.PMC3382861.pdf
"These alterations were erased in patients undergoing long-term remission It appeared that: (1) tumor can induce its own tolerance from NK-cells anti-tumor immunity; (2) invasive characteristics and metastasis occurrence are dependent on the inhibition of NK-cell-mediated *Correspondence to: Emilie Mamessier; Email: mamessier@ciml.univ-mrs.fr Submitted: 10/17/11; Accepted: 10/25/11 http://dx.doi.org/10.4161/onci.18528AUTHOR'S VIEW OncoImmunology 1:3, 365 –367; June/July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 365",Non-OADS,/arxiv_data1/oa_pdf/ed/60/onci-1-366.PMC3382862.pdf
PMID:21937679; http://dx.doi.org/10.1158/0008-5472.CAN-11-0792 3.,Non-OADS,/arxiv_data1/oa_pdf/ed/60/onci-1-366.PMC3382862.pdf
Genome Biol 2007; 8: R157; PMID:17683518; http://dx.doi.org/10.1186/ gb-2007-8-8-r1575.,OADS,/arxiv_data1/oa_pdf/ed/60/onci-1-366.PMC3382862.pdf
Mol Cancer 2011; 10:86; PMID:21777462; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/ed/60/onci-1-366.PMC3382862.pdf
Breast Cancer Res Treat 2011; 126:407-20; PMID:20490655; http://dx.doi.org/10.1007/s10549- 010-0897-9 7.,Non-OADS,/arxiv_data1/oa_pdf/ed/60/onci-1-366.PMC3382862.pdf
Cancer Res 2006; 66:4636-44; PMID:16651414; http://dx.doi.org/10.1158/0008- 5472.CAN-06-00318.,Non-OADS,/arxiv_data1/oa_pdf/ed/60/onci-1-366.PMC3382862.pdf
Biomed Pharmacother 2005; 59(Suppl 2):S375-9; PMID: 16507413; http://dx.doi.org/10.1016/S0753-3322 (05)80082-4 9.,OADS,/arxiv_data1/oa_pdf/ed/60/onci-1-366.PMC3382862.pdf
J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037 www.landesbioscience.com OncoImmunology 367,Non-OADS,/arxiv_data1/oa_pdf/ed/60/onci-1-366.PMC3382862.pdf
"Collectively, these results *Correspondence to: Nathalie Bendriss-Vermare; Email: nathalie.bendriss-vermare@lyon.unicancer.fr Submitted: 11/17/11; Accepted: 11/17/11 http://dx.doi.org/10.4161/onci.18801OncoImmunology1:3,3 381;May/June2012;G2012 Landes Bioscience   77 9– 79AUTHOR'S VIEW www.landesbioscience.com OncoImmunology 379",Non-OADS,/arxiv_data1/oa_pdf/58/b1/onci-1-380.PMC3382863.pdf
Cancer Res 2011; 71:5423-34; PMID:21697280; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/58/b1/onci-1-380.PMC3382863.pdf
Cancer 2011; Epub ahead of press; PMID:21953023; http://dx.doi.org/10.1002/ cncr.265115.,Non-OADS,/arxiv_data1/oa_pdf/58/b1/onci-1-380.PMC3382863.pdf
Trends Immunol 2010; 31:391-7; PMID:20832362; http://dx.doi.org/ 10.1016/j.it.2010.07.004 6.,OADS,/arxiv_data1/oa_pdf/58/b1/onci-1-380.PMC3382863.pdf
Gynecol Oncol 1999; 74:48-52; PMID:10385550; http://dx.doi.org/10.1006/gyno.1999.5455 10.,Non-OADS,/arxiv_data1/oa_pdf/58/b1/onci-1-380.PMC3382863.pdf
N Engl J Med 2010; 363:2511-21; PMID:21175313; http://dx.doi.org/10.1056/NEJMoa1004095 www.landesbioscience.com OncoImmunology 381,Non-OADS,/arxiv_data1/oa_pdf/58/b1/onci-1-380.PMC3382863.pdf
"Even at the disseminated stage, patients with a high memory T cell infiltrate in their resected hepatic meta- stases respond better to chemotherapy and exhibit a better overall survival than Correspondence to: Wolf H. Fridman; Email: herve.fridman@crc.jussieu.fr Submitted: 02/07/12; Accepted: 02/07/12 http://dx.doi.org/10.4161/onci.19651EDITORIAL OncoImmunology 1:3, 261 –262; May/June 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 261",Non-OADS,/arxiv_data1/oa_pdf/ba/43/onci-1-261.PMC3382864.pdf
"In humans, Foxp3+regulatory and activated T cells can be distinguished by the differential expression of CD127 (which is present at high levels in activated T cells and at low levels in Treg)7and by the methylation status of the transcription factor Foxp3 detected by a Foxp3 methylation-specific PCR assay (with demethylation in the DNA encoding Foxp3 in Treg but not in activated T cells).8 Tregs also express effector surface molecules such as CTLA4, LAG3, CD39 or CD73 and co-stimulation molecules, CD28, CD80/86, CD40, OX40 or 4 –1BB, which appear to be impor- tant for their peripheral maintenance and functions.9Integrins and chemokine receptors such as CD62L, CCR4, CCR7 and CCR8 are responsible for Treg homing and migration to lymph*Correspondence to: Eric Tartour; Email: eric.tartour@egp.aphp.fr Submitted: 11/23/11; Accepted: 11/23/11 http://dx.doi.org/10.4161/onci.18852OncoImmunology 1:3, 326 –333; May/June 2012; G2012 Landes Bioscience 326 OncoImmunology Volume 1 Issue 3",Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Nat Rev Immunol 2010; 10:490-500; PMID: 20559327; http://dx.doi.org/10.1038/nri2785 4.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Clin Cancer Res 2011; 17:841-8; PMID:21177412; http://dx.doi.org/10.1158/1078- 0432.CCR-10-2227 9.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Nat Rev Immunol 2008; 8:523-32; PMID:18566595; http://dx.doi.org/10.1038/nri2343 10.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Exp Med 2001; 194:847-54; PMID: 11560999; http://dx.doi.org/10.1084/jem.194.6.847 11.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Exp Med 2005; 202:919-29; PMID:16186184; http://dx.doi.org/10.1084/jem.20050463 12.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Annu Rev Immunol 2009; 27:485-517; PMID:19132915; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Exp Med 2007; 204:1257-65; PMID:17502665; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Immunity 2010; 32: 266-78; PMID:20137985; http://dx.doi.org/10.1016/ j.immuni.2009.11.015 15.,OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Nat Immunol 2007; 8:1353-62; PMID: 17982458; http://dx.doi.org/10.1038/ni1536 16.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Science 2008; 322:271-5; PMID:18845758; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Cancer Res 2008; 68:6350-9; PMID:18676860; http://dx.doi.org/ 10.1158/0008-5472.CAN-08-0050 18.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Blood 2006; 107:628-36; PMID: 16179369; http://dx.doi.org/10.1182/blood-2005-07-2737 www.landesbioscience.com OncoImmunology 331,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Immunother 2008; 31: 101-12; PMID:18157017; http://dx.doi.org/10.1097/ CJI.0b013e318159f5ba 20.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Blood 2005; 106:1008-11; PMID: 15840697; http://dx.doi.org/10.1182/blood-2005-02- 0607 21.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Blood 2011; 118:4853-62; PMID:21908423; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093 23.,OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Cancer Res 2009; 69:2000-9; PMID:19244125; http://dx.doi.org/10.1158/0008-5472.CAN-08-2360 24.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Cancer Res 2011; 71:5601-5; PMID:21846822; http://dx.doi.org/10.1158/0008-5472.CAN-11-1316 27.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Clin Cancer Res 2006; 12:465-72; PMID:16428488; http://dx.doi.org/10.1158/1078- 0432.CCR-05-1886 28.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Clin Oncol 2009; 27:186-92; PMID:19064967; http://dx.doi.org/10.1200/JCO.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Cancer Res 2008; 68:3907-14; PMID: 18483276; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Biomed Pharmacother 1992; 46:473-84; PMID:1306361; http://dx.doi.org/ 10.1016/0753-3322(92)90005-R32.,OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Clin Cancer Res 2008; 14:8314-20; PMID:19088050; http://dx.doi.org/10.1158/1078-0432.CCR-08-0705 33.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Nat Rev Clin Oncol 2011; 8:151-60; PMID: 21364688; http://dx.doi.org/10.1038/nrclinonc.2010.,OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Nature 1974; 249:654-6; PMID:4275846; http://dx.doi.org/10.1038/249654a0 36.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Exp Med 2005; 201:1591-602; PMID:15883172; http://dx.doi.org/ 10.1084/jem.20042167 37.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Mol Ther 2010; 18:1233-43; PMID: 20372107; http://dx.doi.org/10.1038/mt.2010.34 38.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Cancer Immunol Immunother 2007; 56:641-8; PMID:16960692; http://dx.doi.org/ 10.1007/s00262-006-0225-8 39.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Ann N Y Acad Sci 2009; 1174:99-106; PMID: 19769742; http://dx.doi.org/10.1111/j.1749-6632.,OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Blood 2008; 112:610-8; PMID:18519811; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Gut 2009; 58:1363-73; PMID:19505881; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Clin Cancer Res 2008; 14:5242-9; PMID: 18698043; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Exp Med 2004; 200:771-82; PMID:15381730; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Exp Med 2005; 202:885-91; PMID:16186187; http://dx.doi.org/10.1084/jem.20050940 47.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Blood 2005; 105: 2845-51; PMID:15591118; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Exp Med 2008; 205:825- 39; PMID:18362171; http://dx.doi.org/10.1084/jem.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Exp Med 2009; 206:1103-16; PMID:19414558; http://dx.doi.org/10.1084/jem.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Nat Rev Cancer 2007; 7:95-106; PMID:17251916; http://dx.doi.org/10.1038/nrc2051 52.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Trends Immunol 2006; 27:387-93; PMID:16814607; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Science 2005; 309:1380-4; PMID:16123302; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Clin Invest 2010; 120:1285-97; PMID:20237413; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Oncogene 2008; 27:168-80; PMID:18176598; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347 59.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Immunol 2010; 185:5150-9; PMID:20870946; http://dx.doi.org/10.4049/jimmunol.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Exp Med 2007; 204:1327-34; PMID:17548518; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Proc Natl Acad Sci USA 2008; 105:10221-6; PMID:18621704; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
PLoS ONE 2009; 4:e8084; PMID:20011659; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Nat Rev Cancer 2007; 7:880-7; PMID:17957190; http://dx.doi.org/10.1038/nrc2250 66.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Cancer Res 2010; 70:490-500; PMID:20068181; http://dx.doi.org/10.1158/0008- 5472.CAN-09-1890 68.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Cancer Metastasis Rev 2011; 30:83-95; PMID:21249423; http://dx.doi.org/10.1007/s10555-011-9281-4 69.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Clin Cancer Res 2008; 14:6674- 82; PMID:18927310; http://dx.doi.org/10.1158/ 1078-0432.CCR-07-5212 70.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
J Immunother 2010; 33:991-8; PMID:20948437; http://dx.doi.org/10.1097/CJI.0b013e3181f4c208 71.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Blood 2008; 111:5610-20; PMID: 18310500; http://dx.doi.org/10.1182/blood-2007-02- 075945 72.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Eur J Cancer 2011; 47:690-6; PMID:21215610; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Eur J Immunol 2010; 40:197-203; PMID:19902430; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Nat Med 2011; 17:1094-100; PMID:21873989; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Cancer Immunol Immunother 2009; 58:1627-34; PMID:19221744; http://dx.doi.org/10.1007/s00262-009-0671-1 80.,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
Nat Med 2011; 17:700-7; PMID:21552268; http://dx.doi.org/10.1038/nm.2366 www.landesbioscience.com OncoImmunology 333,Non-OADS,/arxiv_data1/oa_pdf/83/f2/onci-1-326.PMC3382865.pdf
"Similar results were achieved with *Correspondence to: Ricky W. Johnstone; Email: ricky.johnstone@petermac.org Submitted: 11/16/11; Revised: 11/18/11; Accepted: 11/18/11 http://dx.doi.org/10.4161/onci.18804OncoImmunology 1:3, 37 378; May/June 2012; G2012 Landes Bioscience 6 6 6 –   66 376 OncoImmunology Volume 1 Issue 3",Non-OADS,/arxiv_data1/oa_pdf/9b/56/onci-1-377.PMC3382866.pdf
Cancer Chemother Pharmacol 2010; 66:611-6; PMID: 20221600; http://dx.doi.org/10.1007/s00280-010- 1302-4 378 OncoImmunology Volume 1 Issue 3,Non-OADS,/arxiv_data1/oa_pdf/9b/56/onci-1-377.PMC3382866.pdf
"*Correspondence to: Andrew R. Green; Email: andrew.green@nottingham.ac.uk Submitted: 10/17/11; Accepted: 10/31/11 http://dx.doi.org/10.4161/onci.18614AUTHOR'S VIEW OncoImmunology 1:3, 363 –364; May/June 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 363",Non-OADS,/arxiv_data1/oa_pdf/94/8a/onci-1-364.PMC3382867.pdf
Nat Immunol 2002; 3:991-8; PMID: 12407406; http://dx.doi.org/10.1038/ni1102-991 2.,Non-OADS,/arxiv_data1/oa_pdf/94/8a/onci-1-364.PMC3382867.pdf
J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037 3.,Non-OADS,/arxiv_data1/oa_pdf/94/8a/onci-1-364.PMC3382867.pdf
Science 2006; 313: 1960-4; PMID:17008531; http://dx.doi.org/10.1126/ science.1129139 4.,OADS,/arxiv_data1/oa_pdf/94/8a/onci-1-364.PMC3382867.pdf
Genome Biol 2007; 8: R157; PMID:17683518; http://dx.doi.org/10.1186/ gb-2007-8-8-r1578.,OADS,/arxiv_data1/oa_pdf/94/8a/onci-1-364.PMC3382867.pdf
Breast Cancer Res 2009; 11:R15; PMID:19272155; http://dx.doi.org/10.1186/ bcr2234 9.,Non-OADS,/arxiv_data1/oa_pdf/94/8a/onci-1-364.PMC3382867.pdf
PMID:21671016; http://dx.doi.org/10.1007/s10549-011-1620-1 10.,Non-OADS,/arxiv_data1/oa_pdf/94/8a/onci-1-364.PMC3382867.pdf
Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013 Figure 1.,OADS,/arxiv_data1/oa_pdf/94/8a/onci-1-364.PMC3382867.pdf
"One presumes this is due to elevated ALDH1A1 expression in these Correspondence to: Albert B. DeLeo; Email: deleoab@gmail.com Submitted: 11/17/11; Revised: 11/21/11/; Accepted: 11/21/11 http://dx.doi.org/10.4161/onci.18826OncoImmunology 1:3, 38 386; May/June 2012; G2012 Landes Bioscience   4 –4 384 OncoImmunology Volume 1 Issue 3",Non-OADS,/arxiv_data1/oa_pdf/c7/33/onci-1-385.PMC3382868.pdf
Nature 2011; 469:314-22; PMID:21248838; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/c7/33/onci-1-385.PMC3382868.pdf
Proc Natl Acad Sci USA 1999; 96:9118-23; PMID:10430905; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/c7/33/onci-1-385.PMC3382868.pdf
Cancer Res 2007; 67:10538-45; PMID:17974998; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/c7/33/onci-1-385.PMC3382868.pdf
Cancer Res 2005; 65:8944-50; PMID:16204067; http://dx.doi.org/10.1158/0008- 5472.CAN-05-0931 6.,Non-OADS,/arxiv_data1/oa_pdf/c7/33/onci-1-385.PMC3382868.pdf
Cell Stem Cell 2007; 1:555-67; PMID:18371393; http://dx.doi.org/ 10.1016/j.stem.2007.08.014 7.,OADS,/arxiv_data1/oa_pdf/c7/33/onci-1-385.PMC3382868.pdf
Clin Cancer Res 2011; 17:6174-84; PMID:21856769; http://dx.doi.org/10.1158/1078- 0432.CCR-11-11118.,Non-OADS,/arxiv_data1/oa_pdf/c7/33/onci-1-385.PMC3382868.pdf
Clin Immunol 2010; 137:221-33; PMID:20708974; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/c7/33/onci-1-385.PMC3382868.pdf
J Clin Oncol 2010; 28:4006-12; PMID:20498387; http://dx.doi.org/10.1200/JCO.2009.27.5388 386 OncoImmunology Volume 1 Issue 3,Non-OADS,/arxiv_data1/oa_pdf/c7/33/onci-1-385.PMC3382868.pdf
"Breaking the tolerance for tumor Targeting negative regulators of TLR signaling Theodore J. Standiford and Venkateshwar G. Keshamouni* Division of Pulmonary and Critical Care Medicine; Department of Internal Medicine; University of Michigan Medical Center; Ann Arbor, MI USA Keywords: tumor tolerance, immunoediting, immunosurveilance, toll-like receptors, IRAK-M, TGF β Abbreviations: TLR, toll-like receptors; sTLR, soluble TLR; sMyD88, short form of MyD88; IRAK, interleukin-1 receptor- associated kinase; TGF, transforming growth factor; NF kB, nuclear factor kappa B; PAMP, pathogen associated molecular pattern; DAMP, danger associated molecular pattern; TNF, tumor necrosis factor; LPS, lipopolysacharide; NOD, nucleotide-binding oligomerization domain protein; SOCS, suppressor of cytokine signaling; TOLLIP, toll- interacting protein; FADD, Fas-associated death domain; TRAF, tumor necrosis factor associated factor; PI3K, phosphotidylinositol 3-kinase; SIGGIR, single immunoglobulin interleukin-1- related receptor; TRAILR, tumor necrosis factor-related apoptosis inducing ligand receptor; TRIF, toll/IL-1 receptor-domain containing adaptor protein inducing IFNβ; TRAM, TRIF-related adaptor molecule; LLC, Lewis lung carcinoma Submitted: 10/03/11 Accepted: 10/16/11 http://dx.doi.org/10.4161/onci.18434 *Correspondence to: Venkateshwar G. Keshamouni; Email: vkeshamo@med.umich.eduTumors arise and progress in immu- nocompetent hosts presumably by activating tolerance mechanisms critical for normal homeostasis.",Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Annu Rev Immunol 2011; 29:235-71; PMID: 21219185; http://dx.doi.org/10.1146/annurev-immunol- 031210-101324 2.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Nat Rev Immunol 2005; 5:446-58; PMID: 15928677; http://dx.doi.org/10.1038/nri1630 3.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Oncogene 2011; 30:2475-84; PMID: 21278795; http://dx.doi.org/10.1038/onc.2010.619 4.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Nat Rev Immunol 2004; 4:499-511; PMID:15229469; http://dx.doi.org/10.1038/nri1391 5.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Scand J Infect Dis 2003; 35: 555-62; PMID:14620134; http://dx.doi.org/10.1080/ 00365540310015683 6.,OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Semin Cancer Biol 2006; 16:38-52; PMID:16139507; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Annu Rev Immunol 2003; 21:807-39; PMID:12615893; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Cell Mol Immunol 2011; 8:388-403; PMID:21822296; http://dx.doi.org/ 10.1038/cmi.2011.26 10.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
J Exp Med 2003; 197:263-8; PMID: 12538665; http://dx.doi.org/10.1084/jem.20021790 13.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Nat Immunol 2004; 5:1052-60; PMID: 15334086; http://dx.doi.org/10.1038/ni1110 16.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Nat Immunol 2004; 5:800-8; PMID:15220916; http://dx.doi.org/10.1038/ni1092 17.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Nat Immunol 2002; 3:875-81; PMID:12154357; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Immunity 2002; 17:583-91; PMID:12433365; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
J Biol Chem 2002; 277:7059-65; PMID:11751856; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Mol Cell Biol 2007; 27:7394-404; PMID:17785432; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
J Biol Chem 2004; 279:27699- 708; PMID:15082713; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Cell 2002; 110:191-202; PMID:12150927; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Nat Immunol 2004; 5:373-9; PMID:15004556; http://dx.doi.org/10.1038/ ni1050 24.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Nat Immunol 2003; 4:920-7; PMID:12925853; http://dx.doi.org/10.1038/ ni968 25.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
Immunity 2004; 21:877-89; PMID:15589175; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/onci-1-340.PMC3382869.pdf
"Since the mean tissue concentration in TDO-expressing tumors was 37 mM and since concentrations of up to 60 mM were measured in the cell culture supernatant of TDO-expressing tumors Kyn-production in gliomas is within a relevant range to activate the AHR.7There are three central questions that need to be addressed: (1) Is the AHR the sole mediator of immunosup- pressive Trp catabolism in the tumor microenvironment, (2) what are the cel- lular determinants of AHR-mediated *Correspondence to: Michael Platten; Email: m.platten@dkfz.de Submitted: 12/14/11; Accepted: 12/14/11 http://dx.doi.org/10.4161/onci.19071OncoImmunology 1:3, 39 396; May/June 2012; G2012 Landes Bioscience   –5AUTHOR'S VIEW www.landesbioscience.com OncoImmunology 395",Non-OADS,/arxiv_data1/oa_pdf/f8/bd/onci-1-396.PMC3382870.pdf
Annu Rev Pharmacol Toxicol 2003; 43:309-34; PMID:12540743; http://dx.doi.org/ 10.1146/annurev.pharmtox.43.100901.135828 2.,Non-OADS,/arxiv_data1/oa_pdf/f8/bd/onci-1-396.PMC3382870.pdf
Nature 2008; 453: 106-9; PMID:18362914; http://dx.doi.org/10.1038/ nature06881 4.,Non-OADS,/arxiv_data1/oa_pdf/f8/bd/onci-1-396.PMC3382870.pdf
J Immunol 2010; 185: 3190-8; PMID:20720200; http://dx.doi.org/10.4049/ jimmunol.0903670 7.,Non-OADS,/arxiv_data1/oa_pdf/f8/bd/onci-1-396.PMC3382870.pdf
Nature 2011; 478:197-203; PMID:21976023; http://dx.doi.org/10.1038/nature10491 8.,Non-OADS,/arxiv_data1/oa_pdf/f8/bd/onci-1-396.PMC3382870.pdf
Nat Med 2005; 11:312-9; PMID: 15711557; http://dx.doi.org/10.1038/nm11969.,OADS,/arxiv_data1/oa_pdf/f8/bd/onci-1-396.PMC3382870.pdf
Nat Med 2003; 9:1269-74; PMID:14502282; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/f8/bd/onci-1-396.PMC3382870.pdf
Biochem Biophys Res Commun 2001; 289:499-506; PMID:11716501; http://dx.doi.org/10.1006/bbrc.,OADS,/arxiv_data1/oa_pdf/f8/bd/onci-1-396.PMC3382870.pdf
"The clinical development paths of both agents have contributed to define and to demonstrate the practical value of the new development paradigm.4 Here we provide a perspective on the recent lessons in the immunotherapy space and summarize the emerging framework*Correspondence to: Axel Hoos; Email: axel.hoos@cri-cic.org Submitted: 09/30/11; Accepted: 01/06/12 http://dx.doi.org/10.4161/onci.19268OncoImmunology 1:3, 334 –339; May/June 2012; G2012 Landes Bioscience 334 OncoImmunology Volume 1 Issue 3",Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Nat Rev Drug Discov 2011; 10:591-600; PMID:21804596; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Immunol Cell Biol 2003; 81:106-13; PMID:12631233; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Nat Biotechnol 2009; 27:129-39; PMID: 19204689; http://dx.doi.org/10.1038/nbt0209-129 4.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Nat Biotechnol 2011; 29:867-70; PMID:21997622; http://dx.doi.org/ 10.1038/nbt.2000 5.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Vaccine 2007; 25(Suppl 2): B97-109; PMID:17916465; http://dx.doi.org/10.1016/ j.vaccine.2007.06.067 7.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
"Cancer Immunol Immunother 2008; 57:285-8; PMID: 17721782; http://dx.doi.org/10.1007/s00262-007-0379-z 8. van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, et al.. Harmonization of immune biomarker assays for clinical studies.",OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
J Natl Cancer Inst 2010; 102: 1388-97; PMID:20826737; http://dx.doi.org/10.1093/ jnci/djq310 10.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078- 0432.CCR-09-1624 11.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Immunity 2009; 31:527-8; PMID: 19833080; http://dx.doi.org/10.1016/j.immuni.2009.,OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Cancer Immunol Immunother 2011; 60:15-22; PMID: 21080166; http://dx.doi.org/10.1007/s00262-010-0940-z 13.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, September 2009. http://www.fda.gov/ downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/ Guidances/Vaccines/UCM182826.pdf.",OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
N Engl J Med 2010; 363:411-22; PMID: 20818862; http://dx.doi.org/10.1056/NEJMoa1001294 16.,OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466 17.,OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Semin Oncol 2010; 37:533-46; PMID:21074069; http://dx.doi.org/10.1053/j.seminoncol.2010.09.015 18.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Cell 2000; 100:57-70; PMID:10647931; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013 20.,OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Nat Immunol 2002; 3:991-8; PMID: 12407406; http://dx.doi.org/10.1038/ni1102-991 21.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Eur J Cancer 2009; 45:228-47; PMID: 19097774; http://dx.doi.org/10.1016/j.ejca.2008.10.026 24.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Clin Cancer Res 2009; 15:7116-8; PMID:19934296; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
"Int J Cancer 2005; 117:596-604; PMID:15945101; http://dx.doi.org/10.1002/ijc.21264 26. van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, et al.",OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
J Clin Oncol 2005; 23:9008-21; PMID:16061912; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Cancer Immunol Immunother 2008; 57:303-15; PMID:17721781; http://dx.doi.org/10.1007/s00262-007-0380-6 29.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Cancer Immunol Immunother 2008; 57:289-302; PMID:17721783; http://dx.doi.org/10.1007/s00262-007-0378-030.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Cancer Immunol Immunother 2009; 58:1701-13; PMID:19259668; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
J Transl Med 2011; 9:108; PMID: 21745365; http://dx.doi.org/10.1186/1479-5876-9-108 32.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Cancer Immunol Immunother 2010; 59:619-27; PMID:20052465; http://dx.doi.org/10.1007/s00262-009-0814-4 33.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Cancer Immunol Immunother 2010; 59:1489-501; PMID:20549207; http://dx.doi.org/10.1007/s00262-010-0875-4 34.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Methods Mol Biol 2012; 792:25-36; PMID:21956498; http://dx.doi.org/ 10.1007/978-1-61779-325-7_2 35.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
1996. http://www.ich.org/ fileadmin/Public_Web_Site/ICH_Products/Guidelines/ Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Expert Rev Vaccines 2008; 7:1-5; PMID:18251686; http://dx.doi.org/10.1586/14760584.7.1.1 37.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
Nat Biotechnol 2008; 26:889-96; PMID:18688244; http://dx.doi.org/ 10.1038/nbt.1411 38.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
"July 22, 2009. http://www.bms.com/news/ press_releases/pages/default.aspx.",Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
N Engl J Med 2008; 358:2704-15; PMID:18565863; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
J Clin Oncol 2003; 21:2415-32; PMID:12805342; http://dx.doi.org/10.1200/JCO.2003.,Non-OADS,/arxiv_data1/oa_pdf/7a/06/onci-1-334.PMC3382871.pdf
"Carmine Stolfi,1,* Francesco Pallone,1Thomas T. Macdonald2and Giovanni Monteleone1,* 1Department of Internal Medicine; University of Tor Vergata; Rome, Italy;2Centre for Immunology and Infectious Disease; Blizard Institute; Barts and the London School of Medicine and Dentistry; London, UK Keywords: colitis-associated colon cancer, STAT3, IL-6, Tregs, IL-17A Submitted: 12/09/11 Revised: 12/15/11 Accepted: 12/19/11 http://dx.doi.org/10.4161/onci.19122 *Correspondence to: Carmine Stolfi and Giovanni Monteleone; Email: carmine.stolfi@uniroma2.it and gi.monteleone@med.uniroma2.itInterleukin (IL)-21, a cytokine pro- duced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney.",Non-OADS,/arxiv_data1/oa_pdf/1a/84/onci-1-351.PMC3382872.pdf
Mutat Res 2008; 659:15-30; PMID: 18485806; http://dx.doi.org/10.1016/j.mrrev.2008.,OADS,/arxiv_data1/oa_pdf/1a/84/onci-1-351.PMC3382872.pdf
J Invest Dermatol 2005; 124:x-xiv; PMID: 15955081; http://dx.doi.org/10.1111/j.0022-202X.,Non-OADS,/arxiv_data1/oa_pdf/1a/84/onci-1-351.PMC3382872.pdf
Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/10.1016/j.cell.,OADS,/arxiv_data1/oa_pdf/1a/84/onci-1-351.PMC3382872.pdf
Cancer Metastasis Rev 2006; 25:315-22; PMID:16967326; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1a/84/onci-1-351.PMC3382872.pdf
Tissue Antigens 2009; 74:467-79; PMID:19845910; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/1a/84/onci-1-351.PMC3382872.pdf
J Exp Med 2011; 208:2279-90; PMID:21987656; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1a/84/onci-1-351.PMC3382872.pdf
Gut 2011; 60:1678- 86; PMID:21948944; http://dx.doi.org/10.1136/ gutjnl-2011-3006129.,Non-OADS,/arxiv_data1/oa_pdf/1a/84/onci-1-351.PMC3382872.pdf
Cancer Res 2005; 65:3998-4004; PMID:15899788; http://dx.doi.org/10.1158/0008-5472.CAN-04-3104 354 OncoImmunology Volume 1 Issue 3,Non-OADS,/arxiv_data1/oa_pdf/1a/84/onci-1-351.PMC3382872.pdf
"Cyto- fluorometric analyses revealed that the vast majority ( .90%) of the CD39-trans- duced cells expressed CD39 at the surface, while control cells lacked detectable CD39 expression.10We then assessed the effect of *Correspondence to: Guido Kroemer; Email: kroemer@orange.fr Submitted: 12/13/11; Accepted: 12/14/11 http://dx.doi.org/10.4161/onci.19070OncoImmunology 1:3, 39 394; May/June 2012; G2012 Landes Bioscience   –2 392 OncoImmunology Volume 1 Issue 3",Non-OADS,/arxiv_data1/oa_pdf/d5/d0/onci-1-393.PMC3382873.pdf
Oncogene 2010; 29:5346-58; PMID:20661219; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/d5/d0/onci-1-393.PMC3382873.pdf
J Pharmacol Exp Ther 2003; 305:9-16; PMID: 12649347; http://dx.doi.org/10.1124/jpet.102.043729 3.,Non-OADS,/arxiv_data1/oa_pdf/d5/d0/onci-1-393.PMC3382873.pdf
Clin Cancer Res 2009; 15:6348-57; PMID:19825957; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d5/d0/onci-1-393.PMC3382873.pdf
Clin Lymphoma Myeloma Leuk 2011; 11:367-72; PMID: 21816376; http://dx.doi.org/10.1016/j.clml.2011.06.,Non-OADS,/arxiv_data1/oa_pdf/d5/d0/onci-1-393.PMC3382873.pdf
Gastroenterology 2010; 139:1030-40; PMID:20546740; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d5/d0/onci-1-393.PMC3382873.pdf
J Immunol 2011; 187:676-83; PMID:21677139; http://dx.doi.org/10.4049/jimmunol.10038847.,Non-OADS,/arxiv_data1/oa_pdf/d5/d0/onci-1-393.PMC3382873.pdf
Nat Rev Clin Oncol 2011; 8:151-60; PMID: 21364688; http://dx.doi.org/10.1038/nrclinonc.2010.,OADS,/arxiv_data1/oa_pdf/d5/d0/onci-1-393.PMC3382873.pdf
Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d5/d0/onci-1-393.PMC3382873.pdf
Cell Cycle 2009; 8: 3723-8; PMID:19855167; http://dx.doi.org/10.4161/ cc.8.22.10026 10.,Non-OADS,/arxiv_data1/oa_pdf/d5/d0/onci-1-393.PMC3382873.pdf
"*Correspondence to: Federica Cavallo; Email: federica.cavallo@unito.it Submitted: 12/20/11; Accepted: 12/20/11 http://dx.doi.org/10.4161/onci.19127OncoImmunology 1:3, 316 –325; May/June 2012; G2012 Landes Bioscience 316 OncoImmunology Volume 1 Issue 3",Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Immunol Today 1997; 18:32-6; PMID:9018972; http://dx.doi.org/10.1016/S0167-5699(97)80012-6 3.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Proc Natl Acad Sci U S A 1982; 79:4718-22; PMID:6981814; http://dx.doi.org/ 10.1073/pnas.79.15.47184.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Nat Rev Cancer 2008; 8:108-20; PMID: 18219306; http://dx.doi.org/10.1038/nrc2326 6.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Immunol Immunother 2008; 57:1711-7; PMID:18273615; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Science 1998; 282:476-80; PMID:9774275; http://dx.doi.org/10.1126/science.282.5388.476 10.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Vaccine 2001; 19:3301-10; PMID: 11312029; http://dx.doi.org/10.1016/S0264-410X (00)00432-1 13.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Proc Natl Acad Sci U S A 1993; 90: 11478-82; PMID:8265577; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Nat Med 2005; 11:899-904; PMID:15965482; http://dx.doi.org/10.1038/nm1264 16.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Curr Gene Ther 2011; 11:447-56; PMID:22023474; http://dx.doi.org/10.2174/156652311798192860 19.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Gene Ther 2008; 15:108-14; PMID:17992201; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Hum Gene Ther 2009; 20:1269- 78; PMID:19619001; http://dx.doi.org/10.1089/hum.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Ann Surg Oncol 2008; 15:2215-22; PMID:18498012; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancers 2011; 3:3225-41; http://dx.doi.org/10.3390/ cancers3033225 23.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Res 2004; 64:2858-64; PMID: 15087404; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Gene Ther 2000; 7:703-6; PMID:10800094; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Vaccine 2005; 23:3280-7; PMID:15837233; http://dx.doi.org/10.1016/j.vaccine.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Clin Cancer Res 2008; 14:3044-51; PMID:18483370; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Res 2007; 67:6425-32; PMID:17616703; http://dx.doi.org/10.1158/0008-5472.CAN-06-4080 29.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Mol Ther 2011; 19:594-601; PMID:21157438; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Gene Ther 2001; 8:447-52; PMID:11313823; http://dx.doi.org/ 10.1038/sj.gt.3301416 32.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
J Exp Med 2001; 194:1195-205; PMID: 11696586; http://dx.doi.org/10.1084/jem.194.9.1195 33.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Res 2004; 64:4001-9; PMID:15173014; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Hum Gene Ther 2009; 20:453-64; PMID:19215191; http://dx.doi.org/10.1089/hum.2008.172 35.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
J Virol 2001; 75:10421- 30; PMID:11581410; http://dx.doi.org/10.1128/JVI.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
J Mol Med (Berl) 2011; 89:1231-40; PMID:21845448; http://dx.doi.org/10.1007/s00109- 011-0794-7 40.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Clin Cancer Res 2008; 14:6933-43; PMID:18980988; http://dx.doi.org/10.1158/1078-0432.CCR-08-1257 41.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Hum Gene Ther 2008; 19:229-40; PMID:18269312; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Res 2006; 66:7734-40; PMID:16885376; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
J Immunol 2010; 184:6124-32; PMID:20435927; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
PMID:22121024; http://dx.doi.org/10.1038/ nature10664 45.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Res 2010; 70:2604-12; PMID:20332241; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cell Immunol 2006; 240:96-106; PMID: 16930573; http://dx.doi.org/10.1016/j.cellimm.2006.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Res 2010; 70:119-28; PMID:20048073; http://dx.doi.org/ 10.1158/0008-5472.CAN-09-2554 48.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Nat Immunol 2002; 3:991-8; PMID: 12407406; http://dx.doi.org/10.1038/ni1102-991 49.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Res 2006; 66:6387-94; PMID:16778217; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Immunol Immunother 2011; 60:319-26; PMID: 21267721; http://dx.doi.org/10.1007/s00262-010- 0968-0 52.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Curr Drug Targets 2011; 12:1957-73; PMID:21158706; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Immunol Immunother 2008; 57:1685-94; PMID:18286283; http://dx.doi.org/10.1007/s00262-008-0481-x 54.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Proc Natl Acad Sci U S A 2006; 103:9208-13; PMID:16754857; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Nat Med 2008; 14:676-80; PMID:18469826; http://dx.doi.org/10.1038/nm176958.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Nat Rev Cancer 2006; 6:204- 16; PMID:16498443; http://dx.doi.org/10.1038/ nrc1815 59.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Immunol Immunother 2011; 60:319-26; PMID:21267721; http://dx.doi.org/10.1007/s00262- 010-0968-0 61.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Nat Rev Immunol 2007; 7:118-30; PMID:17259968; http://dx.doi.org/ 10.1038/nri2017 63.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Math Mod Meth Appl Sci 2006; 16:1091-1124; http://dx.doi.org/10.1142/ S0218202506001479 66.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Adv Immunol 2006; 90:175- 213; PMID:16730264; http://dx.doi.org/10.1016/ S0065-2776(06)90005-467.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Immunol Immunother 2008; 57:907-12; PMID:18004566; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Clin Cancer Res 2005; 11:1941-52; PMID: 15756020; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Vet J 2011; 190:e26- 30; PMID:21482159; http://dx.doi.org/10.1016/j.tvjl.,OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
Cancer Immunol Immunother 2011; 60:1147-51; PMID: 21644035; http://dx.doi.org/10.1007/s00262-011- 1042-2 www.landesbioscience.com OncoImmunology 325,Non-OADS,/arxiv_data1/oa_pdf/14/44/onci-1-316.PMC3382874.pdf
"One well known signal for engulfment by phagocyting cells is a change in the composition of phospholipids on the target cells.13 Furthermore, the interaction of calreticulin with the low-density lipoprotein-related protein (LRP) plays also an important role in apoptotic cell removal, resulting in an activation of the macrophages.14Calreticulin is an intracellular calcium-binding protein and anthracyclines are able to elicit it ’s translocation onto the cell surface.15On the other hand, the interaction between CD47 and the signal regulatory protein a(SIRP a) is a key function to protect viable cells from phagocytosis.16CD47, a widely distributed inhibitory receptor on macrophages that can *Correspondence to: Sorin Armeanu-Ebinger; Email: sorin.armeanu-ebinger@med.uni-tuebingen.de Submitted: 07/25/11; Revised: 10/27/11; Accepted: 10/31/11 http://dx.doi.org/10.4161/onci.18612RESEARCH PAPER OncoImmunology 1:3, 279 –286; May/June 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 279",Non-OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Arch Dis Child 2003; 88:354-7; PMID: 12651771; http://dx.doi.org/10.1136/adc.88.4.354 3.,Non-OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
J Pathol 2002; 196: 254-65; PMID:11857487; http://dx.doi.org/10.1002/ path.10277.,OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Crit Rev Oncol Hematol 2002; 44:143-61; PMID:12413632; http://dx.doi.org/10.1016/S1040- 8428(01)00203-7 8.,Non-OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Cell Immunol 1991; 135:78-87; PMID:1708310; http://dx.doi.org/ 10.1016/0008-8749(91)90255-A 13.,Non-OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Nat Cell Biol 2005; 7:1061-3; PMID:16319968; http://dx.doi.org/10.1038/ncb1205-1061 15.,OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
J Leukoc Biol 2006; 79:896-903; PMID:16641135; http://dx.doi.org/10.1189/jlb.1005550 17.,Non-OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Trends Immunol 2010; 31:212-9; PMID:20452821; http://dx.doi.org/10.1016/j.it.2010.04.001 www.landesbioscience.com OncoImmunology 285,OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Sci Transl Med 2010; 2:63ra94; PMID:21178137; http://dx.doi.org/ 10.1126/scitranslmed.3001375 19.,Non-OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Sci Transl Med 2010; 2:63ra94; PMID:21178137; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Cell 2009; 138:286-99; PMID:19632179; http://dx.doi.org/10.1016/j.cell.2009.,OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Cell 2010; 142:699-713; PMID:20813259; http://dx.doi.org/10.1016/j.cell.2010.,OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Curr Opin Immunol 2007; 19:239-45; PMID:17291742; http://dx.doi.org/10.1016/j.coi.2007.,OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Leuk Res 2005; 29:445-50; PMID:15725479; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Biochem Biophys Res Commun 2004; 315:912-8; PMID:14985099; http://dx.doi.org/10.1016/j.bbrc.2004.01.128 27.,OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Nat Med 1999; 5:1277-84; PMID:10545994; http://dx.doi.org/10.1038/15233 28.,Non-OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Blood 2006; 107:2548-56; PMID:16291597; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
"J Cell Biochem 1997; 66:98-111; PMID: 9215532; http://dx.doi.org/10.1002/(SICI)1097-4644 (19970701)66:1 ,98::AID-JCB11 .3.0.CO;2-9 34.",Non-OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
Int J Oncol 2011; 38:993-1000; PMID: 21271214; http://dx.doi.org/10.3892/ijo.2011.921 35.,OADS,/arxiv_data1/oa_pdf/10/6b/onci-1-279.PMC3382875.pdf
"  OncoImmunology 1:3, 358-360; May/June 2012; © 2012 Landes Bioscience EDITOR’S CA ORNER Immune modulation by molecular cancer targets  and targeted therapies Rationale for novel combination strategies Claudia Rossig Department of Pediatric Hematology and Oncology; University Children’s Hospital Muenster; Muenster, Germany Keywords:  molecular targeted therapies, NK cells, immune escape, microenvironment, immunotherapy Correspondence to: Claudia Rossig; Email: rossig@uni-muenster.de Submitted: 10/10/11; Accepted: 10/13/11 http://dx.doi.org/10.4161/onci.18401Following our recent observation that alterations of the Natural Killer ( NK) cell compartment in the presence of B CR- ABLinduced myeloproliferation fail to revert under targeted therapy, we discuss by what mechanisms oncogenic  molecular pathways and their pharmacological inhibition may interfere with immune functions.",Non-OADS,/arxiv_data1/oa_pdf/23/7c/onci-1-358.PMC3382876.pdf
Clin Cancer Res 2009; 15:7330-4; PMID:19934297; http://dx.doi.org/10.1158/1078-0432.CCR-09-1720 3.,Non-OADS,/arxiv_data1/oa_pdf/23/7c/onci-1-358.PMC3382876.pdf
Leukemia 2011; PMID: 21904381; http://dx.doi.org/10.1038/leu.2011.239 4.,Non-OADS,/arxiv_data1/oa_pdf/23/7c/onci-1-358.PMC3382876.pdf
N Engl J Med 2001; 344:1031-7; PMID:11287972; http://dx.doi.org/10.1056/NEJM2001040534414015.,OADS,/arxiv_data1/oa_pdf/23/7c/onci-1-358.PMC3382876.pdf
Cancer Res 2010; 70:9538-43; PMID:21098713; http://dx.doi.org/10.1158/0008-5472.CAN-10-1003 6.,Non-OADS,/arxiv_data1/oa_pdf/23/7c/onci-1-358.PMC3382876.pdf
Nat Med 2011; 17:1094-100; PMID:21873989; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/23/7c/onci-1-358.PMC3382876.pdf
Cancer Res 2007; 67:5489-97; PMID:17545631; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/23/7c/onci-1-358.PMC3382876.pdf
Blood 2011; 118:3657-60; PMID:21791426; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/23/7c/onci-1-358.PMC3382876.pdf
Cancer Cell 2010; 18:485-98; PMID:21035406; http://dx.doi.org/10.1016/j.ccr.2010.10.002 360 OncoImmunology Volume 1 Issue 3,Non-OADS,/arxiv_data1/oa_pdf/23/7c/onci-1-358.PMC3382876.pdf
"Revisiting the role of T cells in tumor regression Nadège Bercovici1,2,3and Alain Trautmann1,2,3 1Inserm; U1016; Institut Cochin; Paris, France;2CNRS; UMR8104; Paris, France;3Univ Paris Descartes; Paris, France Keywords: T lymphocytes, tumor regression, stroma, innate cells, kinetics, immunotherapy Abbreviations: TIL, tumor-infiltrating lymphocytes Submitted: 11/04/11 Revised: 11/17/11 Accepted: 11/17/11 http://dx.doi.org/10.4161/onci.18800 Correspondence to: Nadège Bercovici and Alain Trautmann; Email: nadege.bercovici@inserm.fr and alain.trautmann@inserm.frThis note challenges the current idea that a key role of T cells in tumor regression is to directly kill tumor cells.",Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Cancer Res 2006; 66:4913-21; PMID:16651448; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449 4.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Eur J Immunol 2006; 36:468- 77; PMID:16385625; http://dx.doi.org/10.1002/eji.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
J Clin Invest 2008; 118:1390-7; PMID:18357341; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Proc Natl Acad Sci USA 2003; 100:4712-7; PMID:12682289; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Cancer Sci 2003; 94:1003-9; PMID:14611679; http://dx.doi.org/10.1111/j.1349- 7006.2003.tb01392.x 11.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Clin Cancer Res 2008; 14: 5220-7; PMID:18698040; http://dx.doi.org/10.1158/ 1078-0432.CCR-08-0133 13.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Cancer 2008; 112:863-75; PMID: 18203207; http://dx.doi.org/10.1002/cncr.23239 14.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
J Immunol 2009; 182:5789-99; PMID:19380827; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Nat Rev Immunol 2006; 6:173-82; PMID:16498448; http://dx.doi.org/10.1038/nri1785 18.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Curr Top Microbiol Immunol 2006; 298:157-74; PMID:16323415; http://dx.doi.org/10.1007/3-540- 27743-9_8 19.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Immunity 2000; 12:677-86; PMID:10894167; http://dx.doi.org/10.1016/S1074- 7613(00)80218-6 21.,OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
J Clin Invest 2008; 118:1691-9; PMID:18398504; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Immunity 2005; 23:53-63; PMID: 16039579; http://dx.doi.org/10.1016/j.immuni.2005.,OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Annu Rev Immunol 2006; 24:175-208; PMID: 16551247; http://dx.doi.org/10.1146/annurev.immunol.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx.doi.org/10.1016/S1471- 4906(02)02302-5 27.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Urol Oncol 2008; 26:341-5; PMID: 18593617; http://dx.doi.org/10.1016/j.urolonc.2007.,OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Cancer Res 2004; 64:3386-90; PMID:15150089; http://dx.doi.org/10.1158/0008-5472.CAN-04-0374 29.,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
Int J Cancer 2010; 126:1666-74; PMID:19830696; http://dx.doi.org/http://dx.doi.org/10.1002/ijc.24961 350 OncoImmunology Volume 1 Issue 3,Non-OADS,/arxiv_data1/oa_pdf/23/40/onci-1-346.PMC3382877.pdf
"*Correspondence to: Guido Kroemer; Email: kroemer@orange.fr Submitted: 03/19/12; Accepted: 03/20/12 http://dx.doi.org/10.4161/onci.20074EDITOR'S CORNER OncoImmunology 1:4, 407– 408; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 407",Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
Br J Radiol 1953; 26:234-41; PMID: 13042090; http://dx.doi.org/10.1259/0007-1285-26- 305-234 2.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
Br J Radiol 1975;48:863-6; PMID:811297; http://dx.doi.org/10.1259/0007-1285-48-574-863 3.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
ClinRadiol 1981; 32:475-80; PMID:7249526; http://dx.doi.org/10.1016/S0009-9260(81)80310-8 4.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
Br J Radiol 1983;56:63-6; PMID:6185172; http://dx.doi.org/10.1259/0007-1285-56-661-63 5.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
Gut1998; 43:575-7; PMID:9824589; http://dx.doi.org/ 10.1136/gut.43.4.575 6.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
Arch Dermatol 2011; 147:870-2; PMID:21768497; http://dx.doi.org/10.1001/archdermatol.2011.176 7.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
Am J Gastroenterol 2008; 103:1320-1; PMID:18477367; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
ClinCancer Res 2008; 14:1159-66; PMID:18281550; http://dx.doi.org/10.1158/1078-0432.CCR-07-4485 10.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
J Clin Oncol 2010; 28:4324-32; PMID: 20697067; http://dx.doi.org/10.1200/JCO.2010.28.9793 11.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
Clin Cancer Res 2009; 15:5379-88; PMID:19706802; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
Cell Death Differ 2007; 14:1848-50; PMID:17657249; http://dx.doi.org/10.1038/sj.cdd.440220113.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
Clin Cancer Res 2007; 13:1493-502; PMID:17332294; http://dx.doi.org/10.1158/1078-0432.CCR-06-1772 15.,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824 408 OncoImmunology Volume 1 Issue 4,Non-OADS,/arxiv_data1/oa_pdf/5b/93/onci-1-407.PMC3382878.pdf
"To test the hypothesis that G-CSF production and the *Correspondence to: Scott I. Abrams; Email: scott.abrams@roswellpark.org Submitted: 01/08/12; Accepted: 01/12/12 http://dx.doi.org/10.4161/onci.19334OncoImmunology 1:4, 550– 551; July 2012; G2012 Landes Bioscience 550 OncoImmunology Volume 1 Issue 4",Non-OADS,/arxiv_data1/oa_pdf/da/e0/onci-1-550.PMC3382879.pdf
Cell 2011; 144:646-74; PMID: 21376230; http://dx.doi.org/10.1016/j.cell.2011.02.,OADS,/arxiv_data1/oa_pdf/da/e0/onci-1-550.PMC3382879.pdf
J Immunol 2009; 182:4499-506; PMID:19342621; http://dx.doi.org/10.4049/jimmunol.08027405.,Non-OADS,/arxiv_data1/oa_pdf/da/e0/onci-1-550.PMC3382879.pdf
Cancer Immunol Immunother 2011; 61:255-63; PMID:22120756; http://dx.doi.org/ 10.1007/s00262-011-1161-9 6.,Non-OADS,/arxiv_data1/oa_pdf/da/e0/onci-1-550.PMC3382879.pdf
Cytokine 2008; 42:277-88; PMID:18400509; http://dx.doi.org/10.1016/j.cyto.2008.03.002 8.,OADS,/arxiv_data1/oa_pdf/da/e0/onci-1-550.PMC3382879.pdf
Cancer Res 2007; 67: 5479-88; PMID:17545630; http://dx.doi.org/10.1158/ 0008-5472.CAN-06-3963 10.,Non-OADS,/arxiv_data1/oa_pdf/da/e0/onci-1-550.PMC3382879.pdf
PLoS One 2011; 6:e27690;PMID:22110722; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/da/e0/onci-1-550.PMC3382879.pdf
"*Correspondence to: Pierosandro Tagliaferri; Email: tagliaferri@unicz.it Submitted: 01/13/12; Accepted: 01/18/12 http://dx.doi.org/10.4161/onci.19404AUTHOR'S VIEW OncoImmunology 1:4, 531– 532; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 531",Non-OADS,/arxiv_data1/oa_pdf/9c/60/onci-1-531.PMC3382880.pdf
Nat Rev Clin Oncol 2011; 8:151-60; PMID:21364688; http://dx.doi.org/10.1038/nrclinonc.2010.223 2.,Non-OADS,/arxiv_data1/oa_pdf/9c/60/onci-1-531.PMC3382880.pdf
J Immunother 2010; 33: 435-41; PMID:20386463; http://dx.doi.org/10.1097/ CJI.0b013e3181d32f014.,Non-OADS,/arxiv_data1/oa_pdf/9c/60/onci-1-531.PMC3382880.pdf
Clin Cancer Res 2012; Epub ahead of print; 18:850-7; PMID: 22142823; http://dx.doi.org/10.1158/1078-0432.CCR-10-3186 5.,Non-OADS,/arxiv_data1/oa_pdf/9c/60/onci-1-531.PMC3382880.pdf
Clin Cancer Res 2008; 14:4192-9; PMID:18593999; http://dx.doi.org/10.1158/1078- 0432.CCR-07-52786.,Non-OADS,/arxiv_data1/oa_pdf/9c/60/onci-1-531.PMC3382880.pdf
Cancer Immunol Immunother 2011; 60:909-18; PMID:21644034; http://dx.doi.org/10.1007/s00262-011-1046-y 7.,Non-OADS,/arxiv_data1/oa_pdf/9c/60/onci-1-531.PMC3382880.pdf
Cancer Microenviron 2011; 4:141-54; PMID: 21909876; http://dx.doi.org/10.1007/s12307-010- 0052-5 8.,Non-OADS,/arxiv_data1/oa_pdf/9c/60/onci-1-531.PMC3382880.pdf
Cancer Cell 2009; 16:183-94; PMID:19732719;http://dx.doi.org/10.1016/j.ccr.2009.06.017 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/9c/60/onci-1-531.PMC3382880.pdf
"Immuno- regulatory CD56hiCD16-NK cells express L-selectin (CD62L, a *Correspondence to: Lisa H. Butterfield and Nikola L. Vujanovic; Email: butterfieldl@upmc.edu and vujanovicnl@upmc.edu Submitted: 02/17/12; Accepted: 02/21/12 http://dx.doi.org/10.4161/onci.19788OncoImmunology 1:4, 448– 457; July 2012; G2012 Landes Bioscience 448 OncoImmunology Volume 1 Issue 4",Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Supplemental Material Supplemental materials may be found here:http://www.landesbioscience.com/journals/oncoimmunology/article/19788/ References 1.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Nat Med 1999; 5:405-11; PMID:10202929; http://dx.doi.org/ 10.1038/7403 2.,OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Eur J Immunol 2008; 38:2938-42; PMID: 18979519; http://dx.doi.org/10.1002/eji.2008388825.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Exp Med 2002; 195:343-51; PMID:11828009; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Exp Med 2002; 195:335-41; PMID:11828008; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Blood 2007; 109:3333-41; PMID: 17164346; http://dx.doi.org/10.1182/blood-2006-06-026385 8.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Immunol Lett 2001; 76:37-41; PMID:11222911;http://dx.doi.org/10.1016/S0165-2478(00)00323-0 10.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Immunother 2008; 31:294- 309; PMID:18317358; http://dx.doi.org/10.1097/CJI.0b013e31816a8910 13.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Cancer Immunol Immunother 2009; 58:121-33; PMID:18488218; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Immunother 2007;30:425-37; PMID:17457217; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Blood 2010; 116:575-83; PMID:20430958; http://dx.doi.org/10.1182/blood- 2009-08-240325 17.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Blood 2005; 106:3465-73; PMID:16037391; http://dx.doi.org/10.1182/blood- 2005-03-0855 19.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Trends Immunol2001; 22:633-40; PMID:11698225; http://dx.doi.org/ 10.1016/S1471-4906(01)02060-9 23.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Blood 2003; 101:3052-7; PMID:12480696; http://dx.doi.org/10.1182/blood-2002-09-2876 24.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Leukoc Biol2004; 76:1187-99; PMID:15356097; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Nat Rev Immunol 2006;6:159-64; PMID:16491140; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Blood 2005; 106:2252-8; PMID:15933055; http://dx.doi.org/10.1182/blood-2005-03-1154 28.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Cancer Res 2008; 68:5965-71; PMID:18632652; http://dx.doi.org/10.1158/0008-5472.CAN-07-6494 29.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Curr Opin Immunol 2002;14:129-35; PMID:11790543; http://dx.doi.org/10.1016/S0952-7915(01)00308-9 30.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Cancer Gene Ther 2005; 12:516-27; PMID:15775996; http://dx.doi.org/10.1038/sj.cgt.7700818 31.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Invest Dermatol 1999; 113:1028-32; PMID:10594747; http://dx.doi.org/10.1046/j.1523- 1747.1999.00779.x 33.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Exp Med 1999; 190:1505-16; PMID:10562324;http://dx.doi.org/10.1084/jem.190.10.150537.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Exp Med 1998; 188:953-60; PMID:9730896; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Exp Med 1998; 187:2065-72; PMID:9625766; http://dx.doi.org/10.1084/jem.187.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Immunother 2004;27:191-200; PMID:15076136; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Allergy Clin Immunol 2010; 125:60-8; PMID:20109737; http://dx.doi.org/10.1016/j.jaci.2009.11.020 44.,OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
J Invest Dermatol 2002;119:850-7; PMID:12406330; http://dx.doi.org/10.1046/j.1523-1747.2002.00132.x 46.,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
"J Virol 2007; 81:4145-57; PMID:17251283;http://dx.doi.org/10.1128/JVI.02685-06 49. Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA.",OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
TrendsImmunol 2004; 25:47-52; PMID:14698284; http://dx.doi.org/10.1016/j.it.2003.10.012 50.,OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
Nat Immunol 2004; 5:1260-5; PMID: 15531883; http://dx.doi.org/10.1038/ni1138 www.landesbioscience.com OncoImmunology 457,Non-OADS,/arxiv_data1/oa_pdf/ab/82/onci-1-448.PMC3382881.pdf
"We have used this T-cell profiling platform to evaluatemelanoma-specific CD8 +T-cell reactivity in patients treated with TIL therapy, focusing on three main questions: (1) Which antigenclasses are predominantly recognized by CD8 +T cells in TIL *Correspondence to: Ton N.M. Schumacher; Email: t.schumacher@nki.nl Submitted: 11/22/11; Accepted: 11/23/11 http://dx.doi.org/10.4161/onci.18851RESEARCH PAPER OncoImmunology 1:4, 409– 418; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 409",Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Supplemental Material Supplemental materials may be found here:http://www.landesbioscience.com/journals/oncoimmunology/article/18851/ References 1.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Immunol Rev 2009; 229:67- 87; PMID:19426215; http://dx.doi.org/10.1111/j.1600-065X.2009.00763.x 2.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
NEngl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466 4.,OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Clin Cancer Res 2009; 15:6267-76; PMID:19789309; http://dx.doi.org/10.1158/ 1078-0432.CCR-09-1254 6.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
JClin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449 7.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Clin Cancer Res 2010; 16:2646-55; PMID:20406835; http://dx.doi.org/10.1158/ 1078-0432.CCR-10-00418.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Clin Cancer Res 2010; 16:6122-31; PMID:20668005; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Nat Med 2006; 12:246-51; PMID:16462803; http://dx.doi.org/10.1038/nm1360 10.,OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Nat Methods 2009;6:520-6; PMID:19543285; http://dx.doi.org/10.1038/ nmeth.1345 11.,OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
J Immunother 2008; 31:742-51; PMID:18779745; http://dx.doi.org/ 10.1097/CJI.0b013e31818403d5 12.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Cancer Res 2008; 68:889-92; PMID:18245491; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-3095 14.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Annu Rev Immunol 2006; 24:175-208; PMID: 16551247; http://dx.doi.org/10.1146/annurev.immunol.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Adv Immunol 2006;92:187-224; PMID:17145305; http://dx.doi.org/10.1016/S0065-2776(06)92005-716.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
J Clin Oncol 2011; 29:917-24; PMID: 21282551; http://dx.doi.org/10.1200/JCO.2010.32.2537 17.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Cancer Res 2011; 71:1253-62; PMID: 21216894; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
J Exp Med 2005; 202:379-86; PMID:16061727; http://dx.doi.org/10.1084/jem.20040613 20.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Transfusion 2011; 51:591-9; PMID:21133926;http://dx.doi.org/10.1111/j.1537-2995.2010.02940.x 21.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
J Immunother2008; 31:199-206; PMID:18481389; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
J Immunother 2007; 30:817- 24; PMID:18049333; http://dx.doi.org/10.1097/CJI.0b013e318155a11c 23.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Genomics2009; 93:17-21; PMID:18692126; http://dx.doi.org/ 10.1016/j.ygeno.2008.07.00524.,OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Nat Genet 2011; 43:442-6; PMID:21499247; http://dx.doi.org/10.1038/ng.810 25.,Non-OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa110378226.,OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
Proc Natl Acad Sci U S A 1992; 89:3429-33; PMID:1565634; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/01/bb/onci-1-409.PMC3382882.pdf
"*Correspondence to: Jean-Jacques Fournié; Email: jean-jacques.fournie@inserm.fr Submitted: 01/04/12; Revised: 01/10/12; Accepted: 01/12/12 http://dx.doi.org/10.4161/onci.19365AUTHOR'S VIEW OncoImmunology 1:4, 555– 556; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 555",Non-OADS,/arxiv_data1/oa_pdf/36/f2/onci-1-555.PMC3382883.pdf
Clin Cancer Res 2009; 15:851- 7; PMID:19188155; http://dx.doi.org/10.1158/1078- 0432.CCR-08-1685 3.,Non-OADS,/arxiv_data1/oa_pdf/36/f2/onci-1-555.PMC3382883.pdf
Cancer Res 2007; 67:7597-604; PMID:17699763; http://dx.doi.org/10.1158/0008-5472.CAN-07-08745.,Non-OADS,/arxiv_data1/oa_pdf/36/f2/onci-1-555.PMC3382883.pdf
Oncogene 2008; 27:1449-60;PMID:17724462; http://dx.doi.org/10.1038/sj.onc.,OADS,/arxiv_data1/oa_pdf/36/f2/onci-1-555.PMC3382883.pdf
Cancer Cell 2011; 20:728-40;PMID:22137796; http://dx.doi.org/10.1016/j.ccr.,Non-OADS,/arxiv_data1/oa_pdf/36/f2/onci-1-555.PMC3382883.pdf
Blood 2009; 114:4713-20; PMID:19786615; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/36/f2/onci-1-555.PMC3382883.pdf
"1 *Correspondence to: Galina Selivanova; Email: Galina.Selivanova@ki.se Submitted: 01/15/12; Accepted: 01/18/12 http://dx.doi.org/10.4161/onci.19409AUTHOR'S VIEW OncoImmunology 1:4, 541– 543; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 541",Non-OADS,/arxiv_data1/oa_pdf/47/7d/onci-1-541.PMC3382884.pdf
Cell Cycle 2011; 10:3346-58; PMID:21941086; http://dx.doi.org/10.4161/cc.10.19.17630 2.,OADS,/arxiv_data1/oa_pdf/47/7d/onci-1-541.PMC3382884.pdf
Cancer Res 2011; 71:5998-6009; PMID:21764762; http://dx.doi.org/10.1158/0008-5472.CAN-10-32113.,Non-OADS,/arxiv_data1/oa_pdf/47/7d/onci-1-541.PMC3382884.pdf
Semin Cancer Biol 2010; 20:46-56; PMID: 20206268; http://dx.doi.org/10.1016/j.semcancer.2010.,OADS,/arxiv_data1/oa_pdf/47/7d/onci-1-541.PMC3382884.pdf
Nature 2007; 445:656-60; PMID:17251933; http://dx.doi.org/10.1038/nature05529 5.,Non-OADS,/arxiv_data1/oa_pdf/47/7d/onci-1-541.PMC3382884.pdf
Cell 2009; 137:609-22; PMID:19450511; http://dx.doi.org/10.1016/j.cell.2009.04.0506.,OADS,/arxiv_data1/oa_pdf/47/7d/onci-1-541.PMC3382884.pdf
Nat Rev Mol Cell Biol 2008; 9:702-12; PMID:18719709; http://dx.doi.org/10.1038/nrm2451 7.,OADS,/arxiv_data1/oa_pdf/47/7d/onci-1-541.PMC3382884.pdf
Cancer Res 2010; 70:5807-17; PMID:20570896; http://dx.doi.org/10.1158/0008-5472.CAN-09-4161 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/47/7d/onci-1-541.PMC3382884.pdf
J Biol Chem 2011; 286:41600-15; PMID:21862591; http://dx.doi.org/10.1074/jbc.M111.240812 9.,OADS,/arxiv_data1/oa_pdf/47/7d/onci-1-541.PMC3382884.pdf
Nature 2005; 436: 1186-90; PMID:15995699; http://dx.doi.org/10.1038/nature0388410.,OADS,/arxiv_data1/oa_pdf/47/7d/onci-1-541.PMC3382884.pdf
Cancer Res 2010; 70:7102-13; PMID:20823164; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/47/7d/onci-1-541.PMC3382884.pdf
"To address this *Correspondence to: Nicolas Larmonier; Email: nrlarmon@email.arizona.edu Submitted: 01/13/12; Accepted: 01/13/12 http://dx.doi.org/10.4161/onci.19370OncoImmunology 1:4, 566– 568; July 2012; G2012 Landes Bioscience 566 OncoImmunology Volume 1 Issue 4",Non-OADS,/arxiv_data1/oa_pdf/20/cc/onci-1-566.PMC3382885.pdf
Cell Death Differ 2008; 15:51-7; PMID:17948028; http://dx.doi.org/10.1038/sj.cdd.4402243 2.,Non-OADS,/arxiv_data1/oa_pdf/20/cc/onci-1-566.PMC3382885.pdf
Curr Opin Immunol 2008; 20:558-65; PMID: 18554881; http://dx.doi.org/10.1016/j.coi.2008.04.006 3.,OADS,/arxiv_data1/oa_pdf/20/cc/onci-1-566.PMC3382885.pdf
Cancer Immunol Immunother 2010; 59:1-11; PMID:19618185; http://dx.doi.org/ 10.1007/s00262-009-0736-1 4.,Non-OADS,/arxiv_data1/oa_pdf/20/cc/onci-1-566.PMC3382885.pdf
Cell Death Differ 2008; 15:58-69;PMID:17948029; http://dx.doi.org/10.1038/sj.cdd.,Non-OADS,/arxiv_data1/oa_pdf/20/cc/onci-1-566.PMC3382885.pdf
Nat Med 2006; 12:207-13; PMID:16444266; http://dx.doi.org/10.1038/nm1352 7.,OADS,/arxiv_data1/oa_pdf/20/cc/onci-1-566.PMC3382885.pdf
J Exp Med2007; 204:2561-8; PMID:17923504; http://dx.doi.org/ 10.1084/jem.20070991 8.,OADS,/arxiv_data1/oa_pdf/20/cc/onci-1-566.PMC3382885.pdf
J Immunol 2010; 184:1876-84; PMID:20089706; http://dx.doi.org/10.4049/jimmunol.09008319.,Non-OADS,/arxiv_data1/oa_pdf/20/cc/onci-1-566.PMC3382885.pdf
Cancer Res 2008; 68:9433-40;PMID:19010918; http://dx.doi.org/10.1158/0008- 5472.CAN-08-0104 10.,Non-OADS,/arxiv_data1/oa_pdf/20/cc/onci-1-566.PMC3382885.pdf
J Immunol 2011; 187:6310-7;PMID:22075702; http://dx.doi.org/10.4049/jimmunol.1101812 568 OncoImmunology Volume 1 Issue 4,Non-OADS,/arxiv_data1/oa_pdf/20/cc/onci-1-566.PMC3382885.pdf
"6 With a cure rate of ,30% at toxicity limits among Stage 4 patients diagnosed at $18 mo of age, there is substantial room for improvement.7 *Correspondence to: Nai-Kong V. Cheung; Email: cheungn@mskcc.org Submitted: 02/27/12; Accepted: 03/01/12 http://dx.doi.org/10.4161/onci.19864RESEARCH PAPER OncoImmunology 1:4, 477– 486; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 477",Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Expert Opin Biol Ther 2008; 8:1151-8; PMID:18613766; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Cancer J 2008; 14:178-83; PMID:18536557; http://dx.doi.org/10.1097/PPO.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
J Clin Oncol2003; 21:2486-91; PMID:12829667; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Semin Cancer Biol 2011; 21:267-75; PMID:21945349; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Lancet Oncol 2008; 9:247-56; PMID:18308250; http://dx.doi.org/10.1016/S1470-2045(08)70069-X 484 OncoImmunology Volume 1 Issue 4,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
J Clin Invest 1988; 81:1122-8; PMID:2450893; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Blood 2002; 99:4166-73; PMID:12010822; http://dx.doi.org/10.1182/blood.V99.11.4166 12.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Stem Cells 2000; 18:10-8; PMID:10661568; http://dx.doi.org/10.1634/ stemcells.18-1-10 13.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Pediatr Blood Cancer 2007; 48:430-4; PMID:16421906; http://dx.doi.org/10.1002/pbc.20765 15.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
J Immunol Methods 1989;125:191-202; PMID:2514231; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Proc Natl Acad Sci U S A 1990; 87:5702-5; PMID:2198570; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
J Clin Oncol 2004; 22:3549-57; PMID: 15337804; http://dx.doi.org/10.1200/JCO.2004.08.143 23.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
J Clin Oncol 2009; 27:85-91; PMID:19047298; http://dx.doi.org/10.1200/JCO.2006.10.3564 24.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
NEngl J Med 2010; 363:1324-34; PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123 25.,OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Br J Cancer 1989; 60:861-6; PMID:2481486; http://dx.doi.org/10.1038/ bjc.1989.380 28.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Cancer Immunol Immunother 2000; 49:259-66; PMID:10941909; http://dx.doi.org/10.1007/ s002620000120 29.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Clin Cancer Res 2009; 15:5923-30; PMID:19737959; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
J Clin Oncol 2003; 21:3940-7; PMID:12975461; http://dx.doi.org/10.1200/JCO.2003.05.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Clin Cancer Res 2004; 10:6248-55; PMID:15448014; http://dx.doi.org/10.1158/1078- 0432.CCR-04-0850 36.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
J Clin Oncol 2008; 26:1789-96; PMID:18347005; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
J Clin Oncol 2009; 27:1122-9; PMID:19164213;http://dx.doi.org/10.1200/JCO.2008.18.0463 38.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
J Clin Oncol 2006; 24:2885-90; PMID:16682723; http://dx.doi.org/10.1200/JCO.2005.04.6011 39.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Brain 2002; 125:2491-506; PMID:12390975; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Blood 2009; 114:5322-30; PMID: 19805620; http://dx.doi.org/10.1182/blood-2009-01-200469 www.landesbioscience.com OncoImmunology 485,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Clin Cancer Res 2008; 14:6697-703; PMID:18927313; http://dx.doi.org/10.1158/1078-0432.CCR-08-0745 45.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
Glycobiology 1998; 8:927-38; PMID:9675226; http://dx.doi.org/10.1093/glycob/8.9.92749.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
J Immunol 2009; 183:5748-55; PMID:19812201; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/00/12/onci-1-477.PMC3382886.pdf
"Taken *Correspondence to: George Coukos; Email: gcks@mail.med.upenn.edu Submitted: 01/06/12; Accepted: 01/18/12 http://dx.doi.org/10.4161/onci.19401AUTHOR'S VIEW OncoImmunology 1:4, 575– 577; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 575",Non-OADS,/arxiv_data1/oa_pdf/4e/37/onci-1-575.PMC3382887.pdf
N Engl J Med 2005; 353:2654-66; PMID:16371631; http://dx.doi.org/10.1056/NEJMoa051424 2.,OADS,/arxiv_data1/oa_pdf/4e/37/onci-1-575.PMC3382887.pdf
NEngl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177 3.,OADS,/arxiv_data1/oa_pdf/4e/37/onci-1-575.PMC3382887.pdf
Nat Med 2004; 10:942-9;PMID:15322536; http://dx.doi.org/10.1038/nm10934.,OADS,/arxiv_data1/oa_pdf/4e/37/onci-1-575.PMC3382887.pdf
J Exp Med 2005; 201:779-91; PMID:15753211; http://dx.doi.org/10.1084/jem.,Non-OADS,/arxiv_data1/oa_pdf/4e/37/onci-1-575.PMC3382887.pdf
Nat Rev Immunol 2010; 10:849-59; PMID:21107346; http://dx.doi.org/10.1038/nri2889 6.,Non-OADS,/arxiv_data1/oa_pdf/4e/37/onci-1-575.PMC3382887.pdf
Nature2011; 475:226-30; PMID:21753853; http://dx.doi.org/ 10.1038/nature101697.,Non-OADS,/arxiv_data1/oa_pdf/4e/37/onci-1-575.PMC3382887.pdf
N Engl J Med 1971; 285:1182-6; PMID:4938153;http://dx.doi.org/10.1056/NEJM197111182852108 8.,OADS,/arxiv_data1/oa_pdf/4e/37/onci-1-575.PMC3382887.pdf
Clin Cancer Res 2007; 13:1947-9; PMID:17404073;http://dx.doi.org/10.1158/1078-0432.CCR-06-2971 9.,Non-OADS,/arxiv_data1/oa_pdf/4e/37/onci-1-575.PMC3382887.pdf
Eur J Immunol 2008; 38:2412-8; PMID:18792019; http://dx.doi.org/10.1002/eji.200838318 10.,Non-OADS,/arxiv_data1/oa_pdf/4e/37/onci-1-575.PMC3382887.pdf
Clin Cancer Res 2008; 14:5947-52; PMID:18829471;http://dx.doi.org/10.1158/1078-0432.CCR-08-0229 www.landesbioscience.com OncoImmunology 577,Non-OADS,/arxiv_data1/oa_pdf/4e/37/onci-1-575.PMC3382887.pdf
"*Correspondence to: Andrea Kröger; Email: andrea.kroeger@helmholtz-hzi.de Submitted: 01/14/12; Accepted: 01/18/12 http://dx.doi.org/10.4161/onci.19405AUTHOR'S VIEW OncoImmunology 1:4, 533– 534; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 533",Non-OADS,/arxiv_data1/oa_pdf/0a/30/onci-1-533.PMC3382888.pdf
Nat Immunol 2002; 3:991-8; PMID: 12407406; http://dx.doi.org/10.1038/ni1102-991 2.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/onci-1-533.PMC3382888.pdf
Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurev-immunol-031210-101324 3.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/onci-1-533.PMC3382888.pdf
Annu Rev Immunol 2001; 19:623-55; PMID: 11244049; http://dx.doi.org/10.1146/annurev.immunol.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/onci-1-533.PMC3382888.pdf
J Interferon Cytokine Res 2002; 22:5-14; PMID:11846971; http://dx.doi.org/ 10.1089/1079990027534526105.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/onci-1-533.PMC3382888.pdf
Nat Immunol 2008; 9:503-10; PMID:18425107; http://dx.doi.org/10.1038/ ni1582 7.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/onci-1-533.PMC3382888.pdf
Nature 2001; 413:165-71; PMID: 11557981; http://dx.doi.org/10.1038/350931098.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/onci-1-533.PMC3382888.pdf
J Immunol 2010; 184:902-11; PMID:20008292; http://dx.doi.org/10.4049/jimmunol.0903225 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/onci-1-533.PMC3382888.pdf
"7The picture becomes even more complex when weconsider that platelets may also influence *Correspondence to: Helmut R. Salih; Email: Helmut.Salih@med.uni-tuebingen.de Submitted: 01/12/12; Accepted: 01/13/12 http://dx.doi.org/10.4161/onci.19367AUTHOR'S VIEW OncoImmunology 1:4, 557– 559; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 557",Non-OADS,/arxiv_data1/oa_pdf/39/87/onci-1-557.PMC3382889.pdf
Science 2011; 331:44-9; PMID:21212348; http://dx.doi.org/ 10.1126/science.1198687 2.,Non-OADS,/arxiv_data1/oa_pdf/39/87/onci-1-557.PMC3382889.pdf
Nat Rev Cancer 2011; 11:123-34; PMID:21258396; http://dx.doi.org/10.1038/nrc3004 3.,Non-OADS,/arxiv_data1/oa_pdf/39/87/onci-1-557.PMC3382889.pdf
Nat Rev Immunol 2011;11:264-74; PMID:21436837; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/39/87/onci-1-557.PMC3382889.pdf
Cancer Res 2011; 72:440-8; PMID: 22127925; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/39/87/onci-1-557.PMC3382889.pdf
Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936 7.,Non-OADS,/arxiv_data1/oa_pdf/39/87/onci-1-557.PMC3382889.pdf
Cancer Res 2009; 69:7775-83; PMID:19738039;http://dx.doi.org/10.1158/0008-5472.CAN-09-21239.,Non-OADS,/arxiv_data1/oa_pdf/39/87/onci-1-557.PMC3382889.pdf
J Clin Invest 1988; 81:1012-9; PMID:3280598; http://dx.doi.org/10.1172/JCI113411 10.,Non-OADS,/arxiv_data1/oa_pdf/39/87/onci-1-557.PMC3382889.pdf
Nat RevImmunol 2007; 7:329-39; PMID:17438573; http://dx.doi.org/10.1038/nri2073 www.landesbioscience.com OncoImmunology 559,Non-OADS,/arxiv_data1/oa_pdf/39/87/onci-1-557.PMC3382889.pdf
"EpCAM isfrequently overexpressed and functionally *Correspondence to: Christopher Heeschen; Email: christopher.heeschen@cnio.es Submitted: 01/13/12; Accepted: 01/13/12 http://dx.doi.org/10.4161/onci.19368OncoImmunology 1:4, 560– 562; July 2012; G2012 Landes Bioscience 560 OncoImmunology Volume 1 Issue 4",Non-OADS,/arxiv_data1/oa_pdf/cf/9d/onci-1-560.PMC3382890.pdf
CA Cancer J Clin 2010; 60:277-300; PMID: 20610543; http://dx.doi.org/10.3322/caac.20073 2.,Non-OADS,/arxiv_data1/oa_pdf/cf/9d/onci-1-560.PMC3382890.pdf
Br J Cancer 2000; 82:1772-5; PMID:10839289; http://dx.doi.org/10.1054/ bjoc.1999.1139 3.,Non-OADS,/arxiv_data1/oa_pdf/cf/9d/onci-1-560.PMC3382890.pdf
Nature 1994; 367:645-8; PMID:7509044;http://dx.doi.org/10.1038/367645a0 4.,Non-OADS,/arxiv_data1/oa_pdf/cf/9d/onci-1-560.PMC3382890.pdf
Cell Stem Cell 2007; 1:313- 23; PMID:18371365; http://dx.doi.org/10.1016/j.stem.,OADS,/arxiv_data1/oa_pdf/cf/9d/onci-1-560.PMC3382890.pdf
Gastroenterology 2009; 137:1102-13; PMID:19501590; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/cf/9d/onci-1-560.PMC3382890.pdf
Clin Cancer Res 2011; 17:6174-84; PMID:21856769; http://dx.doi.org/10.1158/1078-0432.CCR-11-11118.,Non-OADS,/arxiv_data1/oa_pdf/cf/9d/onci-1-560.PMC3382890.pdf
Clin Cancer Res 2012; 18:465-74; PMID: 22096026; http://dx.doi.org/10.1158/1078-0432.CCR- 11-1270 9.,Non-OADS,/arxiv_data1/oa_pdf/cf/9d/onci-1-560.PMC3382890.pdf
Cancer Res 2009; 69:5627-9; PMID:19584271; http://dx.doi.org/ 10.1158/0008-5472.CAN-09-0654 10.,Non-OADS,/arxiv_data1/oa_pdf/cf/9d/onci-1-560.PMC3382890.pdf
Cell 2008; 133:704-15; PMID:18485877; http://dx.doi.org/10.1016/j.cell.2008.03.027 562 OncoImmunology Volume 1 Issue 4,Non-OADS,/arxiv_data1/oa_pdf/cf/9d/onci-1-560.PMC3382890.pdf
"Upon granule exocytosis, the lysosomal-membrane associated glycoprotein CD107a (also known as *Correspondence to: Daniel E. Speiser; Email: doc@dspeiser.ch Submitted: 02/22/12; Accepted: 02/28/12 http://dx.doi.org/10.4161/onci.19856RESEARCH PAPER OncoImmunology 1:4, 467– 476; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 467",Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Immunol Rev 2007; 220:82-101; PMID:17979841; http://dx.doi.org/10.1111/j.1600-065X.2007.00566.x 3.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
ClinCancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116 4.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Immunother 2004; 27:298-308; PMID: 15235391; http://dx.doi.org/10.1097/00002371- 200407000-00006 5.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Clin Invest 2011; 121:2350-60; PMID:21555851;http://dx.doi.org/10.1172/JCI46102 8.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Trends Immunol 2012; Epub aheadof press; PMID:22445288; http://dx.doi.org/10.1016/ j.it.2012.02.006 10.,OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Cell Mol Immunol 2009; 6:15-25; PMID:19254476; http://dx.doi.org/10.1038/ cmi.2009.3 11.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Proc Natl Acad Sci U S A 2008; 105:3849-54; PMID:18319339; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Immunol Methods2003; 281:65-78; PMID:14580882; http://dx.doi.org/ 10.1016/S0022-1759(03)00265-5 13.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Nat Med 2003; 9:1377-82; PMID:14528297; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Exp Med 2004; 199:925-36; PMID:15051762; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Immunol Methods 2006; 311:31-46; PMID:16527300; http://dx.doi.org/10.1016/j.jim.2006.01.011 16.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Eur J Immunol 2009; 39:2259-69; PMID:19637198; http://dx.doi.org/10.1002/eji.200939341 19.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Nat Med 2010; 16:1147-51; PMID:20890291; http://dx.doi.org/10.1038/nm.2232 20.,OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
PLoS Pathog 2009; 5:e1000313; PMID:19247441; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Immunity 2007; 27:670-84; PMID:17950003; http://dx.doi.org/ 10.1016/j.immuni.2007.09.006 22.,OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Nature 1993; 362:758-61; PMID: 8469287; http://dx.doi.org/10.1038/362758a0 23.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Exp Med 1998; 188:2205-13; PMID:9858507; http://dx.doi.org/10.1084/jem.188.12.2205 24.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Virol 2003; 77:4911-27; PMID:12663797; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Clin Invest 2008; 118:1390-7; PMID:18357341; http://dx.doi.org/10.1172/JCI34388 28.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Regulation of interferon- gamma during innate and adaptive immune responses.Adv Immunol 2007; 96:41-101; PMID:17981204;http://dx.doi.org/10.1016/S0065-2776(07)96002-2 30.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Immunol Rev2008; 222:155-61; PMID:18364000; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Immunother 2006; 29:233-40; PMID:16699366; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Exp Med 1997; 186:645-53; PMID: 9271580; http://dx.doi.org/10.1084/jem.186.5.645 34.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Exp Med 1988; 168:143-56; PMID:2899619; http://dx.doi.org/10.1084/jem.168.1.143 36.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Exp Med 2002; 195:1407-18; PMID:12045239; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Eur J Immunol 1996; 26:2017-22; PMID:8814240; http://dx.doi.org/10.1002/eji.183026090838.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Curr Opin Immunol 2005; 17:180-6; PMID:15766679; http://dx.doi.org/10.1016/j.coi.2005.01.008 40.,OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Exp Med 1998; 188:1641-50; PMID:9802976; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Cancer Immunol Immunother2007; 56:259-69; PMID:16758204; http://dx.doi.org/ 10.1007/s00262-006-0186-y 43.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Exp Med 2005; 202:1349-61; PMID:16287711; http://dx.doi.org/10.1084/jem.,OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Cancer Res2006; 66:1912-6; PMID:16488988; http://dx.doi.org/ 10.1158/0008-5472.CAN-05-379349.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Exp Med 1996; 183:1173-83; PMID:8642259; http://dx.doi.org/10.1084/jem.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
J Exp Med 1997; 185:1605-17; PMID:9151898; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
Cytometry A 2011; 79:167-74; PMID:21265010; http://dx.doi.org/10.1002/cyto.a.21015 476 OncoImmunology Volume 1 Issue 4,Non-OADS,/arxiv_data1/oa_pdf/8c/fd/onci-1-467.PMC3382891.pdf
"Do not distribute.Th17 cells have stem cell-like features and promote long-term immunity Shuang Wei,1Ende Zhao,1Ilona Kryczek1,2,3and Weiping Zou1,2,3,* 1Department of Surgery; University of Michigan; Ann Arbor, MI USA;2Graduate Program in Immunology and Tumor Biology; University of Michigan; Ann Arbor, MI USA;3University of Michigan Comprehensive Cancer Center; University of Michigan; Ann Arbor, MI USA Keywords: Th17 cell, memory T cell, survival, apoptosis, stem cell, tumor immunity, IL-17, HIF, Notch, Bcl2 Submitted: 01/14/12 Revised: 01/18/12 Accepted: 01/21/12http://dx.doi.org/10.4161/onci.19440 *Correspondence to: Weiping Zou; Email: wzou@med.umich.eduMemory T cells are one of the most effective components of anti- tumor immunity.",Non-OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Nat Rev Immunol 2002; 2:982-7; PMID:12461571; http://dx.doi.org/10.1038/nri959 2.,Non-OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Science 2001; 293:248-50; PMID: 11452114; http://dx.doi.org/10.1126/science.1062589 3.,OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
N Engl J Med 2005; 353:2654-66; PMID:16371631; http://dx.doi.org/10.1056/NEJMoa051424 4.,OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Science 2006; 313: 1960-4; PMID:17008531; http://dx.doi.org/10.1126/ science.11291395.,OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Nat Med 2001; 7:452-8;PMID:11283672; http://dx.doi.org/10.1038/86523 6.,Non-OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Nat Med 2003; 9:1151-7; PMID:12910264; http://dx.doi.org/ 10.1038/nm914 7.,OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Nat Med 2003; 9:562-7; PMID:12704383; http://dx.doi.org/10.1038/nm863 8.,OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm10939.,OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
J Exp Med 2006; 203:871-81; PMID:16606666; http://dx.doi.org/10.1084/jem.20050930 10.,Non-OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Blood 2009; 114:1141-9; PMID:19470694; http://dx.doi.org/10.1182/blood-2009-03-208249 11.,Non-OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Sci Transl Med 2011; 3: 104ra100; PMID:21998407; http://dx.doi.org/10.1126/ scitranslmed.3002949 13.,Non-OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
"Nat Rev Immunol 2010; 10:248-56; PMID:20336152; http://dx.doi.org/ 10.1038/nri2742 15. Pepper M, Linehan JL, Pagán AJ, Zell T, Dileepan T, Cleary PP, et al.",OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Nat Immunol 2010; 11:83-9; PMID:19935657; http://dx.doi.org/10.1038/ni.182616.,Non-OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Science 2007; 315:1687-91; PMID: 17332376; http://dx.doi.org/10.1126/science.1139393 17.,Non-OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Immunity 2009; 31:834-44; PMID:19879163; http://dx.doi.org/10.1016/j.immuni.2009.09.015 18.,OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Nat Med 2005; 11:1299-305; PMID: 16288282; http://dx.doi.org/10.1038/nm1326 19.,OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Nat Med 2009; 15:808-13; PMID:19525962; http://dx.doi.org/10.1038/nm.198220.,Non-OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Nat Med 2011; 17:1290-7; PMID: 21926977; http://dx.doi.org/10.1038/nm.2446 21.,OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Cell 2011; 146:772-84; PMID:21871655; http://dx.doi.org/10.1016/j.cell.2011.07.033 22.,OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Nat Med2004; 10:909-15; PMID:15340416; http://dx.doi.org/10.1038/nm1100 23.,OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
Nat Rev Immunol 2006; 6:383-93; PMID:16622476; http://dx.doi.org/10.1038/nri1842 www.landesbioscience.com OncoImmunology 519,Non-OADS,/arxiv_data1/oa_pdf/b5/b7/onci-1-516.PMC3382892.pdf
"Moreover, melanoma asso-ciated depigmentation is relatively fre- quently observed after immunotherapy and has been linked to a beneficial *Correspondence to: Reinhart Speeckaert; Email: reinhart.speeckaert@ugent.be Submitted: 01/14/12; Accepted: 01/18/12 http://dx.doi.org/10.4161/onci.19403OncoImmunology 1:4, 526– 528; July 2012; G2012 Landes Bioscience 526 OncoImmunology Volume 1 Issue 4",Non-OADS,/arxiv_data1/oa_pdf/ed/9f/onci-1-526.PMC3382893.pdf
Ann Oncol 2010; 21:409-14; PMID:19622589; http://dx.doi.org/10.1093/annonc/mdp325 2.,Non-OADS,/arxiv_data1/oa_pdf/ed/9f/onci-1-526.PMC3382893.pdf
PMID:22033321; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/ed/9f/onci-1-526.PMC3382893.pdf
The effects of gp100 and tyrosinasepeptide vaccinations on nevi in melanoma patients.J Cutan Pathol 2006; 33:335-42; PMID:16640539; http://dx.doi.org/10.1111/j.0303-6987.2006.00449.x 5.,Non-OADS,/arxiv_data1/oa_pdf/ed/9f/onci-1-526.PMC3382893.pdf
J Transl Med 2005; 3:10; PMID:15740633; http://dx.doi.org/10.1186/1479-5876-3-10 6.,Non-OADS,/arxiv_data1/oa_pdf/ed/9f/onci-1-526.PMC3382893.pdf
Exp Dermatol 2011; 20:92-6;PMID:21255087; http://dx.doi.org/10.1111/j.1600- 0625.2010.01200.x7.,Non-OADS,/arxiv_data1/oa_pdf/ed/9f/onci-1-526.PMC3382893.pdf
"Pigment CellMelanoma Res 2011; 24:673-9; PMID:21689385; http://dx.doi.org/10.1111/j.1755-148X.2011.00878.x 8. van Geel N, Speeckaert R, Mollet I, Brochez L, De Schepper S, De Wolf J, et al.",OADS,/arxiv_data1/oa_pdf/ed/9f/onci-1-526.PMC3382893.pdf
Pigm Cell Melanoma Res 2012; 25:57-65; PMID:21982055;http://dx.doi.org/10.1111/j.1755-148X.2011.00922.x 9.,Non-OADS,/arxiv_data1/oa_pdf/ed/9f/onci-1-526.PMC3382893.pdf
"The data revealed that in 7/9 mice we had targeting of the M202 tumor with Correspondence to: Dimitrios N. Vatakis; Email: dvatakis@ucla.edu Submitted: 01/15/12; Accepted: 01/18/12 http://dx.doi.org/10.4161/onci.19408AUTHOR'S VIEW OncoImmunology 1:4, 539– 540; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 539",Non-OADS,/arxiv_data1/oa_pdf/ae/bf/onci-1-539.PMC3382894.pdf
Science 2002; 298:850-4;PMID:12242449; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/ae/bf/onci-1-539.PMC3382894.pdf
Science 2006; 314:126-9; PMID:16946036;http://dx.doi.org/10.1126/science.1129003 3.,OADS,/arxiv_data1/oa_pdf/ae/bf/onci-1-539.PMC3382894.pdf
"Nat Med 2010; 16:565-70, 1p, 570; PMID: 20400962; http://dx.doi.org/10.1038/nm.21284.",OADS,/arxiv_data1/oa_pdf/ae/bf/onci-1-539.PMC3382894.pdf
Annu Rev Immunol 2001; 19:565-94; PMID:11244047; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/ae/bf/onci-1-539.PMC3382894.pdf
Nat Med 2006; 12:1316-22; PMID:17057712; http://dx.doi.org/10.1038/nm1431 8.,OADS,/arxiv_data1/oa_pdf/ae/bf/onci-1-539.PMC3382894.pdf
Blood 2010; 115:1534-44; PMID:20018916; http://dx.doi.org/10.1182/blood-2009-04-215855 9.,Non-OADS,/arxiv_data1/oa_pdf/ae/bf/onci-1-539.PMC3382894.pdf
PLoS One 2009; 4:e8208; PMID:19997617; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/ae/bf/onci-1-539.PMC3382894.pdf
"Once within cells,nanoparticles undergo a slow metabolization; 11thus, baseline MR*Correspondence to: Heike Daldrup-Link; Email: heiked@stanford.edu Submitted: 01/23/12; Accepted: 01/23/12 http://dx.doi.org/10.4161/onci.19457REVIEW OncoImmunology 1:4, 507– 509; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 507",Non-OADS,/arxiv_data1/oa_pdf/67/30/onci-1-507.PMC3382895.pdf
Cancer Cell 2005; 7:211-7; PMID:15766659; http://dx.doi.org/10.1016/j.ccr.2005.02.013 4.,OADS,/arxiv_data1/oa_pdf/67/30/onci-1-507.PMC3382895.pdf
Cancer Cell 2009; 16:91-102; PMID:19647220; http://dx.doi.org/10.1016/j.ccr.2009.06.018 5.,Non-OADS,/arxiv_data1/oa_pdf/67/30/onci-1-507.PMC3382895.pdf
Cancer Res 2010; 70:7465-75; PMID:20841473; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/67/30/onci-1-507.PMC3382895.pdf
BreastCancer Res Treat 2011; 128:703-11; PMID:20842526; http://dx.doi.org/10.1007/s10549-010-1154-y 8.,Non-OADS,/arxiv_data1/oa_pdf/67/30/onci-1-507.PMC3382895.pdf
Radiology 2003; 229:885-92; PMID:14576446; http://dx.doi.org/10.1148/radiol.2293021045 9.,Non-OADS,/arxiv_data1/oa_pdf/67/30/onci-1-507.PMC3382895.pdf
Clin Cancer Res 2011; 17:5695- 704; PMID:21791632; http://dx.doi.org/10.1158/1078-0432.CCR-10-342010.,Non-OADS,/arxiv_data1/oa_pdf/67/30/onci-1-507.PMC3382895.pdf
Curr Pharm Des 2006; 12: 2661-72; PMID:16842165; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/67/30/onci-1-507.PMC3382895.pdf
Adv Drug Deliv Rev 2006; 58:1471-504; PMID:17116343; http://dx.doi.org/10.1016/j.addr.,OADS,/arxiv_data1/oa_pdf/67/30/onci-1-507.PMC3382895.pdf
Eur Radiol 2006; 16:738-45;PMID:16308692; http://dx.doi.org/10.1007/s00330- 005-0031-2 www.landesbioscience.com OncoImmunology 509,Non-OADS,/arxiv_data1/oa_pdf/67/30/onci-1-507.PMC3382895.pdf
"Inthe following sections we will discuss more studies concerning *Correspondence to: Fan Pan; Email: fpan1@jhmi.edu Submitted: 01/04/12; Accepted: 01/23/12 http://dx.doi.org/10.4161/onci.19457OncoImmunology 1:4, 510– 515; July 2012; G2012 Landes Bioscience 510 OncoImmunology Volume 1 Issue 4",Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Immunity 2009; 30:646-55; PMID:19464987; http://dx.doi.org/10.1016/j.immuni.2009.05.001 2.,Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Exp Mol Med 2011; 43:1-6; PMID:21270506; http://dx.doi.org/10.3858/emm.2011.43.1.007 3.,Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Cell 2008;133:775-87; PMID:18510923; http://dx.doi.org/10.1016/j.cell.2008.05.009 4.,OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Cell2010; 140:845-58; PMID:20303875; http://dx.doi.org/10.1016/j.cell.2010.02.021 5.,OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Immunology 2009; 127:459-65; PMID:19604300; http://dx.doi.org/10.1111/j.1365-2567.2009.03125.x 6.,Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Immunity 2010; 33:301-11; PMID: 20870173; http://dx.doi.org/10.1016/j.immuni.2010.,OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Nat Immunol 2011; 12:295-303; PMID: 21358638; http://dx.doi.org/10.1038/ni.2005 8.,Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
J Exp Med 2011; 208: 1367-76; PMID:21708926; http://dx.doi.org/10.1084/ jem.201102789.,Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Curr Opin Genet Dev 1998; 8:588-94; PMID:9794818; http://dx.doi.org/10.1016/S0959-437X(98)80016-6 10.,OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
J Clin Invest 2005;115:1702-4; PMID:16007247; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Cell 2011; 146:772-84; PMID: 21871655; http://dx.doi.org/10.1016/j.cell.2011.07.033 13.,OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Curr Pharm Des2009; 15:3839-43; PMID:19671047; http://dx.doi.org/10.2174/138161209789649402 15.,Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Nature 2011; 472:486-90; PMID:21441909;http://dx.doi.org/10.1038/nature09978 17.,Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Nat Med 2007; 13:423-31; PMID: 17384649; http://dx.doi.org/10.1038/nm156418.,OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Immunity 2009; 31:787-98; PMID:19879162; http://dx.doi.org/ 10.1016/j.immuni.2009.09.014 20.,Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
J Exp Med 2009; 206: 1457-64; PMID:19564351; http://dx.doi.org/10.1084/ jem.20090207 21.,Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Nat Med 2009; 15:1016-22; PMID:19701202; http://dx.doi.org/10.1038/nm.2015 22.,OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
Ann Rheum Dis 2011; 70:727-32; PMID:21345813; http://dx.doi.org/10.1136/ard.2010.143768 24.,OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
PLoS One 2011;6:e21816; PMID:21760911; http://dx.doi.org/10.1371/ journal.pone.0021816 www.landesbioscience.com OncoImmunology 515,Non-OADS,/arxiv_data1/oa_pdf/76/d1/onci-1-510.PMC3382896.pdf
"Furthermore, the SPAS-1-specific T cells *Correspondence to: Rebecca Waitz; Email: beckywaitz@gmail.com Submitted: 01/18/12; Accepted: 01/21/12 http://dx.doi.org/10.4161/onci.19442OncoImmunology 1:4, 544– 546; July 2012; G2012 Landes Bioscience 544 OncoImmunology Volume 1 Issue 4",Non-OADS,/arxiv_data1/oa_pdf/5f/cc/onci-1-544.PMC3382897.pdf
Curr Opin Immunol 2006; 18:206-13; PMID:16464564; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5f/cc/onci-1-544.PMC3382897.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466 3.,OADS,/arxiv_data1/oa_pdf/5f/cc/onci-1-544.PMC3382897.pdf
N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621 4.,Non-OADS,/arxiv_data1/oa_pdf/5f/cc/onci-1-544.PMC3382897.pdf
Science1996; 271:1734-6; PMID:8596936; http://dx.doi.org/10.1126/science.271.5256.17345.,Non-OADS,/arxiv_data1/oa_pdf/5f/cc/onci-1-544.PMC3382897.pdf
J Exp Med 1999; 190: 355-66; PMID:10430624; http://dx.doi.org/10.1084/jem.190.3.355 6.,Non-OADS,/arxiv_data1/oa_pdf/5f/cc/onci-1-544.PMC3382897.pdf
Cancer Res 2009; 69:7747-55; PMID: 19738077; http://dx.doi.org/10.1158/0008-5472.CAN- 08-32898.,Non-OADS,/arxiv_data1/oa_pdf/5f/cc/onci-1-544.PMC3382897.pdf
Cancer Res 2012; 72:430-9; PMID:22108823; http://dx.doi.org/10.1158/0008- 5472.CAN-11-1782 10.,Non-OADS,/arxiv_data1/oa_pdf/5f/cc/onci-1-544.PMC3382897.pdf
"In this setting, theoverexpression of PCNA resulted in signi-ficantly reduced functions of NK92 cellsexpressing wild type, as compared with *Correspondence to: Angel Porgador; Email: angel@bgu.ac.il Submitted: 01/12/12; Accepted: 01/13/12 http://dx.doi.org/10.4161/onci.19366OncoImmunology 1:4, 572– 574; July 2012; G2012 Landes Bioscience 572 OncoImmunology Volume 1 Issue 4",Non-OADS,/arxiv_data1/oa_pdf/2f/4a/onci-1-572.PMC3382898.pdf
J Immunol 2011; 187:5693-702; PMID:22021614; http://dx.doi.org/10.4049/jimmunol.,Non-OADS,/arxiv_data1/oa_pdf/2f/4a/onci-1-572.PMC3382898.pdf
Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.0133.,OADS,/arxiv_data1/oa_pdf/2f/4a/onci-1-572.PMC3382898.pdf
Biochem Soc Trans 2009; 37:605-13; PMID: 19442257; http://dx.doi.org/10.1042/BST0370605 4.,Non-OADS,/arxiv_data1/oa_pdf/2f/4a/onci-1-572.PMC3382898.pdf
Immunity 2007; 27:965-74; PMID:18055229; http://dx.doi.org/10.1016/j.immuni.2007.,OADS,/arxiv_data1/oa_pdf/2f/4a/onci-1-572.PMC3382898.pdf
Int Immunol 2008; 20:1395-405; PMID: 18815119; http://dx.doi.org/10.1093/intimm/dxn1058.,Non-OADS,/arxiv_data1/oa_pdf/2f/4a/onci-1-572.PMC3382898.pdf
Histochem Cell Biol 2006; 125:615-24; PMID:16491347; http://dx.doi.org/10.1007/s00418-006-0160-y 9.,Non-OADS,/arxiv_data1/oa_pdf/2f/4a/onci-1-572.PMC3382898.pdf
J Cell Biol 2000; 150:1113-24; PMID:10973999; http://dx.doi.org/10.1083/jcb.150.5.111310.,OADS,/arxiv_data1/oa_pdf/2f/4a/onci-1-572.PMC3382898.pdf
PLoS One 2011; 6:e19390; PMID:21572519; http://dx.doi.org/ 10.1371/journal.pone.0019390 574 OncoImmunology Volume 1 Issue 4,Non-OADS,/arxiv_data1/oa_pdf/2f/4a/onci-1-572.PMC3382898.pdf
"For the SNP R248W we genotyped 19 healthy donors, 12 malignant melanoma patients, *Correspondence to: Mads Hald Anderson; Email: mads.hald.andersen@regionh.dk Submitted: 09/09/12; Revised: 02/02/12; Accepted: 02/07/12 http://dx.doi.org/10.4161/onci.19654RESEARCH PAPER OncoImmunology 1:4, 441– 447; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 441",Non-OADS,/arxiv_data1/oa_pdf/9f/58/onci-1-441.PMC3382899.pdf
Oncogene 2008; 27:3889- 900; PMID:18317452; http://dx.doi.org/10.1038/onc.,Non-OADS,/arxiv_data1/oa_pdf/9f/58/onci-1-441.PMC3382899.pdf
Cell Cycle 2009; 8:1818-9; PMID:19471123; http://dx.doi.org/10.4161/cc.8.12.,OADS,/arxiv_data1/oa_pdf/9f/58/onci-1-441.PMC3382899.pdf
J Med Chem 2008;51:4968-77; PMID:18665584; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9f/58/onci-1-441.PMC3382899.pdf
J Med Chem 2008; 51:1706-18; PMID:18318466; http://dx.doi.org/10.1021/jm7014155 7.,Non-OADS,/arxiv_data1/oa_pdf/9f/58/onci-1-441.PMC3382899.pdf
Cancer Res 2007; 67:7082-7; PMID:17671174; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9f/58/onci-1-441.PMC3382899.pdf
"J Am Coll Surg 2009; 208:781-7, discussion 787-9; PMID:19476837; http://dx.doi.org/10.1016/j.jamcollsurg.2008.12.018 11.",OADS,/arxiv_data1/oa_pdf/9f/58/onci-1-441.PMC3382899.pdf
Cancer Res 2011; 71:2038-44; PMID:21406395; http://dx.doi.org/10.1158/0008-5472.CAN-10-3403 12.,Non-OADS,/arxiv_data1/oa_pdf/9f/58/onci-1-441.PMC3382899.pdf
Am J Pathol 2010; 176:2082-7; PMID:20228228; http://dx.doi.org/10.2353/ajpath.,Non-OADS,/arxiv_data1/oa_pdf/9f/58/onci-1-441.PMC3382899.pdf
Nat Med 2005; 11:312-9; PMID: 15711557; http://dx.doi.org/10.1038/nm1196 446 OncoImmunology Volume 1 Issue 4,Non-OADS,/arxiv_data1/oa_pdf/9f/58/onci-1-441.PMC3382899.pdf
"During this period of time, theseanimals were shown to have decreasedstress response to both immune challengeand behavior stressors, and increased peri-pheral innate immune cell function, suchas higher natural killer cell cytotoxicity *Correspondence to: Dipak K. Sarkar; Email: Sarkar@aesop.rutgers.edu Submitted: 01/11/12; Accepted: 01/12/12 http://dx.doi.org/10.4161/onci.19335OncoImmunology 1:4, 552– 554; July 2012; G2012 Landes Bioscience 552 OncoImmunology Volume 1 Issue 4",Non-OADS,/arxiv_data1/oa_pdf/54/b0/onci-1-552.PMC3382900.pdf
Brain BehavImmun 2003; 17(Suppl 1):S27-36; PMID:12615183; http://dx.doi.org/10.1016/S0889-1591(02)00063-6 2.,Non-OADS,/arxiv_data1/oa_pdf/54/b0/onci-1-552.PMC3382900.pdf
Proc Natl Acad Sci U S A 1976; 73:2895-8; PMID:8780; http://dx.doi.org/10.1073/ pnas.73.8.28953.,OADS,/arxiv_data1/oa_pdf/54/b0/onci-1-552.PMC3382900.pdf
J Neurosci Res 1986; 16: 89-96; PMID:3746950; http://dx.doi.org/10.1002/jnr.,Non-OADS,/arxiv_data1/oa_pdf/54/b0/onci-1-552.PMC3382900.pdf
Peptides 1982;3:353-95; PMID:6289277; http://dx.doi.org/10.1016/0196-9781(82)90098-55.,OADS,/arxiv_data1/oa_pdf/54/b0/onci-1-552.PMC3382900.pdf
Cancer Res 2011; 71:6282-91; PMID:21835894; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/54/b0/onci-1-552.PMC3382900.pdf
"demonstrated that activation of p53 by either ectopic overexpression or *Correspondence to: Annette Paschen; Email: annette.paschen@uk-essen.de Submitted: 01/14/12; Accepted: 01/18/12 http://dx.doi.org/10.4161/onci.19406AUTHOR'S VIEW OncoImmunology 1:4, 535– 536; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 535",Non-OADS,/arxiv_data1/oa_pdf/67/d4/onci-1-535.PMC3382901.pdf
Nature 2005; 436:1186-90; PMID:15995699; http://dx.doi.org/10.1038/ nature03884 3.,Non-OADS,/arxiv_data1/oa_pdf/67/d4/onci-1-535.PMC3382901.pdf
Cancer Res 2012; 72:460-71; PMID: 22102694; http://dx.doi.org/10.1158/0008-5472.CAN- 11-1977 4.,Non-OADS,/arxiv_data1/oa_pdf/67/d4/onci-1-535.PMC3382901.pdf
Cell Death Differ 2010; 17:193-9; PMID: 19461653; http://dx.doi.org/10.1038/cdd.2009.565.,Non-OADS,/arxiv_data1/oa_pdf/67/d4/onci-1-535.PMC3382901.pdf
Proc Natl Acad Sci U S A2011; 108:21093-8; PMID:22160687; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/67/d4/onci-1-535.PMC3382901.pdf
Cancer Res 2009; 69:6241-8; PMID:19638586; http://dx.doi.org/10.1158/0008-5472.CAN-09-0337 7.,Non-OADS,/arxiv_data1/oa_pdf/67/d4/onci-1-535.PMC3382901.pdf
Cancer Res 2011; 71:5998-6009; PMID:21764762; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/67/d4/onci-1-535.PMC3382901.pdf
Cell Cycle 2011; 10:3346-58; PMID:21941086;http://dx.doi.org/10.4161/cc.10.19.17630 9.,OADS,/arxiv_data1/oa_pdf/67/d4/onci-1-535.PMC3382901.pdf
Int J Cancer 2009; 124:1594-604; PMID:19089914; http://dx.doi.org/ 10.1002/ijc.24098 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/67/d4/onci-1-535.PMC3382901.pdf
"15,16Genomic V(D)J rearrangements leading to combinatorial diversity is offundamental importance for the generation of diverse antigen *Correspondence to: Christine Menetrier-Caux; Email: christine.caux@lyon.unicancer.fr Submitted: 01/27/12; Accepted: 01/31/12 http://dx.doi.org/10.4161/onci.19545OncoImmunology 1:4, 432– 440; July 2012; G2012 Landes Bioscience 432 OncoImmunology Volume 1 Issue 4",Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Supplemental Material Supplemental materials may be found here: http://www.landesbioscience.com/journals/oncoimmunology/ article/19545/ References 1.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Cancer 2004; 101:2675-80; PMID:15503313; http://dx.doi.org/10.1002/cncr.20688 4.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Br J Cancer 2003; 88:181-6; PMID:12610500; http://dx.doi.org/10.1038/sj.bjc.6600724 5.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Br J Cancer 2001; 85:816-22; PMID: 11556830; http://dx.doi.org/10.1054/bjoc.2001.2011 6.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Cancer Res2009; 69:5383-91; PMID:19549917; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037 8.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Cancer Res 2011;71:5423-34; PMID:21697280; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Clin Cancer Res 2004; 10:7466-74; PMID:15569976; http://dx.doi.org/10.1158/1078-0432.CCR-04-0684 11.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Cancer Res 2009; 69:2000-9; PMID:19244125; http://dx.doi.org/10.1158/0008-5472.CAN-08-236013.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466 14.,OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Semin Oncol 2010; 37:473-84; PMID:21074063; http://dx.doi.org/10.1053/j.seminoncol.2010.09.001 15.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Adv Immunol 2001; 78:169-232; PMID:11432204; http://dx.doi.org/10.1016/S0065-2776(01)78004-2 16.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Nature 1983; 302:575-81; PMID:6300689; http://dx.doi.org/10.1038/302575a0 17.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Eur J Immunol 2009; 39:2136-45; PMID:19572320; http://dx.doi.org/10.1002/eji.200939480 18.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Eur J Immunol 2011; Epub ahead of print; PMID:22105329; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Nat Med 1998; 4:215-21; PMID:9461196; http://dx.doi.org/10.1038/nm0298-215 21.,OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Cancer Res 2010; 70:7084-92; PMID: 20823160; http://dx.doi.org/10.1158/0008-5472.CAN- 10-1326 22.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Cancer Chemother Pharmacol 2011;68:1305-13; PMID:21448592; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Cancer Sci 2011; 102:706-12; PMID:21235683; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
J Exp Med 2006; 203:1701-11; PMID: 16818678; http://dx.doi.org/10.1084/jem.2006077227.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Targeted Oncology 2012;7:55-68; PMID:2238042; http://dx.doi.org/10.1007/ s11523-012-0210-4 29.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
J Exp Med 2008; 205:1701-14; PMID:18573906; http://dx.doi.org/10.1084/jem.20071681 30.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Age (Dordr) 2009; 31:87-97; PMID:19507053; http://dx.doi.org/10.1007/s11357-008- 9084-x 33.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
J Infect Dis 2006; 194:1098-107; PMID: 16991084; http://dx.doi.org/10.1086/507313 34.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Carcinogenesis 2007; 28:1067-73; PMID:17183065; http://dx.doi.org/10.1093/carcin/bgl25035.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Neoplasia 2006; 8:190-8; PMID:16611412; http://dx.doi.org/10.1593/neo.05733 36.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
J Clin Invest 1998; 102: 1715-23; PMID:9802885; http://dx.doi.org/10.1172/ JCI3784 38.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Br J Dermatol 2002; 147:62-70; PMID: 12100186; http://dx.doi.org/10.1046/j.1365-2133.,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Stat Med 1985; 4:39-46; PMID:3857702; http://dx.doi.org/10.1002/sim.4780040107 41.,OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
Stat Med 1995; 14:2581-98; PMID:8746890; http://dx.doi.org/ 10.1002/sim.4780142307 440 OncoImmunology Volume 1 Issue 4,Non-OADS,/arxiv_data1/oa_pdf/cd/10/onci-1-432.PMC3382902.pdf
"Maximizing the activity of cancer vaccines necessitates an appreciation of the complex regulatory pathways that control the *Correspondence to: Jonathan L. Bramson; Email: bramsonj@mcmaster.ca Submitted: 01/25/12; Accepted: 01/30/12 http://dx.doi.org/10.4161/onci.19534RESEARCH PAPER OncoImmunology 1:4, 419– 431; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 419",Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
"45Illumina expression files were created using the IlluminaExpressionFileCreator module avail-able on Gene Pattern (http://genepattern.broadinstitute.org/gp/ pages/index.jsf), similar to Illumina BeadStudio, from raw .IDAT files.",OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Adv Drug Deliv Rev 2006; 58:931-47; PMID:17030074; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Vaccine 2007; 25(Suppl 2):B24-34; PMID:17698262; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Cancer Res 2004; 64:1509-14; PMID:14973051; http://dx.doi.org/10.1158/0008-5472.CAN-03-3227 4.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Cancer Res 2007; 67: 6459-67; PMID:17616707; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Mol Ther 2010; 18:1224-32; PMID:20179673; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Cancer Res 2009; 69:3979-85; PMID:19383917; http://dx.doi.org/10.1158/0008-5472.CAN-08-3385 7.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Nature 1994; 370: 650-2; PMID:7520535; http://dx.doi.org/10.1038/370650a0 9.,OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Science 1998; 281:1305-8; PMID:9721089; http://dx.doi.org/10.1126/science.281.5381.,OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Apoptosis 2003; 8:237-49; PMID:12766484; http://dx.doi.org/10.1023/A:1023668705040 11.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Science 1993; 259:1739-42; PMID:8456300;http://dx.doi.org/10.1126/science.8456300 12.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Curr Opin Immunol 2010; 22:223-30; PMID:20207527; http://dx.doi.org/ 10.1016/j.coi.2010.02.005 14.,OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Annu Rev Immunol 2005;23:23-68; PMID:15771565; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Nat Rev Immunol 2002; 2:116-26; PMID:11910893; http://dx.doi.org/10.1038/nri72716.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
J Exp Med 1997; 186:47-55; PMID: 9206996; http://dx.doi.org/10.1084/jem.186.1.47 17.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Nat Med 1997; 3:682-5; PMID:9176498; http://dx.doi.org/10.1038/nm0697-682 21.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Immunol Cell Biol 2005; 83:344-51; PMID:16033529; http://dx.doi.org/10.1111/j.1440-1711.2005.01330.x 22.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Eur J Immunol 2008; 38:2499- 511; PMID:18792403; http://dx.doi.org/10.1002/eji.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Clin Cancer Res 2007; 13:1757-61; PMID:17363529; http://dx.doi.org/10.1158/1078-0432.CCR-06-2599 25.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Blood 2009; 114:1537-44; PMID:19423728; http://dx.doi.org/10.1182/blood-2008-12-195792 26.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Nature 2006; 439:682-7; PMID:16382236; http://dx.doi.org/ 10.1038/nature04444 27.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Clin Cancer Res 2009; 15:1623-34; PMID:19208793;http://dx.doi.org/10.1158/1078-0432.CCR-08-1825 28.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
J Immunol 2010; 184:3442-9; PMID:20194714; http://dx.doi.org/10.4049/jimmunol.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Cancer Res 2007; 67:8891-9; PMID:17875731;http://dx.doi.org/10.1158/0008-5472.CAN-07-1056 32.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Proc Natl Acad Sci U S A2002; 99:6567-72; PMID:12011421; http://dx.doi.org/ 10.1073/pnas.082099299 33.,OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Cell Mol Immunol 2011; 8:281-4; PMID:21217771;http://dx.doi.org/10.1038/cmi.2010.82 35.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
J Immunol 2011; 186:3093-103; PMID:21263070; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
PLoS Pathog 2011; 7:e1001347; PMID: 21750671; http://dx.doi.org/10.1371/journal.ppat.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Clin Cancer Res 2010; 16:3356-67; PMID:20460471;http://dx.doi.org/10.1158/1078-0432.CCR-09-2509 39.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Curr Opin Immunol 2011; 23:286-92; PMID: 21185705; http://dx.doi.org/10.1016/j.coi.2010.11.013 40.,OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Curr Opin Immunol 2010;22:385-90; PMID:20466529; http://dx.doi.org/10.1016/j.coi.2010.04.005 41.,OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Hum GeneTher 2000; 11:693-9; PMID:10757349; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
BMC Bio- informatics 2008; 9(Suppl 9):S10; PMID:18793455; http://dx.doi.org/10.1186/1471-2105-9-S9-S1045.,OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Biostatistics 2003; 4:249-64; PMID: 12925520; http://dx.doi.org/10.1093/biostatistics/4.2.,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
Breast Cancer Res 2010; 12:R85; PMID:20946665; http://dx.doi.org/10.1186/ bcr2753 www.landesbioscience.com OncoImmunology 431,Non-OADS,/arxiv_data1/oa_pdf/da/ec/onci-1-419.PMC3382903.pdf
"Interestingly, incorporation *Correspondence to: Daniel J. Powell Jr; Email: poda@mail.med.upenn.edu Submitted: 01/17/2012; Accepted: 01/23/12 http://dx.doi.org/10.4161/onci.19458AUTHOR'S VIEW OncoImmunology 1:4, 547– 549; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 547",Non-OADS,/arxiv_data1/oa_pdf/d7/f5/onci-1-547.PMC3382904.pdf
"Nat Immunol 2000; 1:433-40; PMID:11062504; http://dx.doi.org/10.1038/80877 2. van Lier RA, Borst J, Vroom TM, Klein H, Van Mourik P, Zeijlemaker WP, et al.",OADS,/arxiv_data1/oa_pdf/d7/f5/onci-1-547.PMC3382904.pdf
Blood2005; 105:241-50; PMID:15345595; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d7/f5/onci-1-547.PMC3382904.pdf
Blood 2012; 119:696-706; PMID:22117050;http://dx.doi.org/10.1182/blood-2011-03-344275 7.,Non-OADS,/arxiv_data1/oa_pdf/d7/f5/onci-1-547.PMC3382904.pdf
J Allergy Clin Immunol 2012; 129:787-93; PMID:22197273; http://dx.doi.org/10.1016/j.jaci.2011.11.,Non-OADS,/arxiv_data1/oa_pdf/d7/f5/onci-1-547.PMC3382904.pdf
"9Further analysis revealed that tumor cure was associated with the ability to repeatedly block counter-regulation thus allowing for long-term maintenance *Correspondence to: Nejat K. Egilmez; Email: negilmez@buffalo.edu Submitted: 01/13/12; Accepted: 01/13/12 http://dx.doi.org/10.4161/onci.19369AUTHOR'S VIEW OncoImmunology 1:4, 563– 565; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 563",Non-OADS,/arxiv_data1/oa_pdf/1e/a6/onci-1-563.PMC3382905.pdf
Annu Rev Immunol 2009; 27:83-117; PMID: 19007331; http://dx.doi.org/10.1146/annurev.immunol.,Non-OADS,/arxiv_data1/oa_pdf/1e/a6/onci-1-563.PMC3382905.pdf
Clin Cancer Res 2007; 13:5256-61; PMID:17875753; http://dx.doi.org/10.1158/1078-0432.CCR-07-0892 3.,Non-OADS,/arxiv_data1/oa_pdf/1e/a6/onci-1-563.PMC3382905.pdf
Immunol Rev 2011; 241:104-18; PMID:21488893; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1e/a6/onci-1-563.PMC3382905.pdf
J Immunol 2011; 187:126-32; PMID:21632715; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1e/a6/onci-1-563.PMC3382905.pdf
Blood 2006; 107:628-36; PMID: 16179369; http://dx.doi.org/10.1182/blood-2005-07- 27378.,Non-OADS,/arxiv_data1/oa_pdf/1e/a6/onci-1-563.PMC3382905.pdf
Cancer Res 2005; 65:8059-64; PMID:16166275; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1e/a6/onci-1-563.PMC3382905.pdf
J Immunol 2011; 187:4109-18; PMID:21908736; http://dx.doi.org/10.4049/jimmunol.1101136 10.,Non-OADS,/arxiv_data1/oa_pdf/1e/a6/onci-1-563.PMC3382905.pdf
Cancer Res 2010; 70:129-38;PMID:20028855; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/1e/a6/onci-1-563.PMC3382905.pdf
"Previously, we reported that connective tissue growth factor (CTGF), a profibroticand tumor-promoting factor, was strongly expressed at the tumor-stromal border of the Kras +Tgfbr2KO PDAC tissues,4 Correspondence to: Hideaki Ijichi; Email: hideijichi-gi@umin.ac.jp Submitted: 01/10/12; Accepted: 01/18/12 http://dx.doi.org/10.4161/onci.19402AUTHOR'S VIEW OncoImmunology 1:4, 569– 571; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 569",Non-OADS,/arxiv_data1/oa_pdf/62/f3/onci-1-569.PMC3382906.pdf
CA Cancer J Clin 2009; 59: 225-49; PMID:19474385; http://dx.doi.org/10.3322/ caac.20006 2.,Non-OADS,/arxiv_data1/oa_pdf/62/f3/onci-1-569.PMC3382906.pdf
Pancreas 2004; 28:219-30; PMID:15084961; http://dx.doi.org/10.1097/00006676-200404000-00002 3.,Non-OADS,/arxiv_data1/oa_pdf/62/f3/onci-1-569.PMC3382906.pdf
Nat Rev Cancer 2002; 2:897-909;PMID:12459728; http://dx.doi.org/10.1038/nrc949 4.,Non-OADS,/arxiv_data1/oa_pdf/62/f3/onci-1-569.PMC3382906.pdf
Genes Dev 2006; 20:3147-60; PMID:17114585; http://dx.doi.org/10.1101/gad.14755065.,OADS,/arxiv_data1/oa_pdf/62/f3/onci-1-569.PMC3382906.pdf
Nat Rev Cancer 2004; 4:839-49; PMID:15516957; http://dx.doi.org/ 10.1038/nrc1477 6.,Non-OADS,/arxiv_data1/oa_pdf/62/f3/onci-1-569.PMC3382906.pdf
Nat Rev Cancer 2006; 6:392-401; PMID:16572188; http://dx.doi.org/10.1038/nrc1877 7.,Non-OADS,/arxiv_data1/oa_pdf/62/f3/onci-1-569.PMC3382906.pdf
Nat Rev Cancer 2004; 4:71-8; PMID:14708027; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/62/f3/onci-1-569.PMC3382906.pdf
J Clin Invest 2011; 121:4106-17; PMID:21926469; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/62/f3/onci-1-569.PMC3382906.pdf
"The tumors from IL-21 deficient mice were also reduced in *Correspondence to: Stefan Fichtner-Feigl; Email: stefan.fichtner@klinik.uni-regensburg.de Submitted: 01/14/12; Accepted: 01/18/12 http://dx.doi.org/10.4161/onci.19407AUTHOR'S VIEW OncoImmunology 1:4, 537– 538; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 537",Non-OADS,/arxiv_data1/oa_pdf/d8/29/onci-1-537.PMC3382907.pdf
"Gastroenterology 2010; 138: 2101-14, e5; PMID:20420949; http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/d8/29/onci-1-537.PMC3382907.pdf
Curr Opin Pharmacol 2009; 9:405-10; PMID: 19589728; http://dx.doi.org/10.1016/j.coph.2009.06.,OADS,/arxiv_data1/oa_pdf/d8/29/onci-1-537.PMC3382907.pdf
Arthritis Res Ther 2009; 11:257; PMID:20053303; http://dx.doi.org/10.1186/ ar28434.,Non-OADS,/arxiv_data1/oa_pdf/d8/29/onci-1-537.PMC3382907.pdf
Interleukin-21: a multi- functional regulator of immunity to infections.Microbes Infect 2010; 12:1111-9; PMID:20817119;http://dx.doi.org/10.1016/j.micinf.2010.08.008 5.,OADS,/arxiv_data1/oa_pdf/d8/29/onci-1-537.PMC3382907.pdf
"De Nitto D, Sarra M, Pallone F, Monteleone G. Interleukin-21 triggers effector cell responses in the gut.World J Gastroenterol 2010; 16:3638-41; PMID:20677335; http://dx.doi.org/10.3748/wjg.v16.i29.3638 6.",OADS,/arxiv_data1/oa_pdf/d8/29/onci-1-537.PMC3382907.pdf
J Exp Med2011; 208:2279-90; PMID:21987656; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d8/29/onci-1-537.PMC3382907.pdf
Gut 2011; 60: 1678-86; PMID:21948944; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d8/29/onci-1-537.PMC3382907.pdf
Eur J Immunol 2007; 37:3155-63; PMID:17918200; http://dx.doi.org/10.1002/eji.200737766 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/d8/29/onci-1-537.PMC3382907.pdf
"Do not distribute.www.landesbioscience.com  OncoImmunology  493OncoI mmunology 1:4, 493–506; July 2012; © 2012 Landes BioscienceREVIEW  REVIEW *Correspondence to: Guido Kroemer; E-mail: kroemer@orange.fr Submitted: 04/21/12; Accepted: 04/22/12http://dx.doi.org/10.4161/onci.20459During the last two decades, a number of approaches for the  activation of the immune system against cancer has been developed.",Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
J Allergy Clin Immunol 2003; 111(Suppl):S460-75;  PMID:12592293; http://dx.doi.org/10.1067/mai.2003.108.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
J Allergy Clin Immunol 2006; 117(Suppl Mini-Primer):S441-5; PMID:16455343; http://dx.doi.org/10.1016/j.jaci.2005.07.001.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nature 1990; 348:550-2; PMID:2147233; http://dx.doi.org/10.1038/348550a0.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nature 1987; 330:662-4; PMID:3317066; http://dx.doi.org/10.1038/330662a0.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Immunol Cell Biol 2011; 89:739-46; PMID:21263463; http://dx.doi.org/10.1038/icb.2010.168.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Cancer 2004; 4:11-22; PMID:14708024; http://dx.doi.org/10.1038/nrc1252.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nature 2002; 420:860-7; PMID:12490959; http://dx.doi.org/10.1038/nature01322.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Immunol Cell Biol 2011; 89:183-4; PMID:21326315; http://dx.doi.org/10.1038/icb.2010.164.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Front Biosci (Schol Ed) 2010; 2:153-67; PMID:20036936; http://dx.doi.org/10.2741/s53.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Br J Clin Pharmacol 2011; 72:282-93; PMID:21426372; http://dx.doi.org/10.1111/j.1365-2125.2011.03968.x.11.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Arthritis Rheum 2011; PMID:22147649; http://dx.doi.org/10.1002/art.34330.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Arthritis Rheum 2008; 58:1931-9; PMID:18576354; http://dx.doi.org/10.1002/art.23591.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
JAMA 2007; 297:1535-6; PMID:17426263; http://dx.doi.org/10.1001/jama.297.14.1535.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cancer T reat Res 2011; 157:3-10; PMID:21052947; http://dx.doi.org/10.1007/978-1-4419-7073-2_1.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Blood 2008;  111:485-91; PMID:18182579; http://dx.doi.org/10.1182/blood-2007-03-079681.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Hematol Oncol 2004; 22:121-34; PMID:15991222; http://dx.doi.org/10.1002/hon.736.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Cancer 2010; 10:425-34; PMID:20495576; http://dx.doi.org/10.1038/nrc2843.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Eur J Cancer 2010; 46:2926-35; PMID:20797845; http://dx.doi.org/10.1016/j.ejca.2010.07.033.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Br J Cancer 2010; 103:827-36; PMID:20736949; http://dx.doi.org/10.1038/sj.bjc.6605832.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Curr Opin Hematol 2002; 9:183-9; PMID:11953662; http://dx.doi.org/10.1097/00062752-200205000-00002.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
N Engl J Med 2003; 349:727-9; PMID:12930923; http://dx.doi.org/10.1056/NEJMp030076.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Drug Discov 2009; 8:105-6; PMID:19180104; http://dx.doi.org/10.1038/nrd2819.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Science 2003; 300:1527-8; PMID:12791978; http://dx.doi.org/10.1126/sci-ence.1085458.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
J Exp Med 2011; 208:469-78; PMID:21339327; http://dx.doi.org/10.1084/jem.20101876.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Science 1994; 264:95-8; PMID:8140422; http://dx.doi.org/10.1126/science.8140422.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Expert Opin Ther Targets 2005; 9:737-52; PMID:16083340; http://dx.doi.org/10.1517/14728222.9.4.737.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Clin Cancer Res 2007; 13:6469-78; PMID:17975159; http://dx.doi.org/10.1158/1078-0432.CCR-07-1293.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Eur J Cancer 2012; 48:85-93; PMID:22129890; http://dx.doi.org/10.1016/j.ejca.2011.10.014.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Br J Haematol 2011; 152:579-92; PMID:21241278; http://dx.doi.org/10.1111/j.1365-2141.2010.08533.x.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
N Engl J Med 2012; 366:610-8; PMID:22335738; http://dx.doi.org/10.1056/NEJMoa1110352.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Immunol 2011; 11:330-42; PMID:21508983; http://dx.doi.org/10.1038/nri2970.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Immunol 2003; 3:133-46; PMID:12563297; http://dx.doi.org/10.1038/nri1001.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Immunol 2006; 6:595-601; PMID:16868550; http://dx.doi.org/10.1038/nri1901.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nature 2000; 408:57-63; PMID:11081504; http://dx.doi.org/10.1038/35040504.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
J Exp Med 2002; 196:935-46; PMID:12370255; http://dx.doi.org/10.1084/jem.20020772.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cytokine 1994; 6:597-601; PMID:7893968; http://dx.doi.org/10.1016/1043-4666(94)90046-9.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Immunol 2012; 13:343-51; PMID:22430787; http://dx.doi.org/10.1038/ni.2224.46.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Immunity 2012; 36:388-400; PMID:22444631; http://dx.doi.org/10.1016/j.immu-ni.2012.01.018.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
J Biol Chem 1996; 271:20965-72; PMID:8702856; http://dx.doi.org/10.1074/jbc.271.34.20965.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Science 1988; 241:585-9; PMID:2969618; http://dx.doi.org/10.1126/sci-ence.2969618.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nature 1986; 324:266-8; PMID:2946959; http://dx.doi.org/10.1038/324266a0.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
J Clin Invest 1991; 88:1445-51; PMID:1834696; http://dx.doi.org/10.1172/JCI115453.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
J Exp Med 2011; 208:491-503; PMID:21383056; http://dx.doi.org/10.1084/jem.20100269.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cancer Res 2011; 71:4809-20; PMID:21646474; http://dx.doi.org/10.1158/0008-5472.CAN-11-0753.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
N Engl J Med 2009; 360:2426-37; PMID:19494218; http://dx.doi.org/10.1056/NEJMoa0807865.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
N Engl J Med 2006; 355:581-92; PMID:16899778; http://dx.doi.org/10.1056/NEJMoa055137.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
N Engl J Med 2007; 356:1517-26; PMID:17429083; http://dx.doi.org/10.1056/NEJMoa065213.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cancer 2009; 115:859-68; PMID:19140204; http://dx.doi.org/10.1002/cncr.24100.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cancer Res 2011; 71:5393-9; PMID:21724589; http://dx.doi.org/10.1158/0008-5472.CAN-11-0993.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
J Immunother 2009; 32:920-31; PMID:19816189; http://dx.doi.org/10.1097/CJI.0b013e3181b29168.60.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Intern Med 2009; 48:763-73; PMID:19443970; http://dx.doi.org/10.2169/internal-medicine.48.1851.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
T rends Immunol 2002; 23:89-96; PMID:11929132; http://dx.doi.org/10.1016/S1471-4906(01)02149-4.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
J Biol Chem 2002; 277:7341-7; PMID:11706020; http://dx.doi.org/10.1074/jbc.M106043200.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cell 2001; 104:9-19; PMID:11163236; http://dx.doi.org/10.1016/S0092-8674(01)00187-8.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
EMBO J 1997; 16:5894-903; PMID:9312047; http://dx.doi.org/10.1093/emboj/16.19.5894.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cytokine Growth Factor Rev 2010; 21:331-44; PMID:21115385; http://dx.doi.org/10.1016/j.cytogfr.2010.09.002.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Immunol 2003; 4:63-8; PMID:12469119; http://dx.doi.org/10.1038/ni873.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Exp Dermatol 2006; 15:991-1004; PMID:17083366; http://dx.doi.org/10.1111/j.1600-0625.2006.00516.x.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cell 1993; 75:263-74; PMID:8402911; http://dx.doi.org/10.1016/0092-8674(93)80068-P .,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Pharmacol Rev 2003; 55:241-69; PMID:12773629; http://dx.doi.org/10.1124/pr.55.2.4.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Blood 2004; 103:3529-34; PMID:14701701; http://dx.doi.org/10.1182/blood-2003-06-1850.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Ann Oncol 1999; 10:433-40; PMID:10370786; http://dx.doi.org/10.1023/A:1008301602785.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Immunity 2011; 34:149-62; PMID:21349428; http://dx.doi.org/10.1016/j.immuni.2011.02.012.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cell Signal 2011; 23:1069-75; PMID:21130872; http://dx.doi.org/10.1016/j.cellsig.2010.11.022.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cytokine Growth Factor Rev 2003; 14:155-74; PMID:12651226; http://dx.doi.org/10.1016/S1359-6101(03)00002-9.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
C urr Opin Immunol 2011; 23:702-6;  PMID:21899997; http://dx.doi.org/10.1016/j.coi.2011.08.007.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
"Blood 2010; 115:2554-5, author reply 2556-7; PMID:20339108; http://dx.doi.org/10.1182/blood-2009-11-254607.",Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Sci T ransl Med 2010; 2:52ra72; PMID:20926833; http://dx.doi.org/10.1126/scitranslmed.3001107.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
N Engl J Med 2012; 366:1190-9; PMID:22455413; http://dx.doi.org/10.1056/NEJMoa1109997.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
N Engl J Med 2012; 366:1181-9; PMID:22455412; http://dx.doi.org/10.1056/NEJMoa1109017.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Immunol 2002; 2:675-87; PMID:12209136; http://dx.doi.org/10.1038/nri888.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Immunol 2005; 5:375-86; PMID:15864272; http://dx.doi.org/10.1038/nri1604.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cancer J 2011; 17:351-8; PMID:21952286; http://dx.doi.org/10.1097/PPO.0b013e3182325d4d.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/sci-ence.1208347.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Gut 2006; 55:1131-7; PMID:16507585; http://dx.doi.org/10.1136/gut.2005.079392.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cancer Cell 2003; 3:439-43; PMID:12781361; http://dx.doi.org/10.1016/S1535-6108(03)00089-8.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Oncogene 2003; 22:1501-10; PMID:12629513; http://dx.doi.org/10.1038/sj.onc.1206223.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
J Clin Oncol 2005; 23:5357-64; PMID:15928335; http://dx.doi.org/10.1200/JCO.2005.14.068.92.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Clin Oncol 2009; 6:352-66; PMID:19483740; http://dx.doi.org/10.1038/nrclinonc.2009.62.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Cancer 2003; 3:650-65; PMID:12951584; http://dx.doi.org/10.1038/nrc1169.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Cancer 2003; 3:401-10; PMID:12778130; http://dx.doi.org/10.1038/nrc1093.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Med 1999; 5:405-11; PMID:10202929; http://dx.doi.org/10.1038/7403.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Med 1997; 3:625-31; PMID:9176488; http://dx.doi.org/10.1038/nm0697-625.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Science 2006; 312:1175-8; PMID:16728632; http://dx.doi.org/10.1126/sci-ence.1125951.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Oncoimmunol 2012; 1:28-37; http://dx.doi.org/10.4161/onci.1.1.17938.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Med 2011; 17:1094-100; PMID:21873989; http://dx.doi.org/10.1038/nm.2438.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Med 2011; 17:700-7; PMID:21552268; http://dx.doi.org/10.1038/nm.2366.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
T rends Endocrinol Metab 1995; 6:120-7; PMID:18406693; http://dx.doi.org/10.1016/1043-2760(95)00032-D. 104.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Int J Hematol 1997; 65:97-104; PMID:9071813; http://dx.doi.org/10.1016/S0925-5710(96)00542-7.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Mol Cell Biol 2007; 8:970-82; PMID:18000526; http://dx.doi.org/10.1038/nrm2297.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
N Engl J Med 2000; 342:1350-8; PMID:10793168; http://dx.doi.org/10.1056/NEJM200005043421807.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nature 2008; 454:350-2; PMID:18469800; http://dx.doi.org/10.1038/nature07021.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Blood  2009; 114:2012-3; PMID:19729534; http://dx.doi.org/10.1182/blood-2009-06-228544.109.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Arthritis Rheum 2007; 56:323-33; PMID:17195236; http://dx.doi.org/10.1002/art.22289.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Adv Exp Med Biol 2011; 691:585-8; PMID:21153364; http://dx.doi.org/10.1007/978-1-4419-6612-4_61.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Oncogene 2003; 22:8628-33; PMID:14634624; http://dx.doi.org/10.1038/sj.onc.1207232.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cell 2001; 104:487-501; PMID:11239407; http://dx.doi.org/10.1016/S0092-8674(01)00237-9.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
J Exp Med 1968; 128:1267-79; PMID:5693925; http://dx.doi.org/10.1084/jem.128.6.1267.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nature 1984; 312:724-9; PMID:6392892; http://dx.doi.org/10.1038/312724a0.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Cell Death Differ 2012; 19:107-20; PMID:21760595; http://dx.doi.org/10.1038/cdd.2011.96.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Mol Cell Biol 2010; 11:700-14; PMID:20823910; http://dx.doi.org/10.1038/nrm2970.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Immunol 2009; 9:514-9; PMID:19543226; http://dx.doi.org/10.1038/nri2570.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Science 1996; 273:1862-4; PMID:8791591; http://dx.doi.org/10.1126/science.273.5283.1862.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nature 1999; 397:315-23; PMID:9950424; http://dx.doi.org/10.1038/16852.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nature 2010; 468:98-102; PMID:20881962; http://dx.doi.org/10.1038/nature09387.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Med 2006; 12:1372-9; PMID:17143276; http://dx.doi.org/10.1038/nm1518.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Immunity 1995; 3:673-82; PMID:8777713; http://dx.doi.org/10.1016/1074-7613(95)90057-8.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Drug Discov 2003; 2:736-46; PMID:12951580; http://dx.doi.org/10.1038/nrd1175.,OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Clin Oncol 2012; 9:110-8; PMID:22231759; http://dx.doi.org/10.1038/nrclinonc.2011.197.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Rev Rheumatol 2011; 7:631-8; PMID:21931340; http://dx.doi.org/10.1038/nrrheum.2011.130.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Nat Clin Pract Oncol 2006; 3:94-103; PMID:16462850; http://dx.doi.org/10.1038/ncponc0426.130.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Ann Surg Oncol 2012; 19:627-35; PMID:21879272; http://dx.doi.org/10.1245/s10434-011-2030-7.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Br J Surg 2011; 98:1573-80; PMID:21739427; http://dx.doi.org/10.1002/bjs.7621.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
Clin Genitourin Cancer 2009; 7:E7-9; PMID:19692326; http://dx.doi.org/10.3816/CGC.2009.n.014.,Non-OADS,/arxiv_data1/oa_pdf/71/5c/onci-1-493.PMC3382908.pdf
"Do not distribute.A genetic inference on cancer immune responsiveness Ena Wang, Lorenzo Uccellini and Francesco M. Marincola* Infectious Disease and Immunogenetics Section (IDIS); Department of Transfusion Medicine; Clinical Center and trans-NIH Center for Human Immunology (CHI); National Institutes of Health; Bethesda, MD USA Keywords: cancer genetics, immunotherapy, immune responsiveness, cancer microenvironment, melanoma Abbreviations: FNA, fine needle aspiration biopsy; ICR, immunologic constant of rejection; IEFs, immuneeffector genes; IFN, interferon;IL, interleukin; IRF, interferon regulatoryfactor; ISGs, interferon-stimulated genes;SLE, systemic lupus erythematosus; STAT-1, signal transducer and activator of transcription; TSD, immune-mediatedtissue-specific destruction Submitted: 01/22/12 Accepted: 01/30/12http://dx.doi.org/10.4161/onci.19531 *Correspondence to: Francesco M. Marincola; Email: fmarincola@mail.cc.nih.govAcancer immune signature implic- ating good prognosis and respon- siveness to immunotherapy was described that is observed also in other aspectsof immune-mediated, tissue-specificdestruction (TSD).",Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Ann N Y Acad Sci 1969; 164:365-80;PMID:4981901; http://dx.doi.org/10.1111/j.1749- 6632.1969.tb14051.x 2.,OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Immunity 2008; 29:9-11; PMID: 18631452; http://dx.doi.org/10.1016/j.immuni.2008.,OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Curr Opin Immunol 2003; 15:479-86; PMID:14499253;http://dx.doi.org/10.1016/S0952-7915(03)00103-1 4.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Trends Immunol 2008;29:256-62; PMID:18457994; http://dx.doi.org/10.1016/j.it.2008.03.002 5.,OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
J Transl Med 2011; 9:174; PMID:21992116; http://dx.doi.org/10.1186/1479-5876-9-174 7.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
J Transl Med 2011; 9:146; PMID:21875439;http://dx.doi.org/10.1186/1479-5876-9-146 8.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Oncogene 2010; 29:1093-102; PMID: 19946335; http://dx.doi.org/10.1038/onc.2009.416 9.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Clin Cancer Res 2011; 17:7440-50; PMID: 21976537; http://dx.doi.org/10.1158/1078-0432.CCR-11-1650 11.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
J Pathol 1969; 97:459-68; PMID:5360500; http://dx.doi.org/10.1002/path.1710970305 12.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
J Transl Med 2012; 10:1; PMID:22214470; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Breast Cancer Res Treat 2012; 131:871-80; PMID: 21479927; http://dx.doi.org/10.1007/s10549-011-1470-x 14.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
PMID:21964766; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Genome Biol 2007; 8:R8; PMID: 17222352; http://dx.doi.org/10.1186/gb-2007-8-1-r8 19.,OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
J Transl Med 2007; 5:11;PMID:17313672; http://dx.doi.org/10.1186/1479- 5876-5-11 20.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
BMC Genomics 2009; 10:301; PMID:19583830; http://dx.doi.org/10.1186/1471-2164-10-301 21.,OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Expert Rev Vaccines2010; 9:555-65; PMID:20518712; http://dx.doi.org/ 10.1586/erv.10.5522.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
N Engl J Med 2006; 354:709-18; PMID:16481638; http://dx.doi.org/10.1056/NEJMoa053007 24.,OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Clin ExperimentOphthalmol 2001; 29:235-8; PMID:11545422;http://dx.doi.org/10.1046/j.1442-9071.2001.00425.x 25.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
J Eur Acad Dermatol Venereol 2011; PMID:22145691; http://dx.doi.org/10.1111/j.1468-3083.2011.04364.x 26.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
J Dtsch Dermatol Ges 2011; 9:277-86; PMID:21083648; http://dx.doi.org/10.1111/j.,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Science 2001; 294:1540-3; PMID:11711679; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Curr Opin Immunol 2006; 18:676-82; PMID:17011763; http://dx.doi.org/10.1016/j.coi.2006.09.014 29.,OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
Cancer Immunol Immunother 2008; 57:685-91; PMID: 17909797; http://dx.doi.org/10.1007/s00262-007-0407-z www.landesbioscience.com OncoImmunology 525,Non-OADS,/arxiv_data1/oa_pdf/b4/d5/onci-1-520.PMC3382909.pdf
"As a SNP in a promoter region may *Correspondence to: Saumendra N. Sarkar; Email: saumen@pitt.edu Submitted: 03/06/12; Accepted: 03/08/12 http://dx.doi.org/10.4161/onci.19964RESEARCH PAPER OncoImmunology 1:4, 487– 492; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 487",Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
"(n = 9) have the AC-genotype and we identified no individuals with the CC-genotype.7Accordingly, the National Center for Biotechnology Information (NCBI) database for the current SNP (rs12553612) indicates that among a total 947 individualsanalyzed AA-, AC- and CC-genotypes were found in 719, 122and 14 individuals, respectively, with a dominant prevalence ofAC and CC genotypes in Asian populations (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12553612#Diversity).",Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Clin Cancer Res 2011; 17:2619-27; PMID:21372217; http://dx.doi.org/10.1158/1078-0432.CCR-10-1114 3.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
J Exp Med 2011; 208:2005-16; PMID: 21930765; http://dx.doi.org/10.1084/jem.20101159 6.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
J Exp Med 2011; 208:1989-2003; PMID:21930769; http://dx.doi.org/10.1084/jem.20101158 7.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Clin Cancer Res 2010; 16:3409- 19; PMID:20472682; http://dx.doi.org/10.1158/ 1078-0432.CCR-10-0644 8.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Clin Cancer Res 2008; 14:6640-6; PMID:18927306; http://dx.doi.org/10.1158/1078-0432.CCR-07-4681 9.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
J Clin Oncol 2008; 26:5957-64; PMID:19001328; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Vaccine 2008; 26:1731-6; PMID:18325643; http://dx.doi.org/10.1016/j.vaccine.2008.01.01711.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622 13.,OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Cancer Epidemiol Biomarkers Prev 2007; 16:2448-54; PMID:18006935; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Methods Mol Biol 2009; 578:3-22; PMID:19768584; http://dx.doi.org/10.1007/978-1- 60327-411-1_1 15.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.Cancer Immunol Immunother 2010; 59:1401-9; PMID:20549206; http://dx.doi.org/10.1007/s00262- 010-0876-3 16.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Cancer Immunol Immunother 2011; 60:153-60; PMID:21120655; http://dx.doi.org/10.1007/s00262-010-0946-6 17.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
J Clin Oncol 2011; 29:330-6; PMID:21149657; http://dx.doi.org/10.1200/JCO.2010.30.7744 18.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Nucleic Acids Res 1998; 26:362-7; PMID:9399875; http://dx.doi.org/10.1093/nar/26.1.36219.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Eur J Immunol 2007; 37: 306-9; PMID:17273997; http://dx.doi.org/10.1002/ eji.200637009 20.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Cancer Lett 2002; 185:173-9; PMID: 12169391; http://dx.doi.org/10.1016/S0304-3835(02) 00277-X 22.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Science 1991; 253:1022-6; PMID:1887216; http://dx.doi.org/10.1126/science.1887216 23.,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
BMCCell Biol 2010; 11:56; PMID:20637099; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
Mol Cell Biol 2005; 25:8717-31; PMID:16166650; http://dx.doi.org/10.1128/MCB.25.19.8717-8731.2005 492 OncoImmunology Volume 1 Issue 4,Non-OADS,/arxiv_data1/oa_pdf/06/dd/onci-1-487.PMC3382910.pdf
"Notsurprisingly, while in primary epithelial *Correspondence to: Thomas Brunner; Email: thomas.brunner@uni-konstanz.de Submitted: 01/20/12; Accepted: 01/23/12 http://dx.doi.org/10.4161/onci.19459AUTHOR'S VIEW OncoImmunology 1:4, 529– 530; July 2012; G2012 Landes Bioscience www.landesbioscience.com OncoImmunology 529",Non-OADS,/arxiv_data1/oa_pdf/8a/d3/onci-1-529.PMC3382911.pdf
Oncogene 2010; 29:1093-102; PMID: 19946335; http://dx.doi.org/10.1038/onc.2009.416 2.,Non-OADS,/arxiv_data1/oa_pdf/8a/d3/onci-1-529.PMC3382911.pdf
Oncogene 2011; 30:2411-9; PMID:21258413; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/8a/d3/onci-1-529.PMC3382911.pdf
Semin Immunopathol 2009; 31:237-48; PMID:19495759; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/8a/d3/onci-1-529.PMC3382911.pdf
Allergy 2012; 67:227-34; PMID:22111694; http://dx.doi.org/10.1111/j.1398-9995.2011.02749.x5.,OADS,/arxiv_data1/oa_pdf/8a/d3/onci-1-529.PMC3382911.pdf
J Exp Med 2004; 200:1635-46; PMID:15596520; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/8a/d3/onci-1-529.PMC3382911.pdf
J Exp Med 2010; 207:1057-66; PMID:20439544; http://dx.doi.org/10.1084/jem.20090849 7.,Non-OADS,/arxiv_data1/oa_pdf/8a/d3/onci-1-529.PMC3382911.pdf
Proc Natl Acad Sci U S A 2007; 104:13098-103; PMID:17670946; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8a/d3/onci-1-529.PMC3382911.pdf
J Exp Med 2006; 203:2057-62; PMID: 16923850; http://dx.doi.org/10.1084/jem.20060357 10.,Non-OADS,/arxiv_data1/oa_pdf/8a/d3/onci-1-529.PMC3382911.pdf
J Biol Chem 2006; 281:7850-5; PMID:16439367;http://dx.doi.org/10.1074/jbc.M509115200 Figure 1.,OADS,/arxiv_data1/oa_pdf/8a/d3/onci-1-529.PMC3382911.pdf
"15hypothesized that the combination of *Correspondence to: Hinrich Abken; Email: hinrich.abken@uk-koeln.de Submitted: 02/18/12; Accepted: 02/28/12 http://dx.doi.org/10.4161/onci.19855OncoImmunology 1:4, 458– 466; July 2012; G2012 Landes Bioscience 458 OncoImmunology Volume 1 Issue 4",Non-OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/ 10.1126/scitranslmed.3002842 2.,Non-OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Cancer Res 2007; 67:11428-37; PMID:18056471; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Leukemia 2004; 18:676-84; PMID:14961035; http://dx.doi.org/10.1038/sj.leu.,Non-OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Mol Ther 2005; 12:933-41; PMID:15979412; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Immunol Res 2011; 51:170-82; PMID:22139852;http://dx.doi.org/10.1007/s12026-011-8262-6 17.,Non-OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Scand J Immunol 2001; 53:139-47;PMID:11169217; http://dx.doi.org/10.1046/j.1365- 3083.2001.00851.x 18.,Non-OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
"Int J Cancer 1997; 71:630-7; PMID:9178819; http://dx.doi.org/10.1002/ (SICI)1097-0215(19970516)71:4 ,630::AID-IJC20 .",Non-OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Nat Immunol 2007; 8:931-41; PMID:17694059; http://dx.doi.org/10.1038/ni1504 23.,Non-OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Gene Ther 2009; 16:1088-96; PMID:19554034; http://dx.doi.org/10.1038/gt.2009.75 24.,OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Clin Cancer Res 2009; 15:5852-60; PMID:19737958; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Immunol Rev 2003; 192:7-20; PMID: 12670391; http://dx.doi.org/10.1034/j.1600-065X.2003.00008.x 29.,Non-OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Mol Ther 2011; 19:760- 7; PMID:21326215; http://dx.doi.org/10.1038/mt.,OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Curr Gene Ther 2010; 10:77-90; PMID:20222863; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
Science 2003; 302:415-9; PMID:14564000; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/23/54/onci-1-458.PMC3382912.pdf
"The 96 accessions of panel 1 are part of a core collection, established during a Euro- pean project on genetic diversity in Brassica crop species (http://documents.plant.wur.nl/cgn/pgr/brasedb/brasresgen.htm, T able A1 in Appendix).",Non-OADS,/arxiv_data1/oa_pdf/df/8a/fpls-03-00129.PMC3382996.pdf
"Korean Journal of Family Medicine Copyright © 2011 The Korean Academy of Family Medicine  This is an open-access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.can lead to cirrhosis.1) Chronic hepatitis often leads to nonspecific  symptoms such as malaise, fatigue, and weakness, or no symptoms  at all.",Non-OADS,/arxiv_data1/oa_pdf/77/c7/kjfm-32-205.PMC3383125.pdf
"Keywords: Child; Overweight; Gamma-glutamyltransferase; Oxidative stress Received: January 28, 2011, Accepted: March 17, 2011 *Corresponding Author: Kyung-Hee Park Tel: 82-31-380-1785, Fax: 82-31-380-1782 E-mail: pkh71@dreamwiz.com Korean Journal of Family Medicine Copyright © 2011  The Korean Academy of Family Medicine  This is an open-access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.Western countries to Asian countries.1-3) Obesity tends to track from  childhood to adulthood and childhood obesity can be a predictor of  cardiovascular disease during adulthood.4) Additionally, epidemic of  childhood obesity leads to early development of hypertension, type 2  diabetes, dyslipidemia and fa/t_ty liver in childhood.5,6) /T_his increasing  trend of obesity and obesity-related diseases during childhood have  been a threat to the public health.",Non-OADS,/arxiv_data1/oa_pdf/23/88/kjfm-32-182.PMC3383127.pdf
"Keywords: Integrative Medicine; Complementary Medicine; Holism; Medical Education; Attitude Received: February 21, 2011,  Accepted: March 21, 2011 *Corresponding Author:  Duk-Chul Lee Tel: 82-2-2228-2331; Fax: 82-2-362-2473 E-mail: faith@yuhs.ac Korean Journal of Family Medicine Copyright © 2011 The Korean Academy of Family Medicine  This is an open-access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.children,3) and the elderly,4) a trend that holds true for Korea.",Non-OADS,/arxiv_data1/oa_pdf/a7/bd/kjfm-32-197.PMC3383128.pdf
"Keywords: Cholesterol; High Density Lipoprotein; Gender Difference; Korean National Health and Nutrition Survey  (KNHANES) Received: August 31, 2009,  Accepted: February 16, 2011 *Corresponding Author: Hyun Ah Park Tel: 82-2-2270-0097, Fax: 82-2-2267-2030 E-mail: drparkhyunah@gmail.com Korean Journal of Family Medicine Copyright © 2011 /T_he Korean Academy of Family Medicine  This is an open-access article distributed under the terms of  the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0) which permits  unrestricted non-commercial use, distribution, and reproduction in  any medium, provided the original work is properly cited.INTRODUCTION High density lipoprotein cholesterol (HDL-C) is considered  protective in development of cardiovascular diseases.",Non-OADS,/arxiv_data1/oa_pdf/d4/95/kjfm-32-173.PMC3383129.pdf
